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2ABSTRACT
Acute Encephalitis Syndrome (AES) is a group of clinical symptoms and signs, used by 
the World Health Organisation (WHO) and clinicians, to screen for acute encephalitis. 
Viruses are the most important cause of AES worldwide. Japanese encephalitis virus 
(JEV), which causes Japanese encephalitis (JE), accounts for approximately one-quarter 
of AES cases in Nepal. In the absence of defi nite treatments for JE and many other viral 
enecpahlitides, improvements in supportive management are vital. 
In my thesis, the predictors of bad outcome (neurological sequelae or death) among 
patients with AES and JE were investigated. The relationships between weight-
for-age (WFA), hydration status, intravenous fl uids and outcome were studied. In 
addition, a preliminary randomised double blind placebo controlled trial of intravenous 
immunoglobulin (IVIG), as a novel adjunctive treatment for JE, was conducted. 
Prolonged fever duration was identifi ed to be a signifi cant predictor of bad outcome 
in both AES and JE patients. Prolonged fever, low Glasgow coma score (GCS) and 
focal neurological defi cit at hospital admission were signifi cantly associated with bad 
outcome in AES patients. AES patients with focal neurological defi cit were signifi cantly 
more likely to have a fi nal diagnosis of JE. JE patients presented with a signifi cantly 
lower body weight and higher respiratory rate. They also presented with a trend for 
higher urea and potassium levels compared to other AES patients. These fi ndings led 
me to investigate further whether children with JE were more likely to suffer from 
dehydration during acute illness. 
When children are grouped into different weight categories by WFA (Z score), low 
WFA can indicate dehydration or malnutrition. I found a signifi cant association between 
frequency of bad outcome and low WFA among both AES and JE patients at hospital 
admission. To help distinguish dehydration and malnutrition in low WFA children, I 
then studied additional indicators of malnutrition and dehydration status, including mid-
upper arm circumference, blood lactate levels and fl uid status at admission and during 
hospital stay. I found AES patients suffering a bad outcome had signifi cantly higher 
admission serum lactate levels, drunk a lower volume of oral fl uids, and were more 
likely to be prescribed a restricted regimen of intravenous fl uids. These results suggest 
AES patients with bad outcome were more likely to be dehydrated. The implications of 
my fi ndings are that earlier hospital admission during the course of the illness and better 
in hospital administration of adequate and appropriate fl uids may improve outcome 
among AES and JE patients. Since the majority of families self-refer to hospitals, 
provision of this simple message into the community, could help improve the lives of 
people living in high risk areas for JE, like Nepal. 
Improvement in the treatment of JE is necessary to improve the outcome of the disease 
in Nepal. Intravenous immunoglobulin, which contains anti-JE virus neutralising 
antibodies and has anti-infl ammatory properties, may be a useful adjunctive treatment. 
In a preliminary Phase II study, I showed IVIG could be safely administered to JE 
patients, without any signifi cant increase in drug related adverse events. JE patients 
treated with IVIG exhibited higher levels of neutralising antibodies and higher IL-4 and 
IL-6 cytokine levels compared with placebo (saline) treated patients. Although, there 
was no difference in clinical outcome, the data from this small pilot study suggests 
IVIG may be an appealing adjunctive treatment option for a phase III trial in the future.
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Chapter 1: Introduction
1.1 Acute Encephalitis Syndrome (AES)
Acute Encephalitis Syndrome (AES) is defi ned as acute onset of fever, 
with an acute change in mental status (including confusion, disorientation, 
coma or inability to talk) and /or new onset of seizures (excluding simple 
febrile seizures) in a person of any age (1). It is a group of clinical symptoms 
and signs, used by the World Health Organisation (WHO) for surveillance 
purposes, to screen patients with viral encephalitis, including Japanese 
encephalitis (JE). These clinical features suggest the patient has acute 
infl ammation of the brain. These features are also used by clinicians to help 
identify patients with suspected encephalitis. Viruses are regarded as the most 
important cause of encephalitis worldwide. However, encephalitis can also 
be caused by bacteria or parasitic infections, as well as immune mediated 
processes in the brain. Despite intense diagnostic testing, recent studies in 
England, Vietnam and Papua New Guinea did not identify a specifi c aetiology 
among 37%, 59% and 63% of encephalitis patients respectively (1-3). Specifi c 
aetiological agents differ considerably depending on geographical location 
and age of the patient. In the United Kingdom (UK), where there are adequate 
resources, specifi c aetiologies were identifi ed in 33% children and 45% adults, 
with herpes simplex virus (HSV) the most common diagnosis (4). In North 
America, enteroviruses were found to be the most common aetiology in 
children and HSV-1 in adults (5,6). In Southeast Asia, Japanese encephalitis 
is the most common cause in children, accounting for 31%- 45% of cases 
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(6). Emerging viruses, such as Nipah virus, avian infl uenza H5N1 and bat 
lyssavirus, have recently been linked to encephalitis in humans. Discovery 
of known pathogens in new regions, such as West Nile virus in Romania, 
and greater recognition of antibody mediated encephalitis, where antibodies 
develop against neuronal components, such as voltage gated potassium 
channels (VGKC) or N-methyl-D-aspartate receptors (NMDAR) are of an 
increasing global concern (7).
1.2 Aetiology of AES
In the UK, common aetiologies of viral encephalitis are herpes simplex 
virus 1 and 2, varicella zoster virus, enterovirus, parechovirus, adenovirus, 
human herpesvirus-6, mumps virus, measles virus and infl uenza A and B 
viruses (2). Other rarer viral aetiologies include cytomegalovirus, Epstein-
Barr virus, hepatitis viruses, human T-cell lymphotropic virus, parainfl uenza 
virus, parvovirus B19, lymphocytic choriomeningitis virus, polio virus, 
rabies virus, respiratory syncytial virus and human immunodefi ciency virus 
(2). Other viruses suspected to cause AES in other settings include Eastern 
equine encephalitis virus, Western equine encephalitis virus, Venezuelan 
equine encephalitis virus, Hendra virus, Kyasanur forest disease and St 
Louis encephalitis virus (8). Bacteria more often cause meningitis than 
encephalitis. However, bacterial meningitis can present as AES when patients 
exhibit altered consciousness or seizures. Bacteria known to cause AES 
include; Streptococcus pneumoniae, Hemophilus infl uenza type B, Niesseria 
meningitidis, Streptococcus pyogenes, Bacillus anthracis, Bartonella henselae, 
Chlamydia trachomatis, Chlamydophila psittaci, Leptospira, Listeria 
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monocytogenes, Borrelia burgdorferi, Mycoplasma pneumoniae, Salmonella 
and Mycobacterium tuberculosis (7). Other infectious aetiologies, include 
Coxiella burnetii, Rickettsia rickettsii, Toxoplasma gondii and Histoplasma 
capsulatum (7). Acute disseminated encephalomyelitis (ADEM) is the second 
most common diagnosed encephalitis and fi rst most common immune-
mediated encephalitis in the UK (2). Other immune-mediated encephalitis 
include NMDA receptor antibodies, voltage-gated potassium channel 
antibodies, multiple sclerosis and secondary to systemic vasculitis (2). 
A variety of factors infl uence viral pathogens, particularly arboviruses, 
associated CNS infection in Asia. It includes presence of a variety of viral 
vector mosquitoes that bite humans; close interaction between humans and 
animals, such as pigs or birds, which act as intermediate hosts for JEV and 
H1N1 infl uenza virus; poor housing having open windows and thatch roofs, 
which provide access and suitable habitats for mosquitoes to live inside home; 
and wet, warm climates that can promote mosquito breeding and survival. 
Other important contributory factors include, poverty, overcrowding, poor 
sanitation and lack of education. Clinicians often have limited access to 
diagnostics in resource poor settings. AES patients are ideally investigated 
by lumbar puncture. Depending on the laboratory set-up, cerebrospinal fl uid 
(CSF) may, but not always, undergo microscopy for total cell count, white cell 
differential, staining for bacteria (Gram and Acid Fast Bacillary) and bacterial 
culture. CSF may also undergo protein and glucose measurement. In part, 
due to lack of viral culture, molecular assays and limited serological testing, 
aetiology is often unknown. As a result, patient treatment is often undirected. 
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Even hospitals in densely populated areas can have limited diagnostic facilities. 
In these areas, based on clinical features, national surveillance data, and 
reports from population screening programmes, viruses are suspected to be 
the most common cause of AES. Reported viral pathogens include: Japanese 
encephalitis, enteroviruses (e.g. Coxsackie, echovirus or polio), herpes simplex, 
measles, West Nile, varicella-zoster, dengue, Nipah, Chandipura, and Murray 
valley. Other reported causes include; pyogenic bacteria, mycobacteria, fungi, 
malaria, leptospirosis, rickettsia, toxoplasma and rabies. Many non- infectious 
conditions can cause encephalopathy, overlapping the clinical features for 
AES. Such conditions include: hypoglycemia, shock, head injury, poisoning, 
diabetes ketoacidosis, epilepsy, cerebral vasculitis, glomerulonephritis, cerebral 
tumour or Reye’s syndrome. Excluding these conditions poses a challenge to 
clinicians, particularly in resource poor settings (7). In Nepal, aetiology of AES 
has not been extensively studied. 
1.3 Incidence of AES
Since there are many aetiological agents causing encephalitis, and the diagnosis 
is diffi cult to make, acute encephalitis (AE) has been described as a whole 
disease syndrome. Where population based studies have been undertaken, the 
incidence of AES is reported to be 6.34 and 7.4 per 100,000 populations in 
tropical and Western industrialised country settings, respectively. In relation to 
age group, the incidence of AES is reported to be 10.5 per 100,000 AES cases 
in children and 2.2 per 100,000 cases in adults (9).
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1.4 Clinical features of patients of AES
Clinical presentation depends on the aetiological agent, age of the patient, site 
of lesion in the central nervous system (CNS) and immune status of the patient. 
There is substantial overlap between clinical presentations of AE with other 
infections of the CNS. In general, involvement of cerebral cortex, midbrain, 
pons, medulla oblongata and cerebellum cause upper motor lesion types of 
symptoms and signs. Younger children may present with fever, headache, 
vomiting, diarrhoea, cough, sore throat, running nose, shortness of breath, 
lethargy, irritability, urinary retention, urinary incontinence, skin rash, impaired 
consciousness, seizures, change in behaviour and personality, photophobia, 
motor or sensory defi cits, speech or movement disorder (10). Older children 
have milder symptoms such as mild irritability, subtle speech and personality or 
behavioural abnormalities. Sometimes patients may present with characteristic 
clinical features such as tremors and dystonia in JE, emotional instability 
and confused state in herpes simplex virus encephalitis, cerebellar ataxia in 
varicella-zoster virus encephalitis and deafness in mumps encephalitis. On 
rare occasions, JE, Murray Valley encephalitis, St. Louis encephalitis, tick-
borne encephalitis, West Nile virus, non-polio enteroviruses, Louping ill and 
Powassan virus illness may present with acute fl accid paralysis (11). 
1.5 Diagnosis of AES
Investigation depends on the available facilities and likely local pathogens. The 
cerebral spinal fl uid (CSF) contains from a few to a thousand cells. Initially 
neutrophils and later lymphocytes predominate. The CSF protein level may be 
normal or elevated. Glucose level may be normal. However, characteristically, 
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CSF protein may be elevated in herpes simplex virus encephalitis and CSF 
glucose low in mumps virus encephalitis (12). CSF culture may show viruses 
but to increase aetiological diagnosis, it should be combined with specimens 
collected from nasopharyngeal swab, urine and faeces. CSF polymerase chain 
reaction (PCR) can also identify viruses for JE, dengue, Nipah encephalitis, 
Murray Valley encephalitis, St Louis encephalitis, poliomyelitis, rabies 
encephalitis and West Nile encephalitis. CSF serology is a cheap alternative 
to diagnose JE, dengue, tickborne encephalitis, Nipah encephalitis, Murray 
Valley encephalitis, St Louis encephalitis, rabies encephalitis, herpes simplex 
encephalitis and West Nile encephalitis. CSF antibodies against voltage-
gated potassium channels and NMDA receptor could help diagnose immune-
mediated forms of encephalitis (2). 
1.6 Treatment of AES
Management is predominantly supportive. Treatment for AES, in high risk 
areas, include appropriate antibiotics for bacterial meningitis, quinine for 
cerebral malaria and fl uoroquinolones with high dose dexamethasone for 
typhoid encephalopathy. Aciclovir is the only defi nite treatment available 
for viral encephalitis, which is administered for herpes simplex and herpes 
zoster encephalitis. All other viral encephalitis have no defi nite treatment. 
Acetaminophen is administered for fever, codeine for nausea and non-aspirin 
containing analgesics for headache. Severely ill patients require hospitalisation, 
intensive care, anticonvulsants for control of seizures and administration of 
intravenous fl uids. The patients need to be monitored for complications such 
as convulsions, cerebral oedema, raised intracranial pressure, electrolyte 
imbalance, adequate breathing and aspiration pneumonia.
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1.7 Clinical outcome of AES 
Outcome of AES in children differs based on the aetiology of AES, virulence 
of the organism, stage of illness, immunity status of the host, available defi nite 
treatment and supportive management. Since a large majority of AES do 
not have defi nite treatment, estimating the outcome becomes important in 
explaining the prognosis to the parents at the time of admission. In the past, 
different diagnostic criteria have been used to defi ne AES or acute encephalitis 
cases. Some cases have been based on the WHO International Classifi cation 
of Disease (ICD) (13-15). Some cases have been reported based on the fi nal 
diagnosis by consulting physician (16, 17). Encephalitis cases have been 
reported based on a variety of inclusion criteria (18). Some publications have 
failed to provide exclusion criteria (4, 18, 19). Accepting the wide variety of 
case defi nitions for children with AES, mortality rates range between 4- 29%, 
with 14- 60% having neurological sequelae at discharge (3,6,10,20-25). Studies 
that have followed up AES cases in the community report between 2.8- 30% 
of cases exhibit residual neurological sequelae 6 months post-discharge 
(16,26,27).
 
1.8 Sequelae of AES
Residual neuro-psychiatric sequelae are seen in quarter of children with AES. 
Sequelae are more common in JE as compared to other viral encephalitides 
(28). Behavioural problems, such as hyperactivity, are the most common 
sequelae. Other sequelae described include; development delay, expressive 
language diffi culties, receptive language problems, visual impairment, hearing 
impairment, seizures, cranial nerve palsies, bulbar palsy, ataxia, urinary 
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retention or incontinence, monoparesis and hemiparesis. Given the aetiologies 
of AES exhibit seasonal and geographical variation, outcomes are also likely to 
vary between studies conducted in different locations and at different times of 
the year. 
1.9 Prognostic indicators of AES 
In resource-rich settings (29,30), clinical predictive scores are now a 
cornerstone of the management of a range of clinical conditions (30-32). 
Efforts have been made to identify indicators of poor outcome in developing 
countries as well (33, 34). These can help focus attention on the most severe 
patients, who are likely to do badly, as well as providing important clues about 
disease mechanisms. Similarly, indicators of bad outcome in AES and JE have 
been reported in the past. A previous study conducted in Nepali children has 
identifi ed, prolonged duration of fever, as a predictor of bad outcome in AES 
and JE (10). However, these results were from a single location and the authors 
expressed uncertainty regarding its application to other settings.
1.10 Recovery of sequelae in AES
Since there is no defi nite treatment for majority of patients of AES, knowing 
the recovery profi le of patients of AES would help in counselling and 
explaining to parents about the prognosis of AES. In children with viral 
encephalitis other than JE, motor sequelae is seen to decrease from 8/36 (22%) 
at the time of discharge to 5/36 (14%) at 6 weeks (10). Paucity of data and lack 
of defi nite treatment necessitates more research in this area of AES. 
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1.11 Japanese encephalitis (JE) and other Flaviviruses
Although epidemics of encephalitis were described in Japan from 1871, the 
Nakayama strain of JEV was fi rst isolated from a fatal human case in 1935. 
At least fi ve genotypes of JEV circulate in Asia. Although the geographical 
boundaries may overlap between different genotypes, they are of same serotype 
and similar virulence and host preference. Presently genotype 1 is the most 
widely circulating genotype in the world (35). JEV causes JE. JE affects over 
68,000 people annually, leading to 20-30% mortality and 30-50% disability, 
with children bearing the brunt of the disease burden (20, 36-38). JEV (genus 
fl avivirus, family Flaviviridae) is a neurotropic fl avivirus, transmitted by bite of 
an arthropod (Culex mosquito) because of which it is also classifi ed as Group 
B arbovirus. All neurotropic fl aviviruses are antigenically related and derived 
from common ancestor (Figure 1.1). They have small positive sense RNA in 
icosahedral shaped capsid. The vectors are either ticks or mosquitoes. 
Flavivirus encephalitis occurs as a result of complex interaction between 
environment, virulence of the virus, human activity, entomology, bird and 
host immunity. These mosquito borne viruses are transmitted naturally 
between birds in an enzootic cycle by bird biting mosquitoes. Humans become 
incidental dead-end hosts by crossing path in this cycle and because of their 
inability to transmit the virus further (exception being Yellow fever and 
Dengue viruses). Every year, mosquito-borne, St Louis encephalitis in North 
America, West Nile encephalitis in Africa, Murray Valley encephalitis in 
Australia and JE in Asia occur as a result of this interplay. In cooler climates of 
northern Europe and Asia, ticks are more abundant. The tick-borne neurotropic 
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fl avivirus encephalitis that occur more frequently in the region are; Russian 
spring-summer encephalitis in Russia, Western tick-borne encephalitis in 
Germany and Austria and Louping Ill viral encephalitis in UK. 
Figure 1.1: Phylogenetic tree directly amplifi ed from CSF collected in acute 
stage of illness of patient of AES using a 1,381-nt JEV envelope sequence 
between September and November, 2009. Multiple sequence alignment and 
phylogenetic analysis were conducted by using ClustalW software (www.ebi.
ac.uk/Tools/clustalw2/ index.html) and MEGA version 4 (www.megasoftware.
net). The tree was rooted within the JE serogroup by using Murray valley virus 
(GenBank accession No AF 161266). The robustness of branching patterns 
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was tested by 1000 bootstrap pseudo replicates. Each strain is abbreviated 
with accession number, strain name followed by country of origin and year 
of isolation on the right of each tree. Bootstrap values are indicated above the 
major branch; 43 taxa comprised the in-group, and all taxa were rooted with 
Murray valley encephalitis virus (39).
1.12 Morphology of JEV
Morphologically JEV has a 50 nm lipoprotein envelope surrounding a 
nucleocapsid comprised of core protein wrapped around 11 KB of single-
stranded positive-sense RNA. The RNA has three regions: a short 5' and longer 
3' untranslated regions (UTR) and a single open reading frame. The single open 
reading frame encodes for three structural proteins (core – C, pre-membrane 
– prM and envelope – E) and 7 non-structural (NS) proteins (40, 41). The E 
protein is critical for viral attachment and entry into cells and along with NS1 
and NS3 is a major target of the immune response. 
1.13 Enzootic cycle of JE
Although JEV transmission occurs in many animals, those that have high 
viremia are important in the natural cycle. JEV is transmitted naturally between 
birds and pigs by Culex mosquito (Figure 1.2). Collected rain water in paddy 
fi elds for sewing rice during Monsoon provides suitable breeding site for 
female Culex tritaeniorhynchus mosquito an important vector that transmits 
JE in human. The mosquito is known to be infective 14 days after entry of 
JEV from a viraemic host and fl y up-to 5 kilometres; important information 
during epidemics (42). Rice-fi elds are important sites for JEV transmission 
to susceptible birds (cattle egrets and herons) and humans. Pigs are important 
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amplifi er host for the virus because of high and prolonged viraemia, continuous 
source of nascent hosts through off springs and are raised in close proximity 
to human dwelling causing viral transmission and risk of encephalitis. Apart 
from abortions in pigs, the virus does not cause any illness in its natural hosts. 
Although JEV has been recovered from human blood, the low level of viraemia 
is not suffi cient to infect a mosquito. When the mosquito population becomes 
adequately high, JEV transmission spills over from the mosquito-bird-pig cycle 
into human populations through mosquito bite. 
Figure 1.2: JE transmission occurs naturally in an enzootic cycle between 
birds and pigs by Culex mosquitoes. Humans are accidental dead-end hosts.
1.14 Pathogenesis of JE
The pathogenesis of JE is incompletely understood. The immune status 
of the host and integrity of blood brain barrier (BBB) are important in JE 
pathogenesis. After an effective bite of a mosquito the virus enters the body 
and multiplies locally in dermal tissue and draining lymph nodes causing a 
33
transient period of viraemia. The virus reaches the CNS probably through T- 
lymphocytes where the virions bind to vascular endothelial cells of the CNS 
and internalize by endocytosis (43). JE typically develops after an incubation 
period of 5-15 days. It is postulated that during this time JEV resides and 
multiplies inside host leukocytes, which act as a vehicle to transport the virus 
into the CNS. Any therapy which could clear the virus from the lymphatic 
tissue and spleen during this period could prevent JE pathogenesis and prevent 
illness. Infected astrocytes, a component of the BBB, also help in passage of 
JEV from peripheral tissues to CSF. After entering the neuronal cell, JEV can 
cause neuronal death directly by multiplication within the rough endoplasmic 
reticulum and Golgi apparatus.. JEV can also cause cell death indirectly by 
uncontrolled over activation of the microglia's infl ammatory response, with 
microglial releasing of pro-infl ammatory cytokines such as interleukin 6 (IL-
6), tumour necrosis factor α (TNF α), regulated upon activation, normal T cell 
expressed and secreted (RANTES) and monocyte chemotactic protein 1 (MCP 
1). These infl ammatory mediators released into the CSF then trigger a massive 
leukocyte infl ux across the BBB into the CNS compartment. Interferon-
inducible protein 10 secreted by activated astrocytes also causes infi ltration 
of natural killer cells and monocytes causing neuronal death. Improving 
understanding of JE pathogenesis is the key to exploring treatment option. 
1.15 Cytokines in JE
Infl ammatory response to fl avivirus encephalitis suggests infl ammation could 
cause vascular endothelial damage and contribute to JE pathogenesis (44). CSF 
levels of IL-6, tumour necrosis factor (TNF)- α and IL-8 are higher at the time 
of admission in those who died of JE than those who survived. In the plasma, 
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RANTES is higher in those who die of JE as compared to survivors (Table 
1.1). However, correlation of anti-infl ammatory (IL- 4) and pro-infl ammatory 
(IL- 6) markers at the time of admission and again at discharge with death 
and recovery would provide better insight into the role of cytokines in disease 
pathogenesis. 
Table 1.1: Cytokine, chemokine, nitric oxide (NO) and immunoglobulin levels 
on admission to hospital in non-survivors and survivors of JE (45)
CSF
Mediator Non-survivor (n=8) Survivor (n=51) P-value
TNF-α 25.3 (11.6-43.7, 0-60) 0 (0-13.0, 0-116.45) 0.093
IL-4 36.5 (14.6-72.9, 0-175) 58.3 (0-87.5, 0-218.8) 0.535
IL-6 1377 (418-1648, 193-2190) 174.1 (38-849, 0-2821) 0.006
IL-8 1140 (420-1656, 190-3823) 286 (78-799, 0-4714) 0.04
IFN-α 4.4(0.4-13.9, 0-35.6) 0 (0-2.2, 0-53.3) 0.044
IFNγ 60 (0-240, 0-255) 13 ( 0-180, 0-320) 0.511
RANTES 32.2 (13-50.1, 3.1-95.4) 18.5 (6-47.6, 0-353.7) 0.486
NO mmol/l 97.6 (25.9-67.5, 18-503.5) 54.9 (30.7-69, 14.6-170) 0.875
IgM units 60.5 (33.5-60.5, 4-274) 162 ( 67-229.5, 0-412) 0.035
IgG units 5.5(1.5-13, 0-17) 23 (7.5-60, 0-273) 0.003
Plasma
Mediator Non-survivor (n=13) Survivor (n=105) P-value
TNF-α 0 (0-17.5, 0-180) 0 (0-32.5, 0-3970) 0.91
IL-4 23.9 (0.6-89.6, 0-478.4) 15.9 (0-90.9, 0-1530.4) 0.691
IL-6 1.5 (0-6.5, 0-997.7) 7.4 (0-26.4, 0-2466.2) 0.16
IL-8 29.2 (21.3-92.4, 8-182) 54.0 (16.4-252, 0-5632) 0.506
IFN-α 0 (0-0, 0-31.9) 0 (0-2.6, 0-31.7) 0.201
IFNγ 0 (0-5, 0-20.1) 0 (0-40, 0-2510) 0.306
RANTES 11312 (8823-15704, 357-17536) 8269 (6158-10113, 1-29224) 0.0314
NO mmol/l 79.4 (41-61.5, 3.3-436.5) 119.6 (42.8-93.1, 18.8-631.6) 0.121
IgM units 31.5 (12.5-41.5, 2-187) 90.5 (36-148.5, 1-145) 0.009
IgG units 10 (4-13, 0-40) 11 (4-28, 0-188) 0.463
Data are median and interquartile range (IQR) in picograms per millilitre, 
unless otherwise stated in the table. (Winter et al, 2004)
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1.16 Immunology of JE
Both humoral (against E and NS1 protein) and cellular (cytotoxic T 
lymphocytes) immunity play an important role in protection against JE (46). 
After primary infection (JEV as the fi rst flavivirus infection), a rapid and potent 
IgM response occurs in serum and CSF usually within 7 days of infection 
(47). This probably protects the host by arresting viral replication before 
it crosses the blood brain barrier. In established encephalitis, it may limit 
further damage by neutralising extracellular virus and lysing infected cells by 
antibody-dependent cellular cytotoxicity (ADCC). Attempts to isolate virus 
during such raised immune response is usually negative and is associated with 
good outcome. Within 30 days in surviving patients immunoglobulin class 
switch occurs and most have IgG in serum and CSF. Patients of asymptomatic 
infection with JEV have raised IgM in the serum, but not in CSF (47). An 
anamnestic antibody response with early rise in IgG and slow rise in IgM 
has been described in patients with secondary infection (previously infected 
with antigenically related flaviviruses). Animal models of JE have also 
shown cellular immune response to restrict viral replication in acute infection 
and prevent disease progression. Further, administration of inactivated JE 
vaccine has also shown to activate T-cell response (48). However, like other 
neurotropic flavivirus, for JEV, antibody-mediated protection is more effi cient 
than cytotoxic T cell responses for viral clearance (49-51). Hence, presence 
of antibodies in the serum and CSF is associated with survival and recovery 
(Table 1.1) 
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1.17 Clinical features of JE
In humans, most JEV infections are asymptomatic or cause a mild fl u-like 
illness. The symptomatic to asymptomatic ratio following JEV infection 
ranges between1/25 to 1/1000. The clinical features depend on the site of the 
lesion in the brain and stage of illness. First stage, called prodromal stage, 
lasts for 2-3 days and is characterized by non specifi c febrile illness such 
as fever with or without rigors, coryza, nausea and diarrhoea. The second 
stage, called encephalitic stage, lasts for 3-5 days and is characterised by 
headache, vomiting, reduced level of consciousness, seizures, abnormal mental 
status, change in speech, abnormal movements, motor defi cit and cranial 
nerve involvement. Signs of meningeal involvement such as neck stiffness, 
Brudzinski sign and Kernig’s sign may also be seen at this stage. The typical 
features of JE seen include; Parkinson syndrome features such as a dull mask 
like face, wide unblinking eyes, hypophonia, tremors and cogwheel rigidity. 
Other extrapyramidal signs include lip smacking, pill rolling movement 
of hands, dystonia, opsoclonus and myclonus. Opisthotonus posturing and 
generalized spasms on touch suggest severe illness. In fatal cases when the 
brainstem is involved, the patients develop change in respiratory pattern, 
change in oculocephalic and pupillary refl exes, decerebrate or decorticate 
posture and deep coma. 
The movement of an individual depends on the effective function of the upper 
motor neurons (UMN) originating from the motor cortex and descending on 
midbrain, pons, medulla oblongata to spinal cord. In the spinal cord the UMN 
synapses with the lower motor neurons (LMN) which innervate skeletal muscle 
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for contractions and movements. Basal ganglia and thalamus regulate control 
of motor and premotor area of cerebral cortex so that voluntary movement 
can occur smoothly. In JE, the involvement of cerebral cortex, midbrain, 
pons, medulla oblongata and cerebellum causes upper motor lesion type of 
signs. However, the virus has also been reported to affect the anterior horn of 
the spinal cord causing poliomyelitis like acute fl accid paralysis (11). Other 
movement abnormalities are predominantly because of involvement of basal 
ganglia and thalamus. Most of the deaths during the illness occur in this stage. 
All those who survive regain neurological function and progress to the third 
stage called recovery stage. In resource poor settings, where confi rmatory 
testing is not easily available, knowing typical clinical features could help in 
the diagnosis and early referral.
1.18 Diagnosis of JE
On investigation, peripheral leukocytosis and increased erythrocyte 
sedimentation rate are seen in most of the patients. Hyponatremia may occur 
because of syndrome of inappropriate antidiuretic hormone secretion (SIADH). 
Lumber puncture will show CSF pleocytosis of 10- 1000 cells/mm3 with 
lymphocyte predominance. The protein is slightly elevated of 50- 200 mg/
dl with normal sugar. Computer tomography (CT) scan of the brain shows 
bilateral non-enhancing hypodensity in the thalamus, basal ganglia, midbrain, 
pons and medulla oblongata. Magnetic resonance imaging (MRI) of the brain 
is more sensitive and shows high signal intensity on T2 weighted images of 
the thalamus, cerebrum and cerebellum. Mixed signal intensity in T1 and T2 
weighted scan in thalamus would suggest haemorrhage. Bilateral asymmetrical 
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haemorrhagic lesion in one or more area of thalamus in a patient living in an 
endemic area would suggest JE. Acute single photon emission tomography 
(SPECT) studies show hyperperfusion in the thalamus, frontal cortex and 
lentiform area. However, follow up studies have shown hypoperfusion in the 
same areas (52). Electroencephalogram (EEG) abnormalities reported are 
nonspecifi c slowing, burst suppression pattern, epileptiform discharges, theta, 
delta and occasional alpha coma (52,53). It is diffi cult to isolate the virus 
from blood because of low viral titres, rapid production of protective antibody 
and transient viraemia. Intracerebral inoculation in suckling mouse is the 
conventional method to isolate the virus. However, it has rarely been isolated 
from human CSF and brain tissue. 
Viruses cannot grow in non-living culture material. Their isolation thus 
requires inoculation into susceptible living cells, Different cell cultures, such 
as primary chick embryo cells and duck embryo cells can be used to culture 
the virus. Different cell lines such as Vero, LLCMK2, C6/36 and API cells 
are also often used to isolate the virus. Isolation of JEV is also possible by 
inoculation into mosquitoes (54). Isolation of virus directly from serum or CSF 
is rare. This is believed to be due to the low viral titres and rapid production of 
neutralising antibodies in the body. In resource poor settings, frequent freezing 
or thawing of clinical specimens, logistic diffi culty of timely transport, lack 
of skilled human resources and lack of laboratory facilities suitable for virus 
culture impairs successful virus isolation. Other methods of JE diagnosis, 
include demonstration of virus specifi c antigen or antibodies in the pateint's 
CSF and/or serum. Antibody based serological diagnostics are a key method 
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for JE diagnosis (55). Reverse haemagglutination, immunofl uorescence 
and staphylococcal co-agglutination tests using polyclonal and monoclonal 
antibodies are some of the serological approaches used to diagnose JE (56, 57). 
Serological diagnosis of JEV relies on the identifi cation of an anti-JEV 
antibody response. In the past, the following approaches have been used; 
haemagglutination inhibition (HI), complement fi xation (CF), plaque reduction 
neutralisation test (PRNT) and indirect fl uorescent antibody (IFA) detection. 
These approaches have now largely been replaced by antibody capture enzyme 
linked immunosorbent assays (ELISAs). ELISAs have become the accepted 
standard for the diagnosis of JE (58, 59). ELISAs typically recommend using 
paired sera, demonstrating a four-fold rise in antibody titres (between acute and 
convalescent samples), to confi rm the diagnosis.
IgM and IgG ELISAs have been used to detect JEV since the early 1980s. 
Anti-JEV IgM can be detected in almost all patients 7 days after acute onset of 
illness. IgM antibody capture ELISA (MAC-ELISA) is the method of choice 
to demonstrate JEV specifi c antibody in the serum or CSF. It is reported to 
be the most reliable indicator of JEV infection (60, 61). A single sample of 
serum or CSF is adequate to confi rm presence or absence of anti-JEV antibody 
if conducted after 7 days of illness. ELISA is a highly sensitive, relatively 
rapid and reproducible method for detection of JEV. The sensitivity and 
specifi city of ELISA for JEV has been reported as 89% and 91% respectively 
(62). Their use has increased since their development into commercial kits. 
However, they require a relatively sophisticated laboratory that includes an 
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ELISA reader. Avidin biotin system (ABC MAC-ELISA) (63), biotin labeled 
immunosorbent assay to sandwich ELISA (64), nitrocellulose membrane based 
IgM capture dot enzyme immunoassay (MAC DOT) (11), and antibody capture 
radioimmunoassay (ACRIA) (59) are some newer modifi cations of MAC-
ELISA. A commercially available, relatively new IgM/IgG antibody capture 
ELISA for JEV has shown sensitivity of 88% with serum, and 81% with CSF 
(65). 
Another simple and inexpensive method to detect anti-JEV antibody is 
by hydroxyapatite coated nylon beads (Ha-Ny beads) (66). The molecular 
mapping of JEV has paved the way for newer diagnostic techniques (67). The 
reverse transcriptase polymerase chain reaction (RT PCR) amplifi cation of viral 
RNA is an useful test to not only detect but also quantify JEV load in the CSF 
(68). MassTag PCR is a form of multiplex PCR that uses primers with tags of 
different molecular weights to identify the product. The MassTag PCR allows 
a rapid and sensitive diagnostic platform that can screen up to 35 bacterial, 
viral and fungal agents including JEV, using a combination of PCR and mass 
spectrometry (69). 
Whole-genome sequencing is another method of identifying pathogens not 
identifi ed from PCR (70). Enterovirus 75 has recently been detected using 
this technique in cases of aseptic meningitis in Europe (71). Where direct 
pathogen detection is not possible, host- response gene expression patterns can 
be used to asses body’s response to discern whether it has been infected by 
bacterial or viral pathogens (including JEV).The immune cells, circulating in 
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the blood stream, detect and respond to bacterial and viral infection in distinct 
and specifi c manner. These responses can be observed by the activation of 
host genes (expression patterns). This approach has been used to distinguish 
different types of infective pathogens among acutely unwell children in Kenya 
(72). 
1.19 Principle of MAC-ELISA developed by AFRIMS
This ELISA has been designed to detect anti-JEV IgM antibody in serum or 
CSF. IgM antibodies are captured by goat anti-human IgM previously coated 
on the solid phase (wells of ELISA plate). Then the JEV antigen, which only 
binds to anti-JEV IgM, is applied over the captured IgM. The non specifi c 
antibodies are then removed by washing. The presence of JEV antigen bound to 
anti-JEV specifi c antibody is detected by addition of enzyme linked conjugate 
(horse redox peroxidase enzyme and human anti-fl avivirus IgG). This enzyme 
changes the substrate into coloured compound. The intensity of the colour is 
then detected with the help of ELISA reader. 
1.20 Outcome of JE
Around 4- 25% of patients of JE die acutely and 30- 69% have sequelae at 
discharge (10, 20-25). Around half of the children with JE recover completely. 
It may take up to 3 months before the stable outcome following acute 
encephalitis emerges. 
There is paucity of data on the long term outcome of JE. Some studies have 
reported neurological sequelae and death to be more common in JE compared 
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with other viral encephalitis at the time of discharge (6,10). Even after 27 
years, JE patients have been reported to have signifi cantly more neurological 
sequelae, less independent life style and lower IQ than patients affected by 
other forms of encephalitis (73). 
1.21 Sequelae of JE
Patients with neuro-psychiatric sequelae exhibit cognitive, language and 
motor impairments. These impairments can lead to a signifi cant social and 
fi nancial burden (28). Cognitive defects include impaired consciousness, 
altered behaviour, inability to recognize family members, amnesia, altered 
personality, reduced concentration span, depression, impairment in IQ. Motor 
sequelae include fl accid or spastic weaknesses (monoparesis, hemiparesis, 
quadriparesis,), focal or generalized abnormal limb tone (hypertonia, 
hypotonia), focal or generalized abnormal limb refl exes (hyperrefl exia, 
hyporefl exia), cranial nerve palsies or movement disorders. Other problems 
include seizures, movement disorders, bowel or urinary incontinence, diffi culty 
in feeding, poor school performance, diffi culty in speaking, visual or hearing 
impairment or autonomic disturbance (21, 73-76).
1.22 Recovery profi le of patients of JE
Knowing a JE patient’s likely recovery profi le helps clinicians prioritise 
treatment, helps them build a team of specialists, plan rehabilitation strategies 
and explain to the parents or patients the sequence of estimated recovery to 
better prepare them for the patient journey and eventual outcome. 
The recovery profi le of JE has not been well studied. The few studies which 
have followed up JE patients in the community have shown that outcome often 
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changes between hospital discharge and community follow-up, with many 
patients improving and some worsening after discharge (21,74). Complete 
recovery has been observed in patients initially exhibiting severe motor 
sequelae at discharge (10, 21, 74). Occurrence of sequelae at hospital discharge 
does not appear to accurately predict long term outcome. In one study, one in 
every fi ve patients had deteriorated post discharge. Presence of neurological 
sequelae at later community assessment (6 months post-hospital discharge) has 
been reported to better predict long term outcome in JE patients (21). 
1.23 Prognostic indicators of JE
Previous studies have identifi ed prolonged illness, prolonged fever, prolonged 
duration of altered sensorium, poor Glasgow coma score (GCS) below 8, 
multiple convulsions, presence of focal neurological defi cits, abnormal 
breathing, decerebrate posturing and hyponatremia at the time of admission as 
predictors of bad outcome in JE. Often patients present with more than single 
high risk clinical features. A combination of poor perfusion, GCS ≤ 8 and ≥ 
2 witnessed seizures has previously been reported to predict bad long term 
outcome (21). However, these predictors were identifi ed in studies recruiting 
patients from distinct geographic locations. The authors were uncertain whether 
their fi ndings could also represent other locations or countries (10, 21, 37, 77, 
78). 
1.24 Immunization against JE
Vaccination of high risk population is the key strategy for JE prevention. 
There are currently 15 vaccines in use. All the vaccines are based on genotype 
3 strains of JEV. There are fi ve main classes of JEV vaccine. First is a live 
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attenuated vaccine clone, SA-14-14-2. It was generated by serial passage of the 
SA 14 strain in primary hamster kidney cell cultures. Attenuated vaccines are 
generated by passing a virus repeatedly through various cell culture systems 
until the virus becomes non-pathogenic. This live attenuated SA-14-14-2 
vaccine has been licensed for use in China since 1988. It is administered to 
over 20 million children each year. It is commercially manufactured in Korea 
and used in Nepal, Sri Lanka and India. It currently accounts for over 50% 
of the global production of all JE vaccines (79). Second is a live attenuated 
recombinant chimeric vaccine, based on the genes of yellow fever 17D 
backbone spliced with Vero cell propagated SA 14-14-2 strain. Recombinant 
vaccines are based on splicing viruses with other virus protein or nucleic 
acid sequences (80). It has recently been licensed for routine use in Europe, 
America, and Asia (81). Third is an inactivated mouse brain derived JE 
vaccine. It is derived from mouse brain infected by the Nakayama or Beijing-
1 JEV strain. It was initially licensed for use in Japan in 1954 and now being 
produced in Taiwan, India, Russia, Korea, Thailand, China, and Vietnam (79). 
Fourth is an inactivated primary hamster kidney cell derived vaccine based 
on the Beijing-3 strain. It was developed and widely used in China since 1968 
(82). Fifth is an inactivated Vero cell culture vaccine based on the Beijing-
1 JEV strain. It was initially manufactured for local use in Japan and now 
routinely used in Europe, America, and Asia (79, 81).
1.25 JE as a cause of AES in Nepal
JE is an important cause of AES in Nepal. It is associated with considerable 
morbidity and mortality (10). Syndromic surveillance, conducted between 
1978 and 2003, reported 26046 suspected JE cases in Nepal. More recently, 
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laboratory surveillance based on anti-JEV IgM ELISA testing of serum or 
cerebrospinal fl uid (CSF) from suspected AES cases, collected between 2004 
and 2015, has identifi ed a total of 17,875 AES cases and 3067 JE cases (Table 
1.2). The actual numbers of JE cases may still have been under represented 
in the latter study due to logistical issues, deaths before hospital admission, 
and diffi culties in confi rming the diagnosis of JE without paired sera or CSF 
samples.
Table 1.2: Table showing total AES and JE patents after starting laboratory 
based surveillance in Nepal
YEAR AES JE
2004 1533 368
2005 2290 584
2006 1471 293
2007 1650 442
2008 1988 339
2009 1515 146
2010 1572 197
2011 1337 128
2012 952 79
2013 1228 127
2014 1402 226
2015 937 138
Total 17875 3067
(WHO-IPD, Nepal)
A Nepalese hospital based study conducted in a JE endemic region in 2006 
reported JEV accounted for 50% of AES patients and 62% of patients with 
probable viral encephalitis (37). The mortality from JE is reported at 20-60% 
in Nepal (42). Immunisation programmes against JEV began in humans in 
1999 (83,84) and in pigs in 2001. Both programmes began in high risk districts 
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(42). Since introduction of the JEV immunisation in Nepal, numbers of JE and 
AES patients have steadily fallen. These fi ndings suggest that the majority of 
AES cases are due to JEV (Figure 1.3). Nevertheless, cases of JE continue to 
be reported. Recent sero-surveillance studies in Nepal among animal hosts 
for JEV reported high prevalence of JEV. Anti-JEV antibody responses were 
detected in almost half of the pigs and horses and a quarter of ducks tested 
(85). JEV remains a major public health problem in Nepal. There is a pressing 
need to develop better treatment. 
Figure 1.3: Distribution of AES and JE cases on laboratory based surveillance 
(Child Health Division, Ministry of Health, 2014 )
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Figure 1.4: Geographical distribution of JE patients in Nepal. (Child Health 
Division, Ministry of Health, 2014 )
Out of a total of 75 districts in Nepal, JE exhibits a high prevalence in 24 
low lying Southern districts. Sporadic cases have been reported from an 
additional 41 districts located in the mountainous districts (Appendices A & 
B). Between 2004-and 2012, JE cases were detected in 62 districts (Figure 
1.4). Most JE patients (60%) are children (Figure 1.5). Sporadic cases occur 
throughout the year in endemic areas. Every year epidemics occur during 
the monsoon season. An increase in JE cases starts in April, peaks in August, 
and declines in October (Figure 1.6). The tropical climate, paddy ecosystem, 
abundance of Culex mosquitoes, pigs near human dwellings in Southern Nepal 
provides suitable setting for JEV. Although Culex gelidus, Culex vishnui, 
Culex pseudovishnui and Culex fuscocephala have been suspected, JEV has 
been isolated from female Culex tritaeniorhynchus which is the considered the 
principle vector for JEV in Nepal (42). Three strains of JEV namely Nep- 1/90, 
B- 2524 and B- 9548 are found in Nepal. Pigs, ducks and horses are natural 
reservoirs of JEV in Nepal (85). 
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Figure 1.5: Age distribution of JE cases in Nepal. (Child Health Division, 
2014)
Figure 1.6: Distribution of JE cases by months in Nepal. (Child Health 
Division, 2014)
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1.26 JE control strategies
Through extensive knowledge on the epidemiology of JE it is clear that 
rice cultivation, vector densities, and pig rearing close to human habitation 
is important for disease control (36). Human vaccination, pig and horse 
vaccination, use of pesticides in rice fi elds, effective management of pig 
breeding locations relative to human habitation have all contributed to a 
marked reduction of JE cases (36). 
JE is predominantly reported in Asia. According to recent JE epidemiological 
studies and disease surveillance and vaccination strategies, affected countries 
have been divided into 4 groups. First group is represented by Japan, Korea 
and Taiwan, which report less than 30 cases annually and have effective JE 
control measures in place. Second group contitutes of China, India, Nepal, 
Malaysia, Cambodia, Vietnam, Thailand and Srilanka, which have high disease 
burden, effective sentinel surveillance programmes, national and high risk JE 
vaccination programmes and report on disease burden and outbreaks. However, 
these countries still need to improve their JE control strategies. Third group 
constitutes of Indonesia, Burma, Bhutan, Myanmar, Bangladesh, North Korea, 
Pakistan, Papua New Guinea, Philippines and Timor-Leste, which report 
fewer than 100 JE cases annually. They do not have JE sentinel surveillance or 
immunization programmes. There are plans to conduct JE surveillance through 
their national surveillance programmes in the future. Fourth group constitutes 
of Australia, Guam, Russia (Siberia), Singapore and Saipan, which report less 
than 3 cases annually. Maintaining effective surveillance and immunisation 
strategy designed for one-time campaign in target populations are the base of 
JE control strategies in these countries (86). 
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Nepal's JE control strategy is based on effective surveillance, improved case 
management, improved vector management and immunisation of at-risk 
population. Although syndromic surveillance based on signs and symptoms of 
JE began from 1978 (Appendix C), laboratory based surveillance was initiated 
by the Government with support of World Health Organisation-Programme 
for Immunisation Preventable Diseases (WHO-IPD) from 2004 (Table 1). The 
objective of the surveillance is to monitor morbidity and mortality, characterise 
epidemiology, identify high risk geographical area and population, guide 
intervention programme and fi nd out the impact of control measure. Currently 
two epidemiological surveillance and reporting systems exists. Health 
Management Information system (HMIS) is used for routine monthly reporting 
of clinical cases of JE from peripheral health facilities to District Health Offi ce 
and HMIS division of Department of Health Services (DOHS). There is also 
a laboratory based surveillance of JE integrated with acute fl accid paralysis, 
measles and neonatal tetanus surveillance. Technical assistance and quality 
control of this surveillance is being provided by WHO-IPD. 
As an effort to control JE, for JE surveillance, the WHO has developed a 
set of clinical symptoms and signs to capture patients of AES, who are later 
confi rmed and classifi ed, on the basis of laboratory reports, to have JE or 
other causes of AES (Appendix D). The Ministry of Health and Population 
of Nepal, supported by WHO-IPD, has integrated JE surveillance with Acute 
Flaccid Paralysis, Neonatal Tetanus and Measles surveillance, in its National 
surveillance network since 2004. 
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Figure 1.7: AES reporting sites in Nepal (Child Health Division, 2014)
Through a national network of 127 sentinel sites under the surveillance (Figure 
1.7), reports on demography, clinical features and outcome of AES (suspected 
JE) patients and collected CSF and/or serum samples, are delivered to the 
surveillance medical offi cer (SMO) of WHO-IPD, who then transfer them 
to Child Health Division of the Department of Health Services (DOHS) on 
weekly or monthly basis (Figure 1.8). The samples are transferred and tested 
for the presence of anti-JEV IgM antibodies by ELISA in this programme in 
two referral laboratories namely National Public Health Laboratory (NPHL), 
Kathmandu and BP Koirala Institute of Health Sciences (BPKIHS), Dharan, 
using Armed Forces Research Institute of Medical Sciences (AFRIMS), 
Bangkok, Thailand, kit or National Institute of Virology (NIV), Pune, India, kit, 
with external quality assurance performed by The National Institute of Mental 
Health and Neuroscience, Bengaluru, India. Cases are classifi ed as confi rmed 
JE, proven non-JE and JE-status unknown if they are ELISA positive, ELISA 
negative and ELISA negative when tested within the fi rst 7 days of illness or 
never tested for anti-JEV IgM levels by ELISA, respectively. 
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(WHO-IPD, World Health Organisation-Programme for Immunisation 
Preventable Diseases; DHO, District Health Offi ce; DPHO, District Public 
Health Offi ce; BPKIHS, BP Koirala Institute of Health Sciences; RHD, 
Regional Health Directorate, NPHL, National Public Health Laboratory, NIH, 
National Institute of Health of Thailand; CHD, Child Health Division; EDCD, 
Epidemiology and Disease Control Division; HMIS, Health Management 
Information System; WHO SEARO, World Health Organisation South-East 
Asia Regional Offi ce)
Figure 1.8: AES and JE surveillance system in Nepal (Child Health Division, 
2014)
Clinical and laboratory features that distinguish confi rmed JE from other AES 
cases would be highly useful to allied health professionals, who otherwise may 
have to wait for weeks for an ELISA result (samples are batch tested to reduce 
cost causing delay in reporting). The ongoing Nepali National Immunisation 
Schedule has recently included JE vaccination for children of one year of age. 
Improved clinical and laboratory diagnosis of JE would also complement local 
53
monitoring of effectiveness of this schedule. Improved clinical and laboratory 
diagnosis could also be useful to help rationalise antibiotic treatment of AES 
cases. 
Vaccination against for JEV in Nepal has occurred in multiple phases. Sporadic 
vaccination campaigns were conducted between 1999 and 2000 in districts 
highly endemic for JE. In 2006, Nepal initiated it's JE control programme. This 
involved a phased JE vaccination campaign with live attenuated SA-14-14-2 
vaccine. People living in districts with high rates of confi rmed JE transmission 
(≈16.0/ 100,000 population) received vaccine fi rst. Vaccine was administered 
to everyone above 12 months of age. Districts with intermediate rates of 
JE transmission (≈1.6/ 100,000 population) were vaccinated next. Children 
between 12 months and 15 years of age were vaccinated then. JE vaccine 
was introduced in the routine immunisation programme in the post campaign 
districts from 2009. In 2010, an independent evaluation of vaccine impact 
found JE incidence had signifi cantly decreased to 72% in post campaign 
districts (87). The effi cacy of a single dose of this vaccine in preventing JE, 
when administered only days or weeks before exposure to infection, has been 
reported as 99.3% (83). By 2014, the JE immunisation campaign had been 
completed in all 31 high and intermediate risk districts and the vaccine had 
been introduced into the national routine immunisation programme in these 
regions. In May 2015, JE vaccine campaign was conducted in the remaining 
44 low risk hill and mountain districts. Following this, all 75 districts in Nepal 
had JEV vaccine introduced into the routine immunisation schedule. Mass 
vaccination campaign is planned in response to an increase in the incidence 
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of JE. Public private partnership is also being sought to cover cost of JEV 
vaccine for people of all ages at risk of JE. All adverse effects following JE 
immunisation are being investigated in a comprehensive manner (including 
casualty assessment). Research on effi cacy of JE vaccine in post campaign 
districts has been prioritized. In 2001, 200,000 pigs were also vaccinated 
by live attenuated JE vaccine by Department of Livestock, Ministry of 
Agriculture.
There is no insecticide spraying programme for JE in Nepal. An ongoing 
awareness programme conducted in high risk districts aims to improve 
hygiene and encourage personnel application of mosquito repellents. Mosquito 
breeding around residential areas is prevented by cleaning around homes, 
draining stagnant water and fi lling in ditches. The National Health Education, 
Information and Communication Centre of the DOHS prepare and distribute 
materials regarding JE awareness. 
1.27 National Guideline for the diagnosis of JE in Nepal
The defi nition of a case of JE, in the National surveillance program, was 
provided on the basis of a guideline developed by a team of experts attending 
the National workshop on Vector-Borne Diseases at the Ministry of Health 
of Nepal in 1997. According to this guideline, a patient having an elevated 
temperature (> 38°C) and altered consciousness is considered to be "possible 
case of meningitis/encephalitis" or AES case. He or she is then advised a 
lumber puncture (LP). Hence, diagnosis of AES does not require LP but 
confi rmation of CNS infection does require a LP and CSF analysis. If the 
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suspected case has CSF cells < 1000 cells/mm3, he or she is defi ned as 
"probable viral encephalitis". If a case of probable viral encephalitis tests 
positive for anti-JEV IgM in CSF and/or serum, he or she is diagnosed as a 
"confi rmed case of JE". 
1.28 Clinical and laboratory features as a predictor of 
JE from other AES
There is a tendency to treat all patients with fever and seizure as bacterial 
meningitis. This results in excessive misuse of antibiotics. This in turn leads to 
rapid development of bacterial resistance against those antibiotics. Ultimately, 
this presents a grave threat to safe, affordable and effective treatment options. 
Use of a simple clinical and laboratory based predictor score (or clinical 
decision tool), such as the Bacterial Meningitis Score, during initial patient 
evaluation, has been reported to differentiate aseptic meningitis from bacterial 
meningitis with approximately 100% accuracy in children (88). Diagnostic 
tests for JE are not routinely available or affordable in developing countries. 
Hence, a similar tool that accurately differentiates JE from other cause of AES 
could help rationalise antibiotic use in Nepal. 
Prognostic indicators can also be developed by relating clinical information 
available at the time of initial patient evaluation to outcome at discharge. 
Identifying prognostic indicators for residual neuropsychiatric sequelae 
or death at the time of admission among AES cases would help guide 
management and be useful for counselling patients and parents on likely 
outcomes. 
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Prognostic indicators could help encourage early referral to tertiary care 
centres, which in turn may improve outcome. Such indicators would also help 
prevent referral delays, unnecessary wastage of fi nancial resources and support 
clinical management. The use of predictors could have vital implications to 
clinicians treating children with AES and JE. However, there is a need identify 
and test the validity of different clinical predictors in different settings to assess 
their robustness and effectiveness.
1.29 Hydration and nutrition status in AES
Poor hydration status may be associated with morbidity among children 
with AES. Since AES can be associated with brain swelling, clinicians have 
recommended fl uid restriction so that brain swelling is not exacerbated by 
cerebral oedema secondary to fl uid overload or associated shifts in electrolytes 
(89, 90). However, AES patients may be unwell and vomiting for many days. 
They may be unable to eat or drink fl uids on their own which could cause 
dehydration. Restricting fl uid in such cases may be detrimental. Assessing 
hydration status is therefore essential in patients with AES. Hydration status 
can be assessed indirectly by daily measurement of weight. However, the total 
weight of a person is contributed by muscle, fat, water and bone. Consequently, 
weight is also an indicator of nutritional status. In children, weight corresponds 
to age and gender. It increases with increase in age. Weight-for-age (WFA) 
metrics refl ect body weight relative to the child’s age and gender. Weight 
loss or retardation in a children can be assessed by comparing how a child’s 
individual WFA relates to a relevant reference population. Z scores equate to 
standard deviations (SD) around the reference median. In a population with 
a normal WFA distribution, you would expect 15.9%, 2.3%, or 0.13% of 
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children to have a weight for age Z score of -1, -2 or-3 respectively. No single 
baseline WFA distribution chart is available for all age groups for the Nepali 
population. To assess whether weight is lower than expected in children below 
5 years, the WHO child growth standards, can be used to estimate expected 
WFA [http://www.who.int/nutgrowthdb/about/introduction/en/index5.html 
(accessed on 20 February, 2016)]. For older children, aged between 5and 14 
years, the ‘Nepalese Growth Standard for the School-aged Children’ developed 
by the Public Health and Infectious Disease Research Centre, Kathmandu, 
Nepal can be used. Children are categorised with a a standard deviation score 
or Z score (-3, -2, -1, 0, +1, +2, +3 ) based on their actual weight compared to 
their expected weight based on the WFA distribution among males or females. 
Z scores of -1, -2 and -3 are considered low WFA (91). Low WFA can indicate 
malnutrition and/or dehydration. Other clinical and laboratory features, such 
as capillary refi ll, acute changes in serum urea and electrolyte levels can be 
used to help distinguish acute dehydration from malnutrition. Similarly, other 
clinical measures, such as body mass index, mid upper arm circumference 
(MUAC) and skin fold thickness can be used to help identify malnutrition. 
MUAC is a very simple measure that can be used to assess nutritional status 
in children (http://motherchildnutrition.org/early-malnutrition-detection/
detection-referral-children-with-acute-malnutrition/muac.htm). Other indices 
such as Dugdale’s index, Rao’s index and Kanawati index require multiple 
measurements of different body parts. In a low WFA patient with AES or 
JE, MUAC and other supportive laboratory fi ndings may help differentiate 
dehydration from malnutrition. Additional clinical and laboratory features of 
dehydration are presented in Appendix E.
58
My previous work has shown that JE patients who die or have severe 
neurological sequelae have signifi cantly prolonged illness, prolonged altered 
sensorium and presence of focal neurological defi cit including hemiparesis at 
admission than those who recover completely (10). Such patients would not 
be able to feed or drink on their own, making them dependent on others and 
vulnerable to dehydration. Many AES patients, including those with JE, do 
not have defi nite treatments. Appropriate fl uid therapy to adequately hydrate 
patients is an important part of supportive therapy. Appropriate fl uid therapy 
may limit death or development of neurological sequelae. 
Children admitted with an altered sensorium generally receive intravenous 
fl uids in Nepal. The most common type of fl uid used is 0·18% saline with 5% 
dextrose. It is typically administered at a maintenance rate of 100 ml/kg for 
the fi rst 10 kg of bodyweight, 50 ml/kg for the next 10 kg, and 20 ml/kg of 
bodyweight exceeding 20 kg (92). There is a practice, in developing countries, 
to modify and restrict fl uids to two-thirds of maintenance requirements in 
AES and JE patients (93, 94). There is a general fear that intravenous fl uids 
given at maintenance rates may be unsafe, particularly where serum sodium 
concentrations cannot be closely monitored, putting the child at risk for 
developing cerebral oedema. As a consequence, AES and JE patients may 
suffer dehydration, which in-turn may aggravate metabolic acidosis. Excessive 
fl uid restriction is independently associated with a poor outcome among 
traumatic brain injury patients (89). Fluid and sodium restriction has also been 
associated with a poor outcome in JE patients (93). Administration of adequate 
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fl uid to maintain cerebral perfusion pressure without worsening cerebral 
oedema is important when managing brain injury.
Serum lactate level is raised in patients with both brain injury (95) and seizures 
(96, 97). CSF lactate level is also elevated in patients of JE with seizures (20). 
However, currently with no defi nite anti-viral or immunomodulatory treatment, 
there is a need to increase knowledge of fl uid balance, change in weight and 
acidosis status which may be contributing to elevation of intracranial pressure 
and convulsions, causing secondary deterioration of patient’s health after the 
primary insult from viral brain infection. 
1.30 Treatment trials for JE
Since JE is the most common cause of AES, the treatment of JE would help 
improve outcome of AES. However, there is no defi nite treatment of JE at 
the moment. The management is largely supportive. The pathogenesis of 
JE involves combination of viral cytopathology and immunopathology (98- 
101). Both have been explored while seeking defi nite treatment in humans. 
As an adjunctive treatment of JE, a randomised-placebo controlled trial of 
dexamethasone (initially 0.6 mg/kg followed by 0.2 mg/kg intravenously 
every 6 hours for 5 days) was conducted in Thailand. The trial showed a 
reduction in CSF opening pressures and white cell counts but no overall 
benefi t in terms of outcome (102). Similarly, a placebo controlled trial of 
Interferon α-2a, produced as part of the innate response to JEV infection and 
had antiviral activity against the virus in vitro (103), administered at 10 million 
unit/m2 daily for 7 days, also proved to be unhelpful to improve outcome in 
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Vietnam (38). A controlled trial of oral ribavirin (1-β-D-ribofuranosyl-1, 2, 
4-triazole-3-carboxamide), proven effective against JEV in vitro (104, 105), 
at 10 mg/kg/day in four divided doses for 7 days in India, was also not seen 
to affect outcome in children with JE (106). Intravenous immunoglobulin 
(IVIG) has been postulated as a potential treatment of JE because of its anti 
viral and anti infl ammatory properties. Currently IVIG is used as standard 
treatment for a number of childhood immune mediated diseases including 
Guillain-Barré syndrome, Kawasaki’s disease, immune thrombocytopenia and 
dermatomyositis in Nepal. 
IVIG works by its anti-infl ammatory properties, such as down regulation of 
T cell and B cell activation in Kawasaki disease, blockade of FCγ receptors 
causing down regulation of secretory cytokines in thrombocytopenic purpura 
and inhibition of complement binding and prevention of membranolytic 
attack complex formation in Guillain-Barré syndrome and dermatomyositis. 
In addition, IVIG has been used to treat, and later to provide prophylaxis, 
for children with hypo- or agammaglobulinamia with chronic enteroviral 
meningoencephalitis (107). Children with X-linked agammaglobulinaemia and 
enteroviral meningoencephalitis treated with intensive and prolonged IVIG 
therapy have achieved long-lasting clinical and viral remission. However, the 
role of neutralizing antibodies in IVIG has always been speculative. It would 
be interesting to fi nd out if locally manufactured IVIG, could have antibodies 
against this neurotropic virus, which together with its anti-infl ammatory 
properties, may be a useful adjunctive treatment option. 
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1.31 Scope of this thesis
AES is a considerable cause of morbidity, mortality, and a disease of public 
health priority in many countries, including Nepal. In the majority of AES 
cases a specifi c infectious aetiology is not found. Even for known aetiologies, 
there is considerable geographical and age specifi c variation. JEV is the most 
common cause of AES in children in Nepal. Currently, active AES and JE case 
surveillance, case management and immunisation with SA-14-14-2 vaccine 
of at risk population are the key strategies for AES and JE control in Nepal. 
However, we are likely to continue to see cases because, unlike poliovirus, 
there are animal hosts for JEV, which means the virus will never be eradicated. 
In addition, we will continue to see the many cases of JE negative AES. 
Improved insight into clinical features specifi c for JE, or that predict poor 
outcome, would not only help in identify and explain the prognosis for children 
at risk of severe disease, death or sequelae but also help guide management. 
Although some clinical features have been reported as proxy markers for JE or 
poor outcome in the past, the robustness and generalisability of these fi ndings 
are uncertain and needs validation. When there is no defi nite treatment, 
identifying inadequate supportive management in AES and JE patients could be 
an important strategy to reduce morbidity and mortality. Since JEV is the most 
common known pathogen of AES, also exploring adjunctive treatment options 
could behelp reduce death or neurological sequelae. This thesis is therefore 
directed at improvement of the management and outcome of AES, especially 
JE, in Nepal. 
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My thesis has the following objectives: 
1.  Describe the clinical features, laboratory parameters of AES and JE 
in Nepali children, and investigate how these features relate to patient 
outcome. 
2.  Assess the clinical features, laboratory parameters and outcome of AES in 
Nepali children of different weight-for-age categories.
3.  Describe the relationship between fl uid balance, change in weight, blood 
lactate level and outcome of AES and JE patients.
4.  Conduct a pilot randomised double blind placebo controlled trial of 
intravenous immunoglobulin in Japanese encephalitis.
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Chapter 2: General Methods 
2.1 Study Location
Nepal is a landlocked country in Asia which lies between China and India. It 
is located at latitudes 26o22' and 30o27' North and longitudes 80o4' and 88o12' 
East in the globe. Topographically, the 147,181Km2 area is divided into three 
ecological regions, namely northern mountain region which is 4877-8848 
metres above sea level and stretched over 51,817 Km2 area, middle hill region, 
which is 610- 4877 metres above sea level and stretched over 61,345 Km2 area 
and southern plane lowlands called “Terai” region, which is lower than 610 
metres above sea level and stretched over 34,019 Km2 area (Figure 2.1). In the 
mountains, temperature ranges from [(-10C)- 120C] in summer and between 
00C - (-130C ) in winter, in the hills temperature ranges from 19.50C - 28.110C 
in summer and 30C - 19.30C in winter and in Terai, temperature ranges between 
240C - 440C in summer and 100C - 270C in winter. The country has hugely 
diverse nature and climate. The monsoon occurs between June and September 
with precipitation between 180- 225 cm. Water logging is commonly practiced 
for effective use of rain or irrigated water to grow crops. Therefore, these 
climatic conditions are most suitable for the breeding and high density of 
mosquitoes and sand fl ies which are transporters of various vector borne 
diseases such as JE, dengue, malaria and kala-azar. 
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Figure 2.1: Geographical map of Nepal showing mountainous region in the 
north, hilly region in the middle and plains of Terai in the south. 
The fi gure shows spatiotemporal relationship of JE cases in Nepal from 1978- 
2014. It also shows climatic conditions conducive of transmission of JE to 
mountain region of Nepal. Additional JE reporting districts represents those 
districts where JE is not endemic. (Dhimal M et al, 2015)
 
Nepal has a population of around 26.5 million, including 34.9% children below 
14 years of age. The population growth rate is 1.35%. With callous terrain 
and limited access to roads and effective communication, the mountain region 
is inhabited by only 6.7% of the total population. The hill region, including 
valleys such as Kathmandu and Pokhara, centres of national resource, is 
inhabited by 43% of the population. The warm, humid, fertile and more 
industrialized Terai region, although only 23% of the total land, is inhabited 
by 50.3% of the population. About 80% of the population continues to rely 
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on agriculture for their livelihood. The major crops are rice, maize, wheat and 
millet. Paddy ecosystem, predominantly agriculture base for livelihood and 
large population density make Terai region most suitable setting for vector 
borne diseases. 
There are 125 ethnic groups, who speak 123 languages making it a multi-
ethnic and multi-lingual country. Chhetri (16.6%) form the largest ethnic 
group. Nepali is the most commonly (44.6%) spoken language as the mother 
tongue followed by Maithili (11.7%). Hinduism (81.3%) is the most commonly 
practiced religion followed by Buddhism (9.0%). 
 
It is a low income country with gross domestic product per capita at $ 694.10 
in 2013 which is 15 times lower than the global average. The country’s 
political instability is being refl ected in its economy. The majority (80.7%) 
of the households are rural based with signifi cant health inequalities between 
rich urban and poor rural communities. The Gini-Coeffi cient, which purports 
inequality in income distribution, is 0.328, where 0 would be perfect equality 
and 1 as maximal inequality (Child Health Profi le, Child Health Division, 
Ministry of Health, Nepal). 
Administratively, Nepal is divided into 5 regions, 14 zones and 75 districts. 
Districts are further divided into smaller Village Development Committees 
(VDCs, 30- 100 in a district) and urban municipalities. A VDC is the lowest 
political unit and consists of nine wards, while the number of wards in an 
urban municipality depends on the size of the population. At present, there are 
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3,915 VDCs and 58 municipalities. Government facilities are organised in a 
hierarchical structure. A community and village health worker in each ward is 
the frontline health workers for the government. Each VDC has one Sub-health 
Post (manned by Auxillary Health Worker), the lowest Government health 
service unit, which refers patients to Health Post (manned by a Health Assistant 
and 1 in every 8-10 VDC) in turn refers patients to Primary Health Centre 
(manned by clinician and 3- 5 in each district) which reports to the District 
Hospital and Public Health Offi ce. The referral ladder then is zonal hospital, 
regional hospital and central hospital (Figure 2.2).
Figure 2.2: Organisation structure of the health system of Nepal
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Health care is provided by the Government and private sector. Most of the 
cities in Nepal have both private and public hospitals. The private hospitals 
cater primarily to the socio-economically affl uent population and the public 
hospitals to the marginalised. There are no health insurance schemes, so the 
cost for any expenditure on health is out of pocket for the entire public. The 
government provides most of the preventive, promotive and curative health 
services for rural population free of cost. 
The country’s child health policy is guided by WHO’s millennium 
Development Goal (MDG) 4 which is to reduce child mortality. Although 
in the past 16 years, the infant mortality rate has reduced signifi cantly from 
78.5 to 46/1000 live births and the under 5 mortality reduced from 118 to 
54/ 1000 live births, it is still very high. Disability is prevalent in 2% of the 
population, of which physical disability constitutes 36.3%, blindness or low 
vision (18.5%), deaf or hard of hearing (15.4%), speech abnormality (11.5%), 
intellectual disability (2.9%) and others 15.4%. AES is a preventable cause of 
under-fi ve mortality and disability in Asia including Nepal.
2.2 Study Sites
The study was based at three hospitals in Nepal:
1. Kanti Children’s Hospital (KCH), Kathmandu
2. Patan Hospital (PH), Patan
3. BP Koirala Institute of Health Sciences (BPKIHS), Dharan
Kanti children’s Hospital is a 300 bed tertiary care referral centre and the only 
children’s hospital with super-specialties in Nepal. It is a busy hospital located 
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in Kathmandu valley and sees 1000- 1500 patients per day in the Emergency 
Department, and another 300 patients per day through outpatient services. 
It is funded by the government. The hospital fees are minimal, although 
families are made to pay from their pocket. Those who cannot afford receive 
free treatment as judged by the director. Amongst others KCH has a related 
neurology specialty clinical service, pediatric intensive care facilities and 
electroencephalogram (EEG) and Computer Tomography (CT) Scan facilities. 
It receives referral of paediatric patients from all over Nepal.
Patan Hospital is a large multidisciplinary not- for- profi t general hospital 
situated in Patan which is a neighbouring city to Kathmandu, the national 
capital. It is located at the southern end of Kathmandu valley. It serves as a 
major teaching hospital for Patan Academy of Health Sciences. There are 450 
beds (including 60 paediatric beds) and the hospital sees around 1000 patients 
every day. It predominantly caters to population of Lalitpur districts and also 
accepts referrals. 
BP Koirala Institute of Health Sciences is a public University, with four 
colleges namely medical, dental, nursing and public health and a central 700 
bed teaching hospital. It is renowned for its constantly innovative educational 
programme. It is located in a city called Dharan which is at the Southeastern 
end of Nepal, in the Terai region, around 300 Km from Kathmandu. The 
paediatric ward has 60 beds. It also has pediatric intensive care facilities and 
neurology specialty clinic. 
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2.3 Study design
This research was conducted in four parts from 2009- 2016. 
i. The fi rst part of the research was a retrospective study aimed at looking at 
the clinical features, laboratory parameters and outcome of AES and JE. 
ii. The second was a prospective cross-sectional study to validate 
prospectively clinical features which predicted bad outcome in AES and JE 
identifi ed by the fi rst study and also fi nd out the outcome of children with 
AES and JE in relation to low weight for age at the time of admission. 
iii. The third part was a prospective cross-sectional study to identify the role 
of fl uid management in outcome of AES. 
iv. The fourth part was a pilot interventional study (treatment trial) of IVIG 
in JE.
2.4 Timeline of the study 
The total duration for all studies in my thesis was from 2009 until 2016. 
Patients were recruited into the studies between January, 2006 - October, 2012. 
1)  Firstly, the retrospective study was conducted between February and 
March 2009. The patient records were analysed using admission data from 
January 2006 to January 2008 for patients admitted to Kanti Children’s 
Hospital (KCH) and BP Koirala Institute of Health Sciences (BPKIHS). 
2) Secondly, the prospective study was conducted between March 2009 
and March 2011. The patients were recruited between April, 2009 and 
November, 2010 at KCH and BPKIHS. 
3) Thirdly, the next prospective study was conducted between April 2011 and 
April 2013. Patients were recruited from September, 2011 to October, 2012 
in KCH
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4)  Fourthly, the IVIG treatment trial was conducted between April, 2009 and 
September, 2009. A separate group of patients from the second prospective 
study (chapter 4) were recruited in May and June 2009 in KCH and 
BPKIHS.
5) All the four studies were compiled together and written up until March 
2016
 
2.4.1 Contribution 
For the fi rst three studies, I wrote the research proposal, acquired ethical 
clearance, organized and conducted the study with help from research 
assistants; analyzed the data and wrote up the fi ndings. For the fourth study, 
I wrote the research proposal, acquired ethical clearance, organized and 
conducted the study with help from research assistants, analyzed the data and 
wrote up the fi ndings. Laboratory tests such as cytokine levels, Dengue and JE 
virus ELISA, plaque reduction anti-JEV antibody neutralizing titres and real-
time reverse transcription-polymerase chain reaction tests were conducted by 
my supervisors.
 
2.5 Patient recruitment and diagnostic criteria
2.5.1 First part, retrospective study (chapter 3): The hospital records charts 
of all children aged between 1 and 14 years admitted in KCH, Maharajgunj, 
Kathmandu and PH, Lalitpur, Nepal between January, 2006 to January, 2008 
were retrieved from the record sections. Between February and March, 2009, 
13397 records of admitted patients in the paediatric medicine wards (medical 
ward, paying ward, special cabin) and paediatric intensive care (PICU) in 
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KCH and 4532 patients admitted in the paediatric ward and PICU in PH were 
reviewed. Altogether, 17929 records of admitted patients in the two hospitals 
were reviewed with the help of staff working in the record section. 
All hospital in-patients aged 1- 14 years admitted between January 2006 to 
January 2008 with a discharge diagnosis or clinical features and investigations 
fulfi lling the WHO defi nition for AES based on the recorded information 
in the clinical notes from Kanti Children’s Hospital and Patan Hospital 
[http://apps.who.int/iris/bitstream/10665/68334/1/WHO_V-B_03.01_eng.
pdf?ua=1 (assessed on 3rd March 2016)] were included in the study. Relevant 
demographic data, clinical history, investigation reports, treatment provided, 
hospital stay and immediate outcome were recorded in a standardized proforma 
of 225 patients (Appendix F). 
Based on available records, patients who had incomplete information on 
clinical history about AES case defi nition, lacked relevant investigation reports, 
no discharge outcome, fever duration of more than 14 days or age below 1 
year or above 14 years were excluded from the study. Those with diagnosis of 
JE and concomitant infections, bacterial meningitis, cerebral malaria, typhoid 
encephalopathy were also excluded from the study and analysed separately. 
Those without LP reports were also excluded and analysed seperately. 
Pertinent points noted in history were information on date of admission, 
duration of illness, age, fever duration and seizure. Pertinent information of 
examination fi ndings noted, included: fever, altered sensorium, seizure and 
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focal neurological defi cits. haemoglobin, total and differential white cell 
count, platelets count, random blood sugar, total bilirubin, direct bilirubin, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase, urea, creatinine, sodium and potassium, peripheral blood smear 
and/or rapid diagnostic test for malaria and widal test. Date and result of CSF 
investigation such as total and differential cell count, protein, sugar, Gram’s 
stain, culture and sensitivity after LP was also recorded. Information on chest 
x-ray, computerized tomography (CT) scan and magnetic resonance imaging 
(MRI) scan of the brain were also recorded if they were available. 
The anti-JEV immunoglobulin-M (IgM) antibodies measured in serum 
and/or CSF of suspected JE patients admitted in these two hospitals was 
being conducted, as part of the national surveillance of JE, at the National 
Public Health Laboratory (NPHL), Teku, Kathmandu. The NPHL at Teku in 
Kathmandu was then approached with the inpatient number, name and address 
of all the included patients of the two hospitals for the result of serum and/or 
CSF anti-JEV immunoglobulin-M (IgM) antibodies. The JE result acquired 
from NPHL was further verifi ed from the records of the offi ce of WHO-IPD. 
Anti-JEV immunoglobulin-M (IgM) antibodies were measured in serum and/or 
CSF on admission and if possible on day 7 of admission by enzyme-linked 
immunosorbent assay (ELISA) using the Armed Forces Research Institute 
for Medical Sciences (AFRIMS) JE MAC IgM ELISA, which was developed 
at AFRIMS in Bangkok. Therefore, only 145 AES patient of suspected viral 
aetiology were included in the study. These patients were included because 
there was no defi nite treatment for most of the patients and identifying clinical 
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features and prognostic factors could help in patient management. These 
patients were further classifi ed as confi rmed JE and AES of unknown viral 
aetiology (which included non-JE and JE status unknown) as defi ned under 
general case defi nitions in this chapter and analysed. Since signifi cantly higher 
proportion of patients without LP results died or had bad outcome as compared 
to those who had LP, an additional analysis was undertaken, whereby patients 
without LP results were classifi ed into AES categories based on their hospital 
discharge diagnosis supported by their JE serological results. 
Emphasis was given to retrieve information on treatment with mannitol, 
steroids and anti-epileptic drugs. Information on course of the illness in 
the hospital, duration of hospital stay and outcome was also recorded. The 
immediate outcome was classifi ed and recorded as bad outcome and good 
outcome as defi ned in the case defi nitions section of this chapter. The bad 
outcome group were not further classifi ed as mild, moderate or severe residual 
neurological sequelae because of the limited breadth and quality of information 
available in the hospital notes, a pitfall of a retrospective study. 
 
2.5.2 Second part, prospective study (chapter 4): The study was conducted 
in KCH and BPKIHS, from April 2009 to November 2010. 217 patients aged 
1 year to 14 years, fulfi lling clinical history consistent with AES as defi ned by 
the WHO surveillance standard admitted to the Paediatric Ward (Medical Ward, 
Paying Ward, Special Cabin) and PICU in KCH were approached by me; and 
the Paediatric Ward and PICU in BPKIHS were approached by my research 
assistant during the study period for recruitment. 
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After brief introduction, a detailed history including demographic data, 
duration of the fever, seizure and level of consciousness were inquired. The 
character of the seizure was asked and noted. Other relevant history included 
headache, photophobia, vomiting, ear discharge, running nose, cough and loose 
motion. Examination fi ndings included the conscious level, vital signs and 
other relevant systemic fi ndings including signs of meningeal irritation and 
bulged anterior fontanel. Importantly, weight was measured and recorded at 
the time of admission using a digital weighing scale. The quality control of the 
weighing machine was conducted every morning using standard weights.
After initial stabilisation, investigations sent were haemoglobin, red blood 
cells, total white blood cells, differential white blood cells, platelet count, 
random blood sugar, blood for bacterial culture, total bilirubin, direct bilirubin, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase, urea, creatinine, sodium, potassium, peripheral blood smear 
and/or rapid diagnostic test for malaria and widal test. Serum was also sent 
to NPHL, Teku to test for anti-JE IgM antibodies. To identify the cause of 
illness, further investigations conducted included chest X-ray, urine routine and 
culture, stool routine, ultrasonography (USG) of brain, CT scan of brain, MRI 
of brain.
After a separate informed written consent, LP was performed with aseptic 
precaution with patient in lateral position with a disposable needle of different 
gauge and length varying from 22-24 according to age. Around 3 millilitres of 
CSF was collected in 3 sterile vials (aliquots) and sent for investigations. 
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One aliquot containing the CSF was sent for total white blood cell count, 
differential cell count, sugar and protein. The second aliquot was sent for 
Gram’s stain and culture. The samples were transported to the emergency 
laboratory and tested for cell count and biochemical analysis within 1 hour. 
The CSF was analyzed as per standard laboratory methods by laboratory 
technicians. The colour and transparency of the CSF was fi rst noted. For 
glucose estimation, an enzymatic method was employed. CSF was kept in a 
water incubator with glucose oxidase for 10 minutes. If pink colour developed, 
it was quantitated by the colorimeter based on its optical density. To quantitate 
the protein content, equal amount of CSF was mixed with 3% sulfosalicyclic 
acid and later at 10 minutes, if there was turbidity, it was compared with 
standard solution. 
The cells were counted on a Neubauer chamber after dilution with Turk's fl uid. 
For differential count, sediment of the centrifuged CSF sample was stained 
with Wright's stain and cells were counted. The CSF sent for microbiology 
(bacterial culture) was kept in the incubator at 37°C until it was plated on blood 
agar, chocolate agar and Mc Conkey agar for 48 hours. From the colonies, 
Gram's stain and biochemical tests were conducted to identify the organism. 
The third aliquot of 1 millilitre CSF was sent to NPHL, Teku along with serum 
for testing anti-JE IgM antibodies as part of the National Surveillance of JE. 
Following LP, patients who were classifi ed as probable viral encephalitis if 
they had CSF cell count < 1000 cells/mm3, and a CSF/Plasma glucose ratio > 
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40% and absence of organisms on a Gram stain and culture were included in 
the study (37). Since there are no treatments for most viral encephalitis, only 
patients of suspected viral encephalitis were included in the study and analysed.
All the patients who had not undergone LP were excluded from the study. In 
those who had LP, patients having bacterial meningitis, tubercular meningitis, 
typhoid encephalopathy and simple febrile seizure were excluded from 
the study because they were treatable illness. Patients without appropriate 
admission weight records, below 1 year and above 14 years of age, fever 
duration of more than 14 days, failure to provide consent, history of recent 
head trauma and past history of seizure disorder on antiepileptic drugs were 
also excluded from the study. 
A total of 152 patients of suspected viral aetiology after the availability 
of LP result, as defi ned in general case defi nitions in this chapter, were 
recruited in the study. Informed written consent was taken from the parents or 
accompanying caretaker of the included patients. Detailed history, examination 
fi ndings, investigation results were then recorded in a standardised proforma 
(Appendix G). Since the normal weight of children differed with age and sex, 
during analysis, weight for age (WFA) was used instead of just weight. WFA 
was defi ned according to WHO defi nition for children below 5 years of age 
(Appendices H & I) and “Development of the Nepalese Growth Standard for 
the School-aged Children” (Appendix J).
All the recruited patients of AES including JE were reassessed by me at 
the time of discharge in KCH and a research assistant in BPKIHS. During 
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assessment at discharge, parents were interviewed and patients examined 
clinically with emphasis on neurological system using LOS- discharge 
[http://www.liv.ac.uk/infection-and-global-health/research/brain-infections-
group/education (assessed on 3rd March 2016)] (Appendix K). They were 
then prospectively followed-up twice between 6- 24 months (intended at one 
year and 2 years) after discharge in order to fi nd out the long term outcome 
and recovery profi le of the recruited patients. During follow up, they were 
assessed or inquired by phone about recovery, deterioration or death based on 
LOS- follow-up (Appendix L). Those who did not come for follow-up were 
interviewed by telephone. 
2.5.3 Third part, fl uid study (chapter 5): A total of 143 children, aged 1 
month- 14 years, from September 2011- October 2012 attending emergency 
department, paediatric ward and paediatric intensive care unit of KCH with 
clinical features consistent with AES, as defi ned by WHO surveillance 
standard were seen by me or my research assistant. The parent / caregiver were 
explained about the study when they were fi rst seen in hospital. They were 
explained that in order to be eligible for the study the results of the routine 
LP was needed. At this stage any questions or concerns were addressed. 
After confi rming with the entry criteria, a written consent from the parents 
or accompanying guardians were obtained. A detailed history was then taken 
from the accompanying parents or guardian. First, demographic information 
was inquired and recorded. Then clinical history was inquired and fi ndings 
recorded. Then complete clinical examination including neurological 
examination was performed and fi ndings recorded. Special attention was paid 
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to child’s weight, mid upper arm circumference (MUAC), clinical signs of 
dehydration, capillary refi ll time, peripheral oxygen saturation and axillary 
temperature, presence of seizures and clinical signs of raised intracranial 
pressure and brain stem herniation. 
After initial stabilisation, investigations were sent which included blood count, 
liver function test, renal function test, electrolytes, blood for bacterial culture 
including antibody titers against specifi c bacteria measured via a commercial 
kit (PASTOREX MENINGITIS, BIO-RAD, France, 2011), peripheral blood 
smear and/or rapid diagnostic test for malaria and widal test. Aliquot of serum 
was also sent to NPHL, Teku for anti-JE IgM antibodies as part of the National 
Surveillance of JE. To aid diagnosis, further investigations conducted included 
chest X-ray, urine routine and culture, stool routine, ultrasonography (USG) of 
brain, CT scan of brain, MRI of brain. The results of the investigations were 
also recorded.
After a separate written consent, LP was performed with aseptic precaution as 
described above in the second study. Around 3 millilitres of CSF was collected 
in 4 sterile vials (aliquots) and sent for investigation. One aliquot containing 
the CSF was sent for total white blood cell count, differential cell count, sugar 
and protein. The second aliquot was sent for Gram’s stain and culture. The 
samples were transported to the emergency laboratory and tested for cell count 
and biochemical analysis within 1 hour as described above in the second study. 
The third aliquot of 1 millilitre CSF was sent to NPHL, Teku for testing anti-
JE IgM antibodies. The fourth aliquot was tested with Pastorex meningitis kit. 
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The following procedure was conducted with both blood and CSF samples. A 
drop of the pre-treated sample supernatant in each circle of the agglutination 
was placed on a card. The latex reagent bottles were gently shaken. Holding 
the bottles upright, one drop of each latex reagent was placed on the disposable 
card following the indicated distributable pattern: R9, R6, R7, R1 and R2 in 
the white circles and R8, R3, R4 and R5 in the black circles. The latex reagents 
and the sample was mixed gently with a rod, changing the rod for each latex. 
The card was rotated (~120 rotation per minute) gently for 10 minutes and 
watched for the appearance of any agglutination visible to the naked eye within 
10 minutes. While interpreting the result, positive reaction for the aetiological 
diagnosis of meningitis was indicated by fi ne agglutination, visible to the naked 
eye, compared to negative controls at the button hole of the agglutination card. 
A negative reaction (absence of meningitis) was indicated by homogenous 
suspension in the absence agglutination.
Once the LP results were available, I or my research assistant informed the 
parents/ caregiver of the results and what they meant. If 1 month to 14 years 
aged child was eligible for the study; met the inclusion criteria for AES; on LP 
was diagnosed as AES of suspected viral aetiology (not meeting the exclusion 
criteria); and MUAC ≥ 11.5 cm; then the parents or caregivers were informed 
and the patient included in the study (10, 37). 
However, patients diagnosed bacterial meningitis, tubercular meningitis, 
typhoid encephalopathy, cerebral malaria, children with age below 1 month and 
above 14 years, fever duration of more than 14 days, simple febrile seizure, 
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fever more than 2 weeks, MUAC < 11.5 cm and traumatic head injury were 
excluded from the study. Families were also advised that they could withdraw 
consent at any time and that participation was voluntary. If they chose not to 
participate then their child/ teenager received the usual standard supportive 
care provided by the treating clinician. I included infants over one month of 
age in this study because JE cases decreased markedly after mass vaccination 
campaign with JE vaccines in the region. I increased the age range with the aim 
of increasing recruitment of JE cases.
Of the 92 included patients, total fl uid input (oral, nasogastric and intravenous 
including drug diluents) and output (urine, vomit) was monitored daily after 
admission until discharge or death by me or a research assistant. They were 
specially assessed for weight, blood lactate, oxygen saturation (Spo2) and 
capillary refi ll time at the time of admission, at 48 hours after admission and 
at discharge or death. Use of other supportive management procedures such 
as head positioning, sedative (including anti-epileptic drugs), mannitol and 
analgesia provision was also monitored. The immediate outcome at discharge 
was assessed by LOS- discharge (Appendix K). All the information was 
recorded in a standardised proforma (Appendix M). 
The normal weight of children differ with age and sex. Therefore, we used 
sex matched weight for age (WFA) to fi nd out the actual weight of patients 
included in the study. During analysis, WFA was defi ned according to 
WHO defi nition for children below 5 years of age (Appendices H & I) and 
“Development of the Nepalese Growth Standard for the School-aged Children” 
for older children (Appendix J). 
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2.5.4 Fourth part, IVIG treatment trial (chapter 6): During the monsoon 
period in May and June in 2009, patients aged between 1 and 14 years with 
AES as defi ned by WHO surveillance standard such as fever or history of fever 
(<14 days), change in mental status and/ or new onset of seizures (excluding 
simple febrile seizure) were considered for recruitment in the study in KCH 
and BPKIHS (37, 38). Following LP, patients were classifi ed as suspected JE 
(or probable viral encephalitis) if they had CSF cell count < 1000 cells, and a 
CSF/Plasma glucose ratio > 40% and absence of organisms on a Gram stain 
and culture, and included in the study (37). In instances where a LP needed to 
be delayed, because of clinical contraindications, children were entered into the 
study, and LP performed as soon as possible. Summary of the trial protocol is 
shown in Appendix N.
Patients who had asexual Plasmodium falciparum parasites in blood, 
documented antibiotic treatment before admission and bacterial meningitis 
appeared more likely than encephalitis, simple febrile seizure, pregnant or 
breastfeeding female adolescents, age below 1 year and above 14 years and 
fever duration of more than 14 days were excluded from the study. Patients 
with a GCS of 3/15, who were receiving artifi cial ventilation without signs 
of spontaneous respiration and with absent oculocephalic refl ex were also 
excluded from the study (20,37). 
The primary outcome assessed was evidence of side effects of study drug such 
as infusion site reaction, diarrhoea, rise in blood pressure and change in urinary 
output every 12 hours from fi rst day of commencing treatment until death or 
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discharge. Patient on average were administered the study drug on the fi rst day 
of admission. The study drug was administered daily for 5 days. Patients were 
discharged on an average on eighth day (192 hours) of hospital admission. 
The secondary outcome assessed was death or neurological sequelae at the 
time of discharge, an expected average of eighth day of admission and again at 
6 months after discharge. At the time of discharge from the hospital they were 
assessed for time to death, to recover from coma, to sit independently, to stand 
independently, to walk at least 5 metres independently, and to leave hospital 
(Appendix K). At 6 months after discharge they were assessed for history of 
further seizures, behavioural changes, evidence of recovery of neurological 
sequelae such as sit independently, stand independently, walk at least 5 metres 
independently (Appendix L).
After inclusion, a detailed history was taken from the accompanying parent or 
guardian by me or research assistant. Patients were then examined including 
full neurological examination. Attention was focused on presence of seizures, 
and clinical signs of raised intracranial pressure and brainstem herniation 
because of their association with bad outcome. 
Blood was sent for complete blood count (CBC), renal function test, liver 
function test and aliquot of serum sample sent to NPHL to test for anti-JE 
IgM antibodies. Urea and electrolytes were repeated during treatment to 
exclude renal toxicity. LP was done and CSF opening pressure recorded using 
a CSF manometer. CSF was also sent for total cell count, differential cell 
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count, glucose, protein, Gram's stain, bacterial culture and aliquot of sample 
sent to NPHL to test for anti-JE IgM antibodies. Aliquot of CSF and serum 
samples were frozen on site at -20°C, and subsequently transported for further 
investigations to Centers for Disease Control and Prevention (CDC), Division 
of Vector-Borne Diseases in Fort Collins, USA for confi rmatory testing for 
JE and neutralising antibodies levels and the Institute of Infection and Global 
Health, University of Liverpool (UOL), UK, for cytokines levels. Classifi cation 
of the patients as JE negative or positive was by initial JEV IgM ELISA testing 
in Nepal measured in serum on admission and day 7 of admission, and in 
CSF using the AFRIMS JE MAC IgM ELISA as part of national surveillance 
programme. 
Confi rmatory testing was subsequently performed at the CDC, USA using 
the following testing algorithm. Further in the CDC, the last serum sample 
collected from each patient was tested by JEV and DENV IgM capture ELISA. 
Positive or equivocal results were confi rmed by JEV and DENV PRNT90, with 
a 4-fold or greater difference in titre interpreted to be virus specifi c. If the 
fi nal sample was positive or equivocal for JEV and/or DENV IgM all samples 
for that case were tested. In addition, if the last serum sample from a patient 
was collected at less than 7 days post onset of disease and had an IgM ELISA 
negative result, the CSF from that patient was also tested by JEV and DENV 
IgM ELISA.
In addition, if the last serum sample collected from a case had a negative JEV 
and DENV IgM ELISA result and was collected <7 days from illness onset, 
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CSF was tested for the presence of JEV ribonucleic acid (RNA) by two real-
time reverse transcription-polymerase chain reaction (RT-PCR) assays, one 
designed in-house at CDC (JEV239F: GGCTCTTATCACGTTCTTCAAGTTT; 
JEV344R: ACTAGTAAGATGTTTCATTGCCACACTCT; JEV269probe: 
ATTAGCCCCGACCAAGGCGCTTT) and one developed by Parida et al 
(108). Both assays had sensitivities of 0.001 equivalent plaque forming units 
for SA-14-14-2 reference viral RNA. Viral RNA was extracted from 100μl 
of CSF, eluted in 50 μl using the QIAamp Viral RNA Mini Kit (QIAGEN, 
Valencia, CA); 20 μl RNA template was used in a 50μl reaction using the 
iScript One-Step RT-PCR kit for Probes (BioRad, CA). 
To study in more detail the effect of IVIG on the neutralising antibody 
titres, JEV PRNT50 was done on serum from all patients at pre-treatment 
(immediately prior to the fi rst dose), and post-treatment (1hour after the 5th 
dose). Interleukin (IL) -6 and IL-4 cytokine measurements were undertaken 
on aliquots of IVIG and on patients’ serum pre-treatment (before fi rst dose) 
and post-treatment (1 hour after 5th dose), using ELISA kits following 
the manufacture’s protocol (Bender MedSystems GmBh, Wien, Austria). 
Samples were measured in duplicate (50ul) at each time-point. Quality control 
was based on concurrent measurement of negative and positive controls 
supplied in the kits. Other investigations such as blood for bacterial cultures, 
electrocardiogram (ECG), chest radiograph, CT scan of brain, MRI scan of 
brain was performed at the discretion of the admitting physician if clinically 
indicated. 
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Participants were randomly allocated treatment with IVIG or placebo. 
Randomisation was stratifi ed by centre using a variable block size of 4, 6 
or 8, selected on a random basis similar to those schemes used previously 
(38). Each centre was provided with duplicate sealed envelopes with its 
own randomisation schedule. The randomisation code for each patient was 
kept in a sealed envelope in a locked cupboard on a separate ward. Once a 
patient was enrolled, technicians who were not otherwise connected to the 
study opened the envelope, drew up the study drug, covered the syringe in 
opaque tape (because of subtle differences in colour and viscosity of the two 
substances) and delivered it to the ward, where the nurses gave the treatment. 
Of the 23 considered during the study period, 22 patients with suspected JE 
were randomised to receive either IVIG [ImmunoRel™ (batch 20081217)] at 
a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal 
saline (placebo). The infusion rate was initially started at 0.01 to 0.02 ml/kg 
body weight/minute and if tolerated gradually increased to 0.08 ml/kg body 
weight/minute over 30- 60 minutes. Empty vials were concealed in paper bags 
and disposed of. Hence, all investigators, care providers and participants were 
blinded of the study drug. A second sealed envelope was kept with inpatient 
notes in case a physician urgently needed to know which drug a patient had 
received.
I took a detailed history and did daily clinical and neurological examinations 
until death or discharge. Information was recorded on standardised proforma 
(Appendix O). Treatment side effects were monitored daily from the fi rst day 
of commencing treatment (the fi rst day of hospital admission) until death or 
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discharge (on average on eighth day), these included headache, abdominal 
pain, chest tightness, nausea, vomiting, rash, fever, pallor, local site reaction, 
diarrhoea, rise in blood urea, rise in blood creatinine, change in blood pressure 
and urinary output and classifi ed according to the WHO standard protocol for 
drug side effects. An adverse event was observed as any event, side effect, 
or other untoward medical occurrence (including dosing errors), that was 
present during treatment with a study drug. Laboratory adverse events were 
abnormal values obtained on laboratory tests during the acute and follow-up 
period. A Serious Adverse Event (SAE) was any adverse event occurring at 
any drug dose that resulted death, life-threatening event (at immediate risk 
of death), required hospitalisation or prolongation of existing hospitalisation 
or resulted in a signifi cant disability. The Data Safety and Monitoring 
Committee were promptly notifi ed of any serious adverse event, deaths, or life-
threatening problems that were regarded as caused by or associated with the 
administration of the study drug. Occurrence of any adverse events (those that 
were considered non-serious) during the study was documented in the patient's 
medical records and on the case record forms. The summary of the study 
schedule is shown in Appendix P.
Patients were assessed at discharge and 3-6 month follow-up for disability in a 
range of activities using the LOS (109) (Appendices K & L) and a standardised 
neurological assessment (Appendix Q). Children who did not return for follow-
up were reminded by letter or telephone as available. If they were unable to 
return to the hospital they were examined at home either by me or my research 
assistant.
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2.6 General Case Defi nitions
Clinically, a case of AES was defi ned based on WHO recommended case 
defi nition (1). AES case defi nition has been validated previously in 380 patients 
(including 149 children below 15 years of age) for diagnosing JEV infected 
patients in similar setting. It was found to have sensitivity of 100%, specifi city 
of 16%, positive predictive value (PPV) of 6% and negative predictive value 
(NPV) 100% in adults. In children, sensitivity was 65%, specifi city 39%, 
PPV 48% and NPV 56% (1). JE tests, as part of JE surveillance programme, 
were conducted on these identifi ed cases during the study period. The AES 
cases, based on the results of their microbiological and serological tests, 
were classifi ed as AES of suspected viral aetiology (Confi rmed JE, Non-JE 
and JE Status unknown) and AES of non-viral aetiology (AES-bacterial or 
parasitic aetiology). The clinical features within each class were examined. The 
defi nition for AES was based on WHO recommended case defi nition:
2.6.1 AES: Acute onset of fever or recent history of fever (of less than 14 
days), with change in mental status (including confusion, disorientation, coma, 
or inability to talk) and/or new onset of seizures (excluding simple febrile 
seizures). Other early clinical fi ndings could include an increase in irritability, 
somnolence or abnormal behaviour greater than that seen with usual febrile 
illness (1). 
2.6.2 AES of suspected viral aetiology or viral encephalitis (VE): was 
defi ned by fulfi lling the defi nition for AES (above) and having a discharge 
diagnosis of suspected viral encephalitis or menigo-encephalitis, supported by 
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a CSF cell count <1000 cells/mm3 with a lymphocyte predominance and no 
positive identifi cation of non-viral pathogens (e.g. bacteria or parasites) in the 
CSF or blood (37, 38).
2.6.3 Confi rmed JE: AES of suspected viral aetiology or VE, which is shown 
to have IgM antibodies (≥ 40 units) specifi c to JE virus in a single (CSF and/ or 
serum) sample (or a rise in titres among paired samples) as detected by IgM-
capture ELISA.
2.6.4 Non-JE: A suspected viral case which is shown to have an absence of 
IgM antibodies specifi c to JE virus based on a negative test for a single sample 
collected after the ninth day of illness or no change in titres in paired samples 
collected at least seven days apart.
2.6.5 JE Status unknown: A suspected viral case which was either not tested 
for anti-JE IgM antibodies or had samples tested that were collected too early 
in illness course to confi dently rule out JE (as defi ned above).
2.6.6 AES of unknown viral aetiology: A suspected viral case which was not 
confi rmed as JE; this group included both of the categories described above, 
i.e. Non-JE, and JE Status unknown.
2.6.7 JE with concomitant infection: A case of confi rmed JE, with evidence 
of bacterial meningitis, typhoid encephalopathy or cerebral malaria.
2.6.8 AES of non-viral aetiology: 
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2.6.8.1 AES with bacterial meningitis: Case of AES with a CSF cell count > 1000 
cells/mm3, a pleocytosis with a polymorph predominance and raised CSF protein 
(>0.45g/L) and CSF/ plasma glucose <40%, and/or Positive Gram stain from 
CSF and /or bacterial culture from CSF or antibody titre positive against specifi c 
bacteria in serum and /or CSF by PASTOREX MENINGITIS KIT (1, 10, 110).
2.6.8.2 AES of typhoid encephalopathy: Case of AES positive blood culture 
for Salmonella typhi and/or positive Widal test (10, 37).
2.6.8.3 AES of Cerebral malaria: Children of AES with asexual Plasmodium 
falciparum parasites in peripheral blood (10).
2.6.8.4 AES of tuberculous meningitis: An AES case having CSF cell 
count 10-1000 cells (lymphocyte predominance) and CSF/ Plasma glucose 
ratio <40%, CSF protein 50- 500 mg/dl or Acid-Fast Bacilli detected in CSF 
modifi ed Ziehl-Neelsen stain or culture.
2.6.8.5 AES of Hepatic encephalopathy: Children with AES with normal CSF 
fi nding with abnormal liver enzyme levels (10).
2.6.8.6 AES of acute poisoning: Children of AES with evidence of poisoning 
on clinical history and examination and laboratory evidence.
2.6.9 Simple febrile seizure: A child aged 6 months to 5 years with fever and 
a single generalised convulsion lasting less than 5 minutes followed by full 
recovery of consciousness within 60 minutes of convulsion (1).
2.6.10 Good outcome: Being alive with no impairment of consciousness (GCS 
15/15) or neurological sequelae (75). 
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2.6.11 Bad outcome: Death or incomplete recovery (with altered sensorium or 
neurological sequelae at discharge) (75). Bad outcome represents patient death 
or incomplete neurological recovery (with altered sensorium or neurological 
sequelae at discharge). All children with neurological sequelae were regarded 
has having a ‘bad outcome’ because JE patients experiencing ‘mild’ sequelae, 
such as memory impairment or change in personality, have suffered signifi cant 
limitations in social participation, such as stopping school attendance, causing 
huge adverse affects to the family (21, 28). In addition, Nepali families of AES 
patients with moderate or severe sequelae are known to suffer a huge economic 
burden of US$ 1151 (10 times their median monthly income) (28). I used "bad 
outcome" because it was absolute term where as "poor outcome" or "worse 
outcome" were relative. 
2.6.12 Liverpool Outcome Score (LOS): This is a simple validated tool for 
assessing functional impairment in children following JE. It was developed in 
the University of Liverpool with expert inputs from paediatric neurologists, 
paediatricians, neurologists, occupational therapists, psychologists and score 
developers. It was piloted in India and Malaysia in patients of confi rmed JE 
or suspected JEV infections (Appendix R). It is now being used to assess 
disability of JE in Bangladesh, Indonesia, Cambodia, Vietnam and the Lao 
People’s Democratic Republic (109). 
The score is determined by asking 10 simple questions to patients' care 
giver and observing 5 activities. While answering 10 questions for the LOS 
used at the time of discharge, the caregiver compares the child to how they 
were before admission (Appendix K). For the LOS used at follow up, the 
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caregiver compares the child with other children of a similar age in the vicinity 
or the child's sibling when they were at that age (Appendix L). The LOS 
assesses speech, communication, feeding, ability to be left alone, behaviour, 
recognition, school or working, seizures, dressing, bladder/bowel control, 
hearing, sitting, standing, walking and upper limb dexterity. Final LOS is the 
lowest score for any of the 15 functional domains assessed. A LOS score of 2, 
3, 4 or 5 corresponds to an outcome classifi cation of severe, moderate, mild or 
no functional impairment respectively. A LOS score of 1was given, if the child 
died; 2, if there were severe sequelae causing impairment of function likely to 
make the child dependent on others; 3, if there were moderate sequelae only 
mildly affecting function, probably compatible with independent living, 4, if 
there were minor sequelae with mild effects on function or personality change 
or on medication; 5, if there was complete recovery which included normal 
examination.The lower the score the more severe the impairment. Also a total 
score is assigned by adding scores for each question. The total score can range 
from 33-75 points (109). 
There are 125 ethnic groups speaking 123 different languages in Nepal. 
The written format of some of the languages are more formal and different 
from spoken language. Therefore, it was not felt appropriate to translate the 
written questionnaire into local languages. Instead, I and my search assistants 
administered it verbally in Nepali, which is spoken by around 45% of the 
population.
2.6.13 Neurological sequelae: Presence of one or more of the following at 
discharge; impaired consciousness, weakness (monoparesis hemiparesis, 
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quadriparesis), focal or generalised abnormal limb tone (hypertonia, 
hypotonia), focal or generalised abnormal limb refl exes (hyperrefl exia, 
hyporefl exia), diagnosis of new onset or recurrent seizures or new or recurrent 
extra pyramidal movement disorders (75). 
Specifi c case defi nitions are described in related chapters.
2.7 Sample size
2.7.1 First retrospective study (chapter 3): A sample size calculation was 
performed to estimate the number of participants needed to detect a signifi cant 
difference in the proportion of participants with ‘bad outcome’ (suffered death 
or neurological sequelae) at hospital discharge among JE compared to non-JE 
patients. The sample size calculation was performed in OpenEpi, Version 3, 
using the ‘sample size for unmatched case control studies’. Based on a previous 
publication from Malaysia (21) and supported by our similar experience in 
Nepal, the expected proportion of participants to have a bad outcome was 60% 
in JE and 40% in Non-JE patients. Setting the confi dence level at 95% and 
power at 80% and ratio of cases: controls (or JE: Non-JE) at 1:1, the sample 
size was estimated as 96 participants per arm (192 in total). Based on my 
previous study (37), I expected to recruit 200 patients over 2 years from two 
hospitals. 200 participants were estimated to provide suffi cient study numbers 
to examine whether there was a signifi cant difference in the proportion of 
patients with ’bad outcome’ among JE compared to Non-JE patients.
2.7.2 Second study (chapter 4): A sample size calculation was performed to 
estimate the number of participants needed to detect a signifi cant difference in 
patients’ weight at hospital admission among JE compared to Non-JE patients. 
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Again the sample size calculation was performed in OpenEpi, Version 3, this 
time, using the ‘sample size for comparing two means’. The mean weight and 
standard deviation for patients with JE (cases) was 16.2 ± 6.5 Kg and non-JE 
(controls) 20.5 ± 8.7 Kg respectively based upon data from my previous study 
(chapter 3) (75). Setting the confi dence level at 95%, power at 80% and ratio 
between the groups at 1:1; the sample size estimated 102 participants in total 
(51 in each group).
2.7.3 Third study (chapter 5): The sample size calculation was undertaken 
to assess the number of participants needed to detect a signifi cant difference 
in plasma urea among participants with a bad outcome as compared to those 
with a good outcome. Raised plasma urea was used as proxy marker for 
poor hydration status. The following parameters were based upon data from 
my earlier study (chapter 3). The sample size calculation was performed in 
OpenEpi, Version 3, again using the ‘sample size for comparing two means’. 
The mean plasma urea and standard deviation for AES patients with good and 
bad outcome were 7.9 ± 10.1 mmol/l and 15.8±13.9 mmol/l, respectively; 
expected proportion of AES patients with good outcome / bad outcome as 
60/40 (or 1.5). Setting the confi dence level at 95%, power at 80%, the sample 
size estimated 83 participants in total (50 and 33 with a good and bad outcome 
respectively). 
2.7.4 Fourth study (chapter 6): The aim was to examine feasibility, by 
studying approximately 20 patients across two sites. I also wanted to determine 
adverse effects of IVIG or compare anti-JEV antibody titres following 
administration of IVIG and placebo. I could not fi nd any previous human 
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clinical trials of IVIG among JE patients or toxicity studies of IVIG in animals 
with JE to guide sample size. However, there were data on change in anti-JEV 
titre associated with improved outcome in mice given immune splenocytes. 
Mice given immune splenocytes generated a mean anti-JEV titre of 400, 
whereas mice given naïve splenocytes exhibited a mean anti-JEV titre of 40. 
Based on these data, using a signifi cance of 0.95 and a power of 0.8, mean 
titres of 400 and 40 and a standard deviation of 400 and 40 for anti-JEV 
antibody titres in IVIG exposed and non-exposed respectively, 10 subjects were 
required in each arm. Considering10-20% loss to follow up, I aimed to recruit 
22-24 patients. 
2.8 Data analysis
Broadly, all the acquired data for all AES patients was initially validated, coded 
and entered in SPSS Statistics software version 17.0 (IBM-SPSS, New York,) 
for analysis. Percentage, Proportions and Contingency tables were used for 
description of the data. Parameters were analysed for normally distributed data 
using the Student’s t-test, non-normally distributed data using Wilcoxon-Mann-
Whitney U test and differences between proportions by Fischer’s Exact test or 
Chi square test with Yates correction as necessary. Further detailed analysis is 
mentioned in related chapters.
2.9 Ethical Consideration 
Ethical approval had been sought before commencing the work. All four parts 
of this thesis were approved by the Ethical Committees of Liverpool School of 
Tropical Medicine, the Nepal Health Research Council, KCH and BPKIHS. 
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The purpose, design, risks, benefi ts, voluntary participation and confi dentiality 
of data were explained to the patients and their parents by a member of the 
research team. Informed written consent was taken from parents or guardians 
of all participants of prospective study, including treatment trial, before 
inclusion in the study. The number of blood and LP tests was the same as 
recommended by the WHO for diagnosis of JE and were needed by the treating 
clinicians. In the fourth part of the study consent was taken twice. First consent 
was taken to recruit participants in the screening process and conducting a LP. 
A second consent was taken after reviewing results of the LP. If there was high 
clinical suspicion of the participants having JE, they were then included into 
the IVIG treatment trial; and blood and CSF samples and photos/ videos were 
taken for the study. A data safety monitoring committee was constructed to 
review serious adverse events and to take appropriate action if necessary. 
The patient’s relevant clinical information was recorded using a data collection 
sheet which was given a unique study number. Study data was transcribed 
from the case-record form to the study database. The study number was used 
to access the data for all future data analyses. All information obtained was 
kept confi dential. The completed proforma were stored in a designated locker 
of locked research offi ce at each hospital. Databases were stored in a password 
protected laptop. The database was itself password protected. Data was backed 
up on a password encrypted portable hard disk (HD-PS12OU2-WH). The 
password was only accessible to the student and supervisor. 
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Chapter 3: Clinical and prognostic features 
among children with Acute Encephalitis 
Syndrome in Nepal; A retrospective study
Abstract 
Background: Acute encephalitis syndrome (AES) is commonly seen 
among hospitalised Nepali children. Japanese Encephalitis (JE) accounts for 
approximately one-quarter of cases. Although poor prognostic features for JE 
have been identifi ed, and guide management, relatively little is reported on the 
remaining three-quarters of AES cases. 
Methods: Children with AES (n=225) were identifi ed through admission 
records from two hospitals in Kathmandu between 2006 and 2008. Patients 
without available lumbar puncture results (n=40) or with bacterial or 
plasmodium infection (n=40) were analysed separately. The remaining AES 
patients with suspected viral aetiologies were classifi ed, based on positive IgM 
antibody in the serum or cerebral spinal fl uid, as JE (n=42) or AES of unknown 
viral aetiology (n=103). This latter group was sub-classifi ed into Non-JE 
(n=44) or JE status unknown (n=59). Bad outcome was defi ned as "death or 
neurological sequelae at discharge". 
Results: AES patients of suspected viral aetiology more frequently had a bad 
outcome than those with bacterial or plasmodium infection (31% versus 13%; 
P=0.039). JE patients more frequently had a bad outcome than those with AES 
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of unknown viral aetiology (48% versus 24%; P=0.01). Bad outcome was 
independently associated in both JE and suspected viral aetiology groups with 
a longer duration of fever pre-admission (P=0.007; P=0.002 respectively) and 
greater impairment of consciousness (P=0.02; P<0.001). A higher proportion of 
JE patients presented with a focal neurological defi cit compared to patients of 
unknown viral aetiology (13/40 versus 11/103; P=0.005). JE patients weighed 
less (P=0.03) and exhibited a higher respiratory rate (P=0.003) compared to 
Non-JE patients. Lower weight in JE patient could be because of dehydration 
or malnutrition. However, considering presence of indirect markers of 
dehydration in them and that those children of JE and AES who arrived early 
to the hospital did well without receiving treatment of malnutrition, meant 
dehydration was more likely. 
Conclusions: Nepali children with AES of suspected viral aetiology or with 
JE frequently suffered a bad outcome. Despite no specifi c treatment, patients 
who experienced a shorter duration of fever before hospital admission more 
frequently recovered completely. Prompt referral may allow AES patients to 
receive potentially life-saving supportive management. Previous studies have 
indicated supportive management, such as fl uid provision, is associated with 
better outcome in JE. The lower weight and higher respiratory rate among JE 
patients may refl ect multiple clinical complications, including dehydration. 
The fi ndings suggest a more systematic investigation of the infl uence of 
supportive management on outcome in AES is warranted. Whether underlying 
malnutrition exposed the children to the risk of symptomatic JE or resulted in 
adverse outcome also needs further evaluation. 
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3.1 Introduction
Acute encephalitis syndrome (AES) is a constellation of clinical signs and 
/or symptoms, i.e. acute fever, with an acute change in mental status and/or 
new onset of seizures (1). These clinical signs suggest the patient has acute 
infl ammation of the brain and are used by clinicians to identify patients with 
acute encephalitis. Viruses are regarded as the most important cause of the 
AES worldwide. However, the syndrome can be associated with a range of 
pathogens, including acute bacterial or parasitic infection. Where population 
based studies have been undertaken, the incidence ranges between 3.5 and 7.4 
cases per 100,000 patient-years (111). Acute encephalitis can be associated 
with severe complications, including impaired consciousness, seizures, limb 
paresis or death (10).
In Asia, the major identifi ed cause of acute encephalitis is Japanese 
Encephalitis (JE) virus. JE affects over 50,000 people annually, leading to 
8-30% mortality and 50-60% disability, with children bearing the brunt of 
the disease burden (36-38, 112). JE is associated with considerable mortality 
and morbidity among Nepali children specially in endemic areas (37). 
Consequently, the Ministry of Health and Population of Nepal, supported by 
the offi ce of the Programme for Immunisation Preventable Diseases, World 
Health Organisation (WHO-IPD), has integrated JE surveillance with Acute 
Flaccid Paralysis, Neonatal Tetanus and Measles in its National surveillance 
network since 2004 (85). Over 23,000 cases of AES and 2500 cases of JE 
have been reported by the WHO surveillance network since 2004 (personal 
communication: Mr Tika Sedai, Data Manager, WHO-IPD, Kathmandu, 
Nepal).
99
In Nepal, like many countries throughout Asia, test results for JE are often 
not available until weeks after the patient presents to the health care centre, 
because they are performed in a centralised government facility. Consequently, 
health care workers attempt to distinguish JE from other causes of AES based 
on the patient’s clinical features, so that they can focus attention on known 
complications, such as seizures, and avoid unnecessary treatments, such 
as antibiotics. However, this approach can be inaccurate, leading to sub-
optimal or inappropriate management. There have been several publications 
relating admission clinical parameters to outcome among JE cases, and the 
identifi cation of poor prognostic indicators has helped focus attention on 
treatable complications of infection (24, 52, 78). However, relatively little 
work has been done identifying prognostic features among the Non-JE AES 
patients. Therefore it was important to investigate the diagnostic and prognostic 
features that distinguished JE from other causes of AES. I then decided to 
conduct a retrospective descriptive study at two major hospitals catering sick 
children in Kathmandu, Nepal, to examine the aetiology of patients with AES 
of suspected viral aetiology or viral encephalitis relating to outcome which 
would help identify which particular aetiology had a bad or a good outcome 
in this broad group of AES patients. It was also important to study suspected 
viral encephalitis because it had no defi nite treatment and had bad outcome 
as compared to other treatable aetiology of AES such as bacterial meningitis, 
tubercular meningitis, cerebral malaria and typhoid encephalopathy which were 
studied separately. 
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3.2.1 Aim
The aim of this study is to assess the clinical features, laboratory parameters 
and factors contributing to bad outcome of acute encephalitis syndrome in 
Nepali children.
3.2.2 Objectives
1. To identify all children that meet World Health Organisation acute 
encephalitis syndrome case defi nition in the two hospitals in Nepal.
2. To describe the clinical features, laboratory parameters and immediate 
outcome of confi rmed cases of Japanese encephalitis as compared to 
confi rmed cases of non-Japanese encephalitis and those of unknown 
causes.
3. To describe the clinical features and laboratory parameters which predict 
Japanese encephalitis from other causes of acute encephalitis syndrome.
4. To describe the clinical features and laboratory parameters which predict 
bad outcome of acute encephalitis syndrome and Japanese encephalitis.
5. To obtain baseline data for future prospective studies.
3.3 Methods
The hospital records of all children, aged 1-14 years, presenting either to Kanti 
Children’s Hospital, Maharajgunj, Kathmandu, Nepal and Patan Hospital, 
Lalitpur, Nepal, from January 2006 to January 2008 were screened for a history 
consistent with AES. 
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Kanti Children’s Hospital is a busy tertiary level referral centre. It has 300 beds 
and provides health care services to 300-400 children per day. Patan Hospital 
is a general hospital situated at the southern end of Kathmandu. It has 450 beds 
and provides health services to around 1,000 people per day, predominantly 
adults.
I examined the hospital notes, with the help of staff employed in record section, 
within the respective hospitals, as described in detail in chapter 2. Relevant 
clinical features and laboratory parameters present at admission were recorded 
in a standardised proforma (Appendix F). Each proforma was designated a 
unique study number. The study data were transcribed from the proforma to 
the study database. The study number was used to access the data for all future 
data analyses. 
The study was approved by the Institutional Review Committee of Kanti 
Children’s Hospital and Patan Hospital, Kathmandu, ethical committee of 
the Nepal Health Research Council, Kathmandu and the Ethical Review 
Committee of the Liverpool School of Tropical Medicine, Liverpool, UK.
3.3.1 AES and JE case defi nitions 
Case defi nition followed was as described in Chapter 2. Patients that self-
discharged or were referred to another hospital prior to discharge were 
excluded from outcome analysis
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3.3.2 JE diagnostic test 
JE virus exposure was tested by MAC-ELISA (IgM antibody capture-Enzyme 
Linked Immunosorbent Assay). The ELISA plates were supplied by the Armed 
Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand 
(113). ELISA measurements were undertaken following the protocol supplied 
by AFRIMS. Diluted patient sera (1:100) or CSF (1:10) were added to the 
plates. Absorbance of experimental, positive and negative control samples 
were measured in duplicate in 96-well plates using a micro-titre plate reader 
(Huma Reader Single Plus, Human GmbH, Wiesbaden, Germany). Single 
experimental patient samples with a mean absorbance ≥ 40 units (following 
subtraction of the absorbance for the negative controls) were considered 
positive. External quality assurance was undertaken by AFRIMS (113). 
3.3.3 Statistical methods
The acquired data for all AES patients was initially validated, coded and 
entered in SPSS Statistics software version 17.0 (IBM-SPSS, New York) 
for analysis. Differences between clinical groups were compared using 
Student independent samples t-tests (for Normally distributed data), Mann-
Whitney U-tests (for non-Normally distributed data) and Fisher Exact tests 
(for categorical data / proportions). All clinical feature variables (with the 
exception of all duration and numbers of episodes variables apart from duration 
of fever) were entered into a forward stepwise multiple logistic regression 
model to identify variables independently associated with bad outcome or 
JE positive status; multiple imputation methods (10 iterations) were used to 
overcome problems of missing observations and collinearity statistics were 
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examined to ensure independence of the predictor variables. The median age 
and numbers of AES cases were mapped using ArcGIS version 9.3 (Esri Ltd., 
California) software to show their distribution in the different districts across 
Nepal in order to identify any spatial patterns in infection dynamics. Statistical 
signifi cance was set at the conventional 5% level for all analyses. 
3.4 Results
3.4.1 Baseline characteristics 
Of the total of 17,929 children admitted in the two hospitals (KCH, 13,397 and 
PH, 4,532) between January 1st, 2006 and January 1st, 2008, 225 (KCH, 208 
and PH, 17) children of AES were considered for the study. Forty (18%) of 
these patients did not have any lumbar puncture (LP) results available in their 
notes. These patients were analysed separately.
Of the remaining 185 AES patients, 40 (22%) were diagnosed with either 
bacterial (n=39) or Plasmodium falciparum infection (n=1). Eight of these 
patients also had elevated anti-JE virus titres (≥40 units) on serum IgM testing 
during acute illness. Since bacterial co-infection can change clinical features 
and infl uence patient outcome, these patients were analysed separately (Fig. 
3.1).
One hundred and forty fi ve AES patients (145/185;78%) were considered 
to have AES of suspected viral aetiology. Forty-two of these patients (23%) 
were confi rmed as JE. Among the other 103 patients, 44 tested negative to JE 
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using samples collected after the ninth day of their illness and therefore were 
classifi ed as Non-JE. For the remaining 59 patients JE status was unknown (Fig 
3.1).
The majority of JE positive patients, 41/50 (82%), were identifi ed by serum 
testing positive for anti-JEV IgM antibodies, with 31/41 (79%) identifi ed 
by a single serum sample. The other serum samples tested positive in paired 
samples. The remaining 9 patients were diagnosed by testing positive for anti-
JEV IgM antibodies in the CSF. 
The majority of the non-viral AES patients were diagnosed with suspected 
bacterial meningitis based on a raised cell count with a polymorph 
predominance and raised protein in the CSF. The commonest identifi ed cause 
of infection was gram stain positive bacteria in CSF.
Patients presented to Kanti Children’s (n=208) or Patan hospital (n=17) 
from a wide range of outlying districts from Kathmandu including the hill 
and mountain districts. There were no marked differences in geographic 
distribution for the number of cases or age at presentation among the different 
sub-groups of suspected viral AES patients (Fig. 3.2). Route of presentation to 
hospital was documented in 175 AES patients. Self-referral was the commonest 
route of presentation, reported by 96/175 (55%) of AES patients.
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3.4.2 Patient outcome
Outcome at discharge was recorded for 183/185 patients where LP results were 
available and 38/40 patients without LP results. Among the patients without 
LP results, seventeen (45%) had a bad outcome; 10 (26%) died and a further 7 
(18%) had neurological sequelae at discharge.
Among the AES patients with non-viral infection, 38/40 (95%) had an outcome 
at discharge recorded. Five (13%) had a bad outcome; 2 died and a further 3 
had neurological sequelae at discharge. All 8 patients with bacterial and JE 
co-infection exhibited complete recovery at discharge. The one patient with 
Plasmodium falciparum infection recovered completely. 
Among the AES patients with suspected viral infection, 45/145 (31%) had a 
bad outcome; 8 died and 37 had neurological sequelae at discharge. Among the 
sub-set of confi rmed JE patients 20/42 (48%) had a bad outcome; 4 died and 16 
had neurological sequelae (Table 3.1).
A signifi cantly higher proportion of patients without LP results died compared 
to those where LP results were available (10/38 [26%] versus 10/183 [5%]; 
P<0.001). Similarly, the proportion of patients with bad outcome were higher 
among patients without LP results (17/38 [45%] versus 51/183 [28%]; P= 
0.053). Exclusion of the patients without LP results may have infl uenced 
outcome within the AES groups. To help address this issue, an additional 
analysis was undertaken, whereby patients without LP results were classifi ed 
into AES categories based on their hospital discharge diagnosis supported 
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by their JE serological results. The patients contributed to all AES groups. 
Each AES category exhibited a higher rate of bad outcome. There were no 
signifi cant changes in the proportion of patients with bad outcome between 
groups (Table 3.1). 
A signifi cantly higher proportion of patients with AES of suspected viral 
aetiology had a bad outcome compared to AES patients with a non-viral 
infection (45/145 [31%] versus 5/38 [13%]; P=0.039). A signifi cantly higher 
proportion of JE patients exhibited a bad outcome compared to AES patients of 
unknown viral aetiology (20/42 [48%] versus 25/103 [24%]; P=0.01). A similar 
trend was observed when JE patients were compared to Non-JE patients, with a 
higher proportion of JE patients exhibiting a bad outcome (20/42 [48%] versus 
12/44 [27%]); P=0.07; Table 3.1).
3.4.3 Prognostic features associated with bad outcome at dis-
charge 
Multiple parameters were associated with bad outcome at discharge for both 
AES cases of suspected viral aetiology (n=145) and confi rmed JE (n=42) 
(Table 3.2). In both groups, bad outcome was associated with a longer duration 
of fever prior to admission, a lower Glasgow coma score, a focal neurological 
defi cit, older patient age and higher weight at admission. 
To identify whether these features were independently associated with 
bad outcome, these variables were entered into a forward stepwise logistic 
regression model separately for each patient group. For the larger group, all 
AES of suspected viral aetiology, fever duration (P=0.002), GCS (P<0.001), 
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and focal neurological defi cit (P=0.001) were retained in the model for 
outcome. In JE, fever duration (p=0.007) and GCS (p=0.020) were again 
independently associated with bad outcome (but not focal neurological defi cit) 
together with age (P=0.011).
To assess whether length of time from onset of illness to hospital admission 
was a prognostic marker for bad outcome, I used length of reported fever prior 
to admission as a proxy marker. I selected a threshold of 7 days of fever prior 
to admission (Fig 3.3). I found fever duration over 7 days was associated with 
a bad outcome. Fever duration was reported in 142/145 (98%) of patients with 
AES of suspected viral aetiology. Thirty-two patients reported fever duration 
of more than 7 days prior to admission. Of these, 19 had bad outcome and 13 
had good outcome. The remaining 110 patients reported a fever duration under 
7 days, of which 23 had bad outcome and 87 had good outcome (19/32 [59%] 
versus 23/110 [20%]; P< 0.001).This indicates that AES patients who present 
with a prolonged fever prior to hospital admission have an increased risk of 
having a bad outcome at discharge (Relative Risk = 2.8 [95% confi dence 
interval: 1.6 – 4.4]). 
Among the JE patients, a reported fever duration of more than 7 days prior 
to admission was again linked to a signifi cantly higher rate of bad outcome 
compared to those who presented with a shorter duration of fever (9/11 [82%] 
versus 11/31[36%]; P=0.013). Among patients with AES of non-viral aetiology, 
prolonged duration of fever prior to admission was also linked to a higher rate 
of bad outcome (2/6 [33%] versus 3/22 [14%]; P=0.28). 
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Of the treatments given to AES patients of suspected viral aetiology, mannitol 
and phenytoin were more frequently prescribed among those with a bad 
outcome compared to those with a good outcome; 27/61 (44%) versus 19/119 
(16%), P<0.001 for mannitol; 23/61 (38%) versus 12/119 (10%), P<0.001for 
phenytoin, in bad and good outcome patients respectively. 
3.4.4 Clinical features that distinguish between confi rmed JE 
and AES of suspected non-JE viral aetiology 
Confi rmed JE cases were compared to AES cases of unknown viral aetiology 
(Non-JE and JE status unknown). As the latter group also contained patients 
that did not have a confi rmed negative test for JE, a further analysis was 
undertaken comparing JE against Non-JE cases. 
The rates of many clinical features and laboratory parameters were similar 
on admission between confi rmed JE, confi rmed Non-JE and JE-status 
unknown (Tables 3.3 and 3.4). Importantly, the rates of many recorded 
neurological features were comparable between the patient groups. There 
were no signifi cant differences in prevalence of an altered sensorium at 
admission, depth or duration of coma, frequency, duration or type of seizures 
between patient groups. However, there was a signifi cantly higher prevalence 
of patients presenting with focal neurological defi cits at admission among 
confi rmed JE patients compared to AES cases of unknown viral aetiology 
(13/40 versus 11/103; P=0.005; Relative Risk = 3.0 [95% confi dence interval: 
1.4-6.7]). Among AES patients of suspected viral aetiology, presence of a 
focal neurological defi cit at admission had a positive predictive value of 32% 
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(sensitivity 54%) for JE. Absence of a focal neurological defi cit at admission 
had a negative predictive value of 89% (specifi city 77%) for the patient not 
having JE. 
JE patients presented with a lower body weight (15.25 versus 20 Kg; P=0.031), 
and a higher respiratory rate (30 versus 28 breaths per minute; P=0.003) 
compared to confi rmed non-JE patients. With the caveat that serum urea, 
creatinine and electrolytes were measured in only 25 AES patients of suspected 
viral aetiology, there was a trend for higher serum urea (15 versus 8.9 mmol/
L; P=0.27), sodium (137 versus 133 mmol/L; P=0.09) and potassium (4.3 
versus 3.9 mmol/L; P=0.21) among JE compared to Non-JE patients (Table 
3.4). These parameters again showed a non-signifi cant trend for higher median 
values among JE patients compared to AES patients of unknown viral aetiology 
(Table 3.4). 
Both weight and respiratory rate, which were signifi cantly different among JE 
patients compared to Non-JE patients, are in part dependent on patient age. To 
further dissect the infl uence of these parameters, age, weight and respiratory 
rate were entered into a stepwise logistic regression model. Only raised 
respiratory rate (P=0.011) was retained as independently correlated. 
Admission patterns also differed between JE and Non-JE patients. JE 
patients demonstrated a clear peak in hospital admissions rates in the months 
immediately following the rainy seasons each year (August and September in 
2006-2007). Non-JE patients didn’t demonstrate any clear seasonal variation in 
hospital admission rates (Fig. 3.4).
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3.5 Discussion 
This study demonstrates that patients with AES of suspected viral aetiology, 
either where JE was confi rmed or where viral aetiology remained unknown, 
were signifi cantly more likely to have a bad outcome compared to AES patients 
with bacterial or malaria infection.
Appropriately, JE surveillance is a health priority in Nepal. However, public 
health and clinical teams should be aware that patients with AES of unknown 
viral aetiology also have a high risk of morbidity and mortality. Furthermore, 
since there are up to 3 times more Nepali children with AES of unknown viral 
aetiology than proven JE, a bad outcome among the former group impacts on a 
larger number of children Therefore, identifi cation and optimising management 
of patients with AES should also be a priority. 
The lower frequency of bad outcome among the AES patients with bacterial 
or malaria infection is likely to refl ect the availability and effective use of 
antibiotics and anti-malaria treatment to reduce morbidity among these 
patients. Non of the patients of bacterial or malaria infection failed to receive 
antibiotics or anti-malarial respectively. 
AES patients without LP results exhibited a signifi cantly higher rate of 
death. The fi nding is likely to refl ect lumbar punctures being undertaken less 
frequently on children who were critically ill (Table 3.1). The fi nding highlights 
that restricting analyses to patients where LP results are available can lead to an 
underestimation of the frequency of death and bad outcome linked to AES.
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Interestingly, the study has identifi ed that the number of days of fever 
(refl ecting number of days of illness) the patient experienced prior to hospital 
admission is a prognostic indicator of bad outcome in both patients with AES 
of unknown viral aetiology and JE. When analysis was applied to AES patients 
of bacterial aetiology no signifi cant association was identifi ed. Antibiotic use 
in the community may reduce fever duration prior to hospital admission in 
patients with bacterial infection and may confound the association between 
fever duration and bad outcome. In contrast, antibiotics would have limited 
impact on fever duration during viral infection. 
 
Shorter duration of illness (or fever) prior to admission has previously been 
associated with good outcome among children for many diseases. What is 
striking about my fi nding is that there is no specifi c treatment for JE or AES 
of suspected viral aetiology, yet attending hospital earlier in the illness course 
appears to be of benefi t. The fi ndings would suggest that hospital admission 
and the supportive management received there improves outcome.
Patients with impaired consciousness are often unable to drink themselves. 
Consequently, dehydration and metabolic acidosis may complicate AES 
(114). Dehydration and acidosis would fi t the signifi cantly lower body 
weight and higher respiratory rate observed among JE compared to Non-JE 
patients. A previous prospective survey of JE management identifi ed that fl uid 
supplementation was associated with a positive infl uence on outcome (93). 
Although appropriate fl uid provision is a delicate balance when managing brain 
injury (89, 115), one possible explanation of the positive infl uence of hospital 
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admission may be that patients receive fl uid support in hospital during the 
illness.
Given the commonest reported mode of presentation was self-referral, the 
focus on hastening patient attendance would lie with improving patient 
awareness of the features of AES and encouraging families to attend hospital 
promptly. Further research is needed to understand the factors that underlie 
families’ health-seeking behaviours when a child is ill. 
Low weight in JE patients could also be that they were malnourished. Severe 
acute malnutrition resulting from a relatively short duration of nutritional 
defi ciency often complicated by concurrent infections has a high mortality 
rate (116, 117). Previous studies have also reported bacteraemia in 16% - 22% 
of patients of malnutrition (118, 119). This is probably because they have 
limited ability to cope up environmental and infective stresses making them 
vulnerable to infections. Therefore, underlying malnutrition could have also 
been a risk factor for symptomatic JEV infection in these children. JE patients 
with malnutrition may also have additional complications of malnutrition 
such as hypothermia, hypoglycemia, hyponatremia, hypokalemia, anaemia 
or hypoalbuminemia leading to adverse outcome. However, children who 
were brought early to the hospital and administered supportive management, 
without administering separate treatment for malnutrition, in the present study, 
resulted in good outcome meant that they were probably dehydrated rather 
than malnourished. However, whether underlying malnutrition increased risk 
of symptomatic JE or caused bad outcome in these children needs to be further 
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studied. I also did not have information on socioeconomic status (SES) on the 
patients which could have been helpful, pitfall of retrospective study. 
As shown previously, a low Glasgow coma scale (GCS) and / or a focal 
neurological defi cit at hospital admission were independent clinical markers 
of bad outcome among children with AES (120). JE patients frequently exhibit 
raised intra-cranial pressure, brain herniation syndromes (20,52) and focal 
brain lesions on neuro-imaging studies (121), explaining the preponderance of 
focal neurological defi cits in this group.
In line with previous reports, mannitol was prescribed signifi cantly 
more frequently among AES patients who exhibited a bad outcome (93). 
Interestingly, a randomised clinical trial of mannitol among children with 
raised ICP secondary to cerebral malaria (another cause of non-traumatic brain 
injury) did not identify any benefi cial effect (122). A similar study would help 
clarify whether mannitol is a useful supportive treatment in AES (123). 
JE patients exhibited an increased respiratory rate compared to Non-JE 
patients. Furthermore, JE patients who exhibited a high respiratory rate were 
associated with a good outcome, while those with a lower respiratory rate were 
associated with a bad outcome. This pattern can be observed during evolution 
of many complications, including metabolic acidosis, pneumonia, acute fl accid 
paralysis (involving the inter-costal muscles) or brain damage, where there may 
be an initial compensatory rise in respiratory rate followed by a fall when the 
body decompensates.
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Tachypnea is also a feature of the severe brain injury syndrome - paroxysmal 
autonomic instability with dystonia (PAID)(124). Patients with this brain 
injury syndrome exhibit intermittent agitation, diaphoresis, hyperthermia, 
hypertension, tachycardia, tachypnea, and extensor posturing. All of these signs 
overlap with features reported in both JE and AES. PAID may exist among 
AES patients.
As a descriptive analysis this study cannot distinguish cause from consequence. 
Consequently although several clinical features and interventions appear linked 
with outcome, this study is unable to determine whether these parameters 
are causal. Similarly, as a retrospective study it is limited by the breadth 
and quality of information available in the hospital notes. More detailed 
information on acid-base status would help discriminate between respiratory 
and metabolic causes of tachypnea. Similarly, more systematic measurement 
of urea and electrolytes and additional indicators of fl uid balance would help 
assess the infl uence of fl uid support on outcome. Based on their discharge 
diagnosis, the AES patients without LP contributed to all AES groups. 
However, a prospective study with a more systematic investigation of pathogen 
aetiology is warranted to confi rm these fi ndings.
In conclusion, Nepali children with AES of suspected viral aetiology, either 
where JE is confi rmed or where the aetiology remains unknown, exhibit a 
high rate of death and morbidity. One of the more striking fi ndings from the 
study was the association between long duration of fever prior to admission 
and bad outcome. If patients with AES of suspected viral aetiology, including 
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those with confi rmed JE, attend hospital early they are more likely to make 
a full recovery. Despite no specifi c treatment for JE or for patients with AES 
of suspected viral aetiology, the current management in Nepal can limit 
the development of neurological sequelae. The fi ndings imply that family 
members, primary and community health care workers should be aware of AES 
and seek early referral for appropriate and potentially life-saving, supportive 
management. 
Despite many comparable neurological features between JE patients and 
patients with AES of unknown viral aetiology, signifi cantly more JE patients 
exhibited a bad outcome. This, in part, may refl ect the higher proportion of JE 
patients that presented with a focal neurological defi cit at hospital admission. 
Further research is needed to understand the factors that underlie bad outcome 
in AES and JE, including a more systematic investigation of the infl uence of 
supportive measures. 
3.6 Limitation of study
Since this was a retrospective study, the information present in the notes was 
limited by the level of training, knowledge and interest of the treating clinician. 
Therefore, important clinical features for AES and JE patients may have not 
been recorded. This may have infl uenced the clinical and laboratory parameters 
identifi ed to predict JE from other causes of AES. Many patients were excluded 
from the analysis because no LP was performed. Importantly, there were 
signifi cantly more number of deaths in those without an LP, as compared to 
those who had a LP. Again, this could have led to underestimation of the actual 
116
number of patients who suffered a bad outcome; this may have infl uenced 
the laboratory parameters, particularly CSF parameters, which predicted bad 
outcome.
I used a case defi nition of AES according to WHO surveillance standards. 
However, this has not been validated in Nepali children. Further, assessment 
of consciousness and seizure are often diffi cult in children. Rarely, a bulging 
anterior fontanel may be the only presentation of encephalitis in young 
children. Therefore, there is a need to validate clinical features of AES as a 
screening tool to identify children with suspected viral encephalitis which 
could have led to exclusion of some of the children of suspected viral 
encephalitis from this study. 
Although, lower weight and indirect markers of JE as compared to non-JE 
could have been because of dehydration, whether malnutrition is the cause of 
symptomatic JE or bad come is still speculative. Additional information on the 
social economic status (SES) of the patients could have also been helpful. 
3.7 Summary
On analysing two year's records of two major hospitals of Kathmandu, I 
found Nepali children with AES of suspected viral aetiology whether JE or 
of unknown viral aetiology suffered high death rates and severe neurological 
sequelae. Bad outcome was signifi cantly associated with older age and higher 
weight in patients of both AES and JE. Surprisingly, despite many comparable 
clinical features between patients of JE and AES of unknown viral aetiology, JE 
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patients had signifi cantly more focal neurological defi cits and exhibited worse 
outcome as compared to AES of unknown viral aetiology. JE patients also had 
lower body weight, higher respiratory rate, a trend for a higher serum urea and 
potassium levels as compared to patients of non-JE, which could be because 
of dehydration. Patients with impaired consciousness and focal neurological 
defi cit may not have been able to eat or drink suffi ciently which could cause 
dehydration or metabolic acidosis. Therefore, preventing longer duration of 
fever by hastening them to attend hospitals to receive supportive management 
including fl uids early could improve outcome. However, lower body weight 
could also be because of underlying malnutrition in these children. Malnutrition 
could be a risk factor or complicate management AES patients causing adverse 
outcome. Since both the condition causes loss of weight, it is important to 
accurately measure weight and fi nd out it's relationship with outcome. 
Understandably in children, weight increases with increase in age. WFA 
allows you to compare body weight relative to the child’s age and gender at a 
given time and accurately compare whether the weight measured at the time 
of admission was low, high or appropriate for that age and sex. WFA can be 
distributed in different categories based on Z score for a particular gender in 
children such as +3, +2 +1, 0, -1, -2, -3 WFA Z scores. WFA Z scores below 
-1 Z score can be taken to be a marker of acute loss of weight in children (91). 
Therefore, Z scores of 0, +1, +2 and +3 can be considered not to be of low 
WFA and Z scores -1, -2 and -3 as low WFA. Accurate assessment of different 
WFA Z score categories together with clinical and laboratory features could be 
of further value to help differentiate between malnutrition and dehydration.
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Community health workers in Nepal are trained to measure accurate weight 
through public health programmes. Even nurses are trained to measure weight 
of the attending sick children in order to plan treatment. Although, weight-
for-height and body mass index (BMI) maybe better methods to separate 
malnutrition from dehydration, lack of resources and abnormal posturing and 
change in body tone make it diffi cult and inaccurate in patients with AES. 
Since this was a retrospective study, many necessary clinical data, including 
accurate weight of all children, were lacking or questionable in some of the 
cases because it was recorded by different people with different intention and 
qualifi cation. Therefore, I decided to conduct a more systematic prospective 
study to assess the association of immediate and long term outcome of AES 
children with different WFA Z score categories on admission. If successive 
decrease in lower WFA Z scores were associated with death or neurological 
sequelae, then educating the parents and health workers to measure weight to 
help identify high risk patients for immediate referral could save lives. This 
study has been described in my next chapter.
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Figure 3.1: Flow diagram of Acute Encephalitis Syndrome patients based on 
aetiological classifi cation. 
225 children with AES were identifi ed. To analyse AES of different aetiologies 
only patients where LP results were available were taken forward (n =185). 
Patients with non-viral aetiologies were analysed separately (n = 40). The 
remaining AES patients were classifi ed as JE (n = 42) or AES of unknown 
viral aetiology (n = 103) based on presence or absence of high anti-JE virus 
immunoglobulin titres. AES of unknown viral aetiology was further sub-
classifi ed into Non-JE (n = 44) and JE Status Unknown (n = 59) based on 
presence or absence of low or negative anti-JE virus immunoglobulin titres.
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Figure 3.2: Map of residence district for Acute Encephalitis Syndrome patients 
of suspected viral aetiology.
Panel A, All AES patients of suspected viral aetiology; Panel B, JE patients; 
Increasing depth of shading within a district indicates a higher number of AES 
patients were admitted from this district. Unshaded districts indicate no patients 
were admitted from this district. Increasing circle diameter within a district 
indicates AES patients of an older (median) age were admitted. Kathmandu is 
labelled on the map.
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Figure 3.3: Fever duration prior to admission organised by outcome among 
AES patients of suspected viral aetiology.
Panel A, All AES patients of suspected viral aetiology; Panel B, JE patients 
X-axis; fever duration (1-14 days) 
Y-axis; Number of patients that presented to hospital at each day of fever 
duration (1-24)
Solid bar shading; number of patients who exhibited a bad outcome at 
discharge
Hatched bar shading; number of patients who exhibited a good outcome at 
discharge
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Figure 3.4: Monthly admission numbers for Acute Encephalitis Syndrome 
(AES) patients of suspected viral aetiology. 
X-axis; month of admission 
Yaxis; Number of patients admitted to hospital each month 
Solid bar shading; number of JE patients
Hatched bar shading; number of Non-JE patients 
Dotted bar shading; number of patients where JE Status unknown
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Table 3.2: Clinical features for confi rmed JE and AES patients of suspected 
viral aetiology reported by outcome
Clinical Features at 
admission Confi rmed JE (n=42)
AES suspected viral aetiology 
(n=145)
Bad Good p-value Bad Good p-value
 No. patients 20 22 45 100 
Age (years) 10 (1-14) [20] 4.5 (1-13) [22]  0.004 8 (1-14) [45] 6 (1-14) [97]  0.005
Number of males 5 (25) [20] 11 (50) [22]  0.121 13 (29) [45] 30 (31) [98]  1.000
Days of fever prior 
to admission* 7 (3-13) [20] 5 (1-12) [22]  0.010 7 (1-14) [45] 5 (1-13) [100] <0.001
Altered sensorium 17 (85) [20] 13 (59) [22]  0.091 39 (89) [44] 55 (56) [98] <0.001
Duration of altered 
sensorium (days)† 2 (1-5) [13] 2 (1-3) [10]  0.839 2 (1-7) [30] 1 (1-4) [43]  0.009
Modifi ed Glasgow 
coma score* 11 (5-15) [20] 14 (7-15) [22]  0.001 11 (3-15) [44] 14 (4-15) [98] <0.001
Focal neurological 
defi cit 9 (50) [18] 4 (18) [22]  0.046 17 (40) [43] 7 (7) [100] <0.001
Any seizure prior to 
admission 10 (77) [13] 15 (75) [20]  1.000 24 (77) [31] 67 (83) [81]  0.591
Episodes of seizure 
prior to admission‡ 2 (1-12) [9] 2 (1-4) [14]  0.723 2 (1-12) [19] 2 (1-7) [48]  0.034
Neck stiffness 14 (82) [17] 9 (45) [20]  0.040 29 (71) [41] 49 (54) [91]  0.086
Vomiting 10 (71) [14] 13 (87) [15]  0.390 29 (81) [36] 47 (86) [55]  0.573
Days of vomiting 
prior to admission∆ 3 (2-10) [8] 3 (1-7) [9]  0.400 3.5 (1-12) [26] 2 (1-8) [37]  0.019
Weight (kgs) 19.5 (9-30) [20] 13 (1-26) [22]  0.017 19 (4-35) [45] 15 (1-70) [90]  0.040
Axillary temperature 
(˚C)
38.1 (36.7-40.0) 
[20]
37.8 (36.7-39.4) 
[20]  0.170
37.8 (36.1-40.0) 
[44]
37.8 (36.1-
40.0) [86]  0.256
Pulse rate (beats per 
min.) 101 (52-150) [20] 104 (76-130) [22]  0.905
106 (52-160) 
[44]
110 (64-170) 
[96]  0.972
Respiratory rate 
(breaths per min.) 28 (20-50) [20] 36 (20-80) [22]  0.064 28 (3-60) [45]
30 (16-90) 
[92]  0.158
Death prior to 
discharge  4 (20) [20] 0 (0) [22]
---
 8 (18) [45] 0 (0) [100]
---Neurological 
sequelae at 
discharge 
16 (80) [20] 0 (0) [22] 37 (82) [45] 0 (0) [100]
Treatment       
Phenytoin 6 (30) [20] 0 ( 0) [22]  0.007 18 (40) [45]  8 ( 8) [100] <0.001
Phenobarbitone 5 (25) [20] 3 (14) [22]  0.445 10 (22) [45] 10 (10) [100]  0.067
Dexamethasone 6 (30) [20] 4 (18) [22]  0.477 12 (27) [45] 22 (22) [100]  0.533
Mannitol 6 (30) [20] 2 ( 9) [22]  0.123 19 (42) [45] 15 (15) [100]  0.001
Median (range) [number of patients] or Number (%) [number of patients]. Signifi cance 
of difference between groups by Fisher’s Exact test or Mann-Whiney U test. †: patients 
with altered sensorium only ‡: patients with one or more seizures before admission 
only ∆: patients with vomiting prior to admission only
* Parmeters identifi ed as independently associated with bad outcome in both AES 
groups 
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Table 3.3: Clinical features at admission for fi ve categories of Acute Encephali-
tis Syndrome patients
Clinical features Confi med JE AES unknown viral aetiology (n=103) AES bacterial aetiology (n=39)
  Non-JE JE Status Unknown Bact. Inf. Bact. and JEV+
 No. patients (% 
AES patients 
(n=184†))
42(23) 44(24) 59(32) 31(17) 8(4)
Age (years) 7(1-14)[42] 8(1-14)[44] 4.5(1-13)[56] 4.5(1-12)[31] 3.5(1-10)[8]
Number of males 16(38)[42] 16(36)[44] 16(27)[59] 11(35)[31] 8 [100][8]
Days of fever 
prior to admission 5.5(1-13)[42] 6(2-14)[44] 5(1-12)[59] 5(1-13)[30] 5 (1-16)[7]
Altered sensorium 30(71)[42] 29(69)[42] 35(60)[58] 13(43)[31] 5 [63][8]
Duration of 
altered sensorium 
(days)
2(1-5)[23] 2(1-7)[24] 1(0-5)[27] 3(1-4)[9] 1(1-1.1)[3]
Modifi ed Glasgow 
coma score 12(5-15)[42] 14(4-15)[44] 14(3-15)[59] 15(4-15)[30] 12(7-15)[8]
Focal neurological 
defi cit 13(32)[40] 7(16)[44] 4(7)[59] 2(12.5)[16] 1(33)[3]
Any seizure prior 
to admission 25(76)[33] 25(78)[32] 42(89)[47] 21(75)[28] 4(50)[8]
Generalised 
seizure prior to 
admission
22(96)[23] 22(92)[24] 35(92)[38] 21(95)[22] 3(38)[8]
Focal seizure prior 
to admission 1(4)[23] 0(0)[24] 1(3)[38] 0(0)[22] 0(0)[8]
Episodes of 
seizure prior to 
admission
2(2-12)[23] 1(1-7)[17] 2(1-9)[27] 1.5(1-7)[18] 1.2 (1-1.5)[2]
Est. duration of 
longest seizure 
(mins.)
6(3-60)[16] 6(3-60)[16] 5(4-60)[12] 5(1-5)[3] 10(10-10.2)[2]
Neck stiffness 23(62)[37] 27(66)[41] 28(52)[54] 18(58)[31] 5(63)[8]
Vomiting 23(79)[29] 24(83)[29] 29(88)[33] 18(78)[23] 3(38)[8]
Days of vomiting 
prior to admission 3(1-10)[18] 4(1-11)[21] 2(1-12)[25] 3.5(1-10)[12] 1.2(1-2)[5]
Weight (Kg) 15.25(1-30)[42] 20(9-70)[38]* 14(1-60)[55] 15(1-60)[29] 11(1-25)[8]
Axillary 
temperature (˚C) 37.8(36.7-40)[40] 37.2(36.1-40)[38]
37.8(36.1-
40)[52] 37.8(36.7-41.1)[29] 38.9(37.8-39.4)[7]
Pulse rate (beats 
per min.) 101(52-150)[42] 100(69-160)[41] 110[78-170)[57] 100(70-160)[28] 120(72-130)[7]
Systolic BP 
(mmHg) 96(50-120)[17] 93(78-130)[20] 100(9-110)[14] 100(80-140)[11] 100(90-110)[3]
Dystolic BP 
(mmHg) 60(20-90)[17] 60(10-100)[20] 60(0-100)[15] 70(50-110)[11] 70(60-80)[3]
Respiratory rate 
(breaths per min.) 30(20-80)[42] 28(16-60)[40]** 30(3-90)[55] 34(20-50)[30] 34(24-40)[7]
Median (range) [number of patients] or Number (%) [number of patients]. 
Signifi cance of difference between groups by Fisher’s Exact test or Mann-
Whiney U test. †Single patient with Plasmodium infection not presented. 
Signifi cant difference between JE and Non-JE patients; P=0.031*; P=0.003**
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Table 3.4: Laboratory parameters at admission for fi ve categories of Acute 
Encephalitis Syndrome pateints 
Laboratory 
parameters Confi med JE AES unknown viral aetiology (n=103) AES bacterial aetiology (n=39)
Non-JE JE Status Unknown Bact. Bact. and JEV+
 No. patients 42 44 59 31 8
Blood
Hemoglobin (g/L) 112 (80-190) [37] 116 (80-140) [37] 112(60-200)[55] 116(30-460)[24] 112(81-120)[7]
Total leukocyte 
count (x109/L) 10.9 (2.46-33)[41] 9.6 (1.8-25.8)[40] 12.5(4.0-9.8)[56] 9.5(1.48-110)[27] 12 (1.96- 190)[7]
Polymorphs 
(proportion) 0.73 (0.08-0.92) [41] 0.72 (0.3-0.96) [39] 0.75(0.16-0.93)[56]
0.77(0.50-
0.92)[27] 0.82(0.63-0.95)[7]
Lymphocytes 
(proportion) 0.21 (0.08-0.82) [41] 26(0.04-0.7)[39] 0.24(0.06-0.84)[54] 0.21(0.08-0.4)[27] 0.18(0.05-0.34)[7]
Blood sugar 
(mmol/L) 5.1 (2.2-12.1) [13] 5.1(2.2-10.3)[20] 4.4(3.3-7.5)[26] 6.5(3.7-13.3)[4] 7.8(6.4-8.2)[5]
Urea (mmol/L)† 15 (6.8-17.1) [5] 8.9(1.4-18.9)[10] 10.3(0.7-20.3)[10] Nr 9.6(5.3-21.4)[3]
Creatinine (μmol/
L) 44.2(8.8-88)[3] 53.4(8.8-71.6)[11] 53.0(8.8-79.6)[13] Nr 64.5(35- 80)[3]
Sodium (mmol/L) 137(127-160)[12] 133 (126-146) [17] 133(109-149)[20] 139(129-148)[9] 137 (134- 139)[2]
Potassium (mmol/
L) 4.3(3-5)[12] 3.9(3-5)[17] 3.95(2-5)[20] 3.8(3.5-4.9)[9] 3.8 (3.6- 3.9)[2]
Cerebrospinal 
fl uid
Total leukocyte 
count (x109/L) 0.043(0-0.6)[42] 0.041(0-0.83)[44] 0.035(0-0.54)[59] 0.14(0-1.4)[31]* 0.07 (0-0.4)[8]
Polymorphs 
(proportion) 0.1(0-1)[41] 0.3(0-1)[42] 0.26(0-1)[57] 0.7(0-1)[30]* 0.8(0-0.9)[8]
Lymphocytes 
(proportion) 0.5(0-1)[41] 0.38(0-1)[42] 0.6(0-1)[57] 0.3(0-1)[30] 0.15(0-1)[8]
Protein (g/L) 0.4(0-1.2)[39] 0.4(0-1.5)[40] 0.4(0.1-1.5)[53] 0.65(0.2-1.5)[30]* 0.1(0.04-5.8)[8]
Sugar (mmol/L) 3.3(1.4-5.7)[41] 3.3(0.9-5.6)[43] 3.3(1.7-6.1)[53] 2.1(1.1-3.8)[30]* 2.1(0.7- 3.3)[8]
Median (range) [number of patients] or Number (%) [number of patients]. 
Signifi cance of difference between groups by Fisher’s Exact test or Mann-
Whiney U test. *Signifi cant (p<0.01) difference between patients within AES 
of suspected viral aetiology and AES of bacterial aetiology; nr, not recorded; 
†normal range for urea (newborn to 16 years): 1.1-6.4 mmol/L (125).
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Chapter 4: Weighing a child may help predict 
outcome in Acute Encephalitic Syndrome
Abstract
Background: Acute encephalitis syndrome (AES) describes a collection of 
symptoms and signs which help clinicians diagnose acute viral encephalitis 
(VE). Japanese encephalitis (JE) is a major cause of AES in Nepal. Previously 
I have shown in a retrospective study that JE patients had lower body weight, 
higher respiratory rate, a trend for a higher serum urea and potassium levels 
as compared to non-JE patients. JE patients also had signifi cantly more focal 
neurological defi cits and worse outcome as compared to AES of unknown 
viral aetiology. In this study, I wanted to fi nd out the association between low 
weight for age (WFA) on admission and immediate and long term outcomes of 
children with AES and JE. 
Methods: All children, 1-14 years, with fever, altered sensorium and/or 
seizure attending Kanti children’s Hospital (KCH) and BP Koirala Institute of 
Health Sciences (BPKIHS) in Nepal were recruited. Infection with JE virus 
was confi rmed by MAC-ELISA. Outcome was measured using Liverpool 
Outcome Score at discharge and follow up to 2 years. Detailed information on 
socio economic status (SES) could not be obtained and related in the study as 
the study was conducted in two public hospitals of Nepal catering to a diverse 
group of patients of different SES. 
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Results: Of total 152 cases of VE, 39 (25%) were JE, 71 (47%) non-JE and 
42 (28%) JE-status unknown. Among children with VE, those with lower 
WFA were signifi cantly younger, had prolonged illness, more episodes and 
longer seizure duration, more focal neurological defi cit, and higher serum urea 
level. Among JE patients those with low WFA had signifi cantly longer illness, 
and prolonged convulsion duration and compared to normal or higher WFA. 
Moderate to severe sequelae were more common in low WFA group of both 
VE and JE at discharge and follow up. Complete recovery was signifi cantly 
more at 1 year follow up in normal or higher WFA group JE patients. 
Conclusion: There was signifi cantly progressive increase in residual 
neurological sequelae as the WFA Z score decreased in both AES and JE 
patients. Low WFA at admission in children with AES was associated with 
signifi cantly more sequelae at discharge and persistence of sequelae even at 
2 years of follow up. Further work on the relationship between low WFA and 
fl uid and acid base status and malnutrition is recommended.
4.1 Introduction
Acute encephalitis syndrome (AES) describes a collection of symptoms 
and signs consisting of acute onset of fever with either altered level of 
consciousness or seizure or both (1). Most patients with the AES have acute 
viral encephalitis as the underlying cause, but other encephalopathies may also 
present with the same syndrome, including acute bacterial or parasitic central 
nervous system infections, and non-infectious encephalopathies (10).
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Japanese encephalitis (JE) is a major cause of AES in Nepal. Since 2004, 
there has been national surveillance for JE by the government of Nepal 
supported by the World Health Organization (WHO) (126). Because of the 
large disease burden, the SA-14-14-2 live attenuated JE vaccine was used in 
a mass vaccination campaign in areas of high JE transmission in Nepal from 
2006; from 2009 these areas were also covered by the introduction of JE 
vaccination into the routine national immunisation schedule. Although JE has 
been curtailed to some extent by this measure, the burden of AES still remains 
high. Therefore, a huge number of children with AES still arrive at tertiary care 
hospitals and health institutions in the country mainly during the summer. 
The total weight of a person is summation of different body constituents made 
up of muscle, fat, water and bone. Generally, body weight indicates nutritional 
status of the person. Importantly, 60-80% of human body weight is water; less 
so in adults and more in children. Normally in children, weight increases with 
increase in age depending on the gender. Weight can be distributed in different 
categories such as +3, +2 +1, 0, -1, -2, -3 WFA Z scores for a particular gender. 
WFA Z scores below -1 can be considered a marker of acute loss of weight in 
children (91). Therefore, Z scores of 0, +1, +2 and +3 can be considered not to 
be of low and WFA and Z scores -1, -2 and -3 as low WFA (91). Assessment of 
clinical and laboratory features of patients of different WFA Z score could help 
in differentiating dehydration from malnutrition.
Prolonged duration of illness has been reported to be a predictor of bad 
outcome in AES and JE, previously (37, 75). Other indicators of bad outcome 
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are presence of focal neurological defi cit, lower level of consciousness, and 
restriction of fl uid and sodium during treatment (93). Even though there is no 
specifi c treatment for most of the patients of AES and JE, in those who arrived 
early at the hospital in the course of illness, and received supportive care, 
particularly intravenous fl uids, had a better chance of survival and complete 
recovery (75). Patients with prolonged illness and disability may have diffi culty 
feeding themselves causing malnutrition or dehydration; and lighter in weight. 
There was also a possibility that those lighter in weight could have been 
malnourished and vulnerable to JEV infection. 
In the retrospective study (chapter 3), when examining all AES cases (both JE 
and Non-JE patients), higher weight and older age were associated with ‘bad 
outcome’. However, when comparing patients of non-JE with JE, the latter 
were lighter and younger (75). A higher proportion of JE patients experienced 
‘bad outcome’. I could not identify a consistent association between weight 
and bad outcome, because age was a confounder within the AES and JE 
groups. Therefore, there was a need to investigate whether JE patients had 
lower weight-for-age (WFA) as compared to non-JE patients (by relating actual 
weight to expected weight based on population reference values). Lower WFA 
among the JE patients would suggest these patients were more dehydrated 
or malnourished. This may help identify potential mechanisms leading to the 
observed ‘bad outcome’ among the JE cases. 
Loss of weight in children during any illness increases risk of morbidity and 
mortality (127). Most of the health personnel in developing countries including 
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Nepal have been trained to measure accurate weight of children through 
various nutritional related public health programmes. If adverse outcome is 
found in patients of AES or JE with low WFA, then educating the parents and 
health workers, to measure WFA of children could be benefi cial. WFA may be 
used as a screening tool to identify high risk patients for immediate referral and 
explaining the prognosis. 
Measurement of the height of the patients and investigating the association 
of weight-for height and body mass index (BMI) with outcome of AES and 
JE patients would have been another alternative. Although in the UK, nurses 
routinely measure height and weight of the attending patients as a part of their 
hospital practices, it is not the same in Nepal. In most parts of Nepal, nurses are 
constantly encouraged to measure weight of the attending sick children because 
it is needed in the treatment to accurately calculate the dose of drugs, amount 
of intravenous fl uids and monitoring fl uid status. Most of the emergency 
departments do not have a measuring tape or a stadiometer to measure height 
of patients, which could have also discouraged them in measuring height. Even 
when there is one, abnormal posturing and change in body tone of patients of 
AES, make it diffi cult to measure their height. Therefore, I decided to conduct 
a more systematic prospective crossectional study to fi nd out the association of 
WFA on admission with outcome of children with AES and JE.
 
4.2.1 Aim
The aim of this study is to assess the clinical features, laboratory parameters 
and outcome of acute encephalitis syndrome in Nepali children of different 
weight-for-age categories.
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4.2.2 Objectives
1. To validate the clinical features and laboratory parameters which predict 
bad outcome of acute encephalitis syndrome and Japanese encephalitis.
2. To validate the clinical features and laboratory parameters which predict 
Japanese encephalitis from other causes of acute encephalitis syndrome in 
children.
3.  To describe the association of clinical features, laboratory parameters, 
immediate and long term outcome of children of acute encephalitis 
syndrome and Japanese encephalitis with different weight-for-age Z score 
categories on admission.
4.3 Methods
4.3.1 Setting: The study was conducted in Kanti children’s Hospital (KCH) 
and BP Koirala Institute of Health Sciences (BPKIHS) in Nepal. KCH is the 
only tertiary care referral public hospital with paediatric subspecialties located 
in Kathmandu valley (altitude, 4400 feet above sea level, population 2916680, 
under 14 year population of 887991). Most of the patients of JE attending this 
hospital are residents of the Southern low land called “Terai” (128, 129). It 
also receives reffered patients from all over the country. BPKIHS, is a large 
tertiary care teaching Hospital located in a small South-Eastern town of Dharan 
in “Terai” and primarily caters to the Eastern region of the country (altitude 
200- 29028 feet above sea level, population 6149651, under 14 year population 
1697574). 
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4.3.2 Case defi nition: A total of 216 children were recruited from April 2009 
to November 2010 in Kanti Children’s Hospital, Kathmandu and BPKIHS, 
Dharan in Nepal. The case defi nitions were as described in Chapter 2. 
4.3.2.1 Weight-for age Z scores: The level of growth (weight) retardation in 
children can be assessed by the how a child’s individual WFA relates to the 
NCHS/WHO reference child population [http://www.who.int/nutgrowthdb/
about/introduction/en/index5.html (as assessed on 3rd March 2016)](92). Z 
scores equate to standard deviations (SD) around the reference median. In a 
population with a normal WFA distribution, you would expect 15.9%, 2.3%, or 
0.13% of children to have a weight for age Z score of -1, -2 or-3 respectively 
[http://www.who.int/childgrowth/standards/Growth_standard.pdf (as assessed 
on 22 February, 2016)]. Historically the WHO defi ne a child with a WFA Z 
score of less than -2 or -3 as indicating moderate or severe under-nutrition 
[http://www.who.int/nutgrowthdb/about/introduction/en/index5.html (as 
assessed on 3rd March 2016)]. Recent studies have shown child mortality risks 
are not only higher at Z scores of -2 or less, but are also increased (albeit to 
a lesser extent) at -1 Z scores (91). Low WFA indicates under-nutrition, but 
in an acute setting it may also indicate poor fl uid intake (or dehydration). In 
this study, I stratifi ed subjects by their WFA Z score and examined outcome 
among these groups. Since there was no single standard baseline WFA growth 
chart for Nepali children, WFA was defi ned according to WHO defi nition for 
children below 5 years of age (Appendices H & I) and “Development of the 
Nepalese Growth Standard for the School-aged Children” for children above 5 
years of age (Appendix J).
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4.3.2.1.1 High WFA: Z score +1 (Z score between +1 and +2)
4.3.2.1.2 Average WFA: Z score 0 (Z score between +1 and -1)
4.3.2.1.3 Mild low WFA: Z score -1 (Z score between -1 and -2)
4.3.2.1.4 Moderate low WFA: Z score -2 (Z score between -2 and -3)
4.3.2.1.5 Severe low WFA: Z score -3 (Z score below than -3) 
4.3.3 Sample size: The sample size estimated was 102 participants in total (51 
in each group) as previously shown in chapter 3 (General Methods).
4.3.4 Recruitment: All children aged 1- 14 years with AES admitted to KCH 
and BPKIHS were seen by a member of the investigating team. Blood was sent 
for complete blood count (CBC), urea, electrolytes, liver function tests (LFTS), 
glucose, and viral serology as part of routine testing for AES patients. When 
an LP was performed, opening pressure was recorded and cerebrospinal fl uid 
sent for cell count and differential, glucose, protein, microscopy and culture, 
and JE serology. Following LP, patients whose LP results were suggestive of 
AES of suspected viral aetiology (or suspected viral encephalitis) (38), were 
approached for enrollment in the study. Other investigations were performed 
at the discretion of the treating physician. A check-list was used to confi rm that 
the inclusion criteria were met. Following this patients who gave consent were 
recruited into the study. A detailed history was taken from the accompanying 
parent or guardian by a member of the study team. Clinical examination, 
including full neurological examination was then peformed. All the information 
were recorded in specially prepared Proforma (Appendix G). Weight was 
measured at the time of admission using a digital weighing scale, which was 
quality controlled every morning using standard weights. The details of the 
recruitment process was as described in chapter 3 (General Methods).
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4.3.5 JE serology: Infection with JE virus was confi rmed by MAC-ELISA 
(IgM antibody capture-Enzyme Linked Immunosorbent Assay) in serum and/or 
CSF in NPHL, Teku, Kathmandu or BPKIHS, Dharan as described in Chapter 
3 (58, 113, 114). 
4.3.6 Management: The patients were managed according to the hospital 
protocol for management of AES. All children with suspected bacterial 
meningitis were given empirical intravenous (IV) crystalline Penicillin or 
Ceftrioxone. Patients who presented with seizures or were witnessed to have 
a seizure were immediately given intravenous (iv) midazolam or diazepam 
and later intravenous phenytoin or sodium valproate. For uncontrolled seizure, 
intravenous midazolam infusion and mechanical ventilation was provided 
in intensive care. Patients who had signs of raised intracranial pressure were 
managed with elevation of head, intravenous 20% mannitol infusion and/or 
intubation and hyperventilation. Patients who were in shock received volume 
expanders and inotropic support with intravenous dopamine or dobutamine 
infusion. All the recruited patients were monitored daily for change in Glasgow 
coma score (GCS), respiratory rate, pulse rate, blood pressure, temperature, 
maintenance fl uids and use of mannitol and anti-convulsant.
4.3.7 Outcome assessment: All patients with AES who were suspected of viral 
encephalitis including JE were reassessed at the time of discharge by a member 
of the investigating team. During assessment parents were interviewed and 
patients examined clinically with an emphasis on the neurological system also 
using the Liverpool Outcome Score (LOS) (109). They were then prospectively 
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followed-up again between 6- 24 months and were inquired on recovery, 
deterioration or death based on LOS. Those who did not follow-up were 
interviewed by telephone (Appendice K and L).
4.3.8 Ethics: The study was approved by the Institutional Review Committee 
of Kanti Children’s Hospital and BP Koirala Institute of Health Sciences and 
Ethical Committee of Nepal Health Research Council. 
4.3.9 Statistical analysis: All patients were analysed, including subgroup 
analysis for JEV positive patients. Normally distributed data was compared 
using Student’s t-test; data that were not normally distributed was compared by 
the Mann-Whitney U test. Differences between proportions were tested using 
the chi-square test with Yates’ correction or Fisher’s exact test. Comparison of 
more than two groups of normally distributed continuous variables were done 
using ANOVA and continuous but skewed variables were compared using 
Krushkar- Wallis test. P <0.05 was taken to be statistically signifi cant. 
4.4 Results
A total of 217 cases of AES were recruited in the study from the two hospitals. 
Thirty eight (12.8%) presented with fever and seizures (no altered sensorium), 
62 (20.8%) fever with altered sensorium (no seizures) and 117 (39.3%) had 
fever, altered sensorium and seizures. The median (range) duration of illness 
was 14 (3-44) days and median duration of hospital stay was 8 (1-14) days. 
Overall, 146 (49%) patients had a bad outcome, 50 (16.8%) good outcome 
and 71 (23.8%) left against medical advice (LAMA) without informing the 
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hospital staff so the fi nal outcome could not be assessed. Common reasons of 
LAMA were inability to pay the hospital charges after improvement (because 
all medical treatments are out-of-pocket in Nepal) and unavailability of beds 
in the paediatric intensive care unit (PICU). In such situations, they left before 
formal paper work could have been completed either to home or PICUs of 
other hospitals. Since these patients could not be followed up, this could have 
had some effect in the fi nal analysis of the patients. Amongst those who had a 
bad outcome, there were 28 deaths and 118 had residual neurological sequelae. 
First, I validated prospectively the predictors of bad outcome in patients of 
AES and JE; and predictors of JE from patients of AES, which were reported 
in my previous retrospective study (75). I found GCS ≤ 12, fever duration ≥7 
days and presence of focal neurological defi cit to be predictors of bad outcome 
in AES patients and GCS ≤ 12 as predictor of bad outcome in JE. I also found 
presence of focal neurological defi cit at the time of admission in patients of 
AES to predict JE. Presence of GCS ≤12 had a positive predictive value of 
82% (sensitivity 68%) for bad outcome in AES patients and positive predictive 
value of 91% (sensitivity 86%) for bad outcome in JE. Absence of GCS ≤12 
at admission had a negative predictive value of 36% (specifi city 56%) in AES 
and negative predictive value of 55% (specifi city 67%) in JE. I could not 
validate the presence of focal neurological defi cit at the time of admission in 
AES patients as a predictor of a diagnosis of JE probably because of the small 
number JE patients (Table 4.1). 
28 (13%) out of 217 AES cases were of non-viral aetiology and 37 (17%) cases 
did not have admission weight recorded appropriately because it was done 
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by untrained attending doctors who informed late to the research assistant. I 
therefore excluded these from the analysis. Of the total of 152 cases of VE 
recruited (Fig 4.1), 39(25%) were confi rmed JE, 71(47%) confi rmed non- JE 
and 42 (28%) of unknown JE status. 67 (44%) cases had low weight-for-age 
(WFA) and 85 (56%) did not have low WFA. According to WFA on admission 
in patients of VE, normal WFA in 76 (50%) and mild low WFA in 36 (24%) 
were the most common weight group (Figure 4.1). Similarly, in JE, 16 (41%) 
of normal WFA and 12 (31%) mild low WFA were also the most common 
weight group. Overall, in VE, a total of 61/107 (57%) cases discharged were 
followed up at one year [median (range), 342 (15- 631) days] and 51/107(48%) 
cases 2 years [median (range), 637 (570- 750) days] after discharge. Also, in 
JE, 17/34 (50%) cases were followed up at one year [median (range); 321 (15- 
390) days] and 12/34 (35%) cases at 2 years [median (range); 641 (605- 701) 
days] after discharge. The WFA distribution of the cases of VE and JE were as 
shown in fi gure 4.1.
Children with VE who had a lower WFA were signifi cantly younger, had a 
prolonged illness, more episodes of seizures, longer seizure duration, more 
focal neurological defi cit, higher serum urea level and neurological sequelae 
(Table 4.2). There was a non-signifi cant association between low WFA and 
death (p- 0.08). JE children with lower WFA also had signifi cantly prolonged 
illness, longer duration of convulsion and bad outcome especially neurological 
sequelae (Table 4.3). 
A total of 19 children with VE died and 91 had residual neurological sequelae 
at the time of discharge. Moderate sequelae was signifi cantly more in lower 
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WFA group ( -1 or less WFA Z score) and severe sequelae was also more in 
that group than normal or higher WFA group at the time of discharge (Table 
4.4). Complete recovery was observed to be more in normal and higher WFA 
group. Even up-to 2 years of follow up, more children of lower WFA had 
residual sequelae and less recovered completely than normal to high WFA 
group. Similarly in JE, a total of 4 children died and 28 had sequelae (Table 
4.5). Severe and moderate sequelae were more common in the lower WFA 
group at the time of discharge and follow up up-to 2 years. Complete recovery 
was signifi cantly more in the normal and high WFA group at the time of 
discharge. It was also higher in the group of children who were followed up for 
up-to 2 years. 
On assessing disability by LOS at the time of discharge, signifi cantly more 
children with lower WFA had epilepsy or seizures, cognition and motor defect 
such as recognition, feeding and walking diffi culties (Table 4.6). Signifi cantly 
more JE children with lower WFA also had motor abnormalities such as 
diffi culty in feeding and dressing (Table 4.7).
The recovery profi le relating to the neurological sequelae for both VE and JE 
patients was observed over two years. In VE, those who had moderate (-2 ) and 
severe (-3 ) WFA Z scores had more residual neurological sequelae at the time 
of discharge as compared to those who had normal (0) and higher (+1) WFA 
Z scores. Also, the residual sequelae were observed to persist in more than 
half the cases at 2 years follow up in the severe low WFA group as compared 
to those with normal or high WFA group (Table 4.8). The lower the LOS on 
assessment, the more severe the disability. The median LOS at the time of 
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discharge was lower in moderate and severe low WFA groups which continued 
to remain low even at 1 year and 2 year follow up as compared to normal and 
high WFA group. Although there was more residual neurological sequelae 
at the time of discharge in both moderate and severe low WFA group, there 
was no improvement in residual sequelae in 67% and 40% of cases at 1 year 
respectively which persisted in all of the cases at 2 years follow up. Similarly 
in JE, residual neurological sequelae at the time of discharge were seen more 
in moderate and severe low WFA group as compared to those who had normal 
WFA and higher WFA (Table 4.9). The median LOS at the time of discharge 
was also lower in moderate and severe low WFA group, and remained low at 1 
year and 2 year follow up as compared to normal and higher WFA group. 
4.5 Discussion
AES is mostly caused by viruses which lack defi nite treatment. Identifying 
risk factors and correctable supportive management options would help in 
explaining the prognosis to anxious patients and parents, prevent death, and 
decrease disability which could be a source of lifelong misery. Previously 
prolonged illness, prolonged fever, prolonged duration of altered sensorium, 
Glasgow coma score (GCS) below 8, multiple convulsions, presence of 
focal neurological defi cit, abnormal breathing, decerebrate posturing and 
hyponatremia at the time of admission have all been described to be predictors 
of bad outcome in AES and JE (10, 37). Even a combination of poor perfusion, 
GCS ≤ 8 and ≥ 2 witnessed seizures have been described to predict bad 
outcome when more than one risk factors was present in the same patient 
(21). However, the robustness and generalisability of these fi ndings to a range 
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of setting was uncertain (21, 37, 77, 78). Therefore I decided to validate my 
previous fi ndings prospectively in this study. 
Amongst the clinical features shown in Table 4.1 which were predictors of 
bad outcome in AES and JE in my previous retrospective study discussed 
in chapter 3, I validated prospectively GCS ≤ 12, duration of fever ≥7 days, 
presence of focal neurological defi cits at admission to be robust predictors of 
bad outcome in AES patients and GCS ≤ 12 also as predictor of bad outcome 
in JE in this study conducted at two different setting in Nepal. Presence of 
GCS ≤12 had a positive predictive value of 82% (sensitivity 68%) for bad 
outcome in AES patients and positive predictive value of 91% (sensitivity 
86%) for bad outcome in JE. Absence of GCS ≤12 at admission had a negative 
predictive value of 36% (specifi city 56%) in AES and negative predictive 
value of 55% (specifi city 67%) in JE. However, presence of focal neurological 
defi cits in AES which was found to predict JE in my previous study could not 
be validated in the present study. This unusual fi nding may have been because 
of less number of confi rmed JE cases in this study as compared to my previous 
study. Further re-analysis by boot strap method or reanalyzing the predictors 
from the fi rst two-thirds of patients and applying this to the latter one-third may 
have validated my previous fi nding.
Identifying hydration and nutrition status at admission may be important in 
the management of patients of AES. On the one hand, because of the fear 
of cerebral oedema, the traditional approach is to fl uid restrict patients, to 
prevent deterioration of illness (89, 90); on the other hand, when such children 
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have prolonged illness (fever), poor GCS and focal neurological defi cits as 
mentioned above, they are unwell for many days, vomit frequently, are unable 
to drink fl uid and so may be dehydrated. In these situation, restricting fl uids 
could make dehydration even worse and result in metabolic acidosis and 
bad outcome. Therefore, assessment of hydration and nutritional status and 
correction of defi cits maybe the key to successful management. One approach 
is to weigh every child at the time of admission. However, weight is also 
contributed to by muscle, fat and bone besides water. In general, weight is an 
indicator of nutritional status. It also increases with increasing age, and differs 
according to gender. Therefore, WFA refl ects body weight of a child relative 
to age and gender at a given time. Historically the WHO defi ne a child with 
a WFA Z score of less than -2 or -3 as indicating moderate or severe under-
nutrition [ http://www.who.int/nutgrowthdb/about/introduction/en/index5.html 
(as assessed on 3rd March 2016)]. Recent studies have shown child mortality 
risks are not only higher at Z scores of -2 or less, but are also increased (albeit 
to a lesser extent) at -1 Z scores (91). 
In a population with a normally distributed WFA, you would expect just under 
16% of subjects to have a WFA Z score -1 or less. My study shows that almost 
half of all the cases of AES of suspected viral aetiology and confi rmed cases 
of JE had a WFA Z score of -1 or less at the time of admission. My study also 
shows that those with WFA Z score of -2 or -3 increasingly tended to suffer a 
bad outcome, particularly residual neurological sequelae. Prolonged duration 
of fever, signifi cantly prolonged illness, presence of focal neurological defi cits 
and high serum urea in the lower WFA group in my study suggest these 
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children could have been dehydrated, because all of these are likely associated 
with poor fl uid intake. However, they could also have been malnourished. 
Additional signs that could help to separate dehydration from malnutrition 
are weight-for-height, mid upper arm circumference (MUAC) and skin fold 
thickness. These would have been normal in dehydration but they would have 
been below normal in malnutrition. Obvious signs of dehydration (Appendix E) 
may also be absent in malnourished children. MUAC is being used increasingly 
to asses malnutrition status through various nutritional programmes in Nepal 
and most of the health workers would have been trained on it. Weight-for-
height measurement, although more accurate to asses malnutrition, would be 
diffi cult to assess in unconscious child and skin fold thickness would be new 
and requiring expensive tool to assess. Therefore, in a low WFA patient of AES 
or JE, MUAC and other supportive laboratory fi ndings could help differentiate 
dehydration from malnourishment. Further study with more accurate 
assessment of signs of dehydration and systematic measurement of serum urea, 
electrolytes, fl uid balance, markers of acid-base balance and MUAC in children 
of low WFA would help differentiate dehydration from malnutrition in these 
children.
There were also signifi cantly more episodes of seizures and longer total 
duration of seizures in the lower WFA group of AES and JE in my study. 
Repeated seizures and raised intracranial pressures are associated with bad 
outcome in JE (20). However, I found it to be more common in lower WFA 
group. Like several nervous system infections, seizures complicate viral 
encephalitis and JE (20). Cerebral oedema, cortical necrosis and neuronal 
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injury may cause seizures in encephalitis. In Addition, small haemorrhages and 
thrombus formation in the brain have been speculated to cause seizures in JE 
(53). Repeated or uncontrolled seizures are also associated with hypoxemia, 
hypoglycemia, hyperlactataemia or metabolic acidosis which needs effective 
management along with the treatment of nervous system infection. Even brief 
periods of seizure has been associated with raised ICP. 
Every year, severe acute malnutrition affects 20 million children below 5 years 
of age causing around 2 million preventable deaths. The case fatality rate in 
developing countries is higher with rates as high as 20- 60% (130, 131). In 
2011, 2.3 million children in the world died because of lack of nourishment. 
Hence, malnutrition is one of the important and urgent issues in global 
development. In nutritional language, low weight-for-age is described as 
underweight. 58 million children (1 in every 3) in South Asia are under weight 
which is even more than the entire combined population of England and Wales. 
According to Demographic and Health Survey of Nepal conducted in 2011, 
the malnutrition status of children below 5 years of age has been described 
as moderate to severe wasting in 11%, stunting in 41% and underweight in 
29%. Even in the present study, around half of the AES and JE patients were 
underweight. However, malnutrition is not just because of poor food intake 
but a combination of frequent illness, poor quality of food, poor feeding 
practices, poor water and sanitation and inadequate health services in this 
part the world. There is a signifi cant burden of AES and JE in children living 
in the South-Asian subcontinent. Therefore malnutrition needs consideration 
when managing children with encephalitis in these countries where it is very 
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common. Hypoglycemia and hyponatremia are common complications of 
malnutrition which are more likely to cause seizure and result in bad outcome 
in AES children. 
Dehydration is classifi ed as weight loss as a marker of fl uid defi cits (132, 
133). WHO defi nes dehydration as percentage loss of body weight; no 
signs of dehydration ( 3-5%), some signs of dehydration (5-9%), and severe 
dehydration (≥10%) (133). Other symptoms and signs of dehydration are 
lethargy or increased thirst, decreased urinary output, weak pulse, cool 
extremities, sunken eyes, absence of tears, sunken fontanel, prolonged capillary 
refi ll and poor skin turgor; these could help clinicians to differentiate it from 
other clinical conditions. Hyponatremia, hypernatremia, hypoglycemia, 
bacterial toxins, cerebral venous thrombosis are all complications of 
dehydration which could cause seizures resulting in a poor outcome in children 
with AES. Moreover, malnutrition, infection and dehydration are inter-related 
and linked by a vicious cycle. However, management of even dehydration 
in malnourished children requires administration of ReSoMal which is a 
half strength oral rehydration solution over a prolonged duration because 
of the effect of malnutrition in different organs of the body. According to 
"Nepal Demographic and Health Survey conducted in 2011, 11% of children 
are malnourished of which 3% are severely malnourished. My fi ndings of 
almost half of the children with AES and JE of low WFA and signifi cantly 
associated with bad outcome highlight the need to screen and treat underlying 
malnutrition and administer effective and appropriate fl uid therapy in patients 
with AES in order to improve outcome. Anticipating and managing repeated 
seizures in both the conditions could also help improve outcome. 
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This study also highlights the high burden of disability following AES and 
JE which could be relevant to all areas of the world where the disease burden 
is high (28). Importantly I found the functional impairment at the time of 
discharge was signifi cantly higher in those of lower WFA group as compared 
to those who had appropriate or higher WFA in both AES and JE. Specifi cally, 
feeding diffi culties, cognition problems, limb movement diffi culties, 
incontinence and seizures were signifi cantly more common impairments at 
discharge in the lower WFA group among those with AES; additionally poor 
feeding, expressive language and dressing diffi culties were signifi cantly more 
common at discharge in the lower WFA group among JE patients. The risk 
of seizures up to 5 years after CNS infections has previously been reported 
as almost 7%. Early seizures may occur in 10% of encephalitis patients, and 
even after 20 years, the risk of unprovoked seizures has been observed to be 
as high as 22% (53). The identifi cation of children with uncontrolled seizures 
highlights the need to closely follow up VE related seizures. In both AES and 
JE children, the disability was more commonly of moderate to severe degree 
for the lower WFA children. This was the case at the time of discharge and 
also at 2 years follow up. Five deaths (including 3 JE patients) occurred after 
hospital discharge, suggesting that outcome at discharge is a poor refl ection 
of the eventual outcome (21, 74). Importantly, disability increased in children 
of lowest WFA from 20% at 1 year to 33% at 2 year follow up. Although 
some patients deteriorated after follow up, many others improved (21). Thus 
it is important for treatment trials to measure both short term and long term 
outcomes in order to fi nd out the actual effi cacy of a drug. 
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The recovery profi le of AES and JE has been less studied. Some have studied 
long term outcome up-to two years from discharge but have failed to record 
discharge status in-order to assess change in problems over time to describe 
recovery profi le of disability (16, 73). The discharge outcomes in children 
with JE are seen to change in long term follow up (10). Complete recovery is 
possible in follow up from severe motor sequelae at the time of discharge (10, 
21, 74). In my study, I found that in both AES and JE patients, the disability 
seemed to have improved in the 2 year follow up period in children of normal 
WFA (134). However, it seemed to persist or even worsen in those with lower 
WFA. Presently in Nepal, children with motor impairment can receive input 
from the physiotherapist. However, further professional support from speech 
and language, psychosocial or occupational therapist would likely have been 
more benefi cial. 
In conclusion, prolonged illness was a robust predictor of bad outcome in both 
AES and JE patients. There was a signifi cant increase in the association of 
bad outcome as residual neurological sequelae in AES and JE patients with 
decrease in WFA based on their Z score and persistence of sequelae even at 
2 years follow up. Although there is clinical evidence to suggest that in these 
patients the low weight is due to dehydration, there is also the possibility that 
it could be under nutrition. Hence, to explore further the cause of low WFA, I 
planned more detailed study, using a structured and standardised proforma that 
included specifi c questions on patient hydration status, fl uid balance, acid base 
status, serum electrolytes (as a marker of renal function), and measurement of 
weight and changes in weight during hospital stay. This forms the subject of 
my next chapter. 
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4.6 Limitation of study
A total of 37 (17%) of patients did not have their weight accurately 
measured using a digital weighing scale. These participants were excluded 
which could have affected the study results. Since height, discharge weight 
(therefore, change in weight), total intake of fl uids and output, markers of 
dehydration such as blood lactate, pH, capillary refi ll time, temperature 
and oxygen saturation were not measured, it was diffi cult to confi dently 
separate dehydration from malnutrition in these patients. Since height was 
also not measured, it was diffi cult describe whether it was acute weight loss 
(dehydration) or chronic weight loss (malnutrition). Moreover, WFA refl ects 
composite measure of both acute and chronic under nutrition and cannot 
distinguish between the two (135). 
Since height, discharge weight (or change in weight), total intake of fl uids 
and output, markers of dehydration such as blood lactate, ph, capillary refi ll 
time, temperature and oxygen saturation were not measured, it was diffi cult to 
confi dently differentiate dehydration from malnutrition in these patients. Since 
height was also not measured, it was diffi cult describe whether it was acute or 
chronic weight loss (malnutrition). 
 
I have used two reference standards to assess weight-for-age (WFA) within 
the study population. This was undertaken because there is no single set of 
national reference values for weight across all childhood ages in Nepal. The 
fi rst standard, was the international standard developed by WHO for children 
below 5 years of age. The second was a local national standard for use among 
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children above 5 years of age in Nepal. Use of an WHO standard for younger 
children did have potential disadvantages, since this standard is based on 
a reference population from the United States. Consequently, some of the 
children below 5 years of age may have been incorrectly labelled as below a 
certain WFA Z score (based on WHO standards rather than national standards). 
Measurement of mid upper arm circumference (MUAC), weight for height, 
or body mass index (BMI) may have helped differentiate acute from chronic 
weight loss. Since these measures were not recorded, it is still unknown 
whether patients were dehydrated or malnourished. 
The study was conducted in two public hospitals across a diverse group of 
patients. Information on social and economic status (SES) may have helped 
tease apart dehydration form malnutrition among the cases, with the latter 
being more likely in the lower SES group of patients (136- 138). Similarly, I 
could have asked the parents about the dietary habits of their children prior 
to the illness. Again, this information could have further helped differentiate 
the cause of low WFA. Information on how much and type of food (e.g. using 
a pictorial food diary) the children ate prior to illness could have provided 
background information on the child's calorifi c intake and nutritional status 
(139, 140). 
 
4.7 Summary
Prospectively, I fi rst validated the clinical and laboratory features identifi ed 
in my initial retrospective study as predictors of bad outcome in AES and JE. 
Low GCS and longer duration of fever and presence of focal neurological 
defi cit at the time of admission were validated to be robust predictors of bad 
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outcome in AES patients. All of these conditions can cause dehydration. 
Dehydration is expressed as percentage weight loss. JE patients were of lower 
weight. A higher proportion of JE patients exhibited bad outcome as compared 
to non-JE patients in my retrospective study. Interestingly in children weight 
is linked to age. I used Z score to measure weight for age. However, since 
there was no single standard baseline WFA growth chart for Nepali children, 
I used WHO child growth standard for children below 5 years of age and the 
Nepalese growth standard for the school age children developed by Ministry 
of Health for children above 5 years of age. When outcome was correlated 
with different admission WFA groups of AES and JE patients formed by Z 
score value, I found signifi cantly increase in residual neurological sequelae as 
the WFA Z score decreased in AES patients. I also found signifi cant increase 
in bad outcome as the WFA Z score decreased in JE patients. There was also 
persistence of more sequelae in lower WFA group of AES patients even at 2 
years follow up in both AES and JE patients. However, weight below -1WFA 
Z score could be either because of dehydration or malnutrition and sometimes 
the two conditions were indistinguishable at the time of presentation to the 
hospital. Malnourished children have anaemia and depressed immunity making 
them vulnerable to systemic infection resulting in bad outcome. In encephalitis, 
loss of consciousness, focal neurological defi cit, uncontrolled seizures and fl uid 
restrictions by clinicians can cause dehydration and metabolic acidosis causing 
bad outcome. 
Measurement of weight and height for patients with impaired consciousness 
was not routinely undertaken in my hospital setting. Therefore, I opted to 
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undertake a more systematic measurement of serum urea, electrolytes, fl uid 
balance, markers of acid-base balance and MUAC in children of different WFA 
group based on Z score, to help differentiate dehydration from malnutrition. I 
then studied the relationship of fl uid and acid base status with low admission 
weight and changes in weight during hospital and their relationship to outcome. 
This has been described in my next chapter.
152
Fi
gu
re
 4
.1
: S
tu
dy
 P
ro
fi l
e.
 N
um
be
rs
 in
 re
d 
fo
nt
 re
pr
es
en
ts
 n
um
be
r o
f p
at
ie
nt
s i
nf
ec
te
d 
w
ith
 JE
. F
U
, f
ol
lo
w
 u
p
A
ll 
A
ES
 2
17
N
o 
lo
w
 w
ei
gh
t-
fo
r-
ag
e 
VE
 8
5(
56
%
); 
JE
 1
9(
49
%
)
Lo
w
 w
ei
gh
t-
fo
r-
ag
e 
VE
 6
7(
44
%
); 
JE
 2
0(
51
%
) 
Ex
cl
ud
ed
- n
on
-v
ira
l A
ES
 2
8(
13
%
) [
ie
 1
2(
6%
) b
ac
te
ri
al
 m
en
in
gi
? s
, 1
1(
5%
) t
yp
ho
id
 
en
ce
ph
al
op
at
hy
, 5
(2
%
) T
B 
m
en
in
gi
? s
], 
w
ei
gh
t n
ot
 re
co
rd
ed
 in
 3
7 
(1
7%
)
VE
 1
52
[J
E 
39
(2
5%
), 
no
n-
JE
 7
1(
47
%
), 
JE
 s
ta
tu
s 
un
kn
ow
n 
42
(2
8%
)]
Z 
sc
or
e 
0,
VE
 7
6(
50
%
); 
JE
 1
6(
41
%
)
Z 
sc
or
e-
 1
, V
E 
36
(2
4%
); 
JE
 1
2(
31
%
)
Z 
sc
or
e 
-2
,V
E 
18
(1
2%
);J
E 
5(
12
%
)
Z 
sc
or
e 
-3
,V
E 
13
(8
%
); 
JE
 3
(8
%
) 
Z 
sc
or
e 
+1
,V
E 
9(
6%
); 
JE
 3
(8
%
) 
1 
yr
 F
U
, V
E 
31
(2
0%
); 
JE
 8
(2
1%
)
 1
 y
r 
FU
, V
E 
17
(1
1%
); 
JE
 4
(1
0%
)
1 
yr
 F
U
, V
E 
2(
1%
); 
JE
 1
(3
%
)
1 
yr
 F
U
, V
E 
5(
3%
); 
JE
 2
(5
%
)
1 
yr
 F
U
, V
E 
6(
4%
); 
JE
 2
(5
%
)
2 
yr
 F
U
, V
E 
26
(1
8%
); 
JE
 5
(1
3%
)
2 
yr
 F
U
, V
E 
15
(1
0%
); 
JE
 4
(1
0%
)
2 
yr
 F
U
, V
E 
1(
0.
7%
); 
JE
 0
(0
%
)
2 
yr
 F
U
, V
E 
3(
2%
); 
JE
 1
(3
%
)
2 
yr
 F
U
, V
E 
6(
4%
); 
JE
 2
(5
%
)
153
Ta
bl
e 
4.
1:
 V
al
id
at
io
n 
of
 p
re
di
ct
or
s o
f b
ad
 o
ut
co
m
e 
of
 A
ES
 a
nd
 JE
 a
nd
 p
re
di
ct
or
s o
f J
E 
fro
m
 A
ES
 a
s d
er
iv
ed
 fr
om
 p
re
vi
ou
s r
et
ro
sp
ec
tiv
e 
stu
dy
Fe
at
ur
es
 o
n 
ad
m
is
si
on
Pr
es
en
t 
[N
o 
( %
)]
A
bs
en
t 
[N
o 
( %
)]
P-
va
lu
e
O
R
 (9
5%
 C
I)
R
R
 (9
5%
 C
I)
Se
ns
iti
vi
ty
Sp
ec
ifi 
ci
ty
PP
V
N
PV
Ba
d 
ou
tc
om
e 
in
 A
ES
G
la
sg
ow
 c
om
a 
sc
or
e 
(≤
 1
2)
88
 (8
2.
2)
19
 (1
7.
8)
0.
00
59
2.
65
 (1
.2
- 5
.7
)
2.
05
 (1
.2
- 3
.4
)
67
.7
55
.8
82
.2
36
.4
D
ur
at
io
n 
of
 fe
ve
r (
≥7
 d
ay
s)
55
 (8
5.
9)
9 
(1
4.
1)
0.
00
69
0.
33
 (0
.1
- 0
.8
)
0.
43
 (0
.2
- 0
.8
)
54
.2
21
.9
67
14
Fo
ca
l n
eu
ro
lo
gi
ca
l d
efi
 c
it
90
 (8
6.
5)
14
 (1
3.
5)
0.
00
00
05
0.
19
 (0
.0
8-
 0
.4
)
0.
3 
(0
.2
-0
.5
)
27
.4
33
.3
54
.8
13
.5
Ba
d 
ou
tc
om
e 
in
 J
E
G
la
sg
ow
 c
om
a 
sc
or
e 
(≤
 1
2)
31
 (9
1.
2)
3 
(8
.8
)
0.
00
3
12
.4
 (1
.8
- 7
7.
3)
6.
18
 (1
.9
- 2
0.
7)
86
.1
66
.7
91
.2
54
.6
D
ur
at
io
n 
of
 fe
ve
r (
≥7
 d
ay
s)
11
 (8
4.
6)
2 
(1
5.
4)
0.
54
0.
73
 (0
.0
8-
 5
.1
)
0.
8 
(0
.2
- 3
.3
)
68
.6
25
80
15
.4
A
ge
 (>
5 
ye
ar
s)
20
 (7
1)
8 
(2
9)
0.
12
0.
12
 (0
.6
7-
15
1)
0.
4 
(0
.6
-2
6.
3)
 
 
 
 
D
ia
gn
os
is 
of
 J
E 
fr
om
 a
ll 
AE
S
Fo
ca
l n
eu
ro
lo
gi
ca
l d
efi
 c
it
33
 (7
5)
11
 (2
5)
0.
05
2.
09
 (0
.9
- 4
.8
)
1.
8 
(0
.9
7-
 3
.4
)
75
41
25
.6
85
.9
154
Table 4.2: Clinical features of VE
Clinical features Z score + 1 (n=9)
Z score 0
(n= 76)
Z score – 1
(n=36)
Z score -2
(n=18)
Z score -3
(n=13) P- value
Age 9 (4-12) 8 (1-14) 7 (1-13) 6 (2-14) 4 (2-5) 0.01
Weight 28 (17-45) 20 (8-40) 16 (7.5-33) 13 (9-30) 9 (4-12) < 0.0001
Glasgow coma scale 13 (4-15) 11 (3-15) 11.5 (3-15) 9.5 (5-14) 11 (3-15) 0.63
Duration of fever 4 (1-10) 6 (1-14) 6 (2-14) 6 (2-14) 10 (1-13) 0.11
Headache 5/8 (63) 39/73 (53) 18/34 (53) 6/18 (33) 1/12 (8) 0.026
Duration of headache 4 (1-5) 6 (1-13) 5 (1-13) 7 (0-12) 2 (0-4) 0.27
Vomiting 5/9 (56) 42/73 (58) 21/36(58) 7/18 (39) 3/13 (23) 0.13
Duration of vomiting 2 (1-7) 1 (1-12) 2 (1-7) 3 (0-4) 3.5 (1-6) 0.6
Drowsiness 5/6 (83) 30/57 (53) 18/27 (67) 12/13 (92) 6/11 (55) 0.064
Duration of drowsiness 1 (1-3) 2 (1-10) 2.5 (1-8) 3.5 (1-13) 5.5 (1-11) 0.51
Convulsion 6/9 (67) 55/76 (72) 21/36 (58) 15/18 (83) 10/13 (77) 0.35
episodes of convulsion 1 (1-2) 6 (1-18) 3 (1-12) 6 (1-60) 6 (1-9) 0.008
Duration of each episode 
of convulsion (minute) 4 (2-15) 4 (1-32) 3 (1-15) 4 (2-15) 6.5 (2-90) 0.88
Total duration of 
convulsion (minute) 5.5 (2-30) 20 (3-180) 13.5 (3-90) 28.5 (8-180) 24 (6-90) 0.012
Temperature (Farenheight) 101 (98-104) 100 (96-105) 99.5 (97-104) 100.5 (96-104) 100 (98-103) 0.57
Respiratory rate (per 
minute) 30 (26-56) 30 (12-80) 30 (18-52) 29 (20-49) 30 (24-56) 0.75
Pulse (per minute) 100 (96-152) 104 (58-180) 100 (60- 180) 100 (70- 150) 106 (80- 170) 0.34
Systolic blood pressure 
(mm Hg) 100 (70-130) 100 (70- 170) 95 (79- 130) 90 (80-160) 90 (80-120) 0.99
Diastolic blood pressure 
(mm Hg) 60 (50-80) 60 (40-110) 60 (40-90) 60 (50-105) 68 (40-94) 0.94
Focal neurological defi cit 2/9 (22) 43/74 (58) 24/34 (71) 13/17 (76) 11/13(85) 0.017
Total duration of illness 
(days) 9 (5-14) 14 (4-42) 15 (6-28) 16 (7-44) 14 (6-26) 0.034
Hb (gm%) 11.7 (9.7-14.7) 12 (7.8-14.9) 11.2 (8.7-13.5) 11.8 (6.5-13.5) 11.7 (8.7-14.7) 0.58
Random blood sugar 
(mg/dl) 109 (61-127) 96 (48-219) 91.5 (37-170) 105 (68-161) 85.5 (50-100) 0.044
Urea 21 (13-28) 25 (6.8-100) 24 (12-75) 34 (19-97) 28 (18-92) 0.014
Creatinine 0.8 (0.3-1) 0.7 (0.2-3.4) 0.7 (0.4-5.4) 0.65 (0.4-2.2) 0.7 (0.4-1.8) 0.93
Sodium 135 (129-146) 136(120-156) 136(126-146) 138 (129-146) 138(128-160) 0.69
Pottasium 4.1 (3.4-4.7) 4.3 (2.4-7) 4.4 (3-5.8) 4.3 (3.7-5.3) 4.5 (4.1-6.1) 0.32
CSF opening pressure (cm 
of water) 20.5 (15-25) 14.5 (6-30) 20 (8-28) 18 (17-19) 23 (9-35) 0.25
CSF white blood 
corpuscles (per mm3) 2.5 (0-100) 5 (0-4900) 15 (0-575) 101 (0-400) 53 (0-990) 0.26
Raised CSF pressure (cm 
of water) 2/4 (50) 6/32 (19) 4/12 (33) 0/2 (0) 3/4(75) 0.1
JE 3/9 (33) 16/76 (21) 12/36 (33) 5/18 (28) 3/13 (23) 0.68
Non- JE 3/9 (33) 39/76 (51) 17/36 (47) 5/18 (28) 7/13 (54) 0.38
JE status unknown 3/9 (33) 21/76 (28) 7/36 (19) 8/18 (44) 3/13 (23) 0.4
Bad outcome 5/9 (56) 52/68 (76) 28/33 (85) 14/15 (93) 11/12 (92) 0.13
Neurological sequelae 2/6 (33) 41/57 (72) 27/32 (84) 13/14 (93) 8/9 (89) 0.03
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Table 4.3: Clinical features of JE
Clinical features Z score + 1 (n=3)
Z score 0 
(n=16)
Z score – 1 
(n=12)
Z score -2 
(n=5)
Z score -3 
(n=3) P- value
Age 9 (4-11) 9.5 (1-13) 7(1-13) 6 (2-14) 4 (3-5) 0.44
Weight 28 (17-37) 21 (10-38) 15.5 (8-28) 13 (9-28) 10 (9-10) 0.006
Glasgow coma scale 11 (4-14) 8 (3-15) 11 (5-14) 12 (7-14) 10 (6-12) 0.72
Duration of fever 3 (1-5) 6 (4-14) 5.5 (2-8) 5 (3-8) 8 (5-11) 0.16
Headache 2/3 (67) 9/15 (60) 6/11 (55) 1/5 (20) 1/2 (50) 0.61
Duration of headache 3 (1-5) 5 (2-9) 5 (2-9) NA 4(4-4) 0.66
Vomiting 2/3 (67) 11/15 (73) 5/12 (42) 2/5 (40) 0/3 (0) 0.13
Duration of vomiting 1.5 (1-2) 1(1-12) 1 (1-7) 2.5 (2-3) NA 0.43
Drowsiness 3/3 (100) 10/14 (71) 7/9 (78) 5/5 (100) 2/3 (67) 0.57
Duration of drowsiness 1 (1-1) 3 (1-7) 3.5(1-8) 3 (1-6) 1 (1-1) 0.18
Convulsion 2/3 (67) 13/16 (81) 6/12 (50) 5/5(100) 2/3 (67) 0.23
episodes of convulsion 1.5 (1-2) 6 (2-7) 1.5 (1-6) 6 (5-18) 3.5 (1-6) 0.05
Duration of each episode of 
convulsion (minute) 4 (3-5) 10 (3-32) 3 (3-5) 3 (2-3) 90 (90-90) 0.038
Total convulsion duration 
(minute) 5.5 (5-6) 20 (15-180) 10 (3-18) 18 (10-54) 90 (90-90) 0.01
Temperature (Farenheight) 101 (98-103) 100 (97-104) 99.5 (97-103) 102 (98-104) 98.6 (98-100) 0.2
Respiratory rate (per minute) 30 (26-56) 33.5 (20-80) 32 (24-52) 26 (20-36) 28 (24-30) 0.35
Pulse (per minute) 100 (100-140) 104 (86-180) 100 (60- 180) 120 (72- 150) 88 (80- 106) 0.45
Systolic blood pressure (mm 
Hg) 115 (100-130) 107 (90- 170) 90 (79- 120) 90 (90-110) 103 (90-116) 0.73
Diastolic blood pressure (mm 
Hg) 70 (60-80) 60 (40-110) 60 (60-90) 60 (60-70) 69 (68-70) 0.85
Focal neurological defi cit 2/3 (67) 13/16 (81) 9/11 (82) 3/5 (60) 3/3 (100) 0.69
Total duration of illness (days) 9 (5-10) 15 (8-38) 15 (10-28) 14 (13-44) 24 (19-26) 0.041
Hb (gm%) 10.6 (9.7-14.7) 12 (10-14.3) 11.2(9.1-13.5) 11.5(10.6-12.2)
10.4 (10.4-
10.4) 0.24
Random blood sugar (mg/dl) 99 (61- 127) 111.5 (85-219) 88.5 (60-112) 105(92-118) 90 (77-98) 0.03
Creatinine 0.9 (0.8-1) 0.7 (0.2-1.9) 0.7 (0.4-0.8) 1.2 (0.4-2.2) 0.6 (0.5-0.6) 0.15
Sodium 144 (132-146) 133 (122-141) 136 (130-146) 137 (130-139) 131(128-134) 0.37
Pottasium 4.4 (3.4-4.7) 4.3 (3-6) 4.2 (3.4-4.8) 4.2 (3.9-5.2) 4.3 (4.1-4.4) 0.95
CSF opening pressure (cm of 
water) 22 (19-25) 16 (9-30) 19 (8-22) 17 (17-17) 9 (9-9) 0.4
CSF white blood corpuscles 
(per mm3) 80 (0-100) 30 (0-285) 7 (0-150) 44.5(9-50) 25 (0-50) 0.84
Raised CSF pressure (cm 
water) 2/3 (67) 3/10 (30) 1/6 (17) 0/1 (0) 0/1 (0) 0.5
Bad outcome 1/3 (33) 12/16 (75) 11/11 (100) 5/5 (100) 3/3 (100) 0.034
Neurological sequelae 0/2 (0) 9/13 (69) 11/11 (100) 5/5 (100) 3/3 (100) 0.005
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Table 4.4: Outcome of children with VE at the time of discharge, after one and 
two years follow up
WFA +1 Z score 0 Z score -1 Z score -2 Z score -3 Z score p- value
At discharge
Outcome (LOS) n= 9 n= 76 n= 36 n= 18 n= 13
1- Death 3 (33%) 11 (15%) 1 (3%) 1 (6%) 3 (23%) 0.06
2- Severe sequelae 1 (11%) 20 (26%) 7 (19%) 7 (39%) 4 (31%) 0.5
3- Moderate sequelae 0 (0%) 10 (13%) 12 (33%) 4 (22%) 0 (0%) 0.01
4- Mild sequelae 1 (11%) 6 (8%) 6 (17%) 1 (6%) 0 (0%) 0.4
5- Complete recovery 4 (44%) 16 (21%) 4 (11%) 2 (11%) 2 (15%) 0.2
LAMA 0 (0%) 13 (17%) 6 (17%) 3 (17%) 4 (31%) 0.5
At 1 year follow-up
Outcome (LOS) n= 6 n= 31 n= 17 n= 2 n= 5
1- Death 0 (0%) 3 (10%) 1 (6%) 1 (50%) 0 (0%) 0.2
2- Severe sequelae 0 (0%) 2 (7%) 0 (0%) 0 (0%) 1 (20%) 0.4
3- Moderate sequelae 0 (0%) 2 (7%) 2 (12%) 0 (0%) 1 (20%) 0.7
4- Mild sequelae 0 (0%) 3 (10%) 0 (0%) 0 (0%) 1 (20%) 0.4
5- Complete recovery 6 (100%) 21 (68%) 14 (82%) 1 (50%) 2 (40%) 0.2
At 2 years followup
Outcome (LOS) n= 6 n= 26 n= 15 n= 1 n= 3
1- Death 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
2- Severe sequelae 0 (0%) 1 (4%) 0 (0%) 0 (0%) 1 (33%) 0.1
3- Moderate sequelae 0 (0%) 1 (4%) 1 (7%) 0 (0%) 1 (33%) 0.3
4- Mild sequelae 0 (0%) 3 (12%) 1 (7%) 0 (0%) 0 (0%) 0.8
5- Complete recovery 6 (100%) 21 (81%) 13 (87%) 1 (100%) 1 (33%) 0.2
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Table 4.5: Outcome of children with JE at the time of discharge, after one and 
two years follow up
WFA +1 Z score 0 Z score -1 Z score -2 Z score -3 Z score p- value
At discharge
Outcome (LOS) n= 3 n= 16 n= 12 n= 5 n= 3
1- Death 1 (33%) 3 (19%) 0 (0%) 0 (0%) 0 (0%) 0.3
2- Severe sequelae 0 (0%) 9 (56%) 4 (33%) 3 (60%) 3 (100%) 0.1
3- Moderate sequelae 0 (0%) 0 (0%) 4 (33%) 2 (40%) 0 (0%) 0.05
4- Mild sequelae 0 (0%) 0 (0%) 3 (25%) 0 (0%) 0 (0%) 0.1
5- Complete recovery 2 (67%) 4 (25%) 0 (0%) 0 (0%) 0 (0%) 0.03
LAMA 0 (0%) 0 (0%) 1 (8%) 0 (0%) 0 (0%) -
At 1 year follow-up
Outcome (LOS) n= 2 n= 8 n= 4 n= 1 n= 2
1- Death 0 (0%) 2 (25%) 0 (0%) 1 (100%) 0 (0%) 0.2
2- Severe sequelae 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
3- Moderate sequelae 0 (0%) 1 (12%) 0 (0%) 0 (0%) 1 (50%) 0.4
4- Mild sequelae 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (50%) 0.09
5- Complete recovery 2 (100%) 5 (63%) 4 (100%) 0 (0%) 0 (0%) 0.07
At 2 years follow- up
Outcome (LOS) n= 2 n= 5 n= 4 n= 0 n= 1
1- Death 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
2- Severe sequelae 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
3- Moderate sequelae 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (100%) -
4- Mild sequelae 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
5- Complete recovery 2 (100%) 5 (100%) 4 (100%) 0 (0%) 0 (0%) -
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Table 4.6: Disability as assessed by LOS at the time of discharge in children with 
VE
Median LOS at discharge Z score + 1 (n=9)
Z score 0 
(n=76)
Z score -1 
(n=36)
Z score -2 
(n=18)
Z score -3 
(n=13) P- value
Expressive language problem 5 (5-5) 5 (2-5) 5 (2-5) 3 (2-5) 2 (2-5) 0.07
Need help in feeding 5 (5-5) 5 (2-5) 5 (2-5) 3 (2-5) 5 (3-5) 0.024
Can’t be left alone 5 (5-5) 3 (2-5) 5 (2-5) 2.5 (2-5) 2 (2-5) 0.067
Behavioral problem 5 (5-5) 5 (2-5) 5 (2-5) 4 (2-5) 4 (2-5) 0.07
Unable to Recognize relatives 5 (5-5) 5 (2-5) 5 (2-5) 5 (2-5) 5 (3-5) 0.04
Unable to attend school of 
disability 5 (4-5) 4 (3-5) 4 (3-5) 3.5 (2-5) 4 (3-5) 0.18
On anti- epileptic drug or recent 
seizures 5 (5-5) 4.5 (4-5) 4.5 (4-5) 4 (3-5) 4 (4-5) 0.006
Help needed for dressing 5 (5-5) 5 (2-5) 5 (2-5) 2 (2-5) 2 (2-5) 0.06
Bladder or bowel incontinence 5 (5-5) 5 (2-5) 5 (2-5) 4 (2-5) 5 (2-5) 0.014
Hearing or receptive language 
problem 5 (5-5) 5 (4-5) 5 (3-5) 5 (3-5) 5 (5-5) 0.06
Diffi culty sitting 5 (5-5) 5 (2-5) 5 (2-5) 3 (2-5) 3 (2-5) 0.097
Diffi culty in standing up 5 (5-5) 5 (2-5) 5 (2-5) 2 (2-5) 3 (2-5) 0.053
Diffi culty in walking 5 (5-5) 5 (2-5) 5 (2-5) 2 (2-5) 2 (2-5) 0.047
Diffi culty putting hands on head 5 (5-5) 5 (3-5) 5 (3-5) 5 (2-5) 5 (3-5) 0.12
Diffi culty picking up small 
objects 5 (5-5) 5 (2-5) 5 (2-5) 5 (2-5) 5 (2-5) 0.42
Minimum LOS 4 (1-5) 3 (1-5) 3 (1-5) 2 (1-5) 2 (1-5) 0.39
Total LOS 74 (1-75) 68 (1-75) 71 (1-75) 57 (1-75) 46 (1-75) 0.29
Table 4.7: Disability as assessed by LOS at the time of discharge in children with 
JE
Mean disability score at discharge Z score + 1 (n=3)
Z score 0 
(n=16)
Z score – 1 
(n=11)
Z score -2 
(n=5)
Z score -3 
(3) P- value
Expressive language problem 5 (5-5) 3 (2-5) 5 (2-5) 3 (2-3) 2 (2-2) 0.07
Need help in feeding 5 (5-5) 3 (2-5) 5 (5-5) 3 (2-3) 4 (3-5) 0.01
Can’t be left alone 5 (5-5) 2 (2-5) 5 (2-5) 3 (2-5) 2 (2-2) 0.2
Behavioral problem 5 (5-5) 5 (2-5) 5 (4-5) 4 (2-5) 3 (2-4) 0.08
Unable to Recognize relatives 5 (5-5) 5 (2-5) 5 (5-5) 5 (2-5) 4 (3-5) 0.3
Unable to attend school of disability 5 (5-5) 4 (3-5) 4 (4-5) 3 (2-5) 4 (4-4) 0.2
On anti- epileptic drug or recent 
seizures 5 (5-5) 4.5 (4-5) 5 (4-5) 4 (3-4) 4 (4-4) 0.065
Help needed for dressing 5 (5-5) 2 (2-5) 5 (2-5) 2 (2-5) 2 (2-2) 0.037
Bladder or bowel incontinence 5 (5-5) 5 (2-5) 5 (5-5) 3 (2-5) 3.5 (2-5) 0.057
Hearing or receptive language 
problem 5 (5-5) 5 (4-5) 5 (4-5) 5 (3-5) 5 (5-5) 0.8
Diffi culty sitting 5 (5-5) 3 (2-5) 5 (2-5) 4 (2-5) 2.5 (2-3) 0.28
Diffi culty in standing up 5 (5-5) 3 (2-5) 3 (2-5) 2.5 (2-5) 2.5 (2-3) 0.27
Diffi culty in walking 5 (5-5) 2.5 (2-5) 5 (2-5) 2 (2-5) 2 (2-2) 0.16
Diffi culty putting hands on head 5 (5-5) 5 (3-5) 5 (3-5) 5 (3-5) 4 (3-5) 0.73
Diffi culty picking up small objects 5 (5-5) 5 (2-5) 5 (2-5) 5 (2-5) 3.5 (2-5) 0.66
Minimum LOS 5 (1-5) 2 (1-5) 3 (2-4) 2 (2-3) 2 (2-2) 0.44
Total LOS 75 (1-75) 51 (1-75) 71 (36-74) 57 (36-66) 47 (36-49) 0.24
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Chapter 5: Role of fl uid management in the 
outcome of children with Acute Encephalitis 
Syndrome
Abstract
Background: Acute encephalitis syndrome (AES) is a group of symptoms 
and signs used by World Health Organization (WHO) to screen patients of 
viral encephalitis (VE). There is no defi nite treatment for most of the cases of 
VE. Therefore, role of supportive management including fl uid treatment may 
be crucial to improve outcome. Previously, low admission weight has been 
associated with bad outcome which could have been due to dehydration or 
malnutrition. Therefore, I decided to investigate the relationship of fl uids and 
acid-base status with low admission WFA and loss of weight in hospital and 
correlate these with outcome. 
Methods: All children aged 1 month to 14 years with fever and altered 
sensorium and/or new onset seizures from September 2011 to September 
2012 attending Kanti Children’s Hospital, Kathmandu, Nepal were recruited. 
Weight-for-age (WFA) using Z score and serum lactate were assessed at 
admission and discharge. Total fl uid input and output was monitored daily. 
Results: Of the 92 patients, 62% had admission low WFA or weight loss 
during hospital stay (low weight group) and 38% without low WFA or no 
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weight loss (normal weight group). There was 19 times risk of death and 7 
times risk of bad outcome (death or sequelae) in low weight group compared 
to normal weight group. Bad outcome was signifi cantly associated with less 
admission WFA, more fl uid defi cit, and trend for higher admission serum 
lactate. Death was signifi cantly more in patients of longer duration of illness, 
low admission WFA, more weight loss during hospital stay, more 5% dextrose 
and 0.45 normal saline recipients, higher sodium and higher urea at admission.
Conclusion: Optimum & appropriate fl uids may be a life-saving treatment 
option in children with AES. A randomised control trial of different volume & 
types of fl uids is recommended.
5.1 Introduction
Acute encephalitis syndrome (AES) is a group of symptoms consisting of acute 
onset of fever, acute change in mental status and/or new onset of seizure (1). 
Viruses are regarded as the most important cause of AES in the world. In Asia, 
the major identifi ed cause of acute encephalitis is by Japanese Encephalitis 
virus (JEV). However, it can also be caused by other organisms such as 
bacteria or parasites.
Over 50,000 children present every year to different hospitals with clinical 
features suggestive of acute brain infection or AES, in Asia, with over 30% 
of these patients dying or suffering from signifi cant neurological problems 
following their acute illness (1). In the vast majority of cases there are no 
defi nite treatments, although antibiotic and antimalarial drugs are useful for 
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some of them. Supportive management with adequate intravenous fl uids maybe 
crucial for their survival along with mitigation of the secondary complications, 
such as seizures and raised intra-cranial pressure. There are guidelines for 
provision of fl uid among patients with impaired consciousness. The fl uids 
generally used are 0·18% saline with 5% dextrose in children (92). Normal 
maintenance fl uid requirement is equal to insensible, faecal and urinary loss. 
In practice, maintenance fl uid is estimated using Holliday-Segar method for 
calculating maintenance fl uid based on the child’s weight. They are often 
delivered at the rates of 100 ml/kg for the fi rst 10 kg of bodyweight, 50 ml/kg 
for the next 10 kg, and 20 ml/kg for bodyweight exceeding 20 kg (92, 141). 
Some standard pediatric literature caution that hypotonic intravenous 
fl uids given at maintenance rates might be unsafe, especially in hospitals 
in developing countries where serum sodium concentration often cannot be 
measured (92). Even fl uid bolus provision to children with shock, including 
those who were encephalopathic, has been linked with poor outcome as 
compared to normal maintenance fl uids (142). Hence, there is a general 
practice in all children with severe altered sensorium (modifi ed GCS < 8) 
or having clinical features suggestive of raised intracranial pressure to have 
their fl uid intake restricted to two- thirds of maintenance. However, these 
guidelines have largely been based on traumatic brain injury (89). There is 
very limited data available indicating the optimum fl uid management for 
patients with non-traumatic brain injury (93, 143, 144).On the contrary, the 
World Health Organisation (WHO) recommends full maintenance fl uids for 
the routine treatment of bacterial meningitis with an emphasis on glucose and 
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not sodium content. This is partly based on concerns about dehydration (145). 
Excessive fl uid restriction has been shown to be independently associated with 
a poor outcome among traumatic brain injury patients (89). More importantly, 
fl uid and sodium restriction have also been reported to have poor outcome in 
JE patients (93). My previous study also suggested hospital admission with 
supportive management, including adequate fl uids, improved outcome (75).
Fluid provision, with a need to maintain cerebral perfusion pressure without 
worsening cerebral oedema, is a delicate balance when managing brain injured 
children. Hence, without specifi c treatment with anti-viral drugs, optimum 
supportive management with adequate fl uid and acid base status, which may be 
contributing to raised intracranial pressure and convulsions causing secondary 
deterioration of patient’s health, beside the primary insult, seem vital. This re-
opens the question as to what and how much fl uids should be provided in acute 
infectious illness, and makes the area of brain infection even more vexing (20, 
123).
My previous study showed patients with JE were of lower weight and had 
worse outcome as compared to non-JE patients (chapter 3)(75). My another 
study also showed that there was signifi cantly progressive increase in residual 
neurological sequelae as the WFA Z score decreased in both AES and JE 
patients (chapter 4). Those AES and JE patients who had low WFA at the time 
of admission had signifi cantly worse outcome including residual neurological 
sequelae at the time of discharge and even at 2 years follow up. Low WFA 
could have been either by dehydration or malnutrition. It is important to fi nd 
165
out which one of these is contributing to low WFA, because the management is 
different, which could affect outcome. 
Since more than half of the AES patients attended hospital by self referral in 
my previous study (chapter 3) (75), a simple marker of malnutrition which was 
cheap, easily available, user friendly, applicable at community level without 
much training to the community health workers, seemed necessary. Although 
measurement of weight-for-height, BMI or blood micronutrients level may 
have been more appropriate for screening malnutrition from dehydration, 
measurement of mid upper arm circumference (MUAC) was more suitable in 
a rural based resource poor setting like Nepal. Measurement of loss of weight 
after admission, gold standard method for assessment of dehydration, would 
also help in identifying dehydrated patients. Besides clinical history and 
examination fi nding of dehydration, indirect markers of dehydration such as 
oxygen saturation, change in temperature, capillary refi ll time, change in blood 
lactate level, blood urea, serum electrolytes and total fl uid balance would also 
be helpful in separating dehydration from malnutrition. 
In this study, I therefore aimed to fi nd out the relationship of fl uids and acid-
base status with low admission weight and weight loss in the hospital. In the 
absence of consensus on what is the optimum fl uid management for children 
with AES, I also aimed to conduct a systematic investigation of the relationship 
between fl uid and acid base balance and the outcome of AES patients. 
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5.2.1 Aim
The aim of this study is to assess relationship between fl uid balance, change 
in weight, acid base status and outcome in children with acute encephalitis 
syndrome 
5.2.2 Objectives
1. To describe the association of low admission weight and weight loss in 
the hospital, as clinical marker of dehydration, with outcome of patients of 
acute encephalitis syndrome.
2. To describe the association between changes in weight and blood lactate 
levels, at admission and discharge, as indicators of hydration and acid base 
status, and outcome in children with acute encephalitis syndrome.
5.3 Methods
The study was conducted at Kanti Children’s Hospital, a tertiary level 
public paediatric hospital located in Kathmandu. Presence of various sub-
speciality services in paediatrics such as surgery, intensive care, radiology, 
neurology, cardiology, endocrinology, nephrology, dermatology, orthopaedics, 
otolaryngology, dentistry makes it one of its kind in the country. It also makes 
it the fi rst choice of referral for sick children from all over the country. 
A hospital based prospective cross-sectional study was conducted. All children 
of AES as defi ned by WHO surveillance standard, presenting to Emergency 
Department, Paediatric Ward and Paediatric Intensive Care Unit of Kanti 
children’s hospital, Kathmandu, Nepal, were seen either by me or my research 
assistant. The research assistant received one week of orientation training about 
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the research methodology before starting the research activities in order to 
reduce inter- observer variability of research fi ndings. 
A detailed history was then taken from the accompanying parents or guardian. 
Complete clinical examination including a full neurological examination was 
then performed. Attention was given to the child’s weight, mid upper arm 
circumference (MUAC), clinical signs of dehydration, capillary refi ll time, 
peripheral oxygen saturation and axillary temperature. Weight was measured 
using a digital weighing scale which was quality controlled every morning 
using standard weights.
MUAC is the circumference of the left upper arm, measured at the mid-point 
between the tip of the shoulder and the tip of the elbow (olecranon process of 
the ulna bone and the acromion process of scapula) (146). For that, initially, 
straight distance was measured between the acromion process of the scapula at 
the tip of the left shoulder and the olecranon process of the ulna, through the 
midline, over the triceps, on the posterior aspect of the left upper arm, with the 
arm hanging loosely and comfortably at the side. The midpoint was determined 
by measuring the distance between the two landmarks using a tape calibrated 
in centimeters. The lateral side of the arm was marked with a visible marker 
pen and measurement of the circumference of the arm at the mark taken by a 
non stretchable plastic tape. During measurement it was made sure that the tape 
was not twisted and was parallel to the marking. Measurements were recorded 
to the nearest 0.5 mm. 
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Blood was taken for a full blood count, differential leukocyte count, urea, 
creatinine, sodium, potassium, glucose, liver function test, bacterial culture, 
viral serology and serum lactate level. A lumbar puncture was performed and 
CSF taken for leukocyte count and differential, glucose, protein, microscopy 
and culture, and detection of antibodies for viral (anti-JE IgM ELISA) and 
bacterial pathogens [antibody titres against specifi c bacteria Streptococcus 
pneumoniae, Hemophilus infl uenza type B, Niesseria meningitidis measured 
via a commercial kit (PASTOREX MENINGITIS, BIO-RAD, France, 2011)]. 
All children fulfi lling inclusion criteria mentioned in chapter 2 were 
included in the study. Written consent was requested from the parents or 
accompanying guardians, prior to enrolling the children in the study. Patients 
were assessed (including weight, and blood lactate and oxygen saturation 
(Spo2) at admission, at 48 hours after admission and again at discharge by a 
member of the study team. Total fl uid input (oral, nasogastric and intravenous 
including diluents for drugs) and output (urine, vomit) was monitored daily 
after admission until discharge. The input and output were assessed from the 
treatment chart, nurses notes, asking the attendant and researchers observation. 
Use of other supportive management procedures such as head positioning, 
sedatives (including anti-epileptic drugs), mannitol and analgesia provision 
were also recorded. All the information was recorded on a case record form 
( Appendix M). Further details of the methodology is described in chapter 2 
(General Methods).
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5.3.1 Case Defi nition
Case defi nitions followed were as described in Chapter 2.
5.3.1.1 Weight-for-age Z scores: WFA was defi ned using a z score as 
described in chapter 4. In this study, I stratifi ed subjects by their WFA Z score 
and examined outcome among these groups [high WFA: Z score +1 (Z score 
between +1 and +2), average WFA: Z score 0 (Z score between +1 and -1), 
mild low WFA: Z score -1 (Z score between -1 and -2), moderate low WFA: 
Z score -2 (Z score between -2 and -3), severe low WFA: Z score -3 (Z score 
more than -3)](91). Although, low WFA means under-nutrition, in acute 
conditions such as AES, it may also suggest poor fl uid intake (or dehydration). 
5.3.1.2 Low WFA: WFA z-score <0
5.3.1.3 Without low WFA: WFA z-score ≥ 0.
5.3.1.4 Weight Loss: Children who lost weight during hospital stay between 
admission and discharge (or death).
5.3.1.5 No Weight Loss: Children who did not lose weight during hospital stay 
(from admission until discharge or death).
5.3.2 Ethics
The study was approved by the Ethical Committees of the Nepal Health 
Research Council and the Liverpool School of Tropical Medicine as well as the 
Institutional Review Committee of Kanti Children’s Hospital. 
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5.3.3 Data analysis
Data was coded and entered in statistical package for social sciences (SPSS) 
Statistics software version 17.0 (IBM-SPSS, New York, USA) and epi info 6. 
Percentage, Proportions and Contingency tables will be used for description 
of the data. All the clinical features, laboratory parameters and outcomes 
of children with AES with low weight-for-age were compared with normal 
weight-for-age. Normally distributed data was analysed using the Student’s t-
test, non-normally distributed data using Mann-Whitney U test and differences 
between proportions by Fischer's Exact test or Chi square test using Yates 
correction as necessary. Regarding comparison of three groups, normally 
distributed data were compared using ANOVA and skewed data were compared 
using Krushkar- Wallis test. P <0.05 was taken to be statistically signifi cant. 
5.4 Results
Out of 143 patients admitted with a diagnosis of AES with MUAC ≥ 11.5 cm, 
39 (27%) had bacterial meningitis, 7 (5%) typhoid encephalopathy and 5 (3%) 
patients could not have their discharge weight recorded and were excluded 
from the study (Figure 5.1). Of the remaining 92 (64%) AES of suspected 
viral aetiology, 4 (4 %) were JE, 68 (74%) confi rmed non-JE and 20 (22%) 
were of unknown aetiology including unknown JE status. Low WFA was 
seen in 50 (55%). Amongst the low WFA group, 30 (33%) were mild (WFA 
Z score between -1 and -2), 10 (11%) moderate (WFA Z score between -2 
and -3) and 10 (11%) were severe (WFA Z score below -3). Of the total, 30 
(33%) had weight loss after admission. Overall, 23 (25%) were of low WFA 
and had further weight loss after admission, 27 (29%) were low WFA and had 
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no weight loss, 7 (8%) did not have a low WFA and had weight loss during 
admission and 35 (38%) did not have low WFA and no weight loss after 
admission.
Considering low weight may be associated with dehydration and weight loss 
with fl uid loss, I grouped the participants in two groups as low WFA and/or 
weight loss and without low WFA and/or no weight loss. When patients of 
low WFA and/or weight loss and without low WFA and/or no weight loss 
were grouped together, 57 (62%) were of low WFA and/or weight loss and 
35(38%) without low WFA and/or no weight loss. Bad outcome was seen in 
59 (64%) patients and good outcome in 33 (38%) (P- 0.0002). Bad outcome 
was signifi cantly higher in those with a low WFA (P- 0.005) but not those with 
weight loss (P - 0.13) during admission. Together in those with both low WFA 
and/or weight loss, there was 7 times risk of bad outcome as compared to good. 
(Table 5.1) Regarding death, those with low WFA and/or weight loss were 19 
times at greater risk of death (Table 5.1).
The clinical features and laboratory parameters of the two groups are shown in 
Table 5.2. Children with bad outcomes were signifi cantly younger, shorter with 
lower mid-upper arm circumference (MUAC). They also had prolonged fever 
and headache duration, more episodes of seizures, focal neurological defi cits 
and lower levels of consciousness. MUAC and height was even lower in the 
low WFA and/or weight loss group amongst those who had bad outcome. In 
those who had a good outcome, the low WFA and/or weight loss group had 
a signifi cantly longer fever duration than those without low WFA and/or no 
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weight loss. Serum sodium and potassium were signifi cantly higher in the bad 
outcome group. There was also tendency of higher urea in those who had bad 
outcome especially in low WFA and/or weight loss group although it was not 
signifi cant. Also, children who had bad outcome had received signifi cantly 
more phenytoin and phenobarbitone as compared to those who had good 
outcome. 
Residual neurological sequelae were measured using the Liverpool outcome 
score (LOS). In children of low WFA and weight loss group, the mean score on 
the LOS was signifi cantly lower as compared to those without low WFA and no 
weight loss group [2.9 ± 1.5 versus 34.25 ± 1.22 (P- <0.0001)]. Total LOS was 
signifi cantly lower in the low WFA and/or weight loss group as compared to 
those without low WFA and no weight loss [51.59 ± 30.19 versus 69.7 ± 14.78 
(P- <0.0001)]. 
The total fl uid balance constituents monitored are shown in Table 5.3. Children 
who had good outcome received signifi cantly more intravenous fl uids. Even 
though WFA Z score was used to categorize weight, these children were older 
and had higher GCS, they could demand and take signifi cantly more fl uids 
orally. Their oral fl uid intake increased signifi cantly by 48 hours in those with 
good outcome as compared to bad outcome group. Interestingly, there was big 
disparity between IVF ordered by the doctor, written in nurse's note, attendant's 
observation and what was actually given on the day of admission and after 48 
hours. On both the days actual IVF administered was much less than the IVF 
ordered by the doctor in the bad outcome group as compared to good outcome 
group. 
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The fl uid status of the recruited patients is shown in Table 5.4. Those who had 
a bad outcome had a signifi cantly prolonged illness, weighed less at admission 
and at discharge. They also had signifi cantly higher fl uid requirement, fl uid 
defi cit and were restricted from receiving full maintenance IVF. Serum lactates 
at the time of admission were higher in those who had bad outcomes. 
When outcomes were grouped into death, residual neurological sequelae 
and complete recovery, those who died had a signifi cantly longer duration of 
illness, a lower GCS, more focal neurological defi cits, lower WFA Z score, 
more loss of weight during admission, higher blood sodium and urea during 
admission. They also had higher serum lactate on admission and higher rise of 
serum lactate after 48 hours. This all suggest that these children were sicker 
and more dehydrated than those who survived (Table 5.5). These children had 
also received signifi cantly more 0.45% normal saline with 5% Dextrose as 
maintenance IVF as compared to those who had survived with sequelae and 
recovered completely. Those who had complete recovery, had signifi cantly 
less fl uid requirement, less reduced fl uid intake and less fl uid restriction and 
therefore less fl uid defi cits with progressively increased oral fl uid intake and 
urine output from admission up-to 48 hours. 
5.5 Discussion
In this study I found children of AES presenting to the hospital with low WFA 
Z score were signifi cantly associated with bad outcomes. The odds increased to 
7 times more likelihood of having a bad outcome if the patient has a low WFA 
and/or weight loss. The odds of dying was 13 times more if the patient had a 
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low WFA Z score at the time of admission, 10 times more if they had weight 
loss and 19 times if they had a low WFA Z score and/or weight loss. In these 
children, weight could be representative of body water. Since the MUAC of all 
children recruited were ≥11.5 cm, we have considered acute loss of weight to 
be simple surrogate marker of dehydration (141). Therefore, children with low 
WFA and/or weight loss were dehydrated. 
Children who suffered bad outcome were signifi cantly younger, had prolonged 
fever and headaches, lower GCS and more focal neurological defi cit suggesting 
they were sicker than good outcome group. In addition, in the bad outcome 
group, more number of children were found with low WFA Z score on 
admission, more fl uid requirements, more fl uid defi cits, more number of 
children with fl uid restrictions during admissions, lesser intake of oral fl uids, 
higher serum sodium and urea. All of these fi ndings suggest that they these 
patients were sicker and more dehydrated than the good outcome group. 
The state of hypertonic hypovolemia evident in these children also confers 
the likelihood of dehydration (147). This became more evident when the 
outcome was further sub-grouped as death, sequelae and complete recovery. 
Signifi cantly more number of children died who had low WFA Z score, 
higher admission serum urea and sodium and weight loss after admission. 
Signifi cantly more weight was lost during admission in these children who died 
as compared to sequelae and recovery group. Admission serum lactate levels 
were higher and increased further on the second day of admission in this group 
as compared to others. Not surprisingly, those who recovered completely, were 
signifi cantly older, had higher GCS scores, suffered less focal neurological 
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defi cits, required lesser maintenance IVF, suffered lesser fl uid defi ciencies, 
were less fl uid restricted and had more oral fl uid intake than those who died or 
had sequelae indicating good hydration status.
Dehydration is common in children of AES. It may be because they are 
very young and depend on others for food and drinks and even if older 
and independent, they are unable to feed because of altered sensorium and 
neurological defi cits. There is also tendency to restrict total fl uids to two-thirds 
of maintenance fearing cerebral oedema by treating clinicians in these children. 
Adequate perfusion of all the tissues is essential for them to function normally. 
Dehydration can cause cerebral hypo-perfusion and ischemic injury to the brain 
causing anxiety, confusion and stupor. It is known to increase risk of cerebral 
infarction in subarachnoid haemorrhage (93) causing neurological defi cit. 
Renal hypo-perfusion can cause acute renal failure and anuria, hypo-perfusion 
of the gastrointestinal tract causes erosive gastritis or ischemic pancreatitis, 
hypo-perfusion of the liver, ischemic hepatitis. It can also cause coagulation 
abnormalities and thrombocytopenia. The odds of having bad outcome in 
children with low WFA and/or weight loss can be explained by demonstrating 
clinical and laboratory evidence of dehydration in them. A signifi cant number 
of children who suffered a bad outcome were fl uid restricted in our study. 
Restriction of fl uids has also been shown to cause adverse outcomes in both 
traumatic and non-traumatic brain injury patients in other studies (89, 93). 
Hydration status may also have a role in drug therapy. In dehydration, the 
volume of distribution of drug may decrease so that even a standard dose 
for given age and weight may become toxic and produce adverse effects. In 
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these conditions, normal doses of aminoglycosides could be nephrotoxic and 
phenobarbitone highly sedative causing adverse outcome. 
Dehydration decreases oxygen delivery to cells which reduces availability of 
oxygen in the energy cycle and promotes anaerobic metabolism. This causes 
oxidative fermentation of pyruvate to form lactate, which accumulates to cause 
metabolic acidosis. Excessive production of pyruvate may also cause lactic 
acidosis (148). Acidosis further shifts the oxygen-haemoglobin dissociation 
curve to the right, decreasing haemoglobin’s affi nity for oxygen, and hence 
decreasing oxygen delivery. If not corrected, severe acidosis can impair the 
body’s metabolic process, impede neurovascular interaction and even prevent 
pharmacological action of various drugs. This may cause life threatening 
arrhythmias, myocardial depression, respiratory muscle fatigue, seizures, shock 
and multi-organ failure. Elevated serum sodium, serum urea, serum creatinine 
and serum lactate levels on admission with supportive clinical information in 
the patients who died showed presence of metabolic acidosis with impending 
renal failure in our study. The median serum sodium was signifi cantly high 
in those who suffered bad outcomes as compared to good [bad outcome, 139 
(122- 172) versus good outcome, 131 (116- 142) (P- 0.001)] and those who 
died as compared to survivors [death, 145 (139- 172) versus survived, 134 
(116- 149) (P- <0.0001). Raised serum and CSF lactate levels have been 
previously been reported in both traumatic and non-traumatic brain injury 
patients who have complications (20, 95- 97). Therefore, adequate hydration to 
prevent metabolic acidosis and maintain suffi cient cerebral perfusion without 
causing cerebral oedema or rise in intracranial pressure is the key in the 
management of children with brain injury. 
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Total body water in the body is spread over two-thirds of the body as 
intracellular fl uid and one-third as extracellular fl uid (ECF). A quarter of ECF 
is in the intravascular space as plasma and the rest is extravascular (interstitial 
space). A decrease in plasma water causes an increase in plasma sodium 
concentration and osmolality which is sensed by nuclei in the hypothalamus 
which results in increased production of ADH and stimulates the thirst 
mechanism. ADH causes increased renal free water reabsorption in the 
collecting tubule in the kidney to restore plasma water so that plasma sodium 
concentration is brought back to normal. Renin-angiotensin-aldosterone 
system and atrial natriuretic peptides both involved in thirst mechanism also 
regulate fl uid volume by altering sodium excretion. In the cerebral circulation, 
endothelial tight junction prevents easy passage of sodium through the blood 
brain barrier (BBB). With an intact BBB, a fall in osmolality by 5 mmol/L 
decreases osmotic pressure between capillary lumen and brain interstitial space 
by 95 mmHg. This results in movement of water instead of sodium from hypo-
osmolar area towards hyper-osmolar area. This causes accumulation of water in 
the brain cells or interstitial space to develop cerebral oedema (92, 149).
A Child’s daily requirement of sodium as 3mEq/Kg, potassium 2mEq/Kg and 
glucose 5g/Kg is estimated based on electrolyte composition of human and 
cow milk. Normally, an infant weighing 6 Kg administered full hypotonic 
maintenance fl uid as 5% Dextrose with 0.18% saline almost receives all the 
required elements as 100ml/ Kg /day of water, 3 mmol/Kg of sodium and 3.5 
mg/Kg of glucose. This estimation is based on normal physiology of a child. 
However, in severe infections including AES, hyponatremia develops in 20- 
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45% patients with increasing sodium requirement (92, 150). Therefore, the 
use of hypotonic saline in these children can further increase risk of severe 
hyponatremia (141, 151, 152). In this study, signifi cantly more children who 
died had received 5% Dextrose with 0.45% saline. Also there was a positive 
trend for those who received 5 % dextrose (0.9%) normal saline to completely 
recover. This shows that the maintenance IVF calculated based on the normal 
sodium requirement of healthy children may not have been suitable for 
severely ill children of AES who may have a higher sodium requirement. 
Therefore isotonic fl uid such as 5% dextrose (0.9%) normal saline may have 
been more suitable for these children (152). 
In this study, elevated serum sodium on admission was suggestive of metabolic 
acidosis. However serial measurement of electrolytes, lactate and blood gas 
analysis during hospital stay and discharge would have confi rmed this and 
guide fl uid management. Because of the complications related to the illness and 
fl uid status, no single maintenance fl uid is ideal and needs to be individualized 
based on serial fi ndings of body sodium measurement. I also found children 
who were taking oral feeds signifi cantly associated with good hydration 
and outcome. Although it can be argued that those children could have been 
less sick. However, even the markers of dehydration were suggesting good 
hydration status in these children. Therefore, close attention is required to IVF 
until the child becomes conscious and can take oral feeds at liberty because 
one’s own body is the most accurate accessor of salt and water needs. 
Seizures are a treatable complications of AES and measures aimed at 
controlling them improve outcome (20). The most accepted pathogenic 
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mechanism for development of seizures in encephalitis is that of extensive 
infl ammatory response. The infl ammatory peptides, which are produced 
by neurons, astrocytes, and microglia, are increasingly recognized to 
promote excitatory neurotransmitter release and initiate depolarization 
which then causes release of certain proinfl ammatory cytokines, by means 
of co-stimulation. This dynamic interplay between cytokines, chemokines, 
neurotransmitters, and other factors are thought to be the likely cause of 
seizures (153, 154).
I found signifi cant association between more episodes of seizure and bad 
outcome. The episodes were more frequent in the dehydrated group than the 
well hydrated group. Median serum sodium level was also signifi cantly higher 
in those who were dehydrated at the time of admission (P-0.049). In those who 
had seizures, serum sodium level was signifi cantly higher amongst those who 
had a bad outcome (P-0.006); specially those who died (p- <0.0001). There 
was also no association of serum glucose with seizures (P- 0.6), bad outcome 
(P- 0.5) or death (P- 0.6).There is 6.8% risk of having unproved seizure in 
central nervous system infections (53). Single episodes of seizure occur in 
around 40% of patients of JE but do not affect outcome. However, repeated 
seizures and status epilepticus are associated with bad outcome (20). Seizures 
can occur in AES because of cerebral oedema, neuronal injury and neuronal 
necrosis as a result of infl ammatory changes of the brain (53). In JE, cerebral 
oedema, haemorrhage and formation of thrombus has been reported to cause 
cerebral hypoxia and seizure (53). Sometimes co-morbidity with cysticercosis 
can cause seizures (155). However, I found signifi cant association of repeated 
180
seizures with dehydration and metabolic acidosis. Therefore signifi cantly 
increased disabilities observed at discharge in the dehydrated group could be 
the result of cerebral ischemia, acidosis and seizures. 
Other causes of seizure in dehydration can be due to hypernatremia, 
hypoglycaemia, hyperlactataemia because of metabolic acidosis, hyponatremia 
of SIADH in AES, cerebral venous thrombosis, cavernous sinus thrombosis, 
fever triggered seizure, febrile seizure or CO2 retention. Seizures triggers a 
vicious cycle of increased cerebral blood fl ow, then cerebral oedema, raised 
ICP, reduction in cerebral blood fl ow, then exacerbation of hypoxic cerebral 
metabolism, then further increase in cerebral oedema, raised ICP until 
brainstem herniation. Seizures also causes increased use of anti-epileptic drugs. 
There was signifi cant association of bad outcome and death in those who were 
on phenytoin and phenobarbitone. Anti-epileptic drugs can cause excessive 
sedation, clouding of consciousness, suppression of neurological signs, 
inhibition of respiration, choking episodes and aspiration pneumonia.
Some of the patients included could have been malnourished. Since all of the 
children recruited had MUAC ≥ 11.5 cm, we had used MUAC to separate 
children of malnutrition from dehydration. MUAC is a simple age independent 
anthropometric index which can be conducted at initial evaluation to assess 
nutritional status. Weight-for-height would have been better if it was possible 
in children with altered sensorium. Some of the patients of dehydration could 
have been malnourished or could have co-morbidity. Administering IVF in 
these children is often diffi cult because they could develop congestive cardiac 
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failure at normal rate and volume of administration due to inability to handle 
normal fl uid volume having limited cardiac reserve. Therefore, malnutrition 
status could affect outcome adversely.
I used only indirect markers of dehydration in my study. Direct markers such 
as blood ph by arterial blood gas and serum osmolality would have been more 
accurate in categorising patients to be suffering of metabolic acidosis from 
dehydration. 
In conclusion, AES patients with dehydration suffer bad outcomes. Fluid is a 
simple method of treatment. The process of accurately carrying out doctors’ 
advice in the ward rounds should be reviewed and strengthened. Present 
Holliday-Segar recommendations of hypotonic maintenance IVF is not suitable 
for hospitalized children with AES. IVF needs to be individualized based 
on the fi ndings of daily measurement of weight, fl uid balance, electrolytes 
(especially serum sodium level) and clinical parameters. There is no defi nite 
treatment for most of the viral encephalitides including JE, but maintaining 
good hydration status with adequate and appropriate IVF may potentially be a 
simple, cheap, easily available treatment option which could save lives even in 
resource scarce settings like Nepal. However, only a randomised control trial 
of different volume (two- third versus full maintenance) and types (DNS, 0.9% 
NS, 0.45% NS, 0.18% NS) of fl uid would be able to prove that increased and 
appropriate fl uid intake could improve outcome.
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5.6 Limitation of study
In this study, low WFA at admission and loss of weight after admission were 
together considered to be markers of dehydration. Both were signifi cantly 
associated with death. Those who acutely lost weight during hospital stay are 
likely to have suffered dehydration. However, patients having low WFA on 
admission cannot be confi rmed to have dehydration. In these patients, some 
could have been malnourished. Further, subanalysis, to examine the clinical 
features and laboratory parameters of dehydration in LWFA and the weight loss 
groups may have been helpful.
Anthropometry, including MUAC, has poor specifi city to diagnose 
malnutrition because changes in body measurements are sensitive to multiple 
factors including intake of essential nutrients, infection, altitude, stress and 
genetic background. Therefore, some of the patients I included in the study 
with MUAC ≥ 11.5 cm could have been malnourished.
MUAC < 11.5 cm is a useful screening tool for assessment of malnutrition in 
children between 1 and 5 years of age in the community. However, it cannot 
confi rm malnutrition in children below 1 year and above 5 years of age. In 
addition, MUAC < 11.5 cm was used to screen patients of severe malnutrition. 
This meant that there was possibility of patients of moderate and mild 
malnutrition to be included in this study which could have affected outcome. 
There is a possibility that more patients with protein energy malnutrition 
(PEM), as defi ned by WHO, could have been excluded if we had taken 
MUAC <12.5 cm as a cut off value. This has also highlighted the need to 
validate MUAC <11.5 cm and < 12.5 cm as a marker of severe and moderate 
malnutrition in Nepali children.
183
In patients with LWFA and weight loss during hospitalization, I used indirect 
markers of dehydration and acidosis such as blood lactate, oxygen saturation, 
capillary refi ll time. More direct markers such as blood pH and urinary 
osmolality may have been more accurate. Comparison of clinical features, 
examination fi ndings and markers of dehydration in patients of MUAC ≥ 
11.5 cm and <11.5 cm could have helped characterize dehydration even more 
accurately. 
Weight for height, BMI, Kanawati index, Dugdale index or blood 
micronutrients level may have been more accurate markers of malnutrition in 
a well resourced setting. However, I chose MUAC as marker of malnutrition 
because it was affordable and easily applicable at community level in my 
resource poor setting.
I included only patients whose LP results suggested AES of viral aetiology 
because I wanted to accurately describe the fi nding in patients of viral 
encephalitis since there was no treatment in majority of the cases. This caused 
exclusion of patients who did not undergo LP, which could have been because 
they were very sick and were at risk of procedure related complications. 
Exclusion of these patients could have affected the study results. 
I monitored patients until discharge. Outcome is more accurately characterised 
as good or bad until 3 months of illness in patients of JE. Therefore, follow up 
patients up to 6 months for eventual outcome would have been preferable.
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Since JE cases decreased over the years after introduction of JE vaccine, there 
is a need to validate clinical features of AES as defi ned by WHO surveillance 
standard, as a screening tool to diagnose other viral encephalitis beyond JE in 
Nepali children. 
5.7 Summary
As the admission WFA Z score decreased there was a signifi cant increase in 
bad outcome and neurological sequelae in JE and AES patients in my previous 
study. Therefore, I measured weight of all children at the time of admission 
or on initial assessment to fi nd out the hydration status of the patient before 
coming to the hospital and commencement of fl uid therapy; and at the time of 
discharge or death which would refl ect receipt of fl uids during hospital stay. I 
also looked for admission serum lactate level to assess hydration and acidosis 
before hospital admission; and after 2 days to assess dehydration level after 
admission and commencement of fl uid therapy. 
In addition, I assessed markers which seperated dehydration from malnutrition 
by measurement of serum electrolytes and MUAC (≥ 11.5 cm) at the time of 
admission. Daily monitoring of overall fl uid intake such as oral, naso-gastric, 
diluents of drugs and IVF were done. Daily monitoring of output such as 
urine and vomitus were also done. Daily fl uid intake and output was recorded 
from treatment chart for doctors order, from nursing notes for what the nurse 
administered, from interview of attendant for what they observed and from 
researchers own observations. Interestingly, there was also a mismatch between 
what was actually given by the staff and that what the doctor ordered. 
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Since dehydration can be assessed by weight loss, I considered patients with 
weight < 0 WFA Z score as low WFA group, weight ≥ 0 WFA Z score as 
without low WFA group, weight lost during admission as weight loss group 
and no weight loss during admission as no weight loss group. For analysis, low 
WFA at admission and weight loss during admission were grouped together as 
dehydrated group and patients without low WFA at admission and no weight 
loss during admission as non-dehydrated group. 
Bad outcome was signifi cantly associated with lower admission WFA Z score, 
more fl uid defi cit, and a trend for a higher admission serum lactate. Death 
was signifi cantly increased in patients with weight loss during admission, 
low WFA Z score and with a longer duration of illness. Bad outcome patients 
were also more frequently prescribed 5% dextrose and 0.45 normal saline and 
had higher sodium and higher urea at admission. There was a 9 times higher 
the risk of death in the weight loss group. There was also a 19 times higher 
the risk of death and 7 times higher risk of bad outcome (death or sequelae) 
in the LWFA and weight loss combined group compared to other group. As 
in the UK, hospital oral and intravenous fl uids guidelines need to be written 
for children with impaired consciousness. This could be based on existing 
Advanced Paediatric Life Support (APLS) guidelines supported by Liverpool 
Life Support Group with a training being conducted in Nepal, every year. 
To investigate this further a randomised controlled trial of different types 
and volumes of fl uids in admitted patients of AES and JE could enable us to 
see whether the association is casual. Then identifying aetiology of AES and 
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providing aetiology based treatment and immunisation schedules against the 
disease would also help in improving outcome among AES patients. Since JE 
was the most common identifi ed aetiology in AES patients identifying new 
adjunctive treatments for JE, such as IVIG may also help in reducing morbidity 
and mortality of AES patients in Nepal. Whilst fl uid management is important 
for all causes of AES, for JEV there is the possibility of an adjunctive treatment 
with IVIG containing neutralizing anti-JEV antibody. I therefore assessed this 
with a pilot study, described in the next chapter.
Table 5.1: Outcome of the patients based on initial weight and weight loss after 
admission 
Bad outcome (n=59) Good outcome (n=33) P-value OR (95% CI)
Low WFA 39 (66%) 11 (33%) 0.005 3.9 (1.5- 10.7)
Weight loss 23 (39%) 7 (21%) 0.13 2.4 (0.8- 7.2)
low WFA and/or 
weight loss 45 (76%) 12 (36%) 0.00005 7.2 (2.5- 20.9)
Death (n=13) Survived (n=79) P-value OR (95% CI)
Low WFA 12 (92%) 38 (48%) 0.007 13 (1.6- 279)
Weight loss 10 (77%) 20 (25%) 0.0006 9.8 (2.2- 50.7)
low WFA and/or 
weight loss 12 (92%) 45 (57%) 0.015 19.1 (1.1- 195)
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Table 5.3: Constituents of fl uid balance during hospital stay
Bad Outcome Good outcome P- value
(n= 59) (n= 33)
Actual IVF given on D0 (ml/day) # 652 (200- 2100) 1090 (390- 2155) <0.0001
Actual IVF given on D2 (ml/day) ## 570.5 (250- 2260) 958.5 (560- 1650) 0.007
Drug diluents on D0 (ml/day) 100 (14.8- 283) 88 (15- 440) 0.75
Drug diluents at D2 (ml/day) 80 (16- 300) 80 (6- 360) 0.61
Oral fl uid on D0 (ml/day)* 0 (0- 1000) 50 (0- 1850) 0.001
Oral fl uid at D2 (ml/day) 60 (0- 2000) 900 (0- 2060) <0.0001
Nasogastric fl uid on D0 (ml/day) 0 (0- 240) 0 (0- 0) 0.46
Nasogastric fl uid at D2 (ml/day) 0 (0- 260) 0 (0- 600) 0.69
Vomiting on D0 (ml/day) 0 (0- 20) 0 (0- 0) 0.28
Vomiting at D2 (ml/day) 0 (0- 10) 0 (0- 0) 0.43
Urine output on D0 (ml/day) 310 (0- 2150) 500 (80- 1400) 0.2
Urine output at D2 (ml/day) 500 (100- 2325) 650 (150- 1000) 0.36
# IVF ordered by doctor(ml/day) D0, bad outcome, 788.5 (25-1728); good 
outcome, 1040 (223- 2000) (p-0.058), IVF in nurse’s note (ml/day) D0, bad 
outcome, 600 (100- 1750); good outcome,1000 (200- 1860) p-0.13, IVF on 
parents audit (ml/day) D0, bad outcome, 555 (150- 2020); good outcome,1000 
(445- 1840) (p- 0.017)
## IVF ordered by doctor(ml/day) D2, bad outcome, 832 (329- 1762); good 
outcome, 980 (505- 1650) (p-0.34), IVF in nurse’s note (ml/day) D2, bad 
outcome, 783.5 (100- 4788); good outcome, 1000 (560- 1650) (p-0.09), IVF 
on parents audit (ml/day) D2, bad outcome, 753.5 (310- 2000); good outcome, 
832.5 (505- 1650) (p- 0.014)
*Median (range) increase in oral fl uid intake from D0 to D2 for bad outcome 
was 0 (-600-1880) ml/day and good outcome 280 (0-1880) ml/day (P- 0.006) 
Median (range)
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Table 5.4: Fluid status of the recruited patients
Clinical Features Bad Outcome (n=59) Good outcome (n= 33) P- value
Duration of illness at admission (days) 6 (2- 23) 5 (2- 11) 0.014
Admission weight (Kg) on D0 # 10 (4- 40) 17 (6- 40) 0.008
Discharge or death weight (Kg) 10 (4- 40.5) 17 (6.6- 40) 0.006
Fluids required (ml/kg/day) 100 (55.48- 100) 79.41 (47.5- 100) 0.001
Fluids defi cient (ml/kg/day) 20.35 (- 22.2- 68) 0.4 (-30.8- 50) <0.0001
% difference between fl uids required and 
delivered 26.35 (-33- 90.8) 2.7 (-39.6- 50) <0.0001
Received IVF 5% Dextrose with 0.45% 
normal saline 39 (66%) 15 (45%) 0.05
Received IVF Dextrose (0.9%) normal saline 12 (20%) 9 (27%) 0.4
Restriction of IVF to 2/3rd of full maintenance 40 (68%) 15 (45%) 0.04
Serum lactate (mg) on D0 * 2.15 (0.8- 13) 2 (0.8- 3.6) 0.45
Serum lactate (mg) at D2 2.1 (1.2- 8.9) 2.1 (1.1- 7.1) 0.85
# A Median (range) change in weight from D0 (admission day) to discharge or 
death for bad outcome was 0 (- 2.2- 1.5) Kg and good outcome 0 (-1.3- 3) Kg 
(P- 0.3)
*A Median (range) change in serum lactate from D0 (admission day) to D2 
(second day of hospitalization) for bad outcome was -0.1 (- 11.4- 7.3) mg and 
good outcome -0.1 (-1.7- 5.4) mg (P- 0.5)
Median (range), number (%); IVF-Intravenous fl uids
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Table 5.5: Fluid status of the recruited patients by outcome 
 Death(n=13) Sequelae (n=46) Recovery (n=33) P- value
Duration of illness at admission 
(days) 7 (4- 12) 6 (2- 23) 5 (2- 11) 0.029
Duration of hospital stay (days) 6 (2- 10) 9 (1- 23) 9 (3- 18) 0.02
Admission weight (Kg) 9 (4.5- 31) 10 (4- 40) 17 (6- 40) 0.028
Change in weight (Kg)¶ -0.5 (-0.8- 0) 0 (-2.2- 1.5) 0 (-1.3- 3) 0.006
Presence of low WFA 12 (92%) 27 (59%) 11 (33%) 0.001
Presence of weight loss 10 (77%) 14 (30%) 7 (21%) 0.001
Admission modifi ed GCS 8 (5- 14) 11 (3- 15) 14 (6- 15) <0.0001
Presence of FND at admission 9 (69%) 23 (50%) 9 (27%) 0.02
IVF 5% Dextrose with 0.45% 
normal saline 12 (92%) 27 (59%) 15 (45%) 0.01
IVF Dextrose (0.9%) normal 
saline 1 (8%) 11 (24%) 9 (27%) 0.35
Never on IVF 0 (0%) 7 (15%) 9 (27%) 0.08
Fluids required (ml/kg/day) 100 (55.5- 100) 100 (56.7- 100) 79.41 (47.5- 100) 0.008
Fluid defi cient (ml/kg/day) 16.5 (-8.3- 54.1) 22.5 (- 22.5- 68) 0.4 (-30.8- 50) <0.0001
Reduced fl uid intake (ml/kg/
day)* 10 (77%) 32 (70%) 15 (45%) 0.09
% difference between fl uids 
required and delivered 14.6 (- 7- 54.1) 27 (-33- 90.8) 2.7 (-39.6- 50) 0.001
Restriction of IVF to 2/3rd of 
full maintenance 7 (54%) 33 (72%) 15 (45%) 0.06
Oral fl uids (ml/day) D0# 0 (0- 50) 0 (0- 1000) 50 (0- 1850) 0.001
Oral fl uids (ml/day) D2# 0 (0- 60) 150 (0- 2000) 900 (0- 2060) <0.0001
Urine output (ml/day) D0# 355 (30- 500) 250 (0- 2150) 500 (80- 1400) 0.43
Urine output (ml/day) D2# 500 (100- 2350) 461 (120- 1500) 650.4 (150- 1000) 0.65
Serum Na (mmol/L) D0 145 (139- 172) 137 (122- 149) 131 (116- 142) <0.0001
Serum K (mmol/L) D0 4.1 (2.4- 6.6) 4.4 (3.3- 6.4) 3.9 (2.3- 6) 0.035
Serum urea (mg/dl) D0 45 (20- 173) 29 (11- 78) 29 (11- 80) 0.007
Serum creatinine (mg/dl) D0 0.8 (0.3- 3.5) 0.6 (0.3- 1.7) 0.6 (0.4- 1.3) 0.037
Serum Lactate at D0 (mg) ○ 2.6 (1.3- 6.6) 1.8 (0.8- 13) 2 (0.8- 3.6) 0.085
Serum Lactate at D2 (mg) 3.2 (1.6- 4.3) 2.1 (1.2- 8.9) 2.1 (1.1- 7.1) 0.5
¶ The mean ± standard deviation for death was -0.3 ± 0.27, neurological 
sequelae -0.03 ± 0.5 and complete recovery was -0.003 ± 0.65, death. Also for 
difference between D2 and D0 for death it was 0.03 ± 1.3. sequelae -0.18 ± 3.4 
and recovery 0.72 ± 1.9.
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*Reduced total fl uid intake relative to expected. Total fl uids included IVF, oral 
and drug diluents. Expected fl uids was estimated based on 100 ml/kg for the 
fi rst 10 kg, 50 ml/kg for next 10 kg, 20 ml/kg for exceeding 20 kg.
# Oral fl uids include nasogatric fl uids. For death, mean ± standard deviation for 
oral fl uids for D0 was 3.8 ± 13.9 ml/day, oral fl uids D2- 6.7 ± 20 ml/ day, urine 
output D0- 326.3 ± 165 ml/day and urine output D2- 752 ± 901.4 ml/day; for 
neurological sequelae, oral fl uids D0 -131.2 ± 270.7 ml/ day, oral fl uids D2- 
323.6 ± 444.8 ml/ day, urine output D0- 391.3 ± 433.9 ml/ day, urine output on 
D2- 530.5 ± 350.2; and for complete recovery, oral fl uids D0- 431.67 ± 553.8 
ml/ day, oral fl uids D2- 904.1 ± 632.6 ml/ day, urine output D0- 585.5 ± 446.8 
ml/ day, urine output D2- 610.1 ± 268.5 ml/ day. 
○ Median (range) change in serum lactate from D0 to D2 for death was -0.3 
(-1.1- 1.5) mg, residual -0.1 (-11.4- 7.3) and complete recovery -0.1 (-1.7- 5.4) 
mg (P- 0.7). 
Median (range), number (%)
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Chapter 6: A preliminary randomised double 
blind placebo-controlled trial of intravenous 
immunoglobulin for Japanese encephalitis in 
Nepal
Abstract 
Background: Japanese encephalitis (JE) virus (JEV) is a mosquito-borne 
fl avivirus found across Asia that is closely related to West Nile virus. There is 
no known antiviral treatment for any fl avivirus. Results from in vitro studies 
and animal models suggest intravenous immunoglobulin (IVIG) containing 
virus-specifi c neutralizing antibodies may be effective in improving outcome in 
viral encephalitis. IVIG’s anti-infl ammatory properties may also be benefi cial.
Methods: I performed a pilot randomised double-blind placebo-controlled trial 
of IVIG containing anti-JEV neutralising antibody (ImmunoRel™, 400mg/
kg/day for 5 days) in children with suspected JE at two sites in Nepal. I also 
examined the effect on serum neutralising antibody titre and cytokine profi les. 
Results: 22 children were recruited, 13 of whom had confi rmed JE; 11 received 
IVIG and 11 placebo, with no protocol violations. One child (IVIG group) 
died during treatment and two (placebo) subsequently died following hospital 
discharge. Overall, there was no difference in outcome between treatment 
groups at discharge or follow up. Passive transfer of anti-JEV antibody was 
seen in JEV negative children. JEV positive children treated with IVIG had 
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JEV-specifi c neutralizing antibody titres approximately 16 times higher than 
those treated with placebo (p=0.2), which was more than could be explained by 
passive transfer alone. IL-4 and IL-6 were higher in the IVIG group. 
Conclusions: A trial of IVIG for JE in Nepal is possible. IVIG may augment 
the development of neutralising antibodies in JEV positive patients. IVIG 
appears an appealing option for JE treatment but warrants further study. 
Trial registration: ClinicalTrials.gov: NCT01856205
6.1 Introduction
Japanese encephalitis virus (JEV) infection is the most important cause of 
epidemic encephalitis worldwide (156). JEV is found in Southeast Asia, China, 
the Pacifi c Rim and the Asian subcontinent, and its geographical range is 
expanding (52). JEV is a small single-stranded positive-sense RNA fl avivirus, 
closely related to West Nile virus (WNV) that is transmitted between its 
natural bird and pig hosts by Culex tritaeniorhynchus and other mosquitoes. 
JEV transmission occurs mainly in rural areas where rice crops are cultivated 
and where the Culex mosquito favours sources of stagnant water in which 
to breed. People living in rural Asia are exposed to JEV during childhood. A 
small proportion of those exposed develop a simple febrile illness, with an 
even smaller proportion developing symptoms of encephalitis. Those who 
develop JE may present with meningo-encephalitis and/or seizures (20). 
Around one in every four patients of with neuroinvasive JEV infection die, and 
half of the survivors have severe neurological sequelae. This imposes a huge 
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socioeconomic burden in the poor rural settings where JEV is found (157). 
Although vaccines against JEV have become more widely used in recent years, 
the animal reservoir cannot be eradicated, so JEV remains a threat. The virus 
has continued to spread and at present there is no established treatment for JEV, 
or other related fl aviviruses such as WNV. 
The pathogenesis of Japanese encephalitis (JE) is believed to involve a 
combination of viral cytopathology and immunopathology (98- 101); previous 
attempts to develop treatment have explored both of these. After entering the 
body through the bite of an infected mosquito, JEV amplifi es in the dermal 
tissues and lymph nodes leading to viraemia. Virions are thought to then 
bind to the vascular endothelial surface within the CNS, be internalised by 
endocytosis and transferred across the endothelial cells (52). In the brain, JE is 
characterised as perivascular infl ammation with recruitment of macrophages, 
neutrophils and lymphocytes (158- 160). The thalamus, basal ganglia, 
midbrain and anterior horns cells of the spinal cord are particularly affected 
(11, 161). Viral antigens are predominantly in neurons although microglial 
cells, astrocytes and vascular endothelial cells are also infected. JEV is thought 
to cause neuronal cell death in two ways; fi rstly, by direct neuronal killing 
(162, 163), whereby viral multiplication within neuronal cells leads to cell 
death; secondly, by indirect killing, whereby the over activation of microglia, 
astrocytes and recruited macrophages (164) leads to release of excess 
proinfl ammatory cytokines such as interleukin 6 (IL-6), TNF-α, and RANTES 
(regulated upon activation, normal T cell expressed and secreted), which are 
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thought to damage neuronal cells, and increase the permeability of the blood 
brain barrier promoting massive leukocyte migration into the brain and further 
neuronal cell death (165).
The role of corticosteroids in the treatment of JE was examined in a 
randomised-placebo controlled trial inThailand. Although dexamethasone 
caused a reduction in cerebrospinal (CSF) opening pressures and CSF white 
cell counts, there was no overall benefi t in terms of outcome (102). Interferon-
α (IFN-α) is produced as part of the innate response to JEV infection, and has 
antiviral activity against JEV; but a placebo-controlled trial in Vietnam found 
it did not improve outcome (38). Oral ribavirin also proved to be unhelpful in 
a controlled trial in India (106). Intravenous immunoglobulin (IVIG) has been 
postulated as a potential treatment for fl avivirus encephalitis caused by JEV 
and WNV, on account of its antiviral and anti-infl ammatory properties. IVIG is 
postulated to act in two ways; IVIG produced in countries where fl aviviruses 
are endemic contains high titres of specifi c neutralising antibody, because most 
of the population have been exposed to the virus, and thus have antibodies 
(166). In addition IVIG has non-specifi c anti-infl ammatory properties, 
particularly through the suppression of pro-infl ammatory cytokines. However 
IVIG is more diffi cult to administer than intravenous IFN-α, intravenous 
corticosteroids or oral ribavirin (38, 167); it is delivered using a syringe driver, 
and must be started at a low infusion rate, being increased over time if it is well 
tolerated. Where-as the previous trial using intravenous agents were conducted 
in settings with highly developed research infrastructure in Thailand and 
Vietnam, Nepal has no such establishments. 
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In this study I looked at symptomatic cases of JE because there was no 
treatment. IVIG has been postulated to work in in-vitro studies and mouse 
models in JE. It has also been used in patients of JE on a compassionate 
basis, but has not been assessed in a clinical trial (165, 168). JE contributes 
signifi cantly to the total number patients of AES in Nepal. Therefore I was 
provided with initial fund to look at direct effect of IVIG in patients of JE in 
Nepal. However, I was not provided with additional grant to take it onto a 
defi nite clinical trial. Hence, I conducted a pilot randomised placebo-controlled 
trial of IVIG treatment in children with suspected JE in Nepal. I also used the 
opportunity to begin examining changes in immune parameters associated with 
such treatment. 
In the process, regarding safety study, I tested the hypothesis that IVIG could 
be safely given to children with suspected JE, with no increased risk of serious 
adverse events compared with placebo. Similarly regarding effi cacy, I tested 
the hypothesis that compared with placebo, treatment with IVIG halves the 
proportion of JE patients with a bad outcome (death or sequelae) from 66% to 
33%. 
6.2.1 Aim
To conduct a pilot randomised double blind placebo controlled trial of 
intravenous immunoglobulin in Japanese encephalitis
6.2.2 Objectives
1. To conduct a pilot randomised double blind placebo controlled trial to 
assess the safety of intravenous immunoglobulin in Japanese encephalitis 
in children 
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2. To conduct a pilot randomised double blind placebo controlled trial to 
assess the effi cacy of intravenous immunoglobulin in Japanese encephalitis 
in children 
3.  To explore the effect of intravenous immunoglobulin on immunological 
markers of effi cacy in children with Japanese encephalitis
6.3 Methods
6.3.1 Ethics Statement
The study protocol was approved by the Nepal Health Research Council, and 
the ethics committees of BPKIHS, Kanti Children’s Hospital and the Liverpool 
School of Tropical Medicine. Informed written consent was obtained for all 
children from parents or legal guardians. Written consent was also obtained 
from JEV vaccinated individuals.
6.3.2 IVIG selection
JEV-specifi c neutralising antibody titre was measured in pharmaceutical grade 
IVIG obtained from four different suppliers from areas endemic for JEV 
[Bharat serum, India; Hualan Biological Engineering Inc., China; Sichuan 
Yuanda Shuyang Pharmaceutical Co., China; Reliance Biopharmaceutical, 
India] by 50% plaque reduction neutralization titres (PRNT50) against wild type 
JEV (strain P3) infecting a standard culture of Vero cells. IVIG from a low 
JEV prevalence region (Vigam, Bio Products Laboratory, USA) and a sample 
of serum from a JEV vaccinated individual were tested as controls. The test 
was repeated three times. IVIG produced by Reliance Biopharmaceuticals Pvt. 
Ltd. in India and manufactured in China from blood donors in an endemic area 
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known to have high levels of JEV seroprevalence. This had the highest mean 
JEV PRNT50, titre and was selected for use in this trial. In order to confi rm 
the JEV-specifi c neutralising antibody titre as well as characterise background 
immunity to other fl aviviruses known to circulate in Asia, the IVIG was tested 
by dengue virus (DENV), tick-borne encephalitis virus (using Powassan virus), 
and WNV IgM and IgG antibody capture ELISA and PRNT90 at the US Centers 
for Disease Control and Prevention (CDC) Division of Vector-Borne Diseases 
(169-172). The lower limit of quantitation (LLOQ) by PRNT90 was 1:10 
serum dilution. 
6.3.3 Patients
Patients were recruited from two centres in Nepal: Kanti Children’s Hospital 
in Kathmandu, which is the main pediatric center in Nepal, and the Paediatric 
Department at BP Koirala Institute of Health Sciences (BPKIHS), a large 
regional hospital in the town of Dharan in the eastern lowland Terai area 
of Nepal. The JEV mosquito vector is uncommon in Kathmandu due to the 
elevation of 1350 metres (4400 feet) and most cases at Kanti Children’s 
Hospital were referred to this centre from the central lowland Terai area where 
the disease is endemic. 
During monsoon of 2009, I approached children between 1 and 14 years of 
age who were clinically diagnosed AES. AES was diagnosed in children who 
had a history of fever that lasted less than 14 days, altered consciousness 
[Glasgow coma score (GCS) <15] with or without a history of seizures (38, 
75) as described in chapter 2 (General Methods). After lumber puncture (LP), 
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children who had CSF fi ndings consistent with viral encephalitis such as white 
cell count less than 1000 cells/mm3 with no organisms on Gram stain and a 
CSF:plasma glucose ratio > 40% (10, 38), and whose parents provided written 
consent were included in the study. Children who had febrile convulsion were 
excluded. I also excluded those with a positive blood slide or rapid antigen 
test for Plasmodium falciparum parasites and those referred from a peripheral 
health center who had clinical and/or laboratory features suggestive of bacterial 
meningitis where antibiotic treatment had already been commenced. Children 
with a GCS < 3 (out of 15), who were receiving artifi cial ventilation without 
signs of spontaneous respiration, and with absent oculocephalic refl exes were 
excluded, as prior studies have shown an extremely low chance of meaningful 
recovery (20). 
6.3.4 Procedures
I randomly allocated patients to treatment with IVIG or placebo. Methods of 
randomisation (38) and recruitment has been described in detail in chapter 2 
(General Methods). The randomisation schedule is provided as S1 Table. 
I took a detailed history and a member of the study team did daily clinical 
and neurological examinations until death or discharge as described in 
chapter 2 (General Methods). I also wanted to examine any difference in 
anti-JEV antibody titres between children treated and untreated with IVIG. 
Adverse events were graded using WHO recommendations and reported to 
an independent data safety monitoring committee. Information was recorded 
on standardised proforma (Appendix O). Computer tomography scans were 
performed as indicated at the discretion of the admitting physician. There were 
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no onsite facilities for magnetic resonance imaging. Patients with prolonged or 
repeated seizures, respiratory diffi culties or severely reduced consciousness, 
were admitted to a paediatric intensive care unit, which had facilities to 
intubate and ventilate. Mannitol and dexamethasone were given at the 
discretion of the admitting physician, and suspected septicaemia was treated 
with broad-spectrum antibiotics. Patients were assessed at discharge and 3-6 
month follow-up for disability in a range of activities using the LOS (109) 
( Appendix K & L) and a standardised neurological assessment (Appendix 
Q). Children who did not return for follow-up were reminded by letter or 
telephone, as available. If they were unable to return to the hospital, they were 
examined at home. At follow-up, I took particular note of seizures, progress 
at school, and changes in personality. The trial protocol is available online 
[http://clinicaltrials.gov/show/NCT01856205 (as accessed on 3rd March 2016)] 
(Appendices N & P). The CONSORT checklist is also provided as Checklist 
S1. 
6.3.5 Diagnostic and Pathogenetic studies
On admission, patients had routine blood tests (typically; a full blood count 
and white cell differential, glucose, urea and electrolytes) and a blood fi lm or 
rapid antigen test for Plasmodium falciparum. For diagnostic and pathogenetic 
studies, I took blood prior to treatment (IVIG or placebo) and 1 hour after the 
completion of infusion of the 5th (fi nal) dose. If a child required further blood 
tests for clinical reasons, extra samples were collected. Serum was separated 
by centrifuge, frozen at -20oC; aliquots were made and one aliquot went to the 
designated laboratory in Nepal for testing; the other aliquots were transported 
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on dry ice to the Institute of Infection and Global Health, Liverpool, UK, 
and subsequently to CDC Division of Vector-Borne Diseases in Fort Collins, 
Colorado, USA.
On admission, I did a LP with patients in the lateral position, and if the patient 
was calm the opening pressure was recorded using a CSF manometer. The LP 
was delayed in patients who were convulsing, or those with clinical signs of 
raised intracranial pressure (109, 173). CSF samples were examined for cell 
count and differential, protein, glucose and Gram stain. Further, CSF and serum 
samples were frozen on site at -20°C, and subsequently transported for further 
investigations, as above. 
Some of the patients had GCS < 3 or on artifi cial ventilation without signs of 
spontaneous respiration, who had less chances of meaningful survival. Also, 
the IVIG looked more viscous in consistency as compared placebo. However, 
exclusion of those patients and covering the syringes containing the study 
drug with masking tapes, respectively, helped overcome such biases. Some 
of the patients were administered the study drug later in the study because of 
delayed LP. IVIG may have been less effective in these patients as compared to 
those who were administered in the early period of illness, which is one of the 
limitations of this study. 
To diagnose JE locally, anti-JEV immunoglobulin-M (IgM) antibodies were 
measured in all serum samples on admission and day 7 of admission, and 
in all CSF samples by enzyme-linked immunosorbent assay (ELISA) using 
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the AFRIMS JE MAC IgM ELISA as part of the WHO acute encephalitis 
syndrome surveillance programme; these samples were measured in batches at 
the National Public Health Laboratories in Kathmandu, and so the results were 
not available at the time of randomisation. Classifi cation of the patients as JE 
negative or positive was based on the results of this initial JEV IgM ELISA 
testing in Nepal, confi rmed at CDC, USA, as below. I selected day 7 post 
illness onset as the time-point to measure IgM titres because the percentage of 
cases with raised anti-JEV IgM titres in serum or CSF is typically reported as 
100% by then (Figure 6.1) (58, 60). 
Confi rmatory testing was subsequently performed at the CDC Arboviral 
Diseases Branch diagnostic laboratory using the testing algorithm described 
in chapter 2 (General Methods). JEV PRNT50 was done on all patient serum 
at 2 time points: pre-treatment (immediately prior to the fi rst dose) and post-
treatment (1hour after the fi nal dose). In the UOL, UK, Interleukin (IL) -6 
and IL-4 cytokine measurements were undertaken on aliquots of IVIG and on 
patients’ serum pre-treatment and 1 hour post-treatment which has also been 
described in chapter 2 (General Methods).
6.3.6 Sample size
I aimed to recruit 22-24 patients. This has been described in chapter 2 (General 
Methods). 
6.3.7 Statistical analysis
Patient clinical features and laboratory parameters were compared between 
treatment groups (IVIG or placebo). Difference in plaque reduction anti-
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JEV antibody neutralizing titres (PRNTs) pre and post treatment were 
also compared between treatment groups (IVIG or placebo). Similarly, the 
difference in cytokine abundance pre and post treatment (separately for IL4 
and IL6) were compared between treatment groups. Normally distributed 
data were compared using a Student’s t-test. Non-normally distributed data 
were compared using the Wilcoxon-Mann-Whitney test. Differences between 
proportions were tested using the Fisher’s exact test. To examine whether JE 
antibody status of the participant prior to treatment was a source of variation 
in difference in antibody titres or cytokine abundances following treatment, a 
2 way ANOVA was undertaken, where treatment (IVIG or placebo) was the 
column factor and JE status (anti-JEV antibody positive or negative) was the 
row factor. Prism ver.6.04 (Graph Pad Software, Inc) was used for statistical 
analyses and graph generation.
6.4 Results
6.4.1 Patients
Between May and August 2009, 22 (96%) children of the 23 screened met 
the entry criteria; 12 in Kanti Children’s Hospital in Kathmandu and 10 in 
BPKIHS in Dharan. One child was not enrolled in the trial as he was moribund 
and met criteria for exclusion. Eleven (50%) received IVIG and 11 (50%) 
placebo (Fig. 6.2). Twenty-two patients were randomised and there were no 
breaches of randomisation protocol. None of the children were reported to have 
been vaccinated against JE. 7 (64%) patients in the IVIG group and 6 (55%) in 
the placebo group were classifi ed as acute JEV infections by JEV/DENV IgM 
ELISA testing. The initial JE diagnostic classifi cation for all patients in Nepal 
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was confi rmed by the testing at the CDC, USA. Seven out of 10 (70%) were 
positive for JEV in BPKIHS and 6 of 12 (50%) in Kanti Children’s Hospital. 
One child (placebo group) had evidence of a previous fl avivirus infection. 
One patient with an undetermined status after local testing was found to be 
JEV negative by confi rmatory testing at CDC; otherwise there was complete 
concordance between the test results in Nepal and those at CDC. All CSF 
tested were negative for JEV RNA by real time RT-PCR.
The baseline characteristics of the two groups were comparable (Table 
6.1). The median age was 5 and 7 years for treatment and placebo groups 
respectively (not signifi cantly different). Most patients came from rural areas, 
and arrived after approximately 5 days of illness. Median GCS on admission 
was 8 (range 5-15), and the majority of patents had seizures as part of the 
presenting syndrome. All concurrently received antibiotics, most commonly 
cephalosporins. Four patients received dexamethasone alongside study drug; 
all 4 were in the placebo arm. One child received only 1 dose on the fi rst day 
after admission, 2 children had 2 doses each on fi rst and second admission 
days, and 1 child had daily dexamethasone for 5 days (Raw data of patients’ 
characteristics is available as S2 Table). 
The adverse and serious adverse events, according to patients’ JEV status, 
and whether they received IVIG or placebo is presented in Table 6.2; there 
were no signifi cant differences in frequency of adverse events between IVIG 
and placebo. There were no suspected unexpected serious adverse reactions 
(SUSARs). Raw adverse events data is available in S3 Table. 
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6.4.2 Intravenous immunoglobulin 
All IVIG preparations produced in JEV endemic regions had anti-JEV PRNT50 
titres, ranging from 1:320 to 1:640 (Fig. 6.3). Control IVIG from a non-JEV 
endemic area (Vigam, USA) showed minimal PRNT50 titres of 1:10; lower than 
serum from a JEV vaccinated individual who had a titre of 1:40. ImmunoRel™ 
IVIG produced by Reliance Biopharmaceutical (India) had the highest anti-
JEV PRNT50 titre, and was chosen for treatment in this study. This ImmunoRel 
IVIG showed low PRNT50 titres ≤1:20 against DENV, WNV and Powassan 
viruses. 
6.4.3 Outcomes 
One patient, who received the study drug, died of aspiration pneumonia. He 
was a 19 month old boy admitted with a 13 day history of high grade fever, 
repeated generalized tonic clonic seizure, fast breathing and altered sensorium. 
He had not been immunized against JE. His Glasgow Coma Score 10/15, pulse 
140 per minute, respiratory rate 56 breaths per minute, axillary temperature 
38.9ºC, and he had diffuse wheeze in both sides of the chest. On neurological 
examination he had a right sided hemiplegia. Investigations revealed a 
peripheral blood total white cell count of 25.4x109 cells/L (polymorphs 66%, 
lymphocytes 31%), serum creatinine 0.6 mg/dl, serum sodium 143 mmol/L, 
serum potassium 4.5 mmol/L. His CSF was clear and colourless with 10 
cells/mm3 (polymorphs 40%, lymphocytes 66%), protein 80mg/dl, glucose 
48mg/dl (blood glucose 87 mg/dl). X-Ray chest revealed diffuse infi ltration 
more on the right lung fi eld. He was treated with intravenous ceftrioxone 
100mg/kg/day for two days, intravenous midazolam at 0.2mg/kg/dose for two 
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doses, intravenous phenytoin at 20mg/kg loading dose, followed by 7 mg/kg/
day of maintenance dose, intravenous 20% mannitol at 5ml/kg single dose and 
maintenance intravenous fl uids, but died on the fourteenth day of illness. Un-
blinding after death revealed he had received IVIG (400 mg per kilogram body 
weight) at 0.01mL/Kg/minute on the fi rst and second day. He was subsequently 
found to be JEV IgM negative. The investigating member of the Data Safety & 
Monitoring Committee confi rmed that the child died of aspiration pneumonia 
due to repeated uncontrolled seizures, unrelated to the study drug. 
The remaining 21 patients received the full 5 days of treatment. At hospital 
discharge, the commonest Liverpool outcome score was II (major sequelae) 
in both IVIG and the placebo groups [7/11 (64%) and 8/11 (73%) patients per 
group respectively]. When all participants are included at 3-6 month follow-
up; 6 out of 11 (45%) exhibited complete recovery (no neurological sequelae) 
in the IVIG group compared to 2 out of 11 (18%) in the placebo group (Table 
6.3). There was no signifi cant difference in the proportion of patients exhibiting 
complete recovery between the two groups when analysed by intention-to-treat 
either at hospital discharge or at follow-up [p=1 and 0.36 respectively (Table 
6.3)]. 
6.4.4 Neutralising antibodies
The difference in neutralising antibody titres pre and post treatment were 
analysed by treatment group (IVIG or placebo) Neutralising antibody titres 
increased signifi cantly among participants who received IVIG compared to 
placebo (p=0.038: Fig. 6.4). Separating results by anti-JEV IgM antibody 
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status, titres showed a greater increase among those who received IVIG 
compared to placebo in both anti-JEV antibody status groups. The median 
increase in neutralising antibody titre was greater (16 fold) in anti-JEV IgM 
positive compared to negative patients (median increase in titre post treatment 
was 1920 versus 120 for IgM positive and negative patients respectively; 
S4 Table and Fig. S1). However, the increase in neutralising antibody titres 
following IVIG treatment was only signifi cant among anti-JEV IgM negative 
patients (p=0.048 and p=0.24 respectively). Patient anti-JEV IgM status prior 
to treatment was not a signifi cant source of variation in change in neutralising 
antibody titre as assessed by 2 way ANOVA (p=0.29; S5 Table). 
6.4.5 Cytokines
The difference in cytokine abundance pre and post treatment were also 
analysed by treatment group (Fig. 6.5). Cytokine abundance for both IL-6 and 
IL-4 increased among participants who received IVIG compared to placebo. 
This increase was signifi cant for IL-4 (p=0.043). Separating the IL-4 results 
by anti-JEV IgM antibody status, IL-4 levels showed a greater increase among 
those who received IVIG compared to placebo in both anti-JEV antibody status 
groups. The median increase in IL-4 following IVIG treatment was greater (13 
fold) in anti-JEV IgM negative compared to positive patients (median increase 
in abundance post treatment was 0.65 versus 0.05 pg/ml for IgM negative and 
positive patients respectively). Neither increase was signifi cant; p=0.06 and 
p=0.6 for IgM negative and positive patients respectively (S6 Table; S7 Table; 
Fig. S2). Patient anti-JEV IgM status prior to treatment was a signifi cant source 
of variation in change in IL-4 abundance (p=0.0018). However, treatment 
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(IVIG or Placebo) was a more signifi cant source of variation as assessed by 
2 way ANOVA (p=0.0005). Patient anti-JEV IgM status prior to treatment 
was not a signifi cant source of variation in change for IL-6 (S5 Table). A very 
low concentration of IL-6 was detected in the IVIG (0.4 pg/ml). IL-4 was not 
detected. Raw data for PRNT levels are available in S8 Table.
6.5 Discussion
JEV, the most important cause of epidemic encephalitis globally, is just one of 
several important fl aviviruses that cause encephalitis. These include tick-borne 
encephalitis virus, which occurs across northern and eastern Europe, and WNV, 
which circulates in India, Africa, Europe, and since 1999, the Americas. There 
is no established treatment for any fl avivirus. Although JE vaccine programs 
are being implemented across Asia, the disease is continuing to spread, and 
recent estimates put the incidence closer to 70,000 cases annually, rather than 
the previously estimated 50,000. (174). JE was fi rst recorded in Nepal in 1978 
in Rupandehi district of the Western Development Region (42). Thirty four 
years later there were 29,877 clinically diagnosed cases with 5,589 deaths 
(personal communication: Dr Santosh Gurung, WHO-IPD, Kathmandu, Nepal). 
It is currently reported from 65 of total 75 districts. In the early outbreaks, the 
mortality was up to 60%, but more recently this has improved to approximately 
20% (37, 42). Immunisation against JE began in 1999 in 3 districts (83, 84), 
which had been extended to cover 31 high risk districts by 2011. In addition, 
the Government vaccinated around 200 000 pigs in the Terai zone in 2001 (42). 
A recent seroprevalence study in animal hosts in 10 districts in Nepal revealed 
that 48% of pigs, 27% of ducks and 50% of horses were JEV seropositive 
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demonstrating a high transmission of JEV in the wild and confi rming that it is 
likely to remain (85). Hence, JE is still a major public health problem in Nepal, 
and there is a pressing need to develop better treatments.
My pilot study suggests that a multi-centre RCT of IVIG for children with 
suspected JE is possible in this setting with no protocol violations. The double-
blinding procedure, using masking tape to cover syringe contents, has been 
used in a previous study of IFN-α in JE in a very well resourced research 
unit in Vietnam, which employs research nurses and technicians (38); I found 
that it also worked well in this much simpler setting with hospital nurses and 
technicians. In considering the study, there had been concern that starting an 
infusion at a low rate, and then increasing over time would be unacceptable 
to hospital staff if they could not see what drug they were giving; but again 
this aspect worked well. Although the numbers were small, I did not detect 
any signifi cant differences in adverse events between the two groups. I did 
not study the minimum 30 subjects recommended by US FDA Guideline 
on Safety, Effi cacy, and Pharmacokinetic Studies to Support Marketing of 
Immune Globulin Intravenous (Human) as Replacement Therapy for 
Primary Humoral Immunodefi ciency (2008) (http://www.gmp-compliance.
org/guidemgr/fi les/IGIVIMMUNO.PDF). Nor did I employ a dose escalation 
designs used in many oncology studies. However I was not studying Primary 
Humoral Immunodefi ciency or cancer, and recommendations from western 
settings may not always be appropriate for studies in resource-poor settings 
(175). Three patients died. The one death in the IVIG group was attributed 
to severe underlying disease rather than the IVIG, and the two deaths which 
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had occurred by follow-up were both in the placebo group. The proportion of 
patients exhibiting full recovery (without any sequelae) was similar between 
the groups at discharge and slightly higher among in the IVIG group at follow. 
This difference was not signifi cant on intention-to-treat analysis.
In Nepal, IVIG, which has general anti-infl ammatory effects, is currently 
being used to treat a range of paediatric conditions including Guillain-
Barré syndrome, idiopathic thrombocytopenic purpura and Kawasaki 
disease. IVIG from endemic areas is considered a potential treatment for 
fl avivirus encephalitis, including that caused by JEV and WNV, because of 
the neutralising antibody it contains (167). I found IVIG from a range of 
manufactures in Asia contained signifi cant neutralising antibody; most had 
PRNT50 titres ≥1:640. Pre-clinical studies suggest that passively transferred 
antibody may be effective against fl avivirus encephalitis (165, 167,168, 176-
182). 
There is a strong evidence to suggest that JEV, like other neurotropic 
fl aviviruses, may be more susceptible to antibody-mediated, rather than cell-
mediated immune responses. For JEV, and other neurotropic fl aviviruses, 
clearance of virus is not dependent on cytolytic T cell activity, in contrast 
to non-neurotropic viruses (49- 51,179,183, 184). Neurons, as terminally 
differentiated cells, do not express MHC-1, which would subject them to 
lysis by CD8 T cells and non-replacement (49). Animal data support the 
importance of antibody mediated immunity (177, 178). In one study, Konishi 
et. al. immunised mice with plasmid DNAs encoding JEV proteins that induce 
212
neutralising antibody responses or cytotoxic T lymphocyte responses, and 
then challenged with lethal intraperitoneal doses of virus. They showed that 
neutralising antibody prevents virus dissemination from the peripheral site to 
the brain, and that antibody-mediated mechanisms of protection were more 
effi cient than the cytotoxic T cell responses (179). These fi ndings supported 
earlier work showing that anti-envelope protein antibodies, are the most critical 
protective component in a JEV challenge model (183), and more recent passive 
antibody transfer experiments (184). In vitro work in mice shows a protective 
role for IVIG given prophylactically to prevent the fl avivirus causing tick borne 
encephalitis and a protective effect when used as a treatment. In animal studies 
in which IVIG containing anti-WNV specifi c antibody was administered 
during the viraemic phase but before the virus had entered the CNS, there was 
a dramatic 100% survival rate (167, 180), and mortality was reduced up to fi ve 
days after infection (181, 182). 
Antibodies and B cells are directly responsible for limiting WNV dissemination 
in the CNS during early part of infection. Serum viral load has been 
reported 500-fold increased at day 4 of infection which subsequently has 
been reported to increase markedly causing huge viral burden in neurons in 
the CNS at day 6 and rapidly provoking development of fatal encephalitis. 
Antibodies may reduce viral load available for CNS infection by limiting 
haematogenous spread through direct neutralisation, complement activation 
or increased viral uptake by phagocytic cells. Specifi c IgM produced against 
the virus during early viral infection may limit dissemination by temporarily 
containing viraemia and triggering an adaptive IgG response that eliminates 
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viral infection. However, the amount and site of viral inoculation, the kinetics 
of viral replication, administration of antibodies, and the absolute amount 
of natural antibody response, infl uence the effi cacy of natural antibodies 
in preventing infection (180). More relevant for the treatment of patients 
presenting to hospital with WN neuroinvasive disease, in which the virus has 
already entered the CNS, Morrey et al showed that peripheral administration of 
anti-virus monoclonal antibodies in a mouse model neutralises WNV even after 
it has entered the brain (185, 186).
As expected, patients had a greater increase in neutralising antibody titres 
among those treated with IVIG compared to placebo. Interestingly JEV 
antibody positive children treated with IVIG exhibited higher (approximately 
16 times higher) titres of neutralising antibody compared to levels of change 
following IVIG treatment among JEV antibody negative patients (this change 
was not signifi cant). The magnitude of this effect appears greater than can be 
explained by passive transfer of anti-JEV antibody (observed as the increase 
titres among the JE negative patients). The reason for this is not certain, though 
it is possible that passively transferred antibody is enhancing the natural 
production of neutralizing antibody by B cells, perhaps through augmenting the 
uptake of viral particles by antigen presenting cells. Such a mechanism has been 
described in a macaque model of HIV, where the administration of low level 
neutralising monoclonal antibodies to simian HIV led to the rapid development 
of neutralising antibodies through enhanced B cell responses (187). A relatively 
modest neutralising antibody titre (i.e. 1:10) has been shown to protect against 
JEV in animal models, when antibody is administered prior to infection. 
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However, to my knowledge, no studies have determined what titre is required to 
limit the evolution of encephalitis once JEV infection is established in humans. 
My patients all had an antibody titre that was much higher, around 100 fold 
higher, than this and yet still had encephalitis. This may be because most of the 
recruited patients presented late to the hospital with a median duration of illness 
of 10 days. On the basis of mouse models, we know, that the protection caused 
by passive antibodies is directly related to the amount of antibodies applied and 
to the time and dose of the infecting virus (24, 40). Although therapeutic effect 
of virus-specifi c antibodies is possible by both neutralisation of extracellular 
virus during the early period of illness and suppression of intracellular viral 
replication in the late period; it may be that it is most effective if administered 
during early viraemic phase of the infection (167). 
Antibody-dependent enhancement of viral entry into macrophages is also 
important in secondary DENV infections. In this case non-neutralising 
antibody from a prior infection with a different DENV serotype is thought 
to enhance viral entry into macrophages and contribute to increased disease 
severity (188). In tick-borne encephalitis, passive immunisation with 
neutralising antibody containing IVIG has been used as prophylaxis in those 
bitten by infected ticks, before disease develops (189). However, following 
suspicions that this was actually precipitating disease, through postulated 
antibody dependent enhancement, this approach was abandoned. My study 
suggests there were no signifi cant side effects of treatment with IVIG in JE and 
administration was associated with increased JEV-specifi c serum neutralising 
antibody titres.
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Neuronal cell death in JE may occur directly, from viral cytopathology, and 
indirectly via immune mediated mechanisms. This may include over activation 
of microglia cells (190), which release pro-infl ammatory cytokines such as 
interleukin 6 (IL-6), TNF-α, and RANTES (regulated upon activation, normal 
T cell expressed and secreted), causing massive migration and infi ltration of 
leukocytes into the brain (191). IL-6, which is produced by neurons, microglia, 
astrocytes and recruited macrophages in response to viral CNS infection (192-
194), causes an increased permeability of the blood brain barrier, which leads 
to interstitial cerebral oedema, and raised intracranial pressure (195, 196). 
TNF-α is also produced by astrocytes and macrophages. Its multiple pro-
infl ammatory properties include upregulation of class I and II MHC expression, 
upregulation of cellular adhesion molecules, increased permeability of the 
blood brain barrier (197), and upregulation of inducible nitric oxide synthase 
(iNOS), leading to the production of nitric oxide (NO) (198). In addition to 
affecting virally-infected cells, the infl ammatory response in the CNS may also 
damage non-infected cells to cause bystander cell death. 
The elevated IL-6 and IL-4 responses observed in my patients support the 
hypothesis that administration of IVIG modulates the immune response. 
Accepting cytokine responses are complex, I chose to measure IL-6 and IL-
4 because they have been used previously to give a simple refl ection of the 
balance of pro- to anti- infl ammatory responses (45). IVIG treatment has 
previously been linked with both reduced and elevated levels of IL-6 among 
patients (199-205). Similarly, IVIG treatment has been related to increased IL-4 
levels (206,207). Both IL-4 and IL-6 participate in the development of antibody 
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responses; IL-4 promotes B cell proliferation and isotype switching and IL-6 
induces differentiation of B cells into antibody secreting plasma cells (208). 
The modest increase in IL-4 and IL-6 could be consistent with augmentation of 
an antibody response; therefore the increase in both antibody and pro-antibody 
producing cytokines may refl ect part of the same process (209). The variation 
in response among patients with different anti-JEV antibody statuses indicates 
the immune modulation by IVIG is highly intricate. 
Other mechanisms of IVIG induced cytokine production may involve the 
generation of immune complexes of JEV antigen and IVIG derived antibody. 
In turn, these complexes may stimulate monocytes to produce IL-6 via Fc-
receptor interactions (210). Other immunomodulatory factors (e.g., sCD4, 
sCD8, sHLA antigen) present in the IVIG could also induce cytokine 
production (211, 212, 213).
Because previous studies have shown IL6 is sometimes detected in IVIG (205), 
I checked the levels in my treatment batches and found that although there 
were low levels of IL6, this was not enough to explain the elevated titre seen in 
our treated patients. 
When JE is due to primary infection (i.e. fi rst fl avivirus infection) a quick 
and effective IgM response occurs in the serum and CSF within few days, 
and attempts to isolate virus from either sample are unlikely to be successful 
(52). However, absence of IgM is associated with positive virus isolation from 
the CSF and a bad outcome (52). When individuals have asymptomatic JEV 
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infection, antibody probably protects the host by restricting viral replication 
during the viraemic phase, before the virus crosses the blood brain barrier (52). 
Antibody may also limit damage during established encephalitis by neutralising 
extracellular virus and facilitating lysis of infected cells by antibody-dependent 
cellular cytotoxicity.
A better understanding of immunological changes in JE and the effects of IVIG 
will be important for the further development of IVIG treatment (45). Since 
this pilot study showed a randomised double blind placebo controlled trial 
of IVIG in Nepal was possible, a larger study, with further close monitoring 
of adverse effects is recommended. The question of effi cacy will only be 
answered with a full phase III randomised placebo-controlled trial. 
There may be other wider implications of this study: the number of antibody-
mediated encephalitidies being identifi ed is increasing and IVIG is a standard 
treatment option in these cases (2, 214). In addition, IVIG may have a role 
in other viral encephalitis as there is evidence that damage caused is over 
and above that from direct viral infection alone (215, 216). In most series of 
encephalitis patients the aetiology is unknown in the majority of cases, but is 
presumed to be a mixture of microbial and immune mediated causes (2, 6); 
whether IVIG may be a suitable treatment for such patients is unclear. My 
study provides important pilot data, but further research is needed in this area. 
6.6 Limitation of study
The study was restricted to recruiting small of number of patients because of 
lack of funding to continue to build it into a large clinical trial. A larger study 
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with patient followed up for a longer period of time would have provided more 
accurate information about effi cacy of IVIG in patients of JE. In this study I 
looked into only indirect marker of immunological response such as IL-6 and 
IL-4. A detailed study of T cell and B cell response to treatment of IVIG in 
JE positive and JE negative patients would have been more informative on 
immunological markers of effi cacy. Another method of investigating effi cacy 
would also have been by looking at immunological mechanism of high 
antibodies in JE positive patients administered IVIG as compared to placebo. 
However, I did not have adequate number of patients and funding to explore 
both of these further. Treatment trial with monoclonal antibodies directed at 
JE could have been a cheaper alternative to an expensive IVIG trial, in which, 
probably funding would not have been a major issue. 
6.7 Summary
JE is the only known cause of viral encephalitis under the AES surveillance 
in Nepal. It has a bad outcome and there is no specifi c treatment. Therefore, 
identifying treatment for JE would not only help in reducing JE related 
morbidity and mortality but also improve outcome of AES in Nepal. 
Intravenous immunoglobulin containing JE virus-specifi c neutralising antibody 
is thought to neutralise the virus and suppress damaging infl ammation in the 
brain; but has never been examined in a randomised trial before. Therefore, 
when I performed a randomised double-blind placebo-controlled trial of 
intravenous immunoglobulin to assess feasibility, and examine generation of 
anti-JEV specifi c antibodies among children admitted with suspected JE, I 
found children with confi rmed JE treated with the intravenous immunoglobulin 
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Figure 6.1: Shows kinetics of IgM to JEV by MAC ELISA (Burke et al, 1982)
had specifi c neutralising antibody titres16 times higher than those treated 
with placebo. This was more than could be explained by passive transfer 
alone, suggesting an immune augmenting effect. Passive transfer of anti-JEV 
antibody was also seen in JEV negative children. IL-4 and IL-6 were also 
higher in the intravenous immunoglobulin group. Therefore, such a clinical 
trial was feasible, intravenous immunoglobulin safe and appeared to augment 
the development of neutralising antibodies. The anti-infl ammatory properties 
of intravenous immunoglobulin should be useful for a wider use as a treatment 
for encephalitis. A better understanding of immunological changes in JE and 
the effects of intravenous immunoglobulin will be important for the further 
development of intravenous immunoglobulin treatment (45). Since this 
study showed my approach to be feasible, a larger study, with further close 
monitoring of adverse effects is recommended. The question of effi cacy will 
only be answered with a full phase III randomised placebo-controlled trial. 
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Figure 6.2: Flow diagram of study participants’ recruitment and follow-up.
All children enrolled, fi tting the trial criteria, who were alive at discharge were 
attempted to be followed-up (n=21). Twenty-one families were successfully 
contacted. Among these families, two children had died. 
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Figure 6.3: Anti-JEV neutralising antibody in commercially available IVIG.
Mean and standard deviation of reciprocal 50% plaque reduction neutralisation 
titres (PRNT50) in vero cells using P3 wild type strain of JEV are shown for 
a: Serum control from JEV vaccinated individual, b: Vigam (USA), c: Bharat 
(India) batch 1, d: Hualan (China) batch 1, e: Bharat (India) batch 2, f: Hualan 
(China) batch 2, g: Sichuan (China), h: Reliance (India).
Figure 6.4: Difference in neutralising antibody titres to JEV in children with 
acute encephalitis syndrome treated with IVIG or placebo. 
Median and inter-quartile range of the difference in JEV PRNT50 titres pre 
and post treatment is presented. Patients are grouped according to treatment. 
Difference in titres was assessed via Wilcoxon-Mann-Whitney test. Note: 
Two patients who received IVIG were not included in this analysis because of 
insuffi cient sample to undertake PRNT measurements.
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Figure 6.5: Interleukin (IL)-4 and IL-6 abundance in children with acute 
encephalitis syndrome receiving intravenous immunoglobulin (IVIG) and 
placebo. 
Median and inter-quartile range of change in cytokine abundance (pg/ml) 
pre and post treatment is presented for IL-4 and IL-6 separately. Cytokine 
abundance increased for both IL-4 and IL-6. This increase was signifi cant 
for IL-4 (p=0.043 and p=0.068 for IL-4 and IL-6 respectively). Difference in 
abundance was assessed via Wilcoxon-Mann-Whitney test. Note: Four patients 
(three who received IVIG and one who received saline) were not included in 
this analysis because of insuffi cient sample to undertake the ELISA.
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Table 6.1: Baseline characteristics of trial participants.
Parameters No. IVIG (n=11) No. Placebo (n=11) P
Age (years) 11 5 (1-11) 11 7 (1.3-12) NS.
Male 11 5 (.45) 11 7 (.64) NS.
Living in rural area 11 11 (1) 11 9 (.82) NS.
Fever duration (days) 9 5 (2-12) 11 5 (3-10) NS.
Illness duration (days) 10 5 (4-13) 11 6 (3-13) NS.
Altered sensorium 11 10 (.91) 11 9 (.81) NS.
New onset seizures 11 10 (.91) 11 11 (1) NS.
Glasgow Coma Scale (3-15) on admission 11 8 (5-15) 11 8 (5-15) NS.
Temperature (°C) 10 38.3 (36.7-40) 10 38.9 (36.7-40) NS.
Heart rate (beats/minute) 10 95 (68-140) 11 104 (84-130) NS.
Resp. rate (breaths/minute) 10 33.5 (22-56) 11 28 (22-40) NS.
Neck stiffness present 11 4 (.36) 11 4 (.36) NS.
Kernig's sign present 11 1 (.09) 10 2 (.18) NS.
Abnormal limb tone 8 5 (.63) 9 3 (.3) NS.
Abnormal posturing 9 2 (.22) 11 0 (0) NS.
Positive anti-JEV IgM 11 7 (.64) 11 6 (.55) NS.
Haemoglobin (g/dl) 9 12.1 (9.8-13.8) 10 11.8 (8.2-14.3) NS.
White cell count (WCC) - x109/L 9 10.8 (5.2-25.4) 11 13.9 (4.2-18.9) NS.
Polymorphs (%) 9 66 (30-85) 11 68 (30-90) NS.
Lymphocytes (%) 9 31 (12-70) 11 30 (10-70) NS.
Platelets (x109/L) 7 270 (120-659) 9 200 (88-362) NS.
Glucose (mg/dl) 11 100 (80-160) 11 85 (66-170) 0.03
Urea (mg/dl) 7 22.8 (15-35) 9 27.0 (18-58) NS.
Creatinine (mg/dl) 7 0.9 (0.4-2.4) 9 1 (0.5-2.2) NS.
Cerebrospinal fl uid (CSF) WCC -cells/mm3 11 35 (0-125) 11 30 (0-300) NS.
CSF polymorphs (%) 11 10 (0-60) 11 10 (0-95) NS.
CSF lymphocytes (%) 11 70 (0-100) 11 40 (0-100) NS.
CSF protein (mg/dl) 11 39 (28-100) 10 27 (7-68) 0.01
CSF glucose (mg/dl) 11 70 (48-90) 10 61.5 (45-81) NS.
CSF/blood glucose ratio 11 62 (50-82) 10 68.5 (46-100) NS.
Mannitol (given) 11 3 (.27) 11 7 (.64) NS.
Dexamethasone 9 0 (0) 11 4 (.36) NS.
Quinine 11 5 (.45) 11 5 (.45) NS.
Aciclovir 11 1 (.91) 11 2 (.18) NS.
Chloramphenicol 11 1 (.91) 11 0 (0) NS.
Cephalosporin 11 10 (.91) 11 10 (.91) NS.
Phenytoin 11 9 (.82) 11 8 (.73) NS.
Phenobarbitone 11 3 (.27) 11 2 (.18) NS.
Data presented as number of patients (proportion) or median (range). No. - number of 
patients in the clinical group where data for the parameter was available. P - P value 
for Fisher’s Exact or Mann Whitney U test between groups. 
NS. – not signifi cant. 
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Table 6.2: Summary of adverse events 
Symptoms
IVIG Placebo IVIG vs. Placebo
IVIG vs. 
Placebo
JE 
(n=7)
Non-JE 
(n=4)
Total
(n=11)
JE 
(n=6)
Non-JE 
(n=5)
Total
(n=11) P- value
OR 
(95% CI)
Fever 2 (.29) 2 (0.5) 4 (.36) 1 (.17) 1 (0.2) 2 (.18) 0.64 2.6 (0.3- 29)
Dyspnoea 1(.14) 2 (0.5) 3 (.27) 1 (.17) 1 (0.2) 2 (.18) 1 1.7 (0.2- 20.1)
Vomiting 0 (0) 0 (0) 0 (0) 1 (.17) 0 (0) 1 (0.9) 1 0 (0- 18.7)
Irritable 1(.14) 1 (.25) 2 (.18) 2 (.33) 0 (0) 2 (.18) 1 1 (0.07- 13.5)
Non-urticarial skin rash 0 (0) 0 (0) 0 (0) 1 (.17) 0 (0) 1 (0.9) 1 0 (0- 18.7)
Hypotension* 1(.14) 0 (0) 1 (0.9) 1 (.17) 0 (0) 1 (0.9) 1 1 (0- 43.7)
Melena* 1(.14) 0 (0) 1 (0.9) 0 (0) 1 (0.2) 1 (0.9) 1 1 (0- 43.7)
Death* 0 (0) 1(.14) 1 (0.9) 0 (0) 0 (0) 0 (0) 1 NA
Data are number of patients (proportion). * Serious adverse events. NA: not applicable
Table 6.3: Outcome for trial participants.
Outcome at discharge IVIG (n= 11)
Placebo 
(n= 11) P-value
OR 
(95% CI)
Median duration of hospital stay (days) 13 (9-21) 12 (6-18) 0.59  -
Median Glasgow coma score 14 (3-15) 14 (7-15) 0.53  -
Number with complete recovery (LOS V) 1 (.09) 1 (.09) 1 1 (0- 43.7)
Number with minor sequelae (LOS IV) 0 1 (.09) 1 0 (0- 18.7)
Number with moderate sequelae (LOS III) 2 (.18) 1 (.09) 1 2.2 (0.1- 74.9)
Number with severe sequelae (LOS II) 7 (.64) 8 (.73) 1 0.7 (0.07- 5.5)
Number that died (LOS I) 1 (.09) 0 1 NC
 
Outcome at 3-6 months IVIG (n=11) Placebo (n=11) P-value OR (95% CI)
Lost to follow-up 2 (.18) 2 (.18) 1 1 (0.07- 13.5)
Number with complete recovery (LOS V) 5(.45) 2 (.18) 0.36 3.8 (0.4- 41.8)
Number with minor sequelae (LOS IV) 0 3 (.27) 0.21 0 (0- 2.2)
Number with moderate sequelae (LOS III) 1 (.09) 0 (0) 1 NC
Number with severe sequelae (LOS II) 2 (.18) 2 (.18) 1 1 (0.07- 13.5)
Number that died (LOS I) 1 (.09) 2 (.18) 1 0.45 (0.01- 8.4)
Data are number of patients (proportion) or median (range). LOS = Liverpool 
Outcome Score (LOS): 1 – died; 2 - severe sequelae; 3 - moderate sequelae; 4 - minor 
sequelae; 5 - full recovery. NC: not calculable 
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Supporting Information 
S1 Table: Randomisation Schedule
Study Site StudyID Treatment
BPKIHS T111 IVIG
BPKIHS T112 SALINE
BPKIHS T113 SALINE
BPKIHS T114 IVIG
BPKIHS T115 SALINE
BPKIHS T116 IVIG
BPKIHS T117 IVIG
BPKIHS T118 SALINE
BPKIHS T119 SALINE
BPKIHS T120 IVIG
KCH T2 SALINE
KCH T3 IVIG
KCH T4 SALINE
KCH T5 IVIG
KCH T6 IVIG
KCH T7 IVIG
KCH T8 SALINE
KCH T9 IVIG
KCH T10 SALINE
KCH T11 SALINE
KCH T12 IVIG
KCH T13 SALINE
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S1 Checklist: CONSORT checklist (as published in PLoS ONE)
CONSORT 2010 checklist of information to include when reporting a 
randomised trial*
Section/Topic Item 
No
Checklist item Reported on 
page No
Title and abstract
1a Identifi cation as a randomised trial in the title 1
1b Structured summary of trial design, methods, 
results, and conclusions (for specifi c guidance see 
CONSORT for abstracts)
2
Introduction
Background 
and objectives
2a Scientifi c background and explanation of rationale 4
2b Specifi c objectives or hypotheses 4
Methods
Trial design 3a Description of trial design (such as parallel, 
factorial) including allocation ratio
6,7
3b Important changes to methods after trial 
commencement (such as eligibility criteria), with 
reasons
none
Participants 4a Eligibility criteria for participants 5,6
4b Settings and locations where the data were collected 5
Interventions 5 The interventions for each group with suffi cient 
details to allow replication, including how and when 
they were actually administered
6,7
Outcomes 6a Completely defi ned pre-specifi ed primary and 
secondary outcome measures, including how and 
when they were assessed
6,7
6b Any changes to trial outcomes after the trial 
commenced, with reasons
none
Sample size 7a How sample size was determined 9
7b When applicable, explanation of any interim 
analyses and stopping guidelines
None
Randomisation:
Sequence 
generation
8a Method used to generate the random allocation 
sequence
6
8b Type of randomisation; details of any restriction 
(such as blocking and block size)
6
Allocation 
concealment 
mechanism
9 Mechanism used to implement the random 
allocation sequence (such as sequentially numbered 
containers), describing any steps taken to conceal 
the sequence until interventions were assigned
6
Implementation 10 Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants 
to interventions
6
Blinding 11a If done, who was blinded after assignment to 
interventions (for example, participants, care 
providers, those assessing outcomes) and how
6
11b If relevant, description of the similarity of 
interventions
6
Statistical 
methods
12a Statistical methods used to compare groups for 
primary and secondary outcomes
9,10
12b Methods for additional analyses, such as subgroup 
analyses and adjusted analyses
9,10
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Results
Participant 
fl ow (a diagram 
is strongly 
recommended)
13a For each group, the numbers of participants 
who were randomly assigned, received intended 
treatment, and were analysed for the primary 
outcome
Figure 1,
Page 21
13b For each group, losses and exclusions after 
randomisation, together with reasons
Figure 1, page 
21
Recruitment 14a Dates defi ning the periods of recruitment and 
follow-up
11
14b Why the trial ended or was stopped 7
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group
22
Numbers 
analysed
16 For each group, number of participants 
(denominator) included in each analysis and whether 
the analysis was by original assigned groups
22, 23
Outcomes and 
estimation
17a For each primary and secondary outcome, results 
for each group, and the estimated effect size and its 
precision (such as 95% confi dence interval)
14, 23
17b For binary outcomes, presentation of both absolute 
and relative effect sizes is recommended
Ancillary 
analyses
18 Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, 
distinguishing pre-specifi ed from exploratory
Fig 3 &4, page 
21
Harms 19 All important harms or unintended effects in each 
group (for specifi c guidance see CONSORT for 
harms)
7
Discussion
Limitations 20 Trial limitations, addressing sources of potential 
bias, imprecision, and, if relevant, multiplicity of 
analyses
14
Generalisability 21 Generalisability (external validity, applicability) of 
the trial fi ndings
14
Interpretation 22 Interpretation consistent with results, balancing 
benefi ts and harms, and considering other relevant 
evidence
12,13,14
Other information
Registration 23 Registration number and name of trial registry NCT01856205 
ClinicalTrials.
gov
Protocol 24 Where the full trial protocol can be accessed, if 
available
attached
Funding 25 Sources of funding and other support (such as 
supply of drugs), role of funders
15
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 
Explanation and Elaboration for important clarifi cations on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and 
equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this 
checklist, see www.consort-statement.org.
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S4 Table: Change in PRNT titres - pre compared to post treatment. 
 IVIG (n=11) Placebo (n=11)
 1. Total 2. JE +ve 3. JE -ve 4. Total 5. JE +ve 6. JE -ve
Number 9 7 2 11 6 5
Minimum 0 0 80 -1280 -1280 -10
25% Percentile 120 160 80 0 -207.5 -5
Median 320 1920 120 0 160 0
75% Percentile 3720 5040 160 160 1980 0
Maximum 20160 20160 160 5040 5040 0
Lower 95% CI 80 0 80 -10 -1280 80
Upper 95% CI 5040 20160 5040 960 5040 160
P val. Grp. 1 vs. 4 0.038      
P val. Grp. 2 vs. 5  0.244    
P val. Grp. 3 vs. 6   0.048    
The table presents change in PRNT titres (pre versus post treatment) among 
treatment groups. Patients are sub-grouped by their anti-JEV IgM antibody 
status prior to treatment (JE+ or JE-). 
Total - indicates number of patients where PRNT titres were available pre and 
post treatment. 
Confi dence intervals (CI) represent estimated 95% limits around the median. 
There was a markedly higher increase in PRNT titres following IVIG treatment 
among anti-JEV antibody positive compared negative patients (16 x higher). 
This difference was not statistically signifi cant. Negative PRNT values indicate 
a fall in titres following treatment. 
P values calculated by Wilcoxon-Mann-Whitney test. 
Note: Two patients, who received IVIG and were JE antibody negative, did not 
have suffi cient sample to undertake PRNT measurement.
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Figure S1: Change in PRNT among treatment participants, sub-grouped by 
their anti-JEV IgM antibody status
Median and inter-quartile range of the difference in plaque reduction 
neutralising antibody titres (PRNT) against JEV pre and post treatment is 
presented as four groups. Patients are sub-grouped by treatment exposure 
(IVIG or Saline) and anti-JEV IgM antibody status prior to treatment (JE+ or 
JE-). 
Titres showed a greater increase among those who received IVIG compared to 
placebo in both anti-JEV antibody status groups. However, the increase was 
only signifi cant among anti-JEV IgM negative patients (p=0.048). Differences 
between subgroups were assessed via Wilcoxon-Mann-Whitney test. 
Note: Two patients who received IVIG and were anti-JEV IgM negative were 
not included in this analysis because of insuffi cient sample to undertake PRNT 
measurements.
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S5 Table: ANOVA data based on the linear models for the change in neutralis-
ing antibody titres IL-4 and IL-6.
Two-way ANOVA   
Source of Variation % of total variation P value
Interaction for PRNT titres 2.65 0.4843
JE status (Anti-JEV IgM + or -) 6.168 0.2908
Treatment (IVIG or Sal.) 3.057 0.4531
   
Interaction for IL-4 26.86 0.002
JE status (Anti-JEV IgM + or -) 27.77 0.0018
Treatment (IVIG or Sal.) 38.16 0.0005
   
Interaction for IL-6 0.01091 0.9667
JE status (Anti-JEV IgM + or -) 0.4206 0.7954
Treatment (IVIG or Sal.) 7.871 0.2715
The table presents source of variation for change in PRNT, IL-4 and IL-6 
abundance.
The table shows the interaction between participants’ anti-JEV IgM antibody 
status and Treatment group 
The data was calculated via Two-way ANOVA. 
S6 Table: Change in cytokine abundance - pre compared to post treatment.
 IL-4  IL-6 
 IVIG Placebo  IVIG Placebo
Number 8 10  8 10
Minimum -0.01 -0.23  0.13 -0.83
25% Percentile 0.04 -0.07  0.24 -0.08
Median 0.17 0.01  1.17 0.4
75% Percentile 0.61 0.15  2.23 0.78
Maximum 1.15 0.26  2.51 1.68
Lower 95% CI -0.007 -0.096  0.133 -0.189
Upper 95% CI 1.151 0.197  2.506 0.938
P val. IVIG vs. placebo 0.04   0.067  
The table presents change in cytokine abundance (pg/ml) pre versus post 
treatment among treatment groups for IL-4 and IL-6. 
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Number - indicates number of patients where cytokine abundance 
measurements were available pre and post treatment. Negative values indicate 
a fall in abundance following treatment. 
Confi dence intervals (CI) represent estimated 95% limits around the median.
P values calculated via Wilcoxon-Mann-Whitney test. 
Note: Four patients, three who received IVIG and one who received placebo, 
did not have suffi cient sample to undertake cytokine measurements.
S7 Table: Change in IL-4 abundance - pre compared to post treatment, sub-
grouped by anti-JEV antibody status
 Total IL-4 IL-4 JE+ IL-4 JE-
 IVIG (n=8) Sal. (n=10) IVIG (n=5) Sal. (n=6) IVIG (n=3) Sal. (n=4)
Number 8 10 5 6 3 4
Minimum -0.01 -0.23 -0.01 -0.23 0.49 -0.07
25% Percentile 0.04 -0.07 0.01 -0.13 0.49 -0.06
Median 0.17 0.01 0.05 0.02 0.65 -0.02
75% Percentile 0.61 0.15 0.17 0.16 1.15 0.15
Maximum 1.15 0.26 0.24 0.26 1.15 0.2
Lower 95% CI -0.007 -0.096 -0.007 -0.229 0.486 -0.065
Upper 95% CI 1.151 0.197 0.237 0.26 1.151 0.197
P val. IVIG vs. Saline 0.043  0.649  0.057  
The table presents change in IL-4 abundance (pg/ml) pre versus post treatment 
among treatment groups (IVIG or saline). Patients are sub-grouped by their 
anti-JEV IgM antibody status prior to treatment (JE + or JE-). Number - 
indicates number of patients where cytokine abundance measurements were 
available pre and post treatment. 
Confi dence intervals (CI) represent estimate of 95% limits around the median. 
P values calculated via Wilcoxon-Mann-Whitney test. 
The median increase in IL-4 following IVIG treatment was greater (13 fold) in 
JE- compared to JE+ patients (median increase in abundance was 0.65 versus 
0.05 pg/ml respectively).
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Note: Four patients, three who received IVIG and one who received saline, did 
not have suffi cient sample to undertake cytokine measurements. 
Figure S2: Change in IL-4 abundance among treatment participants, sub-
grouped by their anti-JEV IgM antibody status 
Median and inter-quartile range of change in IL-4 abundance (pg/ml) pre 
and post treatment is presented as six groups. Patients are initially grouped 
according to treatment. Then they are sub-grouped by both treatment exposure 
(IVIG or Saline) and anti-JEV IgM antibody status prior to treatment (JE+ 
or JE-). Overall, IL-4 abundance increased signifi cantly among those who 
received IVIG compared to saline (p=0.043). There was no signifi cant 
increase in abundances among JE- or JE + sub-groups (p=0.057 and p=0.65 
respectively). Differences in abundance were assessed via Wilcoxon-Mann-
Whitney test. Note: Four patients (three who received IVIG and one who 
received saline) were not included in this analysis because of insuffi cient 
sample to undertake the ELISA.
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S8 Table: PRNT and cytokine levels (raw data)
Treatment JE status Pre Post Diff
IVIG JE POSITIVE 80 5120 5040
IVIG JE POSITIVE 320 20480 20160
IVIG JE POSITIVE 640 2560 1920
IVIG JE POSITIVE 160 2560 2400
IVIG JE POSITIVE 160 320 160
IVIG JE POSITIVE 320 640 320
IVIG JE POSITIVE 5120 5120 0
IVIG NEGATIVE 0 160 160
IVIG NEGATIVE 0 80 80
IVIG NEGATIVE 0  na
IVIG NEGATIVE 0 320 na
SALINE JE POSITIVE 160 320 160
SALINE JE POSITIVE 160 320 160
SALINE JE POSITIVE 10 160 150
SALINE JE POSITIVE 2560 1280 -1280
SALINE JE POSITIVE 320 1280 960
SALINE JE POSITIVE 80 5120 5040
SALINE NEGATIVE 0 0 0
SALINE NEGATIVE 0 0 0
SALINE NEGATIVE 0 0 0
SALINE NEGATIVE 10 0 -10
SALINE NEGATIVE 20 20 0
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Chapter 7: Final Discussion and Conclusion
AES is associated with high morbidity and mortality affecting all age groups. 
It can be caused by wide range of organisms such as viruses, bacteria, fungus, 
parasites or spirochetes. It can also be immune mediated, chemical or toxins 
induced. Since identifying the pathogen is a laborious, extensive and expensive 
affair; it has not been systematically studied. In most of the cases specifi c 
infectious agent is rarely found (6, 217, 218). Specifi c pathogens even when 
identifi ed show considerable geographical and age specifi c variation. 
Presently, arbovirus encephalitis is one the most devastating diseases of the 
nervous system (219). It a disease to fear, not only due to the high mortality 
rate but also the high rate of residual functional, sensory and cognitive 
damage. Such a disease can severely impair the socioeconomic status of poor, 
marginalized and rural communities living in predominantly Asian countries 
where the disease is particularly prevalent. 
Numerically JE is the most important reported cause of AES worldwide. It is 
estimated, around 3 billion people living in 24 countries mainly of Southeast 
Asia, China and the Western Pacifi c Rim are at risk of the disease (http://www.
who.int/wer). Since JE surveillance is not well established in many countries 
and the laboratory confi rmation is challenging, the actual prevalence of the 
virus and the burden of the disease is not known and therefore it will appear as 
though it's geographical range is ever expanding (52, 220). The recent Public 
Health Emergency of International Concern caused by the related fl avivirus 
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Zika, shows the ability of these viruses to spread and cause neurological 
diseases (221). Globally around 68,000 clinical cases and 20,400 deaths are 
reported every year despite widely available vaccines (175). Involvement of 
children, high mortality and residual intellectual, behavioural and neurological 
sequelae in survivors has made it a signifi cant public health problem. 
A total of 12.5 million people in Nepal are at direct risk of JE. Laboratory 
based AES surveillance began in Nepal since 2004. 17,875 cases of AES and 
3,067 cases of JE (Table 1.2) have been reported since then. JE surveillance 
is integral part of AES surveillance and JEV is the only aetiology tested under 
AES surveillance in Nepal. This may also be the reason why it is the most 
common identifi ed viral cause of AES in Nepal. 
Since there is no specifi c treatment for most of the AES cases, the clinical 
management has been largely based on supportive care. Improved insight 
into pathogen specifi c clinical outcome, identifi cation of clinical features that 
predicted outcome, improvement in supportive care, exploring a defi nitive 
treatment option for known pathogen such as JEV, could guide strategies for 
prevention and clinical management to improve disease outcome. 
7.1 Clinical features that distinguished confi rmed JE 
from non- JE AES
Many clinical features and laboratory parameters were similar on admission 
between patients of confi rmed JE, confi rmed non-JE and JE-status unknown. 
As discussed in chapter 3. In the past, amongst patients of AES, sudden 
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onset of fever, altered sensorium, headache, dystonia or movement disorder, 
opsoclonus or gaze abnormality and residual neuropsychiatric sequelae has 
been reported to support a diagnosis of JE (222, 223). In my study, JE patients 
had signifi cantly more focal neurological defi cits as compared to patients of 
unknown viral aetiology (222). Focal neurological defi cit was present in 72% 
of patients at the time of discharge in my study, which was higher than 29%, 
33% and 57% reported previously (78, 224,225). However it was similar to 
78% reported in India (226). More defi cits may have been observed in my 
study because JE has been disease under surveillance in Nepal since 38 years. 
This has led to increased awareness of JE and detailed surveillance activities 
which may recognize subtle neurological signs in JE patients. Defi cits reported 
in past have been abnormal refl exes in 61%, hemiplegia in 42%, papilledema in 
22% and cranial nerve palsy in 23% in the past (224). In my study JE patients 
with focal neurological defi cit suffered bad outcome. Additionally, I found it to 
be more common in JE patients of lower WFA Z score at the time of discharge 
and follow up. 
Absence of focal neurological signs had a very high predictive value 
which meant that the diagnosis of JE was less likely if there was no focal 
neurological defi cit at the time of admission in patients with AES. This 
information certainly helps in the diagnosis and management. JE has been 
reported to be more common in children than adults and focal neurological 
defi cits are a signifi cantly more common clinical feature of JE in children than 
adults (227- 229). The presence of extrapyramidal features such as dystonia 
(correlated with thalamic involvement in CT Scan or MRI) has been reported 
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to be independent predictor of JE amongst patients of AES previously (227). 
Dystonia is signifi cantly more common in JE in children than adults because 
of the vulnerability of developing CNS to hypoxic or toxic or metabolic insult 
(227, 228). Focal neurological defi cit can be caused by injury to the nerve, 
spinal cord or cerebral cortex affecting it's function partially or completely. JE 
patients frequently develop raised intracranial pressure (20), brain herniation 
syndromes (20) and focal lesions in the brain (122) which could be the cause 
of focal neurological defi cit. JEV commonly affects the cerebral cortex, 
cerebellum, thalamus, substantia nigra, brainstem, basal ganglia and the 
anterior horn cells of the spinal cord. Therefore, different focal neurological 
defi cits reported in JE can be single or a combination of cognitive defi cit, 
mutism, swallowing defi cit, gait abnormality, intention tremors, seventh cranial 
nerve paralysis, cogwheel rigidity, monoparesis, hemiparesis, quadriparesis, 
diplegia, hyperrefl exia, opisthotonus and acute fl accid paralysis of limbs 
(20, 21, 222, 230). In conclusion, AES patients presenting with single or 
combination of any of these signs are highly likely to be JE. 
7.2 Patient outcome at discharge
Many patients with AES either die or have long term sequelae, especially if 
they have JE (73). JE patients have also been reported to have more residual 
sequelae compared to other viral encephalitis (10). Residual neurological 
sequelae were seen in 38% of JE patients in my fi rst study (chapter 3) and 72% 
in my second study (chapter 4). This was more than 30% reported previously 
(52). However, it was comparable to 46% reported in India (225) and 57% 
in Thailand (224) previously. Sequelae could also have been high because 
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my studies were conducted in children. Higher rates of sequelae have been 
reported in children as compared to adults (52, 231). I also found sequelae 
more common in patients with lower WFA Z score. This difference in outcome 
between the studies could be due to more children in Nepal with JE having a 
lower WFA Z score or suffering dehydration than in Thailand. In my study, 
a signifi cant proportion of AES with suspected viral aetiology also had a bad 
outcome. Similarly, viral encephalitis patients have previously been reported 
to have a mortality between 4.6% - 29% and 50% residual sequelae (232). In 
our setting, all the patients with AES receive antibiotics on admission due to 
suspicion of bacterial infection, until arrival of investigation reports. Defi nite 
treatments are available for bacterial meningitis, cerebral malaria, scrub 
typhus and typhoid encephalopathy. These are all causes of AES in our setting 
(37, 233). There are no defi nite treatments for viral encephalitis secondary 
to JE, Dengue, Chikungunya and West Nile virus (42, 126,128, 234- 238). A 
signifi cantly higher proportion of JE patients had bad outcome as compared to 
non-JE viral infection patients (10). It has been reported that complete recovery 
is signifi cantly less in children than in adults with JE (227). Children have 
been reported to have more severe illness as evidenced by deeper coma, higher 
frequency of seizures, more focal neurological defi cit, more extrapyramidal 
tract involvement such as dystonia and Parkinson like features as compared to 
adults in previous studies (8, 228). Dystonia usually co-exists with Parkinson 
like features which could cause severe and protracted illness and a worse 
outcome. 
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7.3 Prognostic features suggesting bad outcome at dis-
charge
In both AES and JE patients, older age, higher weight, longer fever duration, 
lower GCS and presence of focal neurological defi cit (227) at the time of 
admission were associated with bad outcome, as discussed in chapter 3. Fever 
of long duration has been associated with bad outcome even in a previous JE 
study (239). Although there is no specifi c treatment for AES and JE, shorter 
duration of fever at the time of admission suggested that in patients who had 
impaired consciousness and focal neurological defi cit, were more likely to do 
better with hospital admission and supportive management. On the contrary, 
one study has reported longer duration of fever to be associated with complete 
recovery of patients of JE (10). However, this was a small study conducted 
in single centre with limited resources. Brain injury has also been reported 
to be associated with prolonged fever and death (240- 242). Fever has been 
reported to stimulate formation of heat shock proteins which regulates immune 
response to protect host cells. Endogenous antipyretics regulate the body’s 
febrile response by suppressing formation of pro-infl ammatory cytokines 
(243). High or prolonged fever may cause inhibition of apoptosis and enhance 
pro-infl ammatory cytokine response (244). The surge of temperature could 
further damage brain tissue and cause death of patients with brain injury 
(243). In sepsis, fever has also been reported to decrease tolerance to the rise 
in metabolic demand, causing hemodynamic instability and hypoxic tissue 
injury (245). Further cohort studies in hospitalized patients to elucidate the 
association between fever burden (product of fever duration and intensity) and 
outcome are needed. 
Diffi cult geographical terrains causing lack of access to roads make the 
medical referral process unsystematic in Nepal. Most patients are brought to 
243
the hospital by parents on the advice of local paramedics, pharmacists and 
neighbours. Educating the family members, community leaders, pharmacists, 
primary and community health workers to attend hospitals promptly for 
supportive management could be life saving. Thus there is a need for studies 
investigating the feasibility and benefi t of local education to train family 
members and local health care workers in providing supportive measures 
among children with AES. 
Among the treatments given to AES patients with suspected viral encephalitis, 
mannitol and phenytoin were signifi cantly associated with bad outcome, in 
my study. Bad outcome may be explained by mannitol being given to sicker 
children. In traumatic brain injury, mannitol decreases perivascular oedema 
and resultant vascular collapse, resulting in enhanced brain oxygenation, 
without a change in circulation. Therefore, in severe cases of AES, with 
cerebral oedema and raised ICP, mannitol may have a more important effect 
on brain oxygenation than on ICP; and therefore a variable effect on outcome 
(246). Being an osmotic diuretic, it can cause hypokalemic and hypochloremic 
alkalosis, resulting in hypovolemia and reduction in cerebral perfusion leading 
to adverse outcome (246). In patients with non-traumatic brain injury, mannitol 
is reported not to have any benefi cial effect on outcome (122, 246, 247). 
Seizures are a complication of brain infection and are associated with bad 
outcome in both AES and JE (3, 20, 217, 222, 248). Again, patients who 
received phenytoin may have suffered a more severe course of disease and 
more frequently experienced a bad outcome. Phenytoin is cheap and widely 
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available for treatment of seizures in Nepal. Intravenous phenytoin at a loading 
dose of 18- 20 mg/Kg and a maintenance dose of 3- 6 mg/Kg/day in two 
divided doses is often provided for the treatment of seizures in AES patients 
(249, 250). Although the oral route is relatively safe and the intravenous route 
well tolerated, rapid (> 3mg/Kg/min or > 50mg/minute) and sometimes even 
normal infusion rates of phenytoin can cause cardiac arrhythmia, heart block, 
severe hypotension or apnoea which could can lead to death (251- 254). 
Because of toxicity, intravenous phenytoin has been withdrawn from the 
market and replaced with intravenous fosphenytoin in North America (249). 
Additionally phenytoin can cause impaired consciousness, suppression of 
neurological signs or aspiration pneumonia which could also increase the risk 
of adverse outcome. 
7.4 Validation of prognostic features of bad outcome at 
discharge in AES and JE
CNS infections broadly includes bacterial meningitis, aseptic meningitis 
and encephalitis. Encephalitis has a global incidence of 3.5- 7.4 per 100,000 
person years, suggesting the illness is not uncommon (232, 255). There is 
a defi nite treatment for bacterial meningitis. In contrast, the most common 
aetiology for aseptic meningitis and encephalitis are viruses, with no defi nite 
treatment. Although aseptic meningitis is self-limiting, mortality in encephalitis 
ranges from 4.5% - 29% (5, 232, 256). Half of the survivors have residual 
neurological sequelae (2). Therefore, identifying risk factors for bad outcome 
could give clues for improving management. Previously, absence of previous 
fl avivirus infection, prolonged illness, prolonged or high fever, prolonged 
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altered sensorium, GCS < 8, rapid progression to coma, multiple convulsions, 
refractory status epilepticus, focal neurological defi cit, abnormal breathing, 
decerebrate posturing, hypotonia, hyporefl exia, poor perfusion, raised ICP, 
positive Babinski sign, herniation syndrome, albuminuria, hyponatremia, 
low ani-JE IgM or IgG antibodies in serum or CSF, isolation of JEV from 
CSF, CSF cells >1000/mm3 and elevated CSF protein have all been reported 
to be predictors of bad out come in AES and JE (3, 10, 20- 22, 24, 37, 47, 
77, 78, 250, 257). In herpes simplex virus encephalitis, the most common 
sporadic encephalitis, acute symptomatic seizures, low GCS, delay in aciclovir 
treatment and older age are predictors of bad outcome (258, 259).
I also validated, prospectively, variables which were predictors of bad 
outcome in AES and JE, found in my retrospective study (chapter 3), using 
similar outcome defi nition, follow up period and clinical setting. As a result 
of which, I validated that; GCS ≤ 12, duration of fever ≥7 days and a focal 
neurological defi cit at admission to be robust predictors of bad outcome in 
AES patients with GCS ≤ 12 also as independent predictor of bad outcome 
in JE. Validity is the extent to which a scale measures what it is intended to 
measure (260). Therefore, I found that GCS ≤12 in patients of AES or JE 
could fairly accurately predict a bad outcome. However, absence of GCS ≤12 
could not accurately predict absence of bad outcome in neither AES or JE. 
The decrease in GCS is of the same nature in all patients of AES (specially 
JE); the difference being only in severity of altered sensorium. In the past, 
presence of four out of the following six features in AES patients have been 
regarded as pathognomonic of JE such as altered sensorium, slow speech, 
mask like face, course ocular tremor, symmetrical neurological paresis and 
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increased deep tendon refl exes (or abdominal refl ex) (77). It has also been 
reported that JE could be diagnosed with confi dence in patients of AES if they 
had sudden onset of fever, headache and altered sensorium and/or dystonia and 
various movement disorders and/or opsoclonus and gaze abnormalities with 
CSF fi nding of CNS infection of viral aetiology and residual neuropsychiatric 
problems (222). However, my previous fi nding of presence of focal 
neurological defi cits among AES patients, could not be validated to predict JE, 
due to the small number of cases.
7.5 Admission weight for age as a marker of hydration 
status in AES and JE patients
Dehydration and severe acute malnutrition have been reported to be 
independent risk factors for mortality in hospitalized children (261). Therefore, 
identifying and correcting hydration and nutritional status from the time 
of admission may help improve the management of patients of AES. Both 
dehydration and malnutrition status predominantly infl uence weight; best 
described as WFA in children. Dehydration is assessed by percent change 
in weight (262). Dehydration can be classifi ed as mild, moderate and severe 
based on 3-5%, 5- 10% and more than 10% loss of body weight respectively 
(133). Other clinical features which can help identify dehydration are inability 
to drink, thirstiness, restlessness, unconsciousness, lethargy, sunken eyes 
and abnormal skin turgor. Malnutrition is classifi ed as severe or moderate 
by WHO, if the WFA Z score is less than -3 and -2 respectively. Because of 
loss of subcutaneous fat, some signs, such as sunken eyes and abnormal skin 
turgor may also occur in malnutrition and may mislead the treating clinician. 
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However, prolonged capillary refi ll time, abnormal respiration and abnormal 
skin turgor have high positive predictive value for dehydration since there is 
a possibility of malnutrition being over diagnosed among dehydrated children 
(262). Well nourished children tend to exhibit higher body temperature 
compared to malnourished children (263). The recorded body temperature was 
comparable in all WFA groups. This similarity supports the children with low 
WFA being dehydrated rather than malnourished. Other laboratory parameters 
seen in dehydration are; elevated blood urea nitrogen, abnormal serum sodium, 
elevated serum lactate, decreased serum bicarbonate, low urinary sodium 
excretion and high urinary osmolality and specifi c gravity. When I weighed 
the patients of AES at the time of admission and classifi ed them by WHO's 
classifi cation of WFA Z score for malnutrition from -3 up-to +1 Z score, almost 
half of the patients of AES of suspected viral aetiology and JE had a (low) 
WFA of < -1 Z score (as discussed in chapter 3). Prolonged duration of fever, 
prolonged illness, presence of focal neurological defi cit and high serum urea 
suggest the low WFA patients could have had restricted oral intake and suffered 
dehydration compared to normal or high WFA patients. WFA Z score <-2 has 
also been reported to be independent predictor of death or severe neurological 
sequelae in patients with suspected viral encephalitis in a similar setting in the 
past (264). However, I found signifi cantly more patients in WFA Z score < -2 
group suffered dehydration (none in WFA Z score > -2), tachycardia and raised 
serum urea level suggesting death could have been caused by dehydration 
rather than mal nutrition. 
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7.6 Use of Liverpool outcome score to assess functional 
impairment
Previous studies regarding outcome of JE has reported wide variation in 
neurological impairment (28). The major reason for this uncertainty is the 
lack of standard method of assessing functional impairment in resource poor 
settings. Even in resource rich settings tools to assess disability in children 
are not well developed. Although some tools have been redeveloped for use in 
resource poor settings, the tools require a lengthy assessment process and the 
support of a multidisciplinary team (265, 266). Lack of simple tool to measure 
disability has been identifi ed as one of the reasons for a lack of reliable 
information on the disease burden of JE. 
The Liverpool outcome score (LOS) was used to describe and categorise 
neurological sequelae. It is a simple score developed to assess disability 
caused by JE. It can be applied by health care workers in a resource poor 
setting with minimal training. The tool has been validated for robustness and 
generalisability (109) (Appendix R). 
The scores in individual functional domains and a total score (ranging from 
33- 75) from the sum of all individual functional domains is assessed in 
order to identify severity of functional impairment and plan treatment. More 
importantly, for the purposes of epidemiological and health economics, it 
can help classify children with disability into likely to be "dependent" (not 
capable of independent living) or "independent"(capable of independent 
living). Children with a minimum LOS of 2 (severe sequelae) were classifi ed 
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as dependent, while 3- 5 (moderate sequelae, mild sequelae or complete 
recovery) were classifi ed as independent. During its development, the LOS was 
validated by comparing the outcome scores with the results of complete clinical 
examination conducted on the same day. The sensitivity, specifi city. positive 
predictive values and negative predictive values of the LOS to identify children 
likely to be "dependent" were 100%, 98.4%, 84.2% and 100% respectively 
in fi eld testing conducted in Malaysia (109). In my study, children who were 
assessed by LOS in person, also underwent complete clinical examination on 
the same day (Appendix Q). No clinical fi ndings in neurological examination 
were detected where corresponding functional problems had not been detected 
by LOS reconfi rming its high sensitivity to detect functional disability. I found 
LOS simple, easy to administer and user friendly.
In this study, all neurological sequelae were considered as bad outcome 
because even patients of JE with mild sequelae such as impairment of memory 
or change in personality has been reported to stop schooling and social 
participation in past causing huge adverse effect to the family. I used "bad 
outcome" because it was a absolute term where as "poor outcome" or "worse 
outcome" were relative terms.
Malawi Development Assessment Tool (MDAT) is a tool developed in Malawi 
for use by community health workers to assess development outcomes of 
African (non-western) children under six years of age (267). It is a structured, 
developmentally detailed and culturally sensitive tool (developed using a local 
reference population). Assessment is based on 136 items, 34 each in gross 
motor, fi ne motor, language and social domains of development. It also has 
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pictorial representation of many of the items making it understandable to those 
who use it. It has a sensitivity of 97% and specifi city of 82% in assessment 
of neurodisabilities (267). The tool was not appropriate for use in my study 
population for several reasons; fi rstly, the tool is designed for use in children 
below six years of age; secondly, the assessment is designed to be undertaken 
by community health workers (not available for my studies); and thirdly, the 
assessment is reported to take more than 30 minutes to complete in a quiet 
location (longer time than a routine clinical follow-up consultation would 
allow). 
 
Denver development assessment-II was developed as a quick and low cost 
method to screen children for evidence of impaired development for their age. 
It assesses four areas of child development:gross motor, fi ne motor, personal-
social and language (268). The assessment provides information about the 
child's performance as compared to performance of children of the same age 
in all four domains. The result can be interpreted as advances and delays in 
development. It can be used to demonstrate the child's skills and capabilities. 
The sensitivity has been reported 83% and specifi city 43% in identifying 
children with development abnormalities (269). Again this tool was not used in 
my study because it was designed for children from birth to six years of age. 
Disability is defi ned as impairments of structure and/or function which results 
in limitation of activities and restriction of participation (270). Although large 
spectrum of behaviour abnormalities and poor school performance have been 
reported (21), less has been reported on social participation in school, social 
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function and everyday life. Social activities are affected by communication 
skills, cognitive and motor function (271). Child and adolescent scale of 
participation (CASP) composes of 20 questions related with home, community 
and school. It measures the extent to which children participate in home, 
school, and community activities compared to children of the same age as 
reported by parents. It was designed to monitor outcomes of children with 
traumatic and other acquired brain injuries (272). A good agreement has been 
reported between CASP score with LOS in patients of AES, meaning high 
functional ability (high LOS) following AES also had high level of social 
participation (high CASP) (28). Therefore, CASP would be useful addition to 
LOS in assessing disability in children. 
7.7 Relation of admission weight for age with outcome 
in AES and JE patients
I found JE patients with lower WFA (Z score of -1,-2 and -3) at admission to 
have signifi cantly worse outcome at the time of discharge as compared to those 
with normal or high WFA. There was also trend for AES patients with lower 
WFA to also have bad outcome. There were signifi cantly more episodes and 
longer duration of convulsions in low WFA patients, among both AES and JE 
patients. Patients with confi rmed or probable viral encephalitis with a low WFA 
Z score < -2 have also been associated with death or severe sequelae in a similar 
setting in the past. The authors attributed the low WFA to undernutrition (264). 
According Gomez classifi cation, malnutrition has been defi ned as fi rst, second 
and third degree on the basis of 75% - 90%, 60% -74% and < 60% of median 
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desired body WFA and sex respectively (273). Malnutrition is an important 
health problem in resource limited countries. WHO states 85% of the world's 
children live in developing countries, where half of children are malnourished. 
According to Nepal Demographic and Health Survey (NDHS) 2011, 29 % 
children below 5 years of age are undernourished (moderate or severe), 41 % 
stunted and 11 % wasted in Nepal [http://nepal.unfpa.org/sites/asiapacifi c/fi les/
pub-pdf/GF25.pdf (accessed on February 24, 2016)]. 
Malnutrition results from an insuffi cient quantity of calories, protein, 
carbohydrate, vitamins or minerals in the body. Not enough nutrients is 
also called undernutrition. Undernutrition is of two types: protein-energy 
malnutrition (PEM) and dietary defi ciencies. Furthermore. there are two 
severe forms of PEM: marasmus (caused by both protein and calories 
defi ciency) and kwashiorkor (only protein defi ciency). Common micronutrient 
defi ciencies observed are of iron, iodine and vitamin A. Other micronutrients 
which can be defi cient includes zinc, copper, magnesium, calcium and 
vitamins B6, B12, B1, B2, B3, and C (274).
Malnutrition can be assessed by; seeking a relevant history, clinical signs, 
biochemical indicators and anthropometry. Inadequate dietary intake can affect 
functional capacity resulting in adverse health outcomes. Inadequate diet can 
reduce physical activity and slow growth. Signs of wasting of body parts and 
alteration of biochemical parameters such as hypoalbuminaemia may then 
follow. Later activity becomes severely impaired and body wasting becomes 
marked. Oedema, hair and skin changes also appear.
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A detailed dietary history on the amount of calories consumed in a day could 
help in the diagnosis of malnutrition. Additionally, history of suffering from 
infectious diseases such as tuberculosis, gastroenteritis, pneumonia, malaria, 
or measles, which cause increased nutrient requirements, could further help in 
making the diagnosis (273). 
Along with poor weight gain, malnourished children also have poor gain in 
height and defi cits in lean body mass and adipose tissue. The clinical features 
which suggest malnutrition in children are moon facies, dryness of conjunctiva, 
Bitot's spots, angular stomatitis, cheilitis, glossitis, spongy bleeding gums, 
enlarged parotid, sparse and brittle hair, alternating bands of light and normal 
colour hair (fl ag sign), alopecia, loose wrinkled skin, koilonychia, wasting of 
muscles particularly in the buttocks and thighs, hypoalbuminaemia and edema. 
It is a multi system disorder which may lead to reduced cardiac output causing 
cardiac failure, reduced gluconeogenesis in the liver causing hypoglycemia, 
decreased glomerular fi ltration rate in the kidney causing acidosis and 
hyponatremia, reduced insulin levels causing glucose intolerance and reduced 
basal metabolic rate causing hypothermia. Most importantly, there is also 
diminished cell mediated immunity, IgA synthesis, complement level and host 
defence's ability to phagocytose making children at risk of sepsis, diarrhoea 
and dehydration.
Anthropometry has an advantage over clinical and biochemical indicators of 
malnutrition because the latter tend to be most discriminatory at the extremes 
of malnutrition. Anthropometry is simple, non-invasive, cheap and easy to 
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obtain. Anthropometric measurements are important in malnutrition in-order to 
identify by stunting (low height-for-age) and wasting (low weight-for-height). 
The disadvantage of low WFA is that it cannot differentiate between stunting 
(short stature) and wasting (recent weight loss). Therefore low WFA would 
include both and would be unable to identify children with only recent loss of 
weight, important in the study. More accurate anthropometric measurements 
to diagnose malnutrition because of recent weight loss are either weight-for-
height or Body Mass Index (even in children above 5 years of age) (273). 
After selecting WFA and reference population, I used Z scores (standard 
deviation scores) to compare the children to the reference population. 
Although, percentiles and percent-of-median are other classifi cation systems 
which could be used, Z score is now regarded as the most appropriate 
descriptor of nutritional status (273). The risk of mortality is related to the 
anthropometric indicators of nutritional status. Malnutrition has an effect on 
mortality in patients (273). Therefore, malnutrition can lead to bad outcome in 
AES or JE. But there is paucity of data on whether malnutrition itself is a risk 
for AES and JE. In my study it was clear that patients of AES and JE who had 
low WFA Z score (even if some of them were undernourished before the illness 
by WHO criteria ) may have been dehydrated and this could have been the 
predominant cause of bad outcome (264). 
However, a larger prospective study on a cohort of patients seeking relevant 
history, clinical signs of malnutrition, blood levels of relevant micronutrients, 
accurate anthropometric measurements such as weight-for-height, Body Mass 
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Index and mid-upper arm circumference could have been more helpful in 
diagnosing malnourished children. Measurements of arterial blood gas, urinary 
osmolality and specifi c gravity could help differentiate dehydrated children. 
Low WFA could also have been caused by dehydration. The degree of 
dehydration is indicated by the degree of fl uid volume depletion of the patient. 
This depletion is most objectively measured as a loss of weight from baseline. 
An estimation of dehydration based on percent loss of body weight is useful 
when clinical signs are diffi cult to elicit. This has a sensitivity of 74% for mild 
(3- 5% of body weight), 33% for moderate (6-9% of body weight), and 70% 
for severe dehydration (≥10% of bodyweight). Dehydration can also cause 
an increase in serum lactic acid and a decrease in serum bicarbonate leading 
to metabolic acidosis. It can lead to a reduction in fractional excretion of 
sodium, hyponatremia or hypernatremia or cavernous sinus thrombosis causing 
uncontrolled seizures. It can also cause cerebral hypo-perfusion or infarcts 
resulting in confusion, stupor or a focal neurological defi cit (93). 
Repeated seizures have been reported to be associated with bad outcome in JE 
(20). In my studies, what I found new was that, seizures were more common in 
low WFA group. Acute symptomatic seizure occurring within 7 days of CNS 
illness has been reported in 2- 67% of patients (154) following encephalitis. 
The risk of unprovoked seizure after 7 days of CNS illness is also reported 
to increase by 16 times than the normal population (and which could occur 
up-to 20 years) following acute encephalitis illness (258). Often subtle or 
non-convulsive status epilepticus can be missed in comatose patients. In JE, 
appearance of seizure is reported to correlate with high CSF opening pressure, 
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signs of cerebral herniation and death (154). Patients with a witnessed seizure 
in the hospital were 4 times likely to have bad outcome. Furthermore, those 
suffering status epilepticus were more likely to have a bad outcome compared 
to those with self limiting seizures (154). 
In order to improve outcome of patients with AES, dehydration should be 
corrected and seizures controlled appropriately, along with the treatment of 
infection of the nervous system. However, there is still a possibility that some 
of the AES patients with low WFA could have been malnourished. Prevention 
and early management of malnutrition may have a role in preventing 
occurrence of AES and its complications. Malnutrition can be prevented by 
initiation of early breast feeding, complementary feeding through nutritional 
counselling, increasing access to quality food for the poor and marginalized 
through social protection schemes and safety nets and micronutrients 
fortifi cation of food. The government of Nepal has been addressing this 
through its National Nutrition Policy since 2004. Dehydration needs to be 
corrected following standard guidelines, using resuscitation fl uid, replacement 
fl uid and maintenance fl uid therapy [http://whqlibdoc.who.int.liverpool.idm.
oclc.org/publications/2005/9241593180.pdf (accessed on February 24, 2016)]. 
The risk factors for developing seizures during CNS infection are not well 
understood. Risk of seizures appear to relate to the infecting pathogens (such 
as 6- 67% in JE, 40- 65% in herpes simplex virus encephalitis, 10-20% in La 
Crosse virus encephalitis and 2.2% in Nipah virus encephalitis), the degree of 
involvement of cerebral cortex and extent of the infl ammatory response (154, 
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258). Around 60% patients with JE in my fi rst study (chapter 3) and 72% in 
my second study (chapter 4) had seizures. Repeated seizures are reported to 
be associated with hypoxia, hypoglycemia, hyperlactataemia or metabolic 
acidosis. Each of these parameters needs effective management and correction 
in addition to anti-epileptic drugs. Further studies are required to fi nd out the 
association between different CNS infections, seizures, anti-epileptic treatment 
and outcome (154). More research on the outcome and prognosis of post 
encephalitis seizure is also warranted.
7.8 Relation of admission weight for age with neurologi-
cal sequelae in AES and JE patients 
The range of sequelae observed in my studies were similar to what others 
have described (3, 16, 21, 27, 73, 74, 76). What I found new was that the 
residual neurological sequelae at the time of discharge was seen to be 
signifi cantly higher in those with lower WFA as compared to those who had 
appropriate or higher WFA in both AES and JE. AES patients of low WFA had 
signifi cantly more feeding diffi culties, cognitive problems, limb movement 
diffi culties, incontinence and seizures at the time of discharge. Whereas, low 
WFA group of JE patients had signifi cantly more problems of poor feeding, 
expressive language and dressing diffi culties at the time of discharge. In a 
previous study, when JE patients exhibiting movement disorders, dystonia 
or parkinsonian features were evaluated by brain imaging, thalamic, basal 
ganglia and brainstem regions were observed to be hyperintense on T2 and 
FLAIR and hypointense in T1 weighted images in MRI suggesting regions of 
hypoperfusion (275). Since Low WFA may have been related to dehydration, 
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the neurological sequelae in AES and JE could have exacerbated poor cerebral 
perfusion in the brain. Addition of hypoperfusion injuries to the usual reports of 
brain pathology, that include diffuse oedema, congestion, infi ltration of white 
blood cells, widespread neuronophagia and necrosis of the brain, meninges and 
spinal cord in AES and JE patients, could lead to further neurological sequelae 
in this group of patients. SPECT studies have reported hyperperfusion in acute 
stage followed by hypoperfusion in subacute and chronic stages of encephalitis 
(276, 277). In both AES and JE, low WFA patients more frequently exhibited 
moderate or severe residual neurological sequelae. Similar sequelae were 
observed among these patients at follow up 2 year post hospital discharge. 
Some studies report that the degree of cerebral hypoperfusion does not 
correlate with outcome at 6 months post discharge (275). There is need for a 
larger cohort study to look into the relationship between dehydration and the 
occurrence of neurological sequelae. 
 
7.9 Relation of admission weight for age with functional 
recovery in AES and JE
There are limited studies examining the recovery profi le of AES and JE 
patients. Although some studies have examined outcome up-to two years post 
hospital discharge; they have not recorded outcome at discharge(or another 
time-point) making it diffi cult to describe the patients’ recovery profi le over 
time(16, 73). In this study (chapter 4), the patients of AES and JE were 
followed up at two time-points ; fi rst, at one year and second, at 2 years from 
discharge. On the whole, there was improvement in patients between 1 and 
2 years post discharge, especially in aspects of concern to caregivers, such 
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as ability to self-feed and be left alone at home. Functional impairment was 
seen in higher proportion of children with a lower WFA group as compared 
to those with a normal or higher WFA at discharge and 2 years follow up. 
Cerebral hypoperfusion is associated with focal neurological defi cit in acute 
vaso-occlusive disease (278). Whether poor recovery in the low WFA group 
could be because of long term consequence of cerebral hypoperfusion in 
encephalitis is less understood. The proportion of AES and JE patients who 
had functional recovery were higher in the higher WFA group as compared 
to those with a lower WFA. Patients of encephalitis are at risk of developing 
acute symptomatic seizures within 7 days of CNS infection or unprovoked 
seizures later in life. The risk of unprovoked seizures is reported to increase by 
22 times in those who had developed seizure during acute illness and 10 times 
in those with no acute seizure as compared to normal population (154). Early 
seizures in 67% and persistence up-to 20 years in 22% have been reported in 
encephalitis in the past (53, 154). Acute symptomatic seizures are a predictor 
of bad outcome. Seizures and status epilepticus are important risk factors for 
fulminant cerebral oedema in acute encephalitis. This can cause a rise in ICP 
and brain stem herniation, which could cause sudden death, shock or severe 
neurological sequelae (279). In my studies, what I found new was that, seizures 
were present and persisted in higher proportion of AES patients of lower 
WFA. Seizure improvement has been reported to occur over time following 
acute encephalitis, such as anti-N-Methyl- D-aspartate receptor (NMDAR) 
encephalitis (280). Some of the AES patients in my study may have suffered 
anti-NMDAR or another autoimmune encephalitis. This was not investigated 
due to lack of resources. I observed uncontrolled seizures in some patients up-
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to 2 years after discharge. This fi nding highlights the need of a cohort study on 
long term sequelae of encephalitis. 
7.10 Relation of admission weight for age with long 
term outcome which was poor refl ection of discharge 
outcome
Approximately 60-70% of children with encephalitis have neurological 
sequelae (281). Common sequelae after encephalitis are emotional liability, 
cognitive defi cit, behavioural problems, dystonia, spasticity and epilepsy. 
Two-thirds of patients of herpes encephalitis develop neurological sequelae 
at discharge despite treatment with acyclovir (282, 283). Better hospital 
facilities mean reduction in mortality but an increase in number of patients with 
sequelae. 
There have been reports of patient outcome changing between time of 
discharge to time of long term follow up (281, 284, 285). JE patients have 
been reported to have deteriorated functionally at follow up after initial 
improvement at the time of discharge (21). Some children with encephalitis 
discharged as "complete recovery" have been later found to have lower 
intelligence quotient (IQ) scores and a higher prevalence of learning disabilities 
than general population (281). This could happen in very young children 
because impairment cognitive function is diffi cult to assess. Problems with 
cognitive function could become more evident as the child grows older. Subtle 
neurological manifestations could also be overlooked because of variations 
in neurodevelopment among young children (284). Long term low grade 
neuroinfl ammation occurring after encephalitis has also been hypothesised to 
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impair normal function of astrocytes and impair cognitive function in traumatic 
brain injury patients (286). There are reports on viral infection of CNS in early 
childhood which have lead to neurodevelopment and psychiatric disorders such 
as autism and schizophrenia later in life (281, 287). Further studies are needed 
to fi nd out the relationship between CSF cytokines and neurological sequelae. 
There is a pressure on clinicians in low resource settings to discharge patients 
quickly, because of the huge number of patients attending the hospital 
during outbreaks of encephalitis and demands from hospital management 
to reduce hospitalizations days. However, our long term follow up study in 
JE patients have showed that most changes in outcome occur within 3- 6 
months after hospitalization. and not at the time of discharge (21). In this 
study (chapter 4), I observed 5/61 (8%) additional deaths [including 3/17 
(18%) JE patients] among patients after their discharge from the hospital. This 
observation highlights that outcome at discharge is a poor refl ection of the 
eventual outcome (21, 74). A new fi nding in my studies were that functional 
impairments increased in children of low WFA (-3 Z score) from 20% at 
1 year to 33% at 2 year follow up (chapter 4). This increase in functional 
impairment could, in part, also be associated with ongoing seizures in children 
of low WFA in my study. Both neurological sequelae and seizure occur by 
similar mechanisms. Cerebral insults can initiate disruption of the blood brain 
barrier, neuronal reorganization, glial activation and neuronal hyperexcitability 
amongst others to cause seizure. Seizures can cause prolonged neuronal 
excitation, infl ammation and epileptogenesis in encephalitis (281). 
Development of epilepsy has strong association with development of sequelae 
(281, 283, 288, 289). CNS injuries are responsible for 30-49% of seizures 
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and epilepsy. This increased risk for seizure has been observed in encephalitis 
patients up-to 20 years post acute illness (283). Seizures could also have 
directly increased the sequelae in this group of children. In children with low 
WFA and neurological sequelae, physical and psychological rehabilitation 
should be initiated in the hospital to help minimize the impact of sequeale.
7.11 LWA and Nepal
LWA can occur because of undernourishment (290). Undernourishment is a 
physiological impairment created by lack of nutrients in the body. Globally, 
one in every sixth child is either moderately or severely underweight. 
According to the NDHS 2011, 3,229,121 children are below 5 years of age in 
Nepal. Out of these 29% are moderate or severely undernourished. Evidence 
from animal research shows that malnutrition may augment seizures in known 
epileptics (291). Malnutrition has also been shown to increase the risk of death 
in patients with pulmonary tuberculosis (292). 
For the fi rst time in 2004, The National Nutrition Policy and Strategy was 
formed to address the issue of low birth weight, protein energy malnutrition, 
iodine defi ciency disorder, iron defi ciency anaemia, vitamin A defi ciency 
disorder, intestinal worm infestation and life style related issues. The country 
had set targets of reducing undernourished children from 39% in 2010 to 29% 
in 2015 through the implementation of the Nepal Health Sector Program- 
2. One of the major policies embraced to reduce the under 5 mortality was 
to scale up community based newborn care and implement comprehensive 
nutrition programmes. In 2011, Nepal joined the global "Scale Up Nutrition" 
campaign to fi ght against hunger and malnutrition through the Multi-Sector 
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Nutrition Plan (MSNP) which was initially launched from 6 selected districts. 
The national multi-sectoral nutrition planning framework can be found as 
appendix S. Low income countries like Nepal can lose a minimum of 2-3% of 
their gross domestic product to malnutrition. The World Bank has estimated 
that an additional $10.3 billion needs to be spent per year to prevent 1 million 
child deaths and to benefi t the 360 million children from 36 countries with the 
highest burden of malnutrition. The most effective nutritional interventions 
focus on fi rst 1000 days (as in MSNP) because economic returns of investment 
then are very high. The 2008 Copenhagen Consensus ranked that providing 
micronutrients to undernourished children the most cost-effective strategy to 
improve nutrition and social welfare [http://www.copenhagenconsensus.com/
sites/default/fi les/cc08_results_fi nal_0.pdf (accessed on March 4, 2016)]. 
Globally, diarrhoea (and dehydration) is estimated in 9.5% of severely 
undernourished and 3.4% of moderately undernourished children (293). 
Even in undernourished children with AES, clinical features and laboratory 
parameters suggests presence of dehydration. In Nepal, where malnutrition 
is common, dehydration should be suspected when managing children with 
AES or JE (264). Typical signs of dehydration (Appendix E) (133) may not be 
obvious in a severely malnourished children. Lack of subcutaneous fat may 
cause skin turgor to appear poor and eyes sunken in children with marasmus. 
It may be masked by oedema in kwashiorkor. Presence of irritability or 
apathy make assessment of mental status diffi cult in these children. In severe 
malnutrition, it is diffi cult to differentiate mild dehydration from severe 
dehydration, affecting treatment. The only signs which then becomes useful 
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for assessing hydration status in malnourished children are thirst (mild 
dehydration), and lethargy, cool extremities, weak radial pulse, reduced 
urinary output (severe dehydration), and acute weight change. Therefore 
dehydration can easily be missed during hospital presentation. Modifi ed fl uid 
replacement guidelines are available for the treatment of severe dehydration in 
undernourished children. Children with severe malnutrition and mild or severe 
dehydration (not in shock) should be given 5 ml/kg of reduced osmolarity 
ORS solution (ReSoMal) orally or via naso-gastric tube every 30 minutes for 
the fi rst 2 hours [ReSoMal contains a lower amount of sodium (45mmol/L) 
and higher amount of potassium (40 mmol/L) than standard WHO-ORS]. On 
reassessment, if the child is still dehydrated, 5–10 ml/kg/hour of ReSoMal 
should be given every alternate hour with F-75 diet, up to a maximum of 
10 hours. In children with severe acute malnutrition having signs of shock, 
who cannot be rehydrated orally or by naso-gastric tube, should be treated 
with intravenous fl uids. Fluids prescribed include; half-strength Darrow’s 
solution with 5% dextrose, Ringer’s lactate solution with 5% dextrose or 0.45% 
saline + 5% dextrose (294). Therefore, rapid correction of dehydration in an 
undernourished child could cause adverse outcome.
7.12 Low WFA patients of AES or JE could be dehydrated 
Low WFA at admission in children with AES and JE is associated with bad 
outcome at discharge and persistence of sequelae even at 2 years of follow up. 
Low WFA children can be either dehydrated or undernourished (133, 290). 
Acute loss of body weight typically refl ects loss of body fl uid and not body 
mass. Children are at increased risk of dehydration compared to adults, because 
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they have relatively a higher surface area to volume ratio with higher insensible 
water loss, which can easily be accentuated by fever. Very young children and 
older children with focal neurological defi cits, suffering from AES or JE, may 
not be able to independently access food or effectively communicate their need 
for fl uids as compared to adults. I found patients of low WFA to be younger, 
have more focal neurological defi cit, lower GCS and longer duration of fever 
as compared to patients with higher WFA in both AES and JE. The WFA Z 
score was estimated using the WHO reference population.in patients below 5 
years of age. The WFA Z score was estimated using a Nepali national reference 
population in patients above 5 years. The WHO developed their child growth 
curve reference data based on studies involving children from the United 
States of America around 1970. The suitability of these curves for international 
purposes has been challenged more recently (http://www.who.int/nutgrowthdb/
about/introduction/en/index3.html). The WHO reference population may not 
be suitable for comparing Nepali population. Therefore, more children in my 
study (under 5 years) could have appeared falsely to be of low WFA based 
on the WHO reference (273). There is a need for a single national reference 
population to compare the WFA Z score of all age groups of Nepali children. 
It is also possible that younger children may be dehydrated even by modest 
defi ciency of fl uids as compared to older children. This latter suggestion 
could also explain the prolonged fever and presence of focal neurological 
defi cit observed in younger children. Systematic measurement of serum urea, 
electrolytes, fl uid balance, markers of acid-base balance and MUAC in children 
of low WFA would help differentiate dehydration from malnutrition in these 
children. 
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7.13 Relation of low WFA at admission and/or weight 
loss during hospital with outcome 
I grouped patients with low WFA at admission, and patients exhibiting weight 
loss during hospital, together during my study. The former patients may have 
suffered weight loss because of inability to feed. The latter patints may have 
suffered weight loss secondary to restriction of maintenance fl uids by the 
treating clinicians (fearing cerebral oedema or raised ICP). Of a total 92 AES 
patients, more than half had a low WFA and/or weight loss. The odds of having 
a bad outcome was 7 times greater if they were of low WFA and/or had weight 
loss. Furthermore, the odds of dying were 13 times greater if they had low 
WFA at the time of admission, 10 times greater if they had weight loss during 
admission, and 19 times greater if they had low WFA andweight loss. A child's 
arm contains subcutaneous fat and muscle mass. When there is reduced food 
intake, lower levels of subcutaneous fat and muscle mass tend to correspond to 
a decrease in mid upper arm circumference (MUAC). This measurement can be 
used to diagnose malnutrition in infants and children 6–60 months of age (295, 
296). The MUAC of all recruited children between 6- 60 months of age was 
≥11.5 cm which meant there was a strong possibility of acute loss of weight 
being due to dehydration rather than severe malnutrition (141). In 2009, the 
WHO and United Nation's International Children's Emergency Fund (UNICEF) 
recommended MUAC cutoff of <11.5 cm as one of three screening criteria 
for identifying and managing severe acute malnutrition in infants and children 
6–60 months of age. Although previously systematic review of the literature 
showed that children with MUAC measurements <11 cm had signifi cantly 
elevated risk of mortality (297), WHO and UNICEF recommended a slightly 
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higher cutoff to increase sensitivity of the measure, while maintaining high 
specifi city. Changing the MUAC cutoff value from 11 cm to 11.5 cm produced 
a large change in sensitivity (from 16% to 25%) with little loss in specifi city in 
improving the probability of diagnosing severe wasting (298). It also reduced 
false negative results by 12% (298).The sensitivity and specifi city of MUAC 
< 11.5 cm in identifying severe wasting (weight for age Z score < -3) among 
children 6 to 59 months was 4.9% - 47.8% and 99.7% - 97.4% respectively 
(298). MUAC may give false positive result on degree of malnutrition in 
patients with diseases that cause muscle wasting, such as acquired immune 
defi ciency syndrome (AIDS).
 
MUAC is a single measurement, independent of age and gender, of children 
commonly between six months and fi ve years of age. In a time and resource 
limited setting, it is most useful tool to screen for malnutrition. It is better 
than other anthropometric measurements in predicting subsequent mortality 
according to community studies (299, 300). The advantage of MUAC over 
other anthropometric measurements is that, with color codes of red zone (< 
11.5 cm) as severely malnourished, yellow zone (11.5- 12.5 cm) as risk of 
malnutrition and green zone (> 12.5 cm) as not malnourished, it is not only 
useful for even illiterate people but also saves users from memorizing and 
relating the cut-off numbers for each category. It can also be easily taught to 
minimally trained health workers because it requires a simple equipment; and 
can be performed even on debilitated individuals. Errors are fewer during 
measurement of anthropometry by MUAC than Weight-for-Height (297). Since 
MUAC is less affected than BMI by the localized accumulation of excess fl uid 
in famine, it is being increasingly used in adult undernutrition (301, 302). In 
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adults, moderate undernutition is considered if MUAC is < 18.5 cm and severe 
undernutrition < 16 cm.
Another potentially valuable application for MUAC is in screening for obesity. 
It can provide high accuracy for the assessment of obesity in children and 
adolescents in resource-poor settings (303). A number of studies have shown 
that high MUAC has high diagnostic accuracy (sensitivity, specifi city and 
predictive values) for the identifi cation of overweight and obesity (as defi ned 
by BMI for age). 
7.14 AES patients suffering bad outcome may have been 
dehydrated 
Signifi cantly more AES patients who suffered bad outcome had low WFA on 
admission. These patients had higher fl uid requirements, higher fl uid defi cits, 
were more likely to be fl uid restricted (to two-thirds of maintenance), had 
lower intake of oral fl uids, higher serum sodium and more likely to have high 
serum urea and lactate at admission. The fi ndings suggest these patients were 
not just sicker, but also likely to be dehydrated. Consequently, one explanation 
for the observed increased risk of bad outcome among children with low WFA 
and/or weight loss may be due to dehydration. 
7.15 Relation of death, sequelae and recovery with 
hydration status of AES patients 
When outcome was further sub-grouped into death, sequelae or complete 
recovery, I found signifi cantly more children who died had a low WFA, 
higher serum urea and higher serum sodium at the time of admission. Patients 
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who died, exhibited more weight loss during admission, than those who had 
sequelae or who recovered completely. There was also tendency for higher 
admission serum lactate levels in those who died. Serum lactate tended to 
further increase on their second day post admission.. Hence, there was evidence 
of more severe dehydration among those who died, compared to patients who 
suffered sequelae or who recovered completely. In contrast, patients who 
recovered completely required signifi cantly less fl uid replacement, received 
less maintenance IV fl uid, had more oral fl uid intake, and were less fl uid 
restricted. 
7.16 Effect of dehydration in body metabolism
Dehydration causes hypo-perfusion of the tissues. Therefore, there is decreased 
oxygen delivery to cells, reduced availability of oxygen in the energy cycle 
and promotion of anaerobic metabolism. This leads to oxidative fermentation 
of pyruvate to form lactate, which accumulates in the blood to cause metabolic 
acidosis. Akin to sepsis, there may also be excessive production of pyruvate, 
which again is fermented to lactate to further exacerbate lactic acidosis (148). 
Presence of acidosis will shift oxygen-haemoglobin dissociation curve to the 
right, decreasing haemoglobin's affi nity for oxygen causing decrease in oxygen 
delivery. This starts a vicious cycle of poor oxygen delivery- lactic acidosis- 
poor oxygen delivery. Severe metabolic acidosis can impair the body’s 
metabolism,impede neurovascular interaction and affect pharmacological 
action of drugs. In my study, elevated serum sodium, serum urea, serum 
creatinine and serum lactate on admission, together with supporting clinical 
information, indicated that patients who died showed signs of metabolic 
acidosis with impending renal failure.
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7.17 Effect of dehydration in different tissues 
Adequate tissue perfusion is essential for normal cell function. In the nervous 
system, dehydration can cause cerebral hypo-perfusion and ischemia, causing 
confusion and stupor. Dehydration increases the risk of cerebral infarction, 
in turn, increases the risk of neurological defi cit and/or seizures (93). In the 
kidney, dehydration can cause hypo-perfusion and acute renal failure. It 
can also cause hypo-perfusion of the gastrointestinal tract, trigger erosive 
gastritis or ischemic pancreatitis. Hypo-perfusion of the liver can cause 
ischemic hepatitis. In the blood, it can produce coagulation abnormalities and 
thrombocytopenia. In the heart, it can cause life threatening arrhythmias or 
myocardial depression. In the lungs it can cause respiratory muscle fatigue and 
hypoxia. Most importantly it can cause life threatening shock and multi-organ 
failure. 
7.18 Seizures and low WFA and dehydration
Seizures are a treatable complication of AES. Effective management of 
seizuers could improve outcome (20). Of the 70 million people living with 
epilepsy around the world, 60 million live in low or medium income countries; 
half of whom are children (304). Acute symptomatic seizures occur in around 
30% of CNS insults at the time of acute infection. This is also a risk factor 
of later development of epilepsy when recurrent seizures occur after an 
epileptogenesis event. The risk of developing epilepsy after CNS infection 
depends on the aetiology of the infectious agent, severity of brain injury, 
age, genetic factors and other co-morbidities (304). Between infection and 
development of epilepsy various changes in the brain occur such as initiation 
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of immune or infl ammatory response, increased permeability of BBB, 
neuronal hyperexcitability, neuronal loss, gliosis, molecular and structural 
reorganisation and epigentic reprogramming which could cause occurrence of 
spontaneous recurrent epileptogenic seizures (304). Although there is paucity 
of information in humans, in mouse models, IL-1β, TNF- α and IL- 6 trigger an 
infl ammatory response, cause neuronal hyprexcitability, and lower the neuronal 
seizure threshold, to cause seizures (304). Infl ammation can permanently 
alter expression of glutamate receptor subtypes and K+/Cl- co-transporter in 
the brain which in-turn may trigger immediate or long term pathophysiology. 
Infl ammation can impact on seizure recurrence, cause acute and long term 
reduction in the seizure threshold, as well as other cognitive co-morbidities 
(behaviour, learning and memory defi cits) observed in adulthood. Infl ammation 
may also contribute to disease progression (305, 306). Epilepsy and persistence 
of neuroinfl ammation can occur in the immature brain following just a single 
episode of acute symptomatic seizure (304). In my study, I found children of 
low WFA were signifi cantly younger than those with higher WFA. Episodes 
of seizure and bad outcome were also signifi cantly more frequent in young 
children. Young children have less mature brain development. This may put 
them at higher risk of seizures and the pathophysiological changes that can 
follow. 
In my study (chapter 5), I found serum sodium was signifi cantly elevated 
among the dehydrated patients, particularly in the bad outcome group (bad 
outcome 140 mmol/L versus good outcome 131 mmol/L); and in those who 
died (death, 145 mmol/L versus recovered, 131 mmol/L). Hypernatremia can 
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cause repeated seizures. Repeated seizures or status epilepticus are associated 
with bad outcome (20). There was a signifi cant association between repeated 
seizures with dehydration and metabolic acidosis in my study. Acidosis 
can inhibit voltage gated calcium pumps. These pumps facilitate infl ux of 
calcium from the extracellular to intracellular space. Pump failure is linked 
to hypocalcemia and seizure (307). Acidosis could trigger seizures, which in 
turn could be the reason for increased neurological sequelae in dehydrated 
patients. Other causes of seizure in dehydration can be hypoglycaemia, 
hyperlactataemia, hyponatremia, cerebral venous thrombosis, cavernous 
sinus thrombosis, fever triggered seizure or CO2 retention. I did not fi nd 
hypoglycemia as a cause of seizure in these groups.
7.19 Relation of intravenous fl uids and AES
Intravenous fl uids (IVF) are used in the care of sick and injured children. The 
IVF commonly used is 5% dextrose with 0.18% normal saline. Maintenance 
IVF is expected to supply suffi cient sodium chloride for the body's metabolism, 
water to excrete nitrogenous waste by kidneys and glucose to prevent glycogen 
breakdown (Appendix T). 
The Holliday- Seger equation, which estimates amount of kilocalories 
expended and equates with fl uid requirement in millilitre, has been the current 
standard method of calculating and administering maintenance IVF (141). It 
has been argued that a sodium concentration of 30 - 50 mmol/L makes fl uid 
hypotonic, and that sodium concentration should be increased to approximately 
75 mmol/L (0.45% sodium chloride) to be isotonic (308). The WHO, showing 
concern for dehydration, recommends full maintenance fl uids in children 
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with bacterial meningitis with an emphasis on providing IV glucose. Full 
maintenance hypotonic fl uid can cause hospital acquired hyponatremia. Such a 
fl uid regime may be more harmful to children in resource poor settings, where 
serum sodium cannot be regularly monitored. Many researchers have described 
adverse neurological events, such as seizures, status epilepticus, cerebral 
oedema, intracranial hypertension and encephalopathy in children with serious 
infection who have become progressively hyponatremic or who have received 
prolonged hypotonic fl uid (150, 309- 313). Urinary loss of sodium, SIADH 
and shift of water from intracellular to extracellular space has been estimated 
to account for hyponatremia, in 29- 45% of children with encephalitis. In 
the brain, even with an intact BBB, a fall in serum osmolarity favours water 
accumulation in the interstitium or brain cells to cause cerebral oedema (149). 
Assuming normal renal function, 0.18% saline at 100 ml/kg/day is estimated to 
trigger a fall in serum sodium from 135 mmol/L to 131 mmol/L and cause a 5% 
rise in total body water. Whereas 0.9% saline at 75ml/kg/day is estimated to 
trigger an increase in serum sodium by 2 mmol/L and an increase in total body 
water by 1.5% within a day, without any increase in intracellular water (92). 
Unrestricted maintenance fl uids, in children with impaired renal function, 
can disrupt the BBB, cause cerebral oedema and other adverse neurological 
outcomes, depending on the volume of fl uid administered (92). Isotonic saline 
has a pH of 5- 6. Metabolic acidosis can still persist, when saline is used 
in large volumes for children in shock. In such circumstances, bicarbonate 
or another buffer may be needed (92). Rapid rehydration by bolus, using 
ringer lactate or normal saline, in patients with hypernatremia (where sodium 
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monitoring is not available) or receipt of hypertonic rehydration solution 
prior to admission, can cause death. Excess mortality from fl uid boluses in 
patients of severe acidosis and severe shock has been reported previously 
(314). A landmark study conducted in Africa based on a large sample size, 
multi-national sites, good concealment of treatment, high treatment adherence 
and patient follow up in children with compensated shock, concluded there 
was no additional advantage of bolus albumin over saline in resuscitation 
of sick children (142). The study also found children given boluses of fl uid, 
whether albumin or saline, exhibited an increased rate of death, compared 
to control group of children who received normal maintenance IVF over 
2 days and 4 weeks of treatment (142). However, it has been argued that 
the sick children they recruited were neither hypovolemic nor septic, as 
reported, rather they appeared to have malaria or bronchiolitis, in which, fl uid 
boluses were detrimental (142). This diffi culty of case diagnosis is seen in 
Nepal. Pneumonia is frequently diagnosed following WHO criteria. These 
children may instead have bronchiolitis, and could inadvertently receive fl uid 
boluses because of suspected pneumonia with septicaemia. It can be argued 
in shock, when the body is compensating with vasoconstrictor response to 
reduce perfusion to non vital tissues, when resuscitated rapidly with IVF for 
reversal, maybe deleterious. Also fl uid boluses could cause reperfusion injury, 
cardiac failure, pulmonary oedema or rise in ICP. However, the African study 
may have erroneously excluded true septic or hypovolemic sick children as 
gastroenteritis, severe malnutrition or non-infectious shock. Applying their 
recommendation and denying fl uid boluses to children with true hypovolemic 
shock could cause adverse outcome (142). 
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Healthy children excrete larger volumes of water compared to sick children. 
It has been suggested that the quantity of IVF provided should be tailored to 
disease state. Maintenance fl uid should be reduced to less than 75% of normal 
in patients whose free water clearance is reduced by 50%, to avoid oedema. 
However, this approach should not be misinterpreted. Otherwise, there is 
a risk of restricting fl uids to the point of dehydration, because of fears that 
cerebral oedema may adversely affect outcome (315). For example at Kanti 
Children’s Hospital, all children with severe altered sensorium (modifi ed 
GCS < 8) or having clinical features suggestive of raised ICP have their fl uid 
intake restricted to two- thirds of their maintenance fl uid. Adequate IVF also 
helps in appropriate distribution of drugs to achieve therapeutic concentration 
Furthermore, dehydrated patients are at risk for water soluble drug toxicity 
(141). 
There is paucity of data on optimum fl uid management for patients with non-
traumatic brain injury (93, 143, 144). My study aimed to better understand 
the association between hydration (including fl uid supplementation) and 
outcome in children with AES. I observed signifi cantly more children who 
received 0.45% saline with 5% Dextrose compared to other IV fl uids died. In 
contrast, children who received 0.9% saline IV tended to exhibit full recovery. 
I also observed that children who were taking oral feeds more frequently 
exhibited better outcome. My fi ndings re-opens the question as to what fl uid 
management should be provided in acute infectious illness, and makes the 
area of brain infection, where clinicians are balancing the support of cerebral 
perfusion pressure against the risk of cranial or pulmonary oedema, even 
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more challenging (20, 123). Without any specifi c anti-viral treatment for AES, 
optimum supportive management of patients during their acute AES illness is 
vital. A large randomised controlled trial of hypotonic versus isotonic saline 
or different volumes (two- third versus full maintenance) of systemic fl uid 
supplements in children with severe infections, stratifi ed for types of infections 
to fi nd out the differences in frequencies of severe hypernatremia, neurological 
complications or death may tell us which volume and type of IVF could 
improve outcome. Until then 0.9% sodium chloride with dextrose tailored for 
free water clearance maybe the most appropriate for very sick children (92). 
7.20 Intravenous immunoglobulin as a treatment of JE
Intravenous immunoglobulin (IVIG) has been postulated as a treatment for 
fl avivirus encephalitis caused by JEV and WNV, on account of its antiviral and 
anti-infl ammatory properties (168). Pre-clinical studies suggested passively 
transferred antibody could be useful against fl avivirus encephalitis (165, 167, 
168, 176- 182). Konishi et al demonstrated that neutralising antibody prevents 
virus dissemination from the peripheral site to the brain, and that antibody-
mediated mechanisms of protection were more effi cient than cytotoxic T 
cell responses (179). In animal studies in which IVIG containing anti-WNV 
specifi c antibody was administered during the viraemic phase but before the 
virus had entered the CNS, the studies demonstrated a dramatic 100% survival 
rate (167, 180), or that mortality was reduced up to fi ve days after infection 
(181, 182). Peripheral administration of anti-virus monoclonal antibodies in 
a mouse model has been shown to neutralize WNV even after the virus has 
entered the brain (185, 186).
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IVIG in humans has been used on a compassionate basis, but has not been 
assessed in a randomised trial for JEV or WNV (165, 168). The previous 
trials assessing adjunctive agents for JE were conducted in Thailand and 
Vietnam, both highly developed research settings, where-as Nepal has no such 
establishments. Therefore a preliminary randomised placebo-controlled trial of 
IVIG was conducted for treatment of children with suspected JE in Nepal. 
7.21 Selection of Intravenous immunoglobulin for 
treatment
IVIG developed using serum from donors living in endemic areas is considered 
most appropriate for fl avivirus encephalitis, including that of JEV and WNV, 
because of the neutralising antibody it contains (167). I found IVIG from 
a range of manufactures in Asia contained signifi cantly high neutralising 
antibody; most had PRNT50 titres ≥1:640. ImmunoRel™ IVIG produced by 
Reliance Biopharmaceutical (India) had the highest anti-JEV PRNT50 titre, and 
was chosen for treatment in my study. However, ImmunoRel IVIG was found 
to show low PRNT50 titres ≤1:20 against DENV, WNV and Powassan viruses. 
7.22 Intravenous immunoglobulin treatment and 
neutralising antibodies
IVIG treated patients had a greater increase in neutralising antibody titres 
as compared to placebo. What I found new was that, JEV antibody positive 
children treated with IVIG showed approximately 16 times higher titres of 
neutralising antibody compared to levels following IVIG treatment among 
JEV antibody negative patients. The extent of rise appeared greater than can be 
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explained by passive transfer of anti-JEV antibody. Although the mechanism 
is unclear,, it is possible that passively transferred antibody is augmenting the 
natural production of neutralising antibody by B cells, through enhancing the 
uptake of viral particles by antigen presenting cells (187). A 1:10 neutralising 
antibody titre has been shown to protect against JEV in animal models, 
when antibody is administered prior to infection. However, no studies have 
determined appropriate titre required to limit the evolution of encephalitis once 
JEV infection is established in humans.
7.23 Intravenous immunoglobulin treatment and 
cytokines
Neuronal cell death in JE may occur directly, from viral cytopathology, and 
indirectly via immune mediated mechanisms. This may include over activation 
of microglia cells (190), which release pro-infl ammatory cytokines such as 
interleukin 6 (IL-6), TNF-α, and RANTES (regulated upon activation, normal 
T cell expressed and secreted), causing massive migration and infi ltration 
of leukocytes into the brain (191) increasing permeability of the blood brain 
barrier leading to interstitial cerebral oedema and raised intracranial pressure 
(195, 196) as discussed in chapter 3. In addition to affecting virally-infected 
cells, the infl ammatory response in the CNS may also damage non-infected 
cells to cause bystander cell death. 
The rise in IL-6 and IL-4 responses in our patients support the hypothesis that 
administration of IVIG modulates the immune response. IVIG treatment has 
been associated with both reduced and elevated levels of IL-6 (199- 205), 
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and increased IL-4 levels (206, 207) in previous studies. IL-6 and IL-4 were 
chosen because they have previously been used to show balance of pro- to 
anti- infl ammatory responses (45). Both IL-4 and IL-6 are secreted by T cells 
and participate in the development of antibody responses; IL-4 promotes 
B cell proliferation and isotype switching and IL-6 induces differentiation 
of B cells into antibody secreting plasma cells. It may be that the cytokine 
changes I observed refl ect the augmentation of antibody response; therefore 
the increase in both antibody and pro-antibody producing cytokines may have 
lead to the same process (209). The differences in response among patients 
with different anti-JEV antibody statuses indicates immune modulation 
by IVIG. Other mechanisms of cytokine production may involve patients 
generating immune complexes against antibodies present in IVIG which 
could stimulate monocytes to produce IL-6 via Fc-receptor interactions (210). 
Also, other immunomodulatory factors (e.g., sCD4, sCD8, sHLA antigen) 
in the IVIG could stimulate cytokine production (211, 212). Clinically, in 
asymptomatic JEV infection, antibody probably protects the host by restricting 
viral replication before the virus crosses the blood brain barrier (52). However, 
in established encephalitis, it may also restrict damage by neutralising 
extracellular virus and facilitating lysis of infected cells by antibody-dependent 
cellular cytotoxicity.
7.24 Other implications of intravenous immunoglobulin 
treatment
In recent years, neurological conditions account for approximately 43% of 
the IVIG use in clinical practice worldwide (316). IVIG used therapeutically, 
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supplements the immune system with immunoglobulins collected from 
healthy donors which broaden the spectrum of immune response and attenuate 
autoimmune response in recipients (317- 319). Unlike steroids, it modulates 
immune response without increasing risk of opportunistic infection. IVIG is 
prepared from pooled serum immunoglobulins collected from 3000- 10,000 
blood donors. The variety of donors helps expand the spectrum of the IVIG’s 
antibody activities. IVIG contains mostly IgG1 and IgG2. Other minor 
components include IgM, IgA, soluble CD4, CD8, HLA molecules, small 
amount of coagulation factors and cytokines. IVIG acts through multiple 
immunomodulatory and antigen recognizing pathways involving humoral and 
cellular immunity. IVIG also acts on various subsets of B cells and T cells, 
scavenges complement, modulates cytokines and blocks idiotypic antibodies 
(317, 318, 320). IVIG may also alter gene expression associated with 
infl ammation, fi brosis, and regeneration (321). Typically, the dose for acute 
treatment with IVIG is 2 g/kg over 2 to 5 days (316). Subcutaneous is more 
popular than intravenous route because of convenience in administration at 
home and fewer systemic side effects, (322).
In my study, many patients with AES ( i.e. confi rmed non-JE) may have 
been suffering from antibody mediated or autoimmune encephalitis (AIE). 
AIE cases are commonly missed in resource poor setting like Nepal because 
of lack of awareness, skilled human resources and laboratory facilities. 
Antibody mediated encephalitis can be grouped according to the serum 
antibodies and their specifi c targets such as a) intracellular antigens (GAD65) 
b) intranuclear antigens (Hu, Yo and Ma2) c) neuronal membrane antigens 
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(VGKC), various glutamate receptors (NMDA or AMPA receptors ) or the 
GABAB receptor (304). Recently many cases of autoimmune encephalitis 
associated with antibodies against the N-methyl D-aspartate (NMDA) receptor 
called N-methyl-D-aspartate receptor antibody (NMDARAb) encephalitis 
have been reported. The disorder is likely mediated by antibodies against 
the NR1 subunit of the NMDA receptor causing state of reversible NMDA 
receptor hypofunction and characterized by prodromal stage of fever, nausea, 
vomiting followed after few weeks by rapid or subacute onset behavioural 
change, neuropsychiatric features, seizures, unresponsive/catatonic state, 
dyskinesias, and autonomic instability (323- 325). Initially, it was described 
as a paraneoplastic syndrome associated with ovarian teratoma (323), but it is 
now clear that many patients don't have tumours, and that men and children 
are also affected (325). Presence of NMDA receptor antibodies in the serum and/or 
CSF is diagnos? c. Early tumour resection (if present) along with immunotherapy 
(intravenous and/or oral steroids, IVIG, and/or plasma exchange) and second-
line immunotherapy with cyclophosphamide or rituximab is recommended 
(325), although spontaneous prolonged recoveries have been reported (324). 
Over 75% of patients exhibit recovery. IVIG is being increasingly used for its 
treatment.
Another autoimmune encephalitis is Voltage-gated Potassium Channel-
complex Antibody-associated Limbic Encephalitis (VGKC-LE), where 
antibodies are directed against potassium channel complex proteins, such 
as contactin-associated protein-like 2 (Caspr2) and leucine rich, glioma-
inactivated 1 protein (LGI1). The latter proteins are tightly associated with 
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potassium channels in the brain (326). Clinically, these patients present 
with memory loss, confusion, behavioural changes and seizures (326). In 
addition, patients with LGI1 antibodies present with facio-brachial dystonic 
seizures preceding limbic encephalitis (327). Histopathologically, patients 
with antibodies specifi c for LGI1 or caspr2 show infl ammation and severe 
degeneration in the hippocampus. Diagnosis is confi rmed by clinical feature 
and presence of VGKC-antibodies in the serum and CSF. Importantly, antibody 
lowering treatments like plasma exchange and IVIG improve neurological 
defi cits in these patients, suggesting that antibodies directed against the VGKC 
complex are responsible for clinical symptoms (326). Treatment may be 
continued for 1-2 years. Relapse occurs in at least 5% of cases. 
Acute Disseminated Encephalomyelitis (ADEM) accounts for around 10% of 
all known cases of encephalitis. ADEM usually affects children 3- 10 years 
of age and begins after a childhood rash (exanthema), other viral infections 
or immunisations. The white matter of the brain is predominantly affected. 
The initial clinical features are less-specifi c, and include fever, headache, stiff 
neck, vomiting and anorexia. Later there is loss of consciousness, confusion, 
coma, visual deterioration, hemiparesis and seizures. It has a monophasic 
course from weeks to a month. MRI of the brain typically shows multiple 
areas of characteristic white matter abnormality. Antibodies and cellular 
immune responses against specifi c brain antigens has been reported on 
investigation. Although intravenous methyl prednisolone is treatment of choice, 
IVIG and plasma exchange is useful in resistant cases (328). Complete 
remission can occur in 75% of cases. 
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IVIG is also indicated for use in various neuropathies, myopathies and disease 
of neuromuscular junction. It is commonly used in chronic infl ammatory 
demyelinating polyneuropathy (CIDP), a chronic autoimmune neuropathy 
associated with demyelination of peripheral nerve and abnormal humoral 
and cellular immunity. The induction dose of IVIG is 2 g/kg, given over 2 
to 5 days. In Guillain–Barre syndrome (GBS), remission is reported in up to 
53% patients with IVIG (329). Multifocal motor neuropathy (MMN) with 
conduction blocks is a slowly progressive motor neuropathy which also 
respond to IVIG in 94% of patients, even though they may require higher 
dosage of IVIG. IVIG is also administered in IgM associated paraproteinemic 
neuropathies (330), idiopathic infl ammatory myopathies, dermatomyositis, 
polymyositis, refractory necrotizing myopathy, sporadic inclusion body 
myositis (331, 332), exacerbation of myasthenia gravis (MG) (333) and 
Lambert–Eaton myasthenic syndrome (LEMS) (334). IVIG is administered as 
fi rst line treatment for GBS, MMN and CIDP. It is a second line treatment for 
severe and worsening MG, dermatomyositis and LEMS (322). 
IVIG is a potential adjunctive treatment for JE in the future. However, 
further knowledge is required. The role of subcutaneous provision of IgG 
for maintenance therapy, once IV induction has been completed, should 
be explored in JE patients. The ever growing demand for IVIG, its limited 
supply and its expensive processing, all infl uence the cost of immunoglobulin 
treatment (335). Not all patients benefi t from immunomodulatory treatment, 
therefore surrogate markers, which could predict which patients respond best, 
needs to be developed. One surrogate marker may be to profi le expression 
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levels of Fcγ receptors. It has been found that impaired expression of inhibitory 
FcγRIIB on myeloid cells and B lymphocytes in patients with CIDP are up 
regulated following clinically effective IVIG therapy (336, 337). Making 
recombinant antibodies for IVIG could also address expense. A variety of 
critical pathways targeted by IVIG therapy have been explored for replacement 
by recombinant antibodies, such as reduction of auto-antibody half-lives by 
recombinant antibodies blocking neonatal Fc receptors, increased activation of 
Fcγ receptors by forming multimeric IgG Fc preparations that block immune 
complex binding to them and making IVIG preparations with enhanced levels 
of anti-infl ammatory sialic acid-rich IgG glycovariants. Further research is 
also required to improve understanding of most appropriate IVIG preparation 
and most suitable target diseases. Improvement in understanding of IVIG’s 
mechanism of action, especially among neurological illnesses, would help 
develop a more targeted IVIG action, like native IgG.
7.25 Newer treatments of JE and AES
Around 70,000 cases of JE occur every year throughout the world, despite 
effective vaccine. This indicates a pressing need for development of an 
effective antiviral drug. Minocycline decreased neuronal apoptosis, microgial 
activation, proinfl ammatory mediators and JEV viral titres in mice models 
of JEV. A randomised controlled trial of minocycline (initially 5 mg/kg/day 
followed by 2.5 mg/kg 12 hourly for ≤ 12 years and initially 200 mg followed 
by 100 mg 12 hourly in older patients) for seven days in AES patients 
(including JE patients) in India, was not able to demonstrate signifi cant benefi t 
on patient mortality at three months (338). However, when patients that were 
moribund or dying at admission were excluded from analysis, minocycline 
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treated patients showed a trend towards better outcome. Although the study 
was designed to study the effect of minocycline in JE patients, low numbers 
of JE cases were recruited, undermining the power of the study and making 
the impact in JE inconclusive (338). A variety of other drugs have also shown 
activity against JEV infection in animal models, and are potential drugs for 
human trial in future as shown in Appedix U (339).
The neuro-protective effect of cooling, known to be benefi cial in perinatal 
asphyxia, was explored in a study involving children with acute encephalitis 
(340). Delayed cooling, 12 hours after the acute insult was found to be 
deleterious. In contrast, early cooling appeared neuroprotective in children with 
acute encephalitis and encephalopathy. Plasma exchange had been reported 
to be effective in the treatment of severe relapses of acute infl ammatory CNS 
demyelinating diseases in past (341). When children of autoimmune-mediated 
CNS disorders, including encephalitis refractory to standard therapy, were 
treated with daily therapeutic plasma exchange for 5 sessions (at 80-110 ml/
kg of plasma using 4% albumin solution and fresh frozen plasma), effi cient 
removal of the infl ammatory particles were achieved and more than half of 
the children were observed to have a good outcome (342). A randomised trial 
of Ligustrazini hydrochlorioi (at 4 mg/kg infusion intravenously over 4 hours 
per day for 7 days), a traditional Chinese medicine extracted from Ligusticum 
Wallichii Franch plant, known to promote recovery of degenerated nerve cells, 
conducted in China, has also been reported to be safe and effective drug for 
the treatment of encephalitis (http://www.nepjol.info/index.php/JNPS/article/
view/3451). 
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7.26 Challenges of JE control strategies
There has been an increase in geographic spread and disease incidence for JE, 
in much of southeast and southern Asia. This spread is probably because of 
extensions in land irrigation, increases in paddy growing practices and lack of 
co-ordinated immunisation programmes (36). Therefore, JE control has been 
challenged in many areas. During JE surveillance, one of the most important 
practical steps, is to improve on number of patient CSF samples collected after 
10 days of illness and enhance provision of appropriate sample transport back 
to the laboratory. The average CSF sample collection rate in Nepal from 2013 
up-to 2015 is 57%. Therefore, to improve JE surveillance, the Nepal National 
Committee on Immunisation Practices (NCIP), regarding JE surveillance 
strategy, has recommended to continue JE surveillance despite fall in number 
of cases of JE amongst AES, collect serum or CSF samples 10 days after 
onset of symptoms to increase sensitivity of JE test, collect CSF for testing for 
recipient of JE vaccination, monitor evidence of waning immunity which may 
require booster dose of vaccine and 6 months follow up of AES and JE cases 
to determine actual disability. They have also recommended to expand the JE 
laboratory network to other areas of the country and strengthen capacity at the 
National Public Health Laboratory (NPHL) in Kathmandu to be able to conduct 
plaque reduction neutralising tests (PRNTs) for JEV. 
In 2011, in Nepal, the percentage of children who received JE vaccine was 
estimated between 8-73%. This estimate was low compared to target of 87% 
of all vaccine coverage. This low vaccine coverage may make it diffi cult 
to contain JE outbreaks in the future. Furthermore, if the live attenuated 
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vaccine is not provided to people, because of ongoing concerns around 
safety in immunocompromised people, HIV patients, and pregnant women, 
vaccine coverage could decrease further. Even if the percentage of vaccine 
coverage improved, JE control is challenged by the necessity to sustain 
a high rate of immunisation indefi nitely. Hence, there is a fear that even 
with current vaccination campaign resulting in 95% reduction of cases, 
hundreds of cases may still arise every year, and the disease burden remain 
high. A comprehensive information, education and communication package 
emphasizing the need for JE vaccine in routine immunisation would also 
help in maintaining high rates of immunisation status and promote JE control 
efforts. 
Diffi culty in maintaining JE control in Nepal has been indicated by reports 
on JE cases spreading to higher elevation in the Himalayas (128, 220) 
(Appendices A & B). This spread could be a result of climate change and rise 
of temperature, A warmer climate maybe more suitable for vector and viral 
replication, human habitation and population growth, growth in practice of rice 
cultivation and pig rearing. All these factors create a more suitable environment 
for JE transmission. Alternatively, the increase in JE cases it may simply be 
the result of improved case detection, secondary to expansion of effective 
disease surveillance, diagnostics and public awareness. The true reason is yet 
to be known. Phylogeographic studies of JEV and its vectors collected from 
highland and low land areas using Bayesian Evolutionary Analysis Sampling of 
Trees (BEAST) and comparing seroprevalence of reservoir and amplifi er hosts 
living in highland and lowland areas could provide information on whether the 
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emergence of JE in the highlands is recent or recently discovered, and improve 
insight on the extent of transmission (343). 
Between 2006 and 2015, there has been a decrease in AES and JE cases by 
36% and 53% respectively since the introduction of JE vaccine in 2006. 
However, there has only been 5% decrease in proportion of JE cases out total 
AES cases. Through laboratory based surveillance, from 2004 up-to 2015, 
clinical notes and serum and/or CSF samples have been collected from 17875 
patients. JE has been diagnosed in17% of those cases, based on samples 
tested for JE under the surveillance system. The identifi cation of the aetiology 
among the remaining 83% of AES cases will be important to reduce the 
burden of AES in Nepal. There has been reports on presence of Dengue virus 
(235, 344), Chikungunya virus (234), Chandipura virus (345), Nipah virus 
(346), Herpes Simplex virus (347), human parvovirus 4 (348), Enteroviruses 
(347), Infl uenzae virus (349), Measles virus (350), Mumps virus (351), 
Varicella Zoster virus (351), West Nile virus (238), HIV (352), rabies (353), 
Streptococcus pneumoniae (347), Neisseria meningitidis (347), Staphylococcus 
aureus (347), Haemophilus infl uenzae (354), Leptospira (233, 355), Orientia 
tsutsugamushi (233) in Nepal and neighbouring areas which are known to 
cause AES. Therefore, it is now time to move forward from JE surveillance 
to screen for the entire spectrum of pathogens associated with AES. One 
way forward, with limited resources, is to test initially for common known 
viruses and bacteria in AES patients. Improved insight into the specifi c viral 
aetiology and pathogen-specifi c clinical outcome of acute encephalitis in this 
region is essential to guide strategies for prevention and clinical management 
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so that evidence based public health actions can be planned and carried out. 
The integrated efforts of clinicians, veterinarians and entomologists would be 
valuable to achieve better JE control. 
7.27 Limitation of the study
The fi rst study (chapter 3) was a retrospective study. Information was limited 
to the knowledge and interest of the treating clinicians which may or may not 
have been of interest to the researcher- a pitfall of a retrospective study. Lack 
of important variables in this retrospective analysis could have lead to inability 
to validate predictors of JE amongst cases of AES in the prospective study. 
After the JE vaccination campaign with SA-14-14-2 vaccine from 2009 
in Nepal, there was a fall in the diagnosis of JE. Out of 143 patients with 
AES, only 4 patients were diagnosed with JE in the study. This prevented 
me from having a large enough sample size to assess the association of fl uid 
management with outcome in children with JE.
Because of the different practice of follow up among of the treating clinicians, 
geographical location, access to transport and distance from research site, 
patients of AES and JE were followed up at wide variety of intervals during 
intended follow up at one and two years after discharge. Therefore, the follow 
up for one year ranged from 15- 631 days and second year 570- 750 days in 
suspected viral aetiology of AES and 15- 390 days and 605- 701days in JE 
respectively. However, there was no signifi cant difference in the follow up 
duration between different WFA groups in both AES and JE. 
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There were many patients of AES and JE who were willing to participate in 
the study. Despite this, a high proportion of patients were lost to follow up. 
In AES of suspected viral aetiology, 57% of the patients attended an outcome 
assessment as follow up at one year and 48% at two years post hospital 
discharge. Among JE patients, 50% attended follow up at one year and 35% 
at two years. My prospective study had fewer patients attending outcome 
assessment at follow up compared to other follow up studies [81% in Malaysia 
(21) and 90% in Indonesia (74)]. Poor follow up of AES patients could have 
been because of work commitments of parents, diffi culty in access to transport 
or improvement in child's condition. This loss to follow-up may have biased 
my fi ndings.
Despite routine blood and CSF examination, including culture for bacteria, 
in all AES patients, no defi nite aetiology was found in the majority of 
participants. In previous studies, lack of aetiological diagnoses has been 
reported in a high proportion of suspected encephalitis patients (2, 6). 
Limitation of serological diagnosis could have led to false negative for JE if 
samples were collected too early, and false positives may have occurred due 
to recent JE vaccination and infection with dengue virus not tested under the 
surveillance network (356). In this study, the clinical, laboratory features and 
outcome of confi rmed JE negative AES and JE status unknown were similar, 
suggesting the unknown group were less likely to be undiagnosed JE. Even in 
those who were diagnosed JE, results of their testing were often only available 
after discharge from hospital because of limited resources. Given the relative 
scarcity of positive diagnostic results, it was important to approach and manage 
all the cases as AES, based on their clinical syndrome.
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In my study, I only used indirect markers of dehydration. Direct markers such 
as blood pH by arterial blood gas and serum osmolality would have been more 
accurate in distinguishing patients with metabolic acidosis from dehydration. 
Arterial blood gas measurements were initially attempted in the study. 
However, lack of consent and inconsistency in arterial blood gas results made 
me discard this parameter. 
Percentage change in weight is used as a measure to assess hydration status. 
Obvioulsy, any food, drinks and passage of stool or urine shortly before the 
measurement may alter weight, which may have introduced variability in the 
measurements. 
The duration of intravenous fl uid administration was not recorded in my study. 
Recording the total amount of fl uid administered when the child was ‘nil by 
mouth’ may have provided further information on the patient’s fl uid balance. 
There can be serological cross-reactivity between fl aviviruses causing false 
positive results. Cross-reactivity between West Nile (WN) and St Louis 
Encephalitis (SLE) viruses by MAC-ELISA was reported as one reasons why 
the outbreak of WN virus in New York in 1999 was initially thought to be 
caused by SLE virus. Later, comparative studies of SLE, WN, and JE viruses 
by PRNT and recovery of WN virus from human brain and bird tissue were 
completed confi rming WN as the cause of the outbreak (357). Currently, the 
most accurate serologic method for distinguishing closely related fl avivirus 
infections, is PRNT, performed on paired acute phase and convalescent phase 
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serum or CSF against a variety of related fl aviviruses (357). Even in the 
present study, there was a possibility of cross-reactivity between JEV and other 
fl aviviruses such as Dengue.
There are many laboratory techniques available to diagnose JE. In the present 
study, anti-JEV immunoglobulin-M (IgM) antibodies were measured locally 
using the AFRIMS JE MAC IgM ELISA kit as recommended by WHO. This 
has been proved to be a reliable method to diagnose JE (61, 65). In the IVIG 
treatment trial (chapter 6), confi rmatory testing was subsequently performed 
at the Arboviral Diseases Branch diagnostic laboratory at the CDC, USA. The 
last serum sample collected from each patient was tested by JEV and DENV 
IgM capture ELISA. Positive or equivocal results were confi rmed by JEV 
and DENV PRNT90, with a 4-fold or greater difference in titre interpreted to 
be virus specifi c. If the fi nal sample was positive or equivocal for JEV and/or 
DENV IgM all samples for that case were tested. The CSF from that patient 
was also tested by JEV and DENV IgM ELISA. In addition, CSF was also 
tested for the presence of JEV RNA by RT-PCR assays where appropriate. 
JEV PRNT50 was done on all patient serum at the 2 time points. As a result, 
one patient with an undetermined status after local testing by MAC ELISA in 
Nepal was found to be JEV negative at CDC; otherwise there was complete 
concordance between the test results in Nepal and those at CDC. Therefore, 
although the possibility of cross-reactivity of other fl avivirus cannot be 
completely excluded in those JEV positives, there are many reasons to believe 
that the JE results were correct, as shown by the results of the confi rmatory 
testing of the IVIG treatment trial. 
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7.28 Clinical implications of the research
Identifying and validating the clinical features which could predict bad 
outcome at the time of admission in AES and JE patients, would not only help 
in explaining the prognosis to the patient and parents, but also help improve 
patient management in the future. 
This study has highlighted the need of a single standard growth chart for 
Nepali children of all age groups, in order for local health care staff to identify 
children with abnormal weight. Since low WFA at admission in children with 
AES and JE is associated with bad outcome at discharge and persistence of 
sequelae at 2 years follow up, the practice of measuring weight and classifying 
into different WFA group of all AES patients at initial contact could be useful, 
particularly if early referral of those of low WFA for supportive management 
with fl uids was shown to reduce immediate and long term morbidity and 
mortality of these children in the future. 
Maintaining good hydration status with adequate and appropriate IVF may 
potentially be a simple, cheap, easily available treatment option which could 
save lives even in resource poor settings, like Nepal. Therefore, as in the UK, 
hospital oral and intravenous fl uids guidelines need to be written for children 
with impaired consciousness. This could be based on existing Advanced 
Paediatric Life Support (APLS) guidelines, with local training being conducted 
on an annual basis. 
There is a need to develop hospital protocols for hospital management 
and follow-up of AES patients. Knowledge about uncertainty of defi nite 
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outcome at the time of discharge and recovery profi le of AES patients could 
help clinicians counsel the parents for further care at home; also help in 
identifying an end point in assessment of outcome in treatment trials. Access 
to a multidisciplinary team of specialists, besides the general paediatrician, 
such as neurologist, physiotherapist, speech therapist, psychologist, dietician 
and occupational therapist is required during follow up since many sequelae, 
including behavioural problems and uncontrolled seizures were seen to persist 
up-to two years after discharge. IVIG can be safely given to children with 
suspected JE. IVIG appears an appealing potential option for future treatment 
of JE that warrants further investigation. 
7.29 Implications for future research 
Early hospital admission and supportive management improved outcome of 
AES and JE patients. Since most of the patient were brought to the hospital 
by self referral, educating the family members to attend hospitals promptly 
for supportive management could be life saving. Therefore, there is a need 
for further research on "health seeking behaviour of the families with sick 
children" to develop resources for appropriate education. Also more systematic 
investigation on the role of supportive measures on outcome is needed. 
The recovery profi le of AES patients changed over time post discharge. 
Seizures can be treated. Exploration of the prevalence of unprovoked seizure 
in the community following acute AES and its association with eventual 
outcome needs further study. There is also need to fi nd out the proportion of 
autoimmune encephalitis cases within AES children in Nepal. 
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A large number of children with LWFA suffered AES and JE and who also 
had bad outcome. This raises the question, is LWFA a contributory factor in 
developing encephalitis following infection with JEV or other viruses? Is 
greater prevalence of dehydration or undernutrition in children in Asia the 
reason for the large number of cases of JE and AES?
AES patients who died were more likely to suffer weight loss during hospital 
admission. Similarly, AES patients who suffered bad outcome were more 
likely to have LWFA on admission or experience weight loss during admission. 
When there is no defi nite treatment for most AES patients, maintaining good 
hydration status with adequate and appropriate IVF may potentially be a simple 
treatment option. Therefore, a randomised control trial of different volumes and 
types of fl uid is needed to confi rm that increased or maintenance fl uid intake 
could improve outcome.
Since seizure was more common in dehydrated children, the role of 
interventions such as training of health workers on accurate diagnosis and 
effective management of seizures through ongoing International Paediatric 
Epilepsy Training (IPET) and Advanced Paediatric Life Support (APLS) 
trainings in Nepal, and the role of health education materials such as a video 
documentary on epilepsy for patients and parents in improving outcome needs 
to be studied.
In order to fi nd out the cause of changing epidemiology of JE in highlands 
of Nepal, there is a need to fi nd out if this emergence is recent or recently 
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discovered. There is also a need to improve insight on the mode and extent of 
transmission in these areas. 
IVIG was safe, and appeared to augment the development of neutralising 
antibodies. The anti-infl ammatory properties of IVIG may have implications 
for the wider use of IVIG as a treatment for encephalitis which needs further 
research. More research on immunological changes in JE and the effects of 
IVIG will be important for the further development of IVIG treatment (45). 
A double blind randomised placebo controlled trial including large number 
patients would be required to fi nd out if clinical outcome improves among JE 
patients treated with IVIG. Newer immunogenic JEV proteins have also been 
identifi ed and effect of monoclonal antibodies against them as the treatment of 
JE could be potential research area in the future (358).
Since many participants were of confi rmed non-JE viral encephalitis, improved 
detection of pathogens suspected to cause AES would help to plan rationalised 
management and treatment strategies. If any vaccine preventable aetiology is 
identifi ed, it will help plan future National immusization strategies, particularly, 
what other routine vaccines need to be introduced to reduce prevalence of AES 
in Nepal. 
7.30 Final concluding remarks
AES is a devastating illness, that affects children and adults in many countries, 
including Nepal. AES is associated with substantial mortality and neurological 
sequelae in survivors. The range of pathogens causing AES is not well 
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described. Although many neurotropic viruses are reported, JEV remains the 
leading identifi ed cause in most of Asia, including Nepal. Since there is no 
specifi c treatment for most AES cases, identifying and correcting prognostic 
features of bad outcome, being aware of the value of supportive management in 
improving outcome, and identifying novel effective treatments for treating JE, 
are important future strategies to improve outcome among AES patients. 
Patients with AES, particularly JE, were often identifi ed to suffer weight loss 
or be of low weight for age (LWFA) and appeared dehydrated at the time of 
admission. AES cases who died signifi cantly more frequently experienced 
weight loss during hospital admission. Similarly, AES cases who suffered 
bad outcome, more frequently exhibited weight loss or were LWFA at 
admission. Dehydration can be assessed by identifying symptoms and signs 
of dehydration and measuring anthropometric indices, even in resource 
poor settings. Dehydration can be corrected relatively easily through careful 
fl uid supplementation. Training health care workers to identify dehydration 
and developing a safe rehydration strategy for AES cases could save lives. 
Encouraging AES patients to attend hospitals more quickly, to enable them 
to receive supportive management, including adequate and appropriate fl uids 
could also improve outcome. 
Seizures were common in LWFA children. Seizures were again associated 
with bad outcome. Training of health workers on the diagnosis and effective 
management of seizures could help reduce adverse outcomes among AES 
patients. Health education on managing seizures could be provided through 
short documentaries.. The documentaries could advise carers on what to do and 
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what not to do during an acute seizure at home. The documentaries could be 
broadcast via Nepali national television channels, to maximise coverage across 
the country. Public engagement and further public education strategies takling 
AES in Nepal are required. 
My pilot study shows IVIG to be safe to be prescribed in AES children. IVIG 
augmented the development of neutralising antibodies in JE patients making 
it an appealing treatment option. My study supports IVIG being taken forward 
as a phase III trial in JE. IVIG’s anti-infl ammatory properties could also be 
useful for treatment of other encephalitis. Therefore, in the future IVIG could 
reduce JE related morbidity and mortality and potentially also improve overall 
outcome of AES in Nepal.
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Appendix B
Table showing distribution JE cases from 2004- 2015 by districts under the 
National AES surveillance programme.
• DISTRICT 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
• ACHHAM 1           1
• ARGHAKHANCHI 2 2 2 2 1 3 2    3 1
• BAGLUNG    2 2       1
• BAITADI        1     
• BAJHANG  1           
• BANKE 44 94 10 10 4 2 5 7 3 7 6 2
• BARA 11 17 10 14 11 7 8 2  2 3 5
• BARDIYA 37 105 6 11 2 2 2 2 5 9 6 3
• BHAKTAPUR 3 4 4 9 8 3 1 1 2 1 9  
• BHOJPUR     1 1      2
• CHITWAN  3 3 11 7 9 4 4 1 5 5 4
• DAILEKH 1      2    1 1
• DANG 88 89 9 10 8 2 19 4 2 4 9 3
• DHADING   2 7 3 2 1      
• DHANKUTA   1 3 1 1 3 2  1 4 1
• DHANUSHA 6 8 7 15 6 4 3 8  2 7 7
• DOLKHA  1  1 1      4  
• DOTI    1         
• GORKHA   2 5 7   1 1 1 4  
• GULMI 1  2  3 1 2 1   1  
• ILAM  2 1   2 2 2   1 2
• JAJARKOT          1   
• JHAPA 8 11 11 20 14 5 11 4 3 2 14 4
• KAILALI 47 39 7 33 31 19 4 10 8 18 7 24
• KALIKOT  1           
• KANCHANPUR 13 10 28 20 12 2 4 5 1 14 6 10
• KAPILVASTU 13 32 16 6 3 2 3 2 1 4 1 1
• KASKI   1 15 9   1  1   
• KATHMANDU 9 25 26 44 59 22 23 9 13 5 18 5
• KAVRE  6 4 4 4  1 4 1 4 4 2
• KHOTANG     1    1   1
• LALITPUR 3 7 10 14 3 6 3 2 7 4 5 2
• LAMJUNG  1  1 1  1      
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• MAHOTTARI 9 3 2 7 1 3 3 5 1  3 4
• MAKWANPUR  3 4 3 3 4 3 1 1  2  
• MORANG 5 9 29 43 17 7 16 6 5 8 15 8
• MUGU            1
• MYAGDI     1        
• NAWALPARASI 8 16 15 13 9 5 3 9 5 9 7 6
• NUWAKOT   3 4 3      1  
• OKHALDHUNGA         1   1
• PALPA 2 3 3 2 7 4 2 3 1 1 2  
• PANCHTHAR    1 1  1      
• PARBAT    3 4        
• PARSA 3 8 11 9 14 8 3 4 4 8 10 2
• PYUTHAN 3 2 1     1  1 1  
• RAMECHHAP   1 1       4 1
• RAUTAHAT 6 12 12 4 10  3 6 1  6 1
• ROLPA       3    3  
• RUKUM  1         1 2
• RUPANDEHI 16 19 3 5 5 1 3 2  3 5 3
• SALYAN 1 1  4       2 3
• SANKHUWASABHA     1 1 2      
• SAPTARI  2 5 12 3 2 4 1   5 3
• SARLAHI 6 7 5 7 11  5 1  2 6 3
• SINDHULI 3 3 2 5 9  3  2  2 3
• SINDHUPALCHOWK   2 2 6  1   2 3  
• SIRAHA 1 4 5 14 7 2     1 3
• SOLUKHUMBU    1  1       
• SUNSARI 6 18 19 21 4 7 13 9 4 4 7 5
• SURKHET 10 11 2 5 9 1 21 1  1 6 3
• SYANGJA 1 1 1 4 3 1 1 3 2 1 3 1
• TANAHU  1 2 3 4 4 1  3 2 5  
• TERHATHUM   1        3  
• UDAYAPUR 1 2 3 11 5  2 4   5 3
(WHO-IPD, Nepal)
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Appendix C 
Table showing JE epidemiology in Nepal from 1978- 2012 
Year Number of suspected cases Deaths CFR (%)
Syndromic surveillance
1978 422 119 28.2
1979 182 49 26.9
1980 622 231 37.1
1981 54 16 29.6
1982 843 390 46.3
1983 242 36 14.9
1984 142 45 31.7
1985 629 183 29.1
1986 1615 415 25.7
1987 502 140 27.9
1988 1403 380 27.1
1989 868 227 26.2
1990 365 102 27.9
1991 650 114 22.3
1992 702 127 18.1
1993 446 108 24.2
1994 1836 383 20.9
1995 1246 255 20.4
1996 1450 260 17.9
1997 2953 407 13.8
1998 1161 149 12.3
1999 2924 434 14.8
2000 1729 169 9.8
2001 1888 275 10.0
2002 842 168 20.0
2003 330 69 20.9
Laboratory based surveillance
2004 1533 370 26
2005 2290 669 53
2006 1471 295 42
2007 1650 442 61
2008 1988 339 39
2009 1515 147 9
2010 1572 197 1
2011 1337 129 0
2012 952 75 0
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Appendix D 
Figure showing National JE Surveillance Program of Nepal 
 
 
 
 
Patient attending  health institutions in different parts of the country
Physician defi nes the patient as a case of AES following standard 
case defi nition and recruits 
CSF collected following lumber 
puncture
Blood collected by vein 
puncture and serum separated
Cell count and biochemical 
analysis done locally
CSF delivered in a labeled screw capped 
vial and stored at 2-8°C
SMO of WHO-IPD Informed by 
attending physician
Serum/CSF sent to 
NPHL directly
(Department of Health, Ministry of Health, Nepal)
Serum delivered in a labeled screw 
capped vial and stored at 2-8°C
Sample transported to SMO offi ce in an ice box and a case identity 
given to each sample
At SMO offi ce, sample stored at 2-8°C  and delivered 
to NPHL/BPKIHS
Samples transported to NPHL/BPKIHS in an ice box 
along with corresponding forms
Samples tested for anti-JEV IgM by MAC-ELISA
At NPHL/BPKIHS, samples received, checked and stored at  -20°C 
Results stored in computer and also reported to WHO-IPD and 
NPHL (even from BPKIHS)
 NPHL gives  lab identity 
number to each sample
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Appendix E
Table showing assessment of dehydration 
Variable Mild, 3-5% Moderate, 6- 9% Severe, ≥ 10%
Blood pressure Normal Normal Normal to reduced
Quality of pulses Normal Normal or slightly decreased Moderately decreased
Heart rate Normal Increased Increased
Skin turgor Normal Decreased Decreased
Fontanelle Normal Sunken Sunken
Mucous membrane Slightly dry Dry Dry
Eyes Normal Sunken orbits Deeply sunken orbits
Extremities Warm, normal capillary refi ll Delayed capillary refi ll Cool, mottled
Mental status Normal Normal to listless Normal to lethargic or comatose
Urine output Slightly decreased < 1 ml/Kg/h << 1 ml/Kg/h
Thirst Slightly decreased Moderately increased Very thirsty or too lethargic to indicate
(Duggan et al, 1992)
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Appendix F
Proforma of Retrospective study
Clinical, laboratory and prognostic features among children with Acute 
Encephalitis Syndrome in Nepal; a retrospective study
History (WHO CASE ID:   VENEPCDR________) Study No: _________
Initials / Name ______________________  Hosp IP No. _______ Age___ Sex M  F /  F F   D.O.B.__________ 
Address of home:  ____________________________________________________
Corresponding Address ____________________________________________________
Date Admitted to Hospital___________Date Admitted to Study_________ Time_______ Date of discharge_________ Outcome________
Referred from:  District Hospital  F / General Practioner F /  Primary health centre F / home  F / other:______
Does the child meet WHO AES case definition?
Acute Febrile Illness
PLUS Change in mental status
 (including symptoms such as confusion, disorientation, coma, or inability to talk) 
AND/OR 
New onset of seizures  
  (excluding simple febrile seizures*) 
 Enter AES Documentation study
Collect samples
Acute CSF
Acute Serum
Convalescent serum (later)
_______________________________________________________________________________________________
SUMMARY INFORMATION (Complete after patient discharge)
Adm GCS  E= ___   M= ____ V=____      Discharge GCS E = ____  M =____ V = _____
Discharged Day __  Date ______   Discharge Outcome score  I (died) /  II (Severe)  / III (Mod )  / IV  (Mild)  / V (No) Sequelae
JE status   Acute CSF   Pos / Neg      Acute Serum Pos / Neg     Conv Serum  Pos  / Neg  
N  F / Y F Date_____________________
N  F / Y F Date _____________________
N  F / Y F Details ___________________
N  F / Y F Details ___________________
N  F / Y F Details ___________________
N  F / Y F Date _____________________
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History Study No: _________
 Initials/  Name ____________ Age__________  Sex M F /  F F        D.O.B.__________
Date Admitted to Hospital____________Date Admitted to Study__________  Time_______
Date admitted to any hospital:_____________ Where?___________________
Referred from:  District Hospital F / General Practioner F /  Primary health centre F / home F / other:______
Handedness: Right F  / Left F Ethnicity: ___________________________________
Attends school        Y F / N F / too young for school F Does family rear pigs? Y F / N F 
Normal Milestones   Y F / N F Describe__________________________
Do parents think child is normal self today? Y F / N F Details_____________________________________
Date of onset of illness  ____________  Today is day_________ of illness.
Fever Feeding      
If fever Drowsy    U F / N F / Y F ______day to _____day
Rigors/Chills: Irritable
Headache: Confused:
Neck pain Unconscious:
Photophobia Convulsions
Sore throat Spasms
Cough
Runny nose
Vomiting:
Diarrhoea
Illness biphasic
Rash / Conjuctivitis / Abdo distension / GI Bleed / Jaundice / Others U F  / N  F / Y F decribe, including days: _________________
__________________________________________________________________________________________________________
Confused,  N F / Y F describe, giving example(s)____________________________________________________
Describe convulsions: number of attacks, when occurred, duration, partial, generalised, Status? incontinence? Frothing? 
Post-ictal phenomenon, Todd's paresis?woke up after? _______________________________________________________
_________________________________________________________________________________________________
Simple febrile convulsions only? N F / Y F (details) ____________________________
Facial or Limb paralysis:  N F / Y F (where and when, day to max weakness) ____________________________
Preceeding illness in the last 2 months?  None F / Yes F (give details)_____________________________
Recent Vaccines No F /Yes F          
Details _________________________________________________________________________________________
Other history (including other symptoms and past Hx of convulsions,  unusual features, family Hx): 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
Treatment given before admission to study: N F / Y F / unknown medication F
(if yes tick and give details: what, dose, when, where from): 
Aspirin F / Paracetamol F / Over the counter medicine F / Traditional Medicine F / Unknown antibiotic F 
Chloramphenicol F / Penecillin F / Ceftrioxone F / Midazolam F / Diazepam F / Phenobarb F / Phenytoin F / Haloperidol F  
Saline F / Dextrose F   Mannitol F / Steroids F details:____________
Other drugs: No F  / Yes F (details) _________________________________________
U F  / N F / Y F ______day to _____day
JE Vaccine No F/ Yes F/ Not Sure F    Date____________ Any reaction to JE vaccine No F /Yes F        
U F  / N F / Y F decribe: ___________
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
High grade F / low grade F
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F / N F / Y F ______day to _____day
N F  / Y F describe below
N F  / Y F ______describe below
 Normal  F / reduced F / not at all F
U F / N F / Y F ______day to _____day
U F / N F / Y F ______day to _____day
Clinical, laboratory and prognostic features among children with Acute 
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General Examination Study No.________ 
 Initials / Name________________________________  Date:_________    Time:__________
Temp ________degrees F Resp. rate ______ / min
Pulse_______ / min  Height/ length____________cm (if available)
BP:__________mmHg Weight __________kg
Neck stiffness N F  / Y F Saliva dribbling: N F  / Y F
Kernig's positive N F  / Y F Jaundice: N F  / Y F
Vacant stare N F  / Y F Malnutrition (calculate lateN F  / Y F
N F  / Y F Cough: N F  / Y F
Bulging fontanelle: N F  / Y F Coryza: N F  / Y F
Full bladder: N F  / Y F Lymphadenopathy N F / Y F (details) ____________
Rash N F / Y F:   Macular F / papular F /vesicular F /other F: where____________
Enanthemas (mucous membrane eruptions) N F  / Y F  (describe type and location)____________
Oedema N F / Y F (Where?)_______________________________________________
Any haemorrhagic manifestations: N F  / Y F (describe)____________________________________
Heart Sounds: Normal ? / Abnormal ?(specify)___________________
Breath sounds: Normal ? / Abnormal ?(specify)___________________
Pattern:  Regular F /  Hypervent F /  Cheyne Stokes F /  Pauses F /  Irregular F  /  Gasping F
ENT: normal / abnormal (describe) ___________________________
Hepatomegaly: No F / Yes F  ____ cm in mid clav line   Texture: _______  Tender  No F  / Yes F
Ascites: N F  / Y F Tense:N F / Y F        Splenomegaly: _N F / Y F
Abdominal other: N F  / Y F
Nasogastric tube: N F  / Y F Reason for NG tube:   aspiration F / feeding F
NG aspirate N F / Y F (coffee grnd aspirate? N F / Y F fresh bld ?  N F / YF)
Urinary Catheter: N F  / Y F For: retention F / incontin F / monitoring output F
If catheterised current hourly urine output  _______  mls / hr
Endotracheal intubation: N F  / Y F Froth from E/T tube? None F  / White F / Pink F
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    Admission Neurological Examination Study  No:__________
Initials / Name Date: Time:________________________________ _________ __________
Cranial nerves
Pupil Size Right:   pinpoint F / normal F / dilated F
Left:   pinpoint F / normal F / dilated F
Pupil response Normal F / Abnormal F (describe) _____________________________________
F F FFundi Right: Normal  /  Not done  / Abnormal    (describe)____________________
Left: Normal F /  Not done F / Abnormal  F  (describe)_____________________
Spont Eye movements Normal F / Abnormal F (describe) _____________________________________
Doll's Eye reflex Normal F / Abnormal F (describe) _____________________________________
Response to menace Normal F / Abnormal F (describe) ___________________________________
VIIth N l F / Ab l F (d ib ) nerve orma   norma  escr e  ___________________________________
Swallowing Normal F / Abnormal F IF ABNORMAL or PATIENT UNCONCIOUS:
Gag: Normal F / Abnormal F / Absent F
Stridor No F  / Yes F
Speech Normal F / Abnormal F (describe) ___________________________________
Abnormal movements No F  / Yes F
Tremor F / Lip smacking or chewing F / Teeth grinding F / Agitated F / twitching F  / Choreoathetosis F / 
Hiccoughs F / Rigidity spasms F   (Details) ________________________________________________________
Posture
Head position: Normal  F / turned to left F / turned to right F
Extensor / Flexor posturing : No F / Yes F
Mental State Normal F / Abnormal F (describe) ___________________________________
Other Comments __________________________________________________________________
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Admission Neurological Examination Study  No:________
Peripheral nervous system
Abl t Sit Independently F / With help F / Not at all Fe o :    
Able to Stand: Independently F  / With help F  / Not at all F
Any fasciculation: N F / Y F details: __________________________________________
Neck tone: Normal F / Increased F  / Neck rigid F
Flaccid limbs (LMN signs): No F / Yes F  Details:________________________________________
Head lag (when pulled to sit):  No head lag F / head lag F
Limb Tone/Posture      [Normal (N) /Flexion (F) /  Extension (E) / Gen Increased (I)/  Decreased (D) / Cogwheel (C)
Right Arm: ___                 Left Arm: ___
Right Leg ___                  Left Leg ___
Equine feet (toes pointing downwards):      Right: No F  / Yes F               Left: No F / Yes F
Clonus:           Right Ankle: No F / Yes F      Left Ankle: No F / Yes F
Tendon Reflexes, Draw:
Code:
 - absent
 + reduced
 ++ normal
 +++ increased
Symetrical/Asymetrical Sym F /Asy F
Plantar reflexes:
Right: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Left: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Abdominal reflexes Any present F  / none present F 
Tone Overall: Normal F  / Generally Flaccid F / Generally Spastic F / Mixed F / Neither F
Power                 (Grade 1-5,  1= no movement, 2= not against gravity, 3 = against gravity, 4= reduced, 5= full)
Right Arm      ______  Left Arm ___________
Right Leg________     Left Leg ___________
Hands fall on face Right Hand    N F  / Y F          Left hand    N F / Y F
Knees flop out Right Knee    N F  / Y F          Left Knee    N F / Y F
Paresis: Hemiparesis F / Paraparesis F / Quadraparesis F / Monoparesis F / 
None F / Unknown F / Moving all 4 limbs F
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Results Study No:
 Initials / Name_______________  Time:__________ Date:_________    Time:__________
DATE
Random blood sugar: _________
Polym    %   Lymphs  % Eosin   %    Mono   %
neg/pos
(Dengue if done)
neg/pos
CSF
Results Date
Opening
Pressure/c
m water
WCC % Polys % Lymps Protein CSFGlucose
RBS
Glucose
CSF / 
Plasma
Glucose
Other
info
1st
2nd
3rd
CSF Gram stain _________ Hib Latex ___________  CSF Culture ________________________________________ 
LFT: TB ________    Direct Bilirubin ________ SGOT ________ SGPT ___________ Alp Phos _________ PT ________
Renal:  Urea_________ Creat __________ Na _________  K _________ 
Others
Radiology
CXR (if done) Date ________  Result ____________________________
CT head (if done) Date ________  Result ____________________________
MRI head (if done) Date ________  Result ____________________________
Others
JE serology CSF 1 Date _______ neg / pos Date _______ neg / pos CSF 2 (if taken) Date _______ neg / pos
Serum 1 Date _______ neg / pos Date _______ neg / pos Serum 2 Date _______ neg / pos
OTHER (please fill below):
Malaria screen
(Widal if done)
Blood cultures
Specify (PS report/Ag):
Hb
Specify:
Total Count
Diff Count
Plats
RBS (gluc)
ESR
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Proforma of WFA study
Weighing a child may help predict outcome in Acute Encephalitic 
Syndrome
History (WHO CASE ID:   VENEPCDR________) Study No: _________
Initials / Name ______________________  Hosp IP No. _______ Age___ Sex M F /  F F   D.O.B.__________
Address of home:  ____________________________________________________
Corresponding Address ____________________________________________________
Date Admitted to Hospital___________Date Admitted to Study_________ Time_______ Date of discharge_________ Outcome________
Referred from:  District Hospital F / General Practioner F /  Primary health centre F / home F / other:______
Does the child meet WHO AES case definition?
Acute Febrile Illness
PLUS Change in mental status
 (including symptoms such as confusion, disorientation, coma, or inability to talk) 
AND/OR
New onset of seizures 
  (excluding simple febrile seizures*) 
Collect samples
Acute CSF
Acute Serum
Convalescent serum (later)
_______________________________________________________________________________________________
SUMMARY INFORMATION (Complete after patient discharge)
Adm GCS  E= ___   M= ____ V=____      Discharge GCS E = ____  M =____ V = _____
Discharged Day __  Date ______ Discharge Outcome score  I (died) /  II (Severe)  / III (Mod )  / IV  (Mild)  / V (No) Sequelae
3-6 mo FU  Day __  Date ______ FU Outcome score  I (died) /  II (Severe)  / III (Mod )  / IV  (Mild)  / V (No) Sequelae
Others FU
JE status   Acute CSF   Pos / Neg      Acute Serum Pos / Neg     Conv Serum  Pos  / Neg
N F / Y F Date_____________________
N F / Y F Date _____________________
N F / Y F Details ___________________
N F / Y F Details ___________________
N F / Y F Details ___________________
N F / Y F Date _____________________
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Weighing a child may help predict outcome in Acute Encephalitic 
Syndrome
History Study No: _________
 Initials/  Name ____________ Age__________  Sex M F /  F F        D.O.B.__________
Date Admitted to Hospital____________Date Admitted to Study__________  Time_______
Date admitted to any hospital:_____________ Where?___________________
Referred from:  District Hospital F / General Practioner F /  Primary health centre F / home F / other:______
Handedness: Right F  / Left F Ethnicity: ___________________________________
Attends school        Y F / N F / too young for school F Does family rear pigs? Y F / N F 
Normal Milestones   Y F / N F Describe__________________________
Do parents think child is normal self today? Y F / N F Details_____________________________________
Date of onset of illness  ____________  Today is day_________ of illness.
Fever Feeding      
If fever Drowsy    U F / N F / Y F ______day to _____day
Rigors/Chills: Irritable
Headache: Confused:
Neck pain Unconscious:
Photophobia Convulsions
Sore throat Spasms
Cough
Runny nose
Vomiting:
Diarrhoea
Illness biphasic
Rash / Conjuctivitis / Abdo distension / GI Bleed / Jaundice / Others U F  / N  F / Y F decribe, including days: _________________
__________________________________________________________________________________________________________
Confused,  N F / Y F describe, giving example(s)____________________________________________________
Describe convulsions: number of attacks, when occurred, duration, partial, generalised, Status? incontinence? Frothing? 
Post-ictal phenomenon, Todd's paresis?woke up after? _______________________________________________________
_________________________________________________________________________________________________
Simple febrile convulsions only? N F / Y F (details) ____________________________
Facial or Limb paralysis:  N F / Y F (where and when, day to max weakness) ____________________________
Preceeding illness in the last 2 months?  None F / Yes F (give details)_____________________________
Recent Vaccines No F /Yes F          
Details _________________________________________________________________________________________
Other history (including other symptoms and past Hx of convulsions,  unusual features, family Hx): 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
Treatment given before admission to study: N F / Y F / unknown medication F
(if yes tick and give details: what, dose, when, where from): 
Aspirin F / Paracetamol F / Over the counter medicine F / Traditional Medicine F / Unknown antibiotic F 
Chloramphenicol F / Penecillin F / Ceftrioxone F / Midazolam F / Diazepam F / Phenobarb F / Phenytoin F / Haloperidol F  
Saline F / Dextrose F   Mannitol F / Steroids F details:____________
Other drugs: No F  / Yes F (details) _________________________________________
U F / N F / Y F ______day to _____day
N F  / Y F describe below
N F  / Y F ______describe below
 Normal  F / reduced F / not at all F
U F / N F / Y F ______day to _____day
U F / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
High grade F / low grade F
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
JE Vaccine No F/ Yes F/ Not Sure F    Date____________ Any reaction to JE vaccine No F /Yes F        
U F  / N F / Y F decribe: ___________
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
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Weighing a child may help predict outcome in Acute Encephalitic 
Syndrome
General Examination Study No.________ 
 Initials / Name________________________________  Date:_________    Time:__________
Temp ________degrees F Resp. rate ______ / min
Pulse_______ / min  Height/ length____________cm (if available)
BP:__________mmHg Weight __________kg
Neck stiffness N F  / Y F Saliva dribbling: N F  / Y F
Kernig's positive N F  / Y F Jaundice: N F  / Y F
Vacant stare N F  / Y F Malnutrition (calculate lateN F  / Y F
N F  / Y F Cough: N F  / Y F
Bulging fontanelle: N F  / Y F Coryza: N F  / Y F
Full bladder: N F  / Y F Lymphadenopathy N F / Y F (details) ____________
Rash N F / Y F:   Macular F / papular F /vesicular F /other F: where____________
Enanthemas (mucous membrane eruptions) N F  / Y F  (describe type and location)____________
Oedema N F / Y F (Where?)_______________________________________________
Any haemorrhagic manifestations: N F  / Y F (describe)____________________________________
Heart Sounds: Normal ? / Abnormal ?(specify)___________________
Breath sounds: Normal ? / Abnormal ?(specify)___________________
Pattern:  Regular F /  Hypervent F /  Cheyne Stokes F /  Pauses F /  Irregular F  /  Gasping F
ENT: normal / abnormal (describe) ___________________________
Hepatomegaly: No F / Yes F  ____ cm in mid clav line   Texture: _______  Tender  No F  / Yes F
Ascites: N F  / Y F Tense:N F / Y F        Splenomegaly: _N F / Y F
Abdominal other: N F  / Y F
Nasogastric tube: N F  / Y F Reason for NG tube:   aspiration F / feeding F
NG aspirate N F / Y F (coffee grnd aspirate? N F / Y F fresh bld ?  N F / YF)
Urinary Catheter: N F  / Y F For: retention F / incontin F / monitoring output F
If catheterised current hourly urine output  _______  mls / hr
Endotracheal intubation: N F  / Y F Froth from E/T tube? None F  / White F / Pink F
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Weighing a child may help predict outcome in Acute Encephalitic 
Syndrome
    Admission Neurological Examination Study  No:__________
Initials / Name Date: Time:________________________________ _________ __________
Cranial nerves
Pupil Size Right:   pinpoint F / normal F / dilated F
Left:   pinpoint F / normal F / dilated F
Pupil response Normal F / Abnormal F (describe) _____________________________________
F F FFundi Right: Normal  /  Not done  / Abnormal    (describe)____________________
Left: Normal F /  Not done F / Abnormal  F  (describe)_____________________
Spont Eye movements Normal F / Abnormal F (describe) _____________________________________
Doll's Eye reflex Normal F / Abnormal F (describe) _____________________________________
Response to menace Normal F / Abnormal F (describe) ___________________________________
VIIth N l F / Ab l F (d ib ) nerve orma   norma  escr e  ___________________________________
Swallowing Normal F / Abnormal F IF ABNORMAL or PATIENT UNCONCIOUS:
Gag: Normal F / Abnormal F / Absent F
Stridor No F  / Yes F
Speech Normal F / Abnormal F (describe) ___________________________________
Abnormal movements No F  / Yes F
Tremor F / Lip smacking or chewing F / Teeth grinding F / Agitated F / twitching F  / Choreoathetosis F / 
Hiccoughs F / Rigidity spasms F   (Details) ________________________________________________________
Posture
Head position: Normal  F / turned to left F / turned to right F
Extensor / Flexor posturing : No F / Yes F
Mental State Normal F / Abnormal F (describe) ___________________________________
Other Comments __________________________________________________________________
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Syndrome
Admission Neurological Examination Study  No:________
Peripheral nervous system
Abl t Sit Independently F / With help F / Not at all Fe o :    
Able to Stand: Independently F  / With help F  / Not at all F
Any fasciculation: N F / Y F details: __________________________________________
Neck tone: Normal F / Increased F  / Neck rigid F
Flaccid limbs (LMN signs): No F / Yes F  Details:________________________________________
Head lag (when pulled to sit):  No head lag F / head lag F
Limb Tone/Posture      [Normal (N) /Flexion (F) /  Extension (E) / Gen Increased (I)/  Decreased (D) / Cogwheel (C)
Right Arm: ___                 Left Arm: ___
Right Leg ___                  Left Leg ___
Equine feet (toes pointing downwards):      Right: No F  / Yes F               Left: No F / Yes F
Clonus:           Right Ankle: No F / Yes F      Left Ankle: No F / Yes F
Tendon Reflexes, Draw:
Code:
 - absent
 + reduced
 ++ normal
 +++ increased
Symetrical/Asymetrical Sym F /Asy F
Plantar reflexes:
Right: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Left: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Abdominal reflexes Any present F  / none present F 
Tone Overall: Normal F  / Generally Flaccid F / Generally Spastic F / Mixed F / Neither F
Power                 (Grade 1-5,  1= no movement, 2= not against gravity, 3 = against gravity, 4= reduced, 5= full)
Right Arm      ______  Left Arm ___________
Right Leg________     Left Leg ___________
Hands fall on face Right Hand    N F  / Y F          Left hand    N F / Y F
Knees flop out Right Knee    N F  / Y F          Left Knee    N F / Y F
Paresis: Hemiparesis F / Paraparesis F / Quadraparesis F / Monoparesis F / 
None F / Unknown F / Moving all 4 limbs F
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Syndrome
Results Study No:
 Initials / Name_______________  Time:__________ Date:_________    Time:__________
DATE
Random blood sugar: _________
Polym   % Lymphs  % Eosin   % Mono   %
neg/pos
(Dengue if done)
neg/pos
CSF
Results
Date
Opening
Pressure/c
m water WCC % Polys % Lymps
Protein CSF 
Glucose
RBS
Glucose
Plasma
Glucose
ratio
Other
info
1st
2nd
3rd
CSF Gram stain _________ Hib Latex ___________  CSF Culture ________________________________________ 
LFT: TB ________    Direct Bilirubin ________ SGOT ________ SGPT ___________ Alp Phos _________ PT ________
Renal:  Urea_________ Creat __________ Na _________  K _________ 
Others
Radiology
CXR (if done) Date ________  Result ____________________________
CT head (if done) Date ________  Result ____________________________
MRI head (if done) Date ________  Result ____________________________
Others
JE serologyCSF 1 Date _______ neg / pos Date _______ neg / pos CSF 2 (if taken) Date _______ neg / pos
Serum 1 Date _______ neg / pos Date _______ neg / pos Serum 2 Date _______ neg / pos
OTHER (please fill below):
Malaria screen
(Widal if done)
Blood cultures
Specify (PS report/Ag):
Hb
Specify:
Total Count
Diff Count
Plats
RBS (gluc)
ESR
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Appendix H
Weight for age in boys
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Appendix I
Weight for age in girls
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Appendix J
A. Table showing Weight (Kg) for age for male students
Age (years) M-3SD M-2SD M-1SD Median M+1SD M+2SD M+3SD
5 9.6 12.0 14.4 16.8 19.2 21.6 24.0
6 7.15 10.7 14.4 17.9 21.5 25.1 28.7
7 9.3 12.7 16.1 19.5 22.9 26.3 29.7
8 9.4 13.5 17.6 21.7 25.8 29.9 34.0
9 11.1 15.3 19.5 23.7 27.9 32.1 36.3
10 10.2 15.4 20.6 25.8 31.0 36.2 41.4
11 14.1 19.0 23.9 28.8 33.7 38.6 43.5
12 12.5 19.0 25.5 32.0 38.5 45.0 51.5
13 16.2 23.3 30.4 37.5 44.6 51.7 58.8
14 21.3 28.7 36.1 43.5 50.9 58.3 65.7
15 27.1 34.3 41.5 48.7 55.9 63.1 70.3
16 28.9 36.3 43.7 51.1 58.5 65.9 73.3
17 33.8 39.7 45.6 51.5 57.4 63.3 69.2
18 35.0 41.4 47.8 54.2 60.6 67.0 73.4
19 36.9 43.1 49.3 55.5 61.7 67.9 74.1
[School Health and Nutrition Project, Child Health Division, MOH, 2011 (http://library.nhrc.
org.np:8080/nhrc/bitstream/handle/123456789/128/657.pdf?sequence=1)]
B. Table showing Weight (Kg) for age for female students
Age 
(years) M-3SD M-2SD M-1SD Median M+1SD M+2SD M+3SD
5 8.8 11.2 13.6 16.0 18.4 20.8 23.2
6 9.7 12.3 14.9 17.5 20.1 22.7 25.3
7 10.2 13.1 16.0 18.9 21.8 24.7 27.6
8 8.3 12.5 16.7 20.9 25.1 29.3 33.5
9 10.9 15.2 19.5 23.8 28.1 32.4 36.7
10 10.3 15.4 20.5 25.6 30.7 35.8 40.9
11 12.0 17.9 23.8 29.7 35.6 41.5 47.4
12 13.4 20.3 27.2 34.1 41.0 47.9 54.8
13 21.2 27.2 33.2 39.2 45.2 51.2 57.2
14 25.8 31.5 37.2 42.9 48.6 54.3 60.0
15 25.2 31.8 38.4 45.0 51.6 58.2 64.8
16 27.4 33.3 39.2 45.1 51.0 56.9 62.8
17 28.8 35.0 41.2 47.4 53.6 59.8 66.0
18 29.7 35.6 41.5 47.2 53.3 59.2 65.1
19 29.4 35.6 41.8 48.0 54.2 60.4 66.6
[School Health and Nutrition Project, Child Health Division, MOH, 2011 (http://library.nhrc.
org.np:8080/nhrc/bitstream/handle/123456789/128/657.pdf?sequence=1)]
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Appendix K
Liverpool Outcome Score at Discharge
Answer each question. Write the score in the square
Ask the parent or caregiver the following questions: 
For some of these questions, you ask the parent or caregiver how the child 
compares with how they were immediately before the illness (irrespective of 
length of time in hospital).
1. Speech or communication 
Compared with before the illness, is the child’s speech or communication: 
Score (2- 5)
• The same (5) 
• Reduced (3)
• Not speaking or communicating (2)    
2.  Feeding
The child’s feeding is: 
• The same as before illness (5)
• Occasionally needs help (3)
• Always needs more help (2)
3. Leaving Alone
Before the illness, could this child be left alone without coming to harm?
• If No score 5 (5) 
If Yes, can this child now be left alone? 
• Yes (5)
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• Yes briefl y in familiar environment (3)
• No (2)
4.  Behaviour
Compared with before the illness do the caregivers think the child’s behaviour 
is altered?
• No completely normal (5)
• Gets angry easily (4)
• Other behavioural problems (4)
• Severely abnormal (2)   
If abnormal give details:   
5.  Recognition
Could the child recognise their family members, other than their main carer, 
before the illness?
• If No, score 5 (5)
If Yes, can this child now recognise their family members, other than their 
main carer? 
• Yes (5)
• Some (3)
• None (2)          
6.  School and working
Before the illness, was the child at school or working?
If Yes, do the carers think the child will go back to school or work?  
• Yes (5) 
375
• No (3) 
If No, do the carers think the child will still able to do the same tasks at home 
and follow the same routine:
• Yes (5)
• No (3)
7. Epilepsy/ Seizures 
Did the child have any seizures during this illness?
• If No, score 5 (5)
If Yes, Is the child still having seizures?
• No seizures and not on anti-epileptic drugs (5)
• No seizures and on anti-epileptic drugs (4)
• Yes still having seizures (3)
• Yes, seizures most days (2)
8.  Dressing
Is the child’s ability to dress: 
• The same as before illness (5)
• Occasionally needs extra help (3)
• Needs more help than before (2)    
9.  Bladder and Bowel control
Is urinary and faecal continence:
• The same as before the illness (5)
• Needs more help or is incontinent of bowel or bladder (2)
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10.  Hearing
Does the parent think this child’s hearing is: 
• Normal (5)
• Reduced in one or both ears (4)
• Cannot hear at all (3)
Observation of the child’s abilities
For these questions you observe what the child can do. If you cannot get the 
child to cooperate, answer these questions based on what the caregiver says.
11. Sitting
Could the child sit before the illness?
• If No, score 5 (5) 
If Yes, observe, can this child sit?
• Yes independently (5)
• Needs help (3)
• Not at all (2)
12. Standing up
Could the child get from sitting to standing before the illness?
• If No, score 5 (5)
If Yes, observe, can the child get from sitting to standing?
• Yes, independently (5)
• Needs help (3)
• Not at all (2)
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13.  Walking 
Could the child walk before the illness? 
• If No, score 5 (5)
If Yes, observe this child walking 5 metres across room. The child walks: 
• Normally (5)
• Abnormally, but independently +/- crutches/stick (3)
• Not able to walk (2)
14. Hands on head
Put both your hands on your head, and ask the child to copy you. Child is: 
• Too young (5)
• Normal both hands (5)
• Abnormal one or both hands (4)
• Unable one or both hands (3)
15.  Picking Up
Ask child to pick up pea-sized ball of paper or small coin. Child is:
• Too young (5)
• Normal pincer grasp both hands (5)
• Unable one hand (3)
• Abnormal one hand or both hands (3)
• Unable both hands (2)        
Outcome Score =Lowest score for any single question (range 2-5):   
 
Total Score = all the individual scores added up (range 33 –75):   
 
(If the child died, the score = 1)
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Appendix L
Liverpool Outcome Score at follow up
Answer each question. Write the score in the square
Ask the parent or caregiver the following questions: 
For some of these questions, you ask the parent or caregiver how this child 
compares with other children of a similar age in their locality, e.g., how does 
this child compare in speaking or walking or talking to other children of the 
same age in the community. 
1.  Speech or communication: 
Compared with other children the same age in the community, is the child’s 
speech or communication: Score (2- 5)
• The same as other children of this age (5)
• Changed or reduced (3)
• Not speaking or communicating (2)
2.  Feeding
The child’s feeding is: 
• The same as other children (5)
• Occasionally needs help (3)
• Always needs more help (2)
3.  Leaving Alone
Before the illness, could a child of this age be left alone without coming to 
harm?
• If No score 5 (5)
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If Yes, can this child be left alone? 
• Yes (5) 
• Yes briefl y in familiar environment (3)
• No (2)
4.  Behaviour
Compared with other children of this age, do the caregivers think the child’s 
behaviour is altered?
• No, completely normal (5) 
• Gets angry easily (4)
• Other behavioural problems (4)
•  Severely abnormal (2)
• If abnormal give details______________
5.  Recognition
Can other children of this age recognise their relatives, other than their main 
carer?
• If No, score 5 (5)
If Yes, can this child recognise their relatives, other than their main carer?
• Yes (5) 
•  Some (3) 
• None (2)  
6.  School and working
Are other children of the same age at school or working?
If Yes, is the child 
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• Now back to normal at school or work (5)
• Not doing as well (4)
• Dropped a school grade or no longer attending school or work (3)
If No, is the child:  
• Still able to do the same tasks at home and follow the same routine (5)
•  Not able to do as well as before (4)
• Not able to do at all (3) 
7.  Epilepsy/ Seizures 
Has the child had any seizures in the last 2 months? 
• No seizures and not on anti-epileptic drugs (5) 
•  No seizures and on anti-epileptic drugs (4)
• Yes has had seizures (3)
• Yes, seizures most days (2)
8.  Dressing
Is the child’s ability to dress: 
• The same as other children the same age (5)
• Occasionally needs extra help (3)
• Always needs more help than other children of the same age (2) 
9.  Bladder and Bowel control
Is urinary and fecal continence: 
• The same as other children the same age (5)
• Needs more help or is incontinent of bowel or bladder (2)  
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10.  Hearing
Does the parent think this child’s hearing is: 
• Normal (5) 
• Reduced in one or both ears (4)
• Cannot hear at all (3) 
Observation of the child’s abilities
For these questions you observe what the child can do. If you cannot get the 
child to cooperate, answer these questions based on what the caregiver says.
11.  Sitting 
Can other children of the same age sit?
• If No, score 5 (5)       
If Yes, observe, can this child sit?
Yes independently (5)
•  Needs help (3)
• Not at all (2) 
12.  Standing up 
Can other children of this age get from sitting to standing?
• If No, score 5 (5)  
If Yes, observe, can the child get from sitting to standing?
• Yes, independently (5) 
•  Needs help (3)
• Not at all (2)
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13.  Walking
Can other children of this age walk? 
• If No, score 5 (5)
If Yes, observe this child walking 5 metres across room. The child walks:
•  Normally (5)
• Abnormally, but independently +/- crutches/stick (3) 
• Not able to walk (2) 
14.  Hands on head 
Put both your hands on your head, and ask the child to copy you. Child is: 
• Too young (5)
• Normal both hands (5)
• Abnormal one or both hands (4) 
• Unable one or both hands (3)  
15.  Picking Up
Ask child to pick up pea-sized ball of paper or small coin: 
• Normal pincer grasp both hands (5)
•  Unable one hand (3) 
• Abnormal one hand or both hands (3) 
• Unable both hands (2)      
Outcome Score =Lowest score for any single question (range 2-5):   
Total Score = all the individual scores added up (range 33 –75):   
(If the child died, the score = 1 )
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Appendix M 
Proforma of fl uid study
Role of fl uid management in the outcome of children with Acute 
Encephalitis Syndrome
History (WHO CASE ID:   VENEPCDR________) Study No: _________
Initials / Name ______________________  Hosp IP No. _______ Age___ Sex M  F /  F F   D.O.B.__________ 
Address of home:  ____________________________________________________
Corresponding Address ____________________________________________________
Date Admitted to Hospital___________Date Admitted to Study_________ Time_______ Date of discharge_________ Outcome________
Referred from:  District Hospital  F / General Practioner F /  Primary health centre F / home  F / other:______
Does the child meet WHO AES case definition?
Acute Febrile Illness
PLUS Change in mental status
 (including symptoms such as confusion, disorientation, coma, or inability to talk) 
AND/OR 
New onset of seizures  
  (excluding simple febrile seizures*) 
Collect samples
Acute CSF
Acute Serum
Convalescent serum (later)
_______________________________________________________________________________________________
SUMMARY INFORMATION (Complete after patient discharge)
Adm GCS  E= ___   M= ____ V=____      Discharge GCS E = ____  M =____ V = _____
Discharged Day __  Date ______   Discharge Outcome score  I (died) /  II (Severe)  / III (Mod )  / IV  (Mild)  / V (No) Sequelae
3-6 mo FU  Day __  Date ______   FU Outcome score  I (died) /  II (Severe)  / III (Mod )  / IV  (Mild)  / V (No) Sequelae
Others FU
JE status   Acute CSF   Pos / Neg      Acute Serum Pos / Neg     Conv Serum  Pos  / Neg  
N  F / Y F Date_____________________
N  F / Y F Date _____________________
N  F / Y F Details ___________________
N  F / Y F Details ___________________
N  F / Y F Details ___________________
N  F / Y F Date _____________________
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Role of fl uid management in the outcome of children with Acute 
Encephalitis Syndrome
History Study No: _________ Hospital IP No_____
First Initials of Name ____________ Age__________  Sex M F /  F F        D.O.B.__________
Date Admitted to Hospital____________Date Admitted to Study__________  Time_______
Date admitted to any hospital:_____________ Where?___________________
Referred from:  District Hospital F / General Practioner F /  Primary health centre F / home F / other:______
Address: District______, Ward no______ VDC________ Mobile no:
Handedness: Right F  / Left F
Attends school        Y F / N F / too young for school F
Normal Milestones   Y F / N F Describe__________________________
Animals/birds near the home /school (within 50 metres)?: N F/ Y F which?  pigs F/ chickens F/ other_____
Do parents think child is normal self? Y F / N F Details_____________________________________
Date of onset of illness  ____________  Today is day_________ of illness.
Fever Feeding      
If fever Vomiting:
Rigors/Chills: Diarrhoea
Headache: Abdo distens.
Neck pain GI bleed      
Photophobia Jaundice
Sore throat Drowsy    
Cough Irritable
Runny nose Confused:
Conjunctivitis Unconscious:
Rash Convulsions
Illness biphasic Spasms
Confused,  N F / Y F describe, giving example(s)____________________________________________________
Facial or Limb paralysis:  N F / Y F (where and when, day to max weakness) ____________________________
if paralysis complete additional examination sheet
Preceeding illness in the last 2 months?  None F / Yes F (give details)_____________________________
Recent Vaccines No F /Yes F          
Details _________________________________________________________________________________________
Other history (including other symptoms and past Hx of convulsions,  unusual features, family Hx): 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
Treatment given before admission to study: N F / Y F / unknown medication F
(if yes circle and give details: what, dose, when, where from): 
Aspirin F / Paracetamol F / Over the counter medicine F / Traditional Medicine F / Unknown antibiotic F 
Midazolam F / Diazepam F / Phenobarb F / Phenytoin F / Chloramphenicol F / Haloperidol F  
Saline/ fliuds F /     Type of fluids _________   Dextrose F   
Other drugs: No F  / Yes F (details) _________________________________________
Any reaction to JE vaccine No F /Yes F        
N F / Y F
N F  / Y F fill in convulsion sheet
N F  / Y F ______describe below
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
 Normal  F / reduced F / not at all F
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
Mannitol F / Steroids F details:____________
N F / Y F ______day to _____day
N F / Y F ______day to _____day
High grade F / low grade F
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
N F / Y F ______day to _____day
JE Vaccine No F/ Yes F/ Not Sure F    Date____________
N F / Y F ______day to _____day
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General Examination Study No.________ Hosp IP No________
First Initials of Name________________________________  Date:_________    Time:__________
Temp ________degrees C Resp. rate ______ / min
Pulse_______ / min  Height/ length____________cm (if possible)
BP:__________mmHg Weight __________kg CRT_____sec
Neck stiffness N F  / Y F Mouth dribbling: N F  / Y F
Kernig's positive N F  / Y F Jaundice: N F  / Y F
Fixed stare N F  / Y F Malnutrition N F  / Y F
McEwans sign N F  / Y F Cough: N F  / Y F
Bulging fontanelle: N F  / Y F Coryza: N F  / Y F
Full bladder: N F  / Y F Lymphadenopathy N F / Y F (details) ____________
Rash N F / Y F:   Macular F / papular F /vesicular F /other F: where____________
Enanthemas (mucous membrane eruptions) N F  / Y F  (describe type and location)____________
Oedema N F / Y F (Where?)_______________________________________________
Bleeding from oral mucosa? N F  / Y F
Other haemorrhagic manifestations: N F  / Y F (describe)____________________________________
Signs of dehydration N F  / Y F if yes describe ____________________________________
Heart Sounds: Normal ? / Abnormal ?(specify)___________________
Breath sounds: Normal ? / Abnormal ?(specify)___________________
Pattern:  Regular F /  Hypervent F /  Cheyne Stokes F /  Pauses F /  Ataxic F  /  Gasping F
ENT: normal / abnormal (describe) ___________________________
Hepatomegaly: No F / Yes F  ____ cm in mid clav line   Texture: _______  Tender  No F  / Yes F
Abdominal other: N F  / Y F
Abdomen tender other than liver?  N F / Y F
Ascites: N F  / Y F Tense:N F / Y F        Splenomegaly: _N F / Y F
Nasogastric tube: N F  / Y F Reason for NG tube:   aspiration F / feeding F
NG aspirate N F / Y F (coffee grnd aspirate? N F / Y F fresh bld ?  N F / YF)
Urinary Catheter: N F  / Y F For: retention F / incontin F / monitoring output F
If catheterised current hourly urine output  _______  mls / hr
Endotracheal intubation: N F  / Y F Froth from E/T tube? None F  / White F / Pink F
ABG Done N F  / Y F If yes answer: Prolonged bleeding after ABG  NF /YF
Bleeding for  _______ seconds after arterial blood gases
MUAC______cm
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       Admission Neurological Examination Study  No:__________
GCSFill  and drugs and history on daily progress sheet
Cranial nerves
Pupil Size Right:   pinpoint F / normal F / dilated F
Left:   pinpoint F / normal F / dilated F
Pupil response Normal F / Abnormal F (describe) _____________________________________
Fundi Right: Normal F / Not done F / Abnormal F (describe) ____________________
Left: Normal F /  Not done F / Abnormal  F  (describe)_____________________
Eye movements Normal F / Abnormal F (describe) _____________________________________
Doll's Eye reflex Normal F / Abnormal F (describe) _____________________________________
Response to menace Normal F / Abnormal F (describe) ___________________________________
VIIth nerve Normal F / Abnormal F (describe) ___________________________________
Swallowing Normal F / Abnormal F IF ABNORMAL or PATIENT UNCONCIOUS:
Gag: Normal F / Abnormal F / Absent F
Stridor No F  / Yes F
Speech Normal F / Abnormal F (describe) ___________________________________
Pout reflex: Absent F / Present  F                     
Abnormal movements No F  / Yes F
Tremor F / Lip smacking or chewing F / Teeth grinding F / Agitated F / twitching F  / Choreoathetosis F / 
Hiccoughs F / spasms F   (Details) _________________________________________________________
Posture
H d iti N l F / t d t l ft F / t d t i ht Fea  pos on: orma    urne  o e  urne  o r g  
Decerbrate / decorticate posturing : No F / Yes F
Rigidity spasms No F  / Yes F (details)_________
Mental State Normal F / Abnormal F (describe) ___________________________________
Other Comments __________________________________________________________________
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     Admission Neurological Examination 
Peripheral nervous system Study  No:________
Abl t Sit Independently F / With help F / Not at all Fe o :    
Able to Stand: Independently F  / With help F  / Not at all F
Any fasciculation: N F / Y F details: __________________________________________
Neck tone: Normal F / Increased F  / Neck rigid F
Flaccid limbs (LMN signs): No F / Yes F  Details:________________________________________
Head lag (when pulled to sit):  No head lag F / head lag F
Limb Tone             [Normal (N) /Flexion (F) /  Extension (E) / Gen Increased (I)/  Decreased (D) / Cogwheel (C)
Right Arm: ___                 Left Arm: ___
Right Leg ___                  Left Leg ___
Equine feet (toes pointing downwards):      Right: No F  / Yes F               Left: No F / Yes F
Clonus:           Right Ankle: No F / Yes F      Left Ankle: No F / Yes F
Tendon Reflexes, Draw:
Code:
 - absent
 + reduced
 ++ normal
 +++ increased
The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.
Symetrical/Asymetrical: Sym F /Asy F
Plantar reflexes:
Right: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Left: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Abdominal reflexes Any present F  / none present F 
Tone Overall: Normal F  / Generally Flaccid F / Generally Spastic F / Mixed F / Neither F
Power                 (Grade 1-5,  1= no movement, 2= not against gravity, 3 = against gravity, 4= reduced, 5= full)
Right Arm      ______  Left Arm ___________
Right Leg________     Left Leg ___________
Hands fall on face Right Hand    N F  / Y F          Left hand    N F / Y F
Knees flop out Right Knee    N F  / Y F          Left Knee    N F / Y F
Paresis: Hemiparesis F / Paraparesis F / Quadraparesis F / Monoparesis F / 
None F / Unknown F / Moving all 4 limbs F
388
Role of fl uid management in the outcome of children with Acute 
Encephalitis Syndrome
In
iti
al
s:
A
ge
M
/F
St
ud
y 
N
o:
D
ay
: 0
D
ay
: 1
D
ay
: 2
D
ay
: 3
D
ay
: 4
D
ay
: 5
D
ay
: 6
D
ay
: 7
D
ay
: 8
D
ay
 o
f i
lln
es
s:
D
at
e:
D
at
e:
D
at
e:
D
at
e:
D
at
e:
D
at
e:
D
at
e:
D
at
e:
D
at
e:
G
C
S
Ti
m
e:
 
Ti
m
e:
 
Ti
m
e:
 
Ti
m
e:
 
Ti
m
e:
 
Ti
m
e:
 
Ti
m
e:
 
Ti
m
e:
 
Ti
m
e:
 
sp
on
ta
ne
ou
s 
an
d 
se
ei
ng
4
4
4
4
4
4
4
4
4
to
 lo
ud
 v
oi
ce
3
3
3
3
3
3
3
3
3
to
 p
ai
n
2
2
2
2
2
2
2
2
2
no
t 
at
 a
ll 
(o
r 
fix
ed
 s
ta
re
)
1
1
1
1
1
1
1
1
1
or
ie
nt
at
ed
 (
w
or
ds
 o
f 
an
y 
so
rt
)
5
5
5
5
5
5
5
5
5
co
n f
us
ed
 (
m
on
os
yl
ab
le
s)
4
4
4
4
4
4
4
4
4
in
ap
pr
op
ria
te
 w
or
ds
 (
cr
ie
s/
sc
re
am
s/
m
oa
ns
)
3
3
3
3
3
3
3
3
3
in
co
m
pr
eh
en
si
bl
e 
so
un
ds
 (
gr
un
ts
)
2
2
2
2
2
2
2
2
2
no
ne
1
1
1
1
1
1
1
1
1
ob
ey
s 
co
m
m
an
ds
6
6
6
6
6
6
6
6
6
lo
ca
lis
es
 p
ai
nf
ul
 s
tim
ul
us
 (
kn
uc
kl
es
 o
n 
5
5
5
5
5
5
5
5
5
w
it h
dr
aw
s 
(f
ro
m
 p
re
ss
ur
e 
to
 n
ai
lb
ed
)
4
4
4
4
4
4
4
4
4
ab
no
rm
al
 f
le
xi
on
 p
os
tu
rin
g 
to
 p
ai
n
3
3
3
3
3
3
3
3
3
ex
te
ns
io
n 
to
 p
ai
n
2
2
2
2
2
2
2
2
2
no
ne
1
1
1
1
1
1
1
1
1
  A
dm
is
si
on
 D
at
e:
TO
TA
L
 P
ro
gr
es
s 
su
m
m
ar
y 
   
   
   
   
   
   
   
   
   
   
   
   
  D
ay
 o
f s
tu
dy
:
Best Motor
Best
Eyes
Best Verbal 
(2-5y in 
brackets)
Im
pr
ov
in
g?
   
   
   
   
   
   
   
   
   
   
N
o
ch
an
ge
/Y
es
/N
o
N
eu
ro
M
ac
E
w
an
's
/N
ec
k 
st
iff
ne
ss
Fo
ca
l n
eu
ro
lo
gy
/A
cu
te
 fl
ac
ci
d 
pa
ra
ly
si
s
Cr
an
ia
l N
er
ve
s
Pu
pi
ls
/F
un
di
To
ne
Re
fle
xe
s
de
ep
 t
en
do
n 
re
fle
xe
s
pl
an
ta
r 
re
fle
xe
s
do
lls
 e
ye
 re
fle
x 
(n
or
m
/a
bn
or
m
)
Ga
it
Si
t/
St
an
d/
W
al
k 
w
ith
 o
r 
w
ith
ou
t 
as
si
st
an
ce
If 
Ye
s 
de
sc
rib
e 
/ 
co
m
pl
et
e 
se
iz
ur
e 
ch
ar
t
RS
/C
V
S/
PA
/S
ki
n
Se
iz
ur
es
/S
pa
sm
s/
Po
st
ur
in
g
   
   
   
   
   
   
Ye
s/
N
o
N
ew
 c
om
pl
ai
nt
s
Ge
ne
ra
l: 
Pu
ls
e,
 R
R,
 T
em
p,
 B
P,
 C
RT
Im
pr
ov
in
g?
N
o
ch
an
ge
/Y
es
/N
o
389
Role of fl uid management in the outcome of children with Acute 
Encephalitis Syndrome
Results
DATE Study No: Hosp IP No__
Polym %Lymphs      % Eosin        Mono      %
neg/pos
neg/pos
Sample 1 neg/pos
Sample 2 neg/pos
Sample 3 neg/pos
CSF
Results
Date
.
Pressure
/cm
water WCC 
%
Lymphocytes
Protein
.
Glucose
(Glu st/ 
lab)
RBS
Glucose Other info
1st
2nd
3rd
Urea Creatinine T Bil D Bil SGPT SGOT
Date: Date: Date: Date: Date: Date:
Alk Phos Na K
Date: Date: Date:
Pastorix test Date
serum Pos/Neg Organism_____________
csf Pos/Neg Organism_____________
 EEG performed  Y F / N F  Nerve conduction (if flaccid)  Y F / N F    CT (unless full recovery)  Y F / N F
OTHER (please fill below):
Malaria screen
Blood cultures
JE serology 
Specify (PS report/Ag):
Hb
Specify:
Total Count
Diff Count
Plats
RBS (gluc)
ESR
%
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Appendix N 
Flow diagram shows summary of protocol timeline and recruitment 
process
Screening
?
Consent to screening Lumbar Puncture (LP) and blood tests
?
      ?
                                                LP meets entry criteria            LP not suggestive of JE  
       ?
                                                                    Patient not for treatment trial 
?
Consent to treatment trial
?
Randomize to IVIG / placebo
For 5 days 
?
Daily review whilst in-patient
?
Day 5-7 or discharge repeat serology
At Discharge detailed neurological examination and 
Liverpool Outcome Score
?
Follow up 3-6 months detailed neurological examination and 
Liverpool Outcome Score
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Appendix O 
Proforma of IVIG study
A preliminary randomized double blind placebo-controlled trial of 
intravenous immunoglobulin for JE in Nepal
History (WHO CASE ID:   VENEPCDR________) Study No: _________
Initials / Name ______________________  Hosp IP No. _______ Age___ Sex M F /  F F   D.O.B.__________
Address of home:  ____________________________________________________
Corresponding Address ____________________________________________________
Date Admitted to Hospital___________Date Admitted to Study_________ Time_______ Date of discharge_________ Outcome________
Referred from:  District Hospital F / General Practioner F /  Primary health centre F / home F / other:______
Does the child meet WHO AES case definition?
Acute Febrile Illness
PLUS Change in mental status
 (including symptoms such as confusion, disorientation, coma, or inability to talk) 
AND/OR
New onset of seizures 
  (excluding simple febrile seizures*) 
Collect samples
Acute CSF
Acute Serum
Convalescent serum (later)
_______________________________________________________________________________________________
SUMMARY INFORMATION (Complete after patient discharge)
Adm GCS  E= ___   M= ____ V=____      Discharge GCS E = ____  M =____ V = _____
Discharged Day __  Date ______ Discharge Outcome score  I (died) /  II (Severe)  / III (Mod )  / IV  (Mild)  / V (No) Sequelae
3-6 mo FU  Day __  Date ______ FU Outcome score  I (died) /  II (Severe)  / III (Mod )  / IV  (Mild)  / V (No) Sequelae
Others FU
JE status   Acute CSF   Pos / Neg      Acute Serum Pos / Neg     Conv Serum  Pos  / Neg
N F / Y F Date_____________________
N F / Y F Date _____________________
N F / Y F Details ___________________
N F / Y F Details ___________________
N F / Y F Details ___________________
N F / Y F Date _____________________
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History Study No: _________
 Initials/  Name ____________ Age__________  Sex M F /  F F        D.O.B.__________
Date Admitted to Hospital____________Date Admitted to Study__________  Time_______
Date admitted to any hospital:_____________ Where?___________________
Referred from:  District Hospital F / General Practioner F /  Primary health centre F / home F / other:______
Handedness: Right F  / Left F Ethnicity: ___________________________________
Attends school        Y F / N F / too young for school F Does family rear pigs? Y F / N F 
Normal Milestones   Y F / N F Describe__________________________
Do parents think child is normal self today? Y F / N F Details_____________________________________
Date of onset of illness  ____________  Today is day_________ of illness.
Fever Feeding      
If fever Drowsy    U F / N F / Y F ______day to _____day
Rigors/Chills: Irritable
Headache: Confused:
Neck pain Unconscious:
Photophobia Convulsions
Sore throat Spasms
Cough
Runny nose
Vomiting:
Diarrhoea
Illness biphasic
Rash / Conjuctivitis / Abdo distension / GI Bleed / Jaundice / Others U F  / N  F / Y F decribe, including days: _________________
__________________________________________________________________________________________________________
Confused,  N F / Y F describe, giving example(s)____________________________________________________
Describe convulsions: number of attacks, when occurred, duration, partial, generalised, Status? incontinence? Frothing? 
Post-ictal phenomenon, Todd's paresis?woke up after? _______________________________________________________
_________________________________________________________________________________________________
Simple febrile convulsions only? N F / Y F (details) ____________________________
Facial or Limb paralysis:  N F / Y F (where and when, day to max weakness) ____________________________
Preceeding illness in the last 2 months?  None F / Yes F (give details)_____________________________
Recent Vaccines No F /Yes F          
Details _________________________________________________________________________________________
Other history (including other symptoms and past Hx of convulsions,  unusual features, family Hx): 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
Treatment given before admission to study: N F / Y F / unknown medication F
(if yes tick and give details: what, dose, when, where from): 
Aspirin F / Paracetamol F / Over the counter medicine F / Traditional Medicine F / Unknown antibiotic F 
Chloramphenicol F / Penecillin F / Ceftrioxone F / Midazolam F / Diazepam F / Phenobarb F / Phenytoin F / Haloperidol F  
Saline F / Dextrose F   Mannitol F / Steroids F details:____________
Other drugs: No F  / Yes F (details) _________________________________________
U F  / N F / Y F ______day to _____day
JE Vaccine No F/ Yes F/ Not Sure F    Date____________ Any reaction to JE vaccine No F /Yes F        
U F  / N F / Y F decribe: ___________
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
High grade F / low grade F
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F  / N F / Y F ______day to _____day
U F / N F / Y F ______day to _____day
N F  / Y F describe below
N F  / Y F ______describe below
 Normal  F / reduced F / not at all F
U F / N F / Y F ______day to _____day
U F / N F / Y F ______day to _____day
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General Examination Study No.________ 
 Initials / Name________________________________  Date:_________    Time:__________
Temp ________degrees F Resp. rate ______ / min
Pulse_______ / min  Height/ length____________cm (if available)
BP:__________mmHg Weight __________kg
Neck stiffness N F  / Y F Saliva dribbling: N F  / Y F
Kernig's positive N F  / Y F Jaundice: N F  / Y F
Vacant stare N F  / Y F Malnutrition (calculate lateN F  / Y F
N F  / Y F Cough: N F  / Y F
Bulging fontanelle: N F  / Y F Coryza: N F  / Y F
Full bladder: N F  / Y F Lymphadenopathy N F / Y F (details) ____________
Rash N F / Y F:   Macular F / papular F /vesicular F /other F: where____________
Enanthemas (mucous membrane eruptions) N F  / Y F  (describe type and location)____________
Oedema N F / Y F (Where?)_______________________________________________
Any haemorrhagic manifestations: N F  / Y F (describe)____________________________________
Heart Sounds: Normal ? / Abnormal ?(specify)___________________
Breath sounds: Normal ? / Abnormal ?(specify)___________________
Pattern:  Regular F /  Hypervent F /  Cheyne Stokes F /  Pauses F /  Irregular F  /  Gasping F
ENT: normal / abnormal (describe) ___________________________
Hepatomegaly: No F / Yes F  ____ cm in mid clav line   Texture: _______  Tender  No F  / Yes F
Ascites: N F  / Y F Tense:N F / Y F        Splenomegaly: _N F / Y F
Abdominal other: N F  / Y F
Nasogastric tube: N F  / Y F Reason for NG tube:   aspiration F / feeding F
NG aspirate N F / Y F (coffee grnd aspirate? N F / Y F fresh bld ?  N F / YF)
Urinary Catheter: N F  / Y F For: retention F / incontin F / monitoring output F
If catheterised current hourly urine output  _______  mls / hr
Endotracheal intubation: N F  / Y F Froth from E/T tube? None F  / White F / Pink F
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    Admission Neurological Examination Study  No:__________
Initials / Name Date: Time:________________________________ _________ __________
Cranial nerves
Pupil Size Right:   pinpoint F / normal F / dilated F
Left:   pinpoint F / normal F / dilated F
Pupil response Normal F / Abnormal F (describe) _____________________________________
F F FFundi Right: Normal  /  Not done  / Abnormal    (describe)____________________
Left: Normal F /  Not done F / Abnormal  F  (describe)_____________________
Spont Eye movements Normal F / Abnormal F (describe) _____________________________________
Doll's Eye reflex Normal F / Abnormal F (describe) _____________________________________
Response to menace Normal F / Abnormal F (describe) ___________________________________
VIIth N l F / Ab l F (d ib ) nerve orma   norma  escr e  ___________________________________
Swallowing Normal F / Abnormal F IF ABNORMAL or PATIENT UNCONCIOUS:
Gag: Normal F / Abnormal F / Absent F
Stridor No F  / Yes F
Speech Normal F / Abnormal F (describe) ___________________________________
Abnormal movements No F  / Yes F
Tremor F / Lip smacking or chewing F / Teeth grinding F / Agitated F / twitching F  / Choreoathetosis F / 
Hiccoughs F / Rigidity spasms F   (Details) ________________________________________________________
Posture
Head position: Normal  F / turned to left F / turned to right F
Extensor / Flexor posturing : No F / Yes F
Mental State Normal F / Abnormal F (describe) ___________________________________
Other Comments __________________________________________________________________
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Admission Neurological Examination Study  No:________
Peripheral nervous system
Abl t Sit Independently F / With help F / Not at all Fe o :    
Able to Stand: Independently F  / With help F  / Not at all F
Any fasciculation: N F / Y F details: __________________________________________
Neck tone: Normal F / Increased F  / Neck rigid F
Flaccid limbs (LMN signs): No F / Yes F  Details:________________________________________
Head lag (when pulled to sit):  No head lag F / head lag F
Limb Tone/Posture      [Normal (N) /Flexion (F) /  Extension (E) / Gen Increased (I)/  Decreased (D) / Cogwheel (C)
Right Arm: ___                 Left Arm: ___
Right Leg ___                  Left Leg ___
Equine feet (toes pointing downwards):      Right: No F  / Yes F               Left: No F / Yes F
Clonus:           Right Ankle: No F / Yes F      Left Ankle: No F / Yes F
Tendon Reflexes, Draw:
Code:
 - absent
 + reduced
 ++ normal
 +++ increased
Symetrical/Asymetrical Sym F /Asy F
Plantar reflexes:
Right: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Left: Flexor (down) F  / Extensor  (up) F / No movement F / Unsure F
Abdominal reflexes Any present F  / none present F 
Tone Overall: Normal F  / Generally Flaccid F / Generally Spastic F / Mixed F / Neither F
Power                 (Grade 1-5,  1= no movement, 2= not against gravity, 3 = against gravity, 4= reduced, 5= full)
Right Arm      ______  Left Arm ___________
Right Leg________     Left Leg ___________
Hands fall on face Right Hand    N F  / Y F          Left hand    N F / Y F
Knees flop out Right Knee    N F  / Y F          Left Knee    N F / Y F
Paresis: Hemiparesis F / Paraparesis F / Quadraparesis F / Monoparesis F / 
None F / Unknown F / Moving all 4 limbs F
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Adverse events
Study No:
 Initials / Name________________________ Time:__________ Date:_________   
No Clinical Features Yes No
1 Abdominal pain
2 Headache
3 Chest tightness
4 Facial flushing
5 Nausea
6 Vomiting
7 Dyspnoea
8 Hot sensation
9 Itching
10 Non. Urt. rash
11 Fever
12 Pallor
13 Irritable
14 Hypotension
15 Oliguria / Anuria
16 Hemolysis
17 Melena
18 Raised Urea
19 Raised Creatinine
20 Death
21 Others
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Results Study No:
 Initials / Name_______________  Time:__________ Date:_________    Time:__________
DATE
Random blood sugar: _________
Polym    % Lymphs   % Eosin   % Mono   %
neg/pos
(Dengue if done)
neg/pos
CSF 
Results Date       
Opening 
Pressure/c
m water
WCC % Polys % Lymps Protein     CSF Glucose
RBS 
Glucose
CSF / 
Plasma 
Glucose 
ratio
Other 
info
1st
2nd
3rd
CSF Gram stain _________ Hib Latex ___________  CSF Culture ________________________________________ 
LFT: TB ________    Direct Bilirubin ________ SGOT ________ SGPT ___________ Alp Phos _________ PT ________
Renal:  Urea_________ Creat __________ Na _________  K _________ 
Others
Radiology
CXR (if done) Date ________  Result ____________________________
CT head (if done) Date ________  Result ____________________________
MRI head (if done) Date ________  Result ____________________________
 EEG performed  Y  ? / N  ?  Nerve conduction (if flaccid)  Y  ? / N  ?    CT (unless full recovery)  Y  ? / N  ?
RT-PCR
IL-4 IL-6
Others (JEV neutralizing Antibody levels)
JE serology CSF 1 Date _______ neg / pos Date _______ neg / pos CSF 2 (if taken) Date _______ neg / pos
Serum 1 Date _______ neg / pos Date _______ neg / pos Serum 2 Date _______ neg / pos
Hb
Specify:
Total Count
Diff Count
Plats
RBS (gluc)
ESR
OTHER (please fill below):
Malaria screen   
(Widal if done)
Blood cultures   
Specify (PS report/Ag):
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Appendix P
The Table shows summary of study schedule 
Screening
Day 
0
Baseline 
Day 1 Day 2 Day 3 Day 4
Day 
5
Daily follow 
up until 
discharge
Discharge Follow Up
If meets 
LP/ clinical 
criteria
3-6 
months
Initial assessment ♦
Full Clinical & 
Neurological 
Examination
♦ ♦ ♦
Brief Clinical 
examination ♦ ♦ ♦ ♦  ♦ ♦
Study Drug IVIG/ 
Placebo • • • • •
Study drug adverse 
effect ♦ ♦ ♦ ♦ ♦ ♦ ♦
Clinical Outcome ♦ ♦
Weight ♦
Glasgow Coma Score 
(GCS) ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
Liverpool Outcome 
Score (LOS) ♦ ♦
Negative P. falciparum ♦
Clinical Investigations
CBC, RFT, glucose, 
LFTs
(U&Es and other 
investigations as 
clinically indicated)
♦
Lumbar puncture and 
opening pressure ♦ ♦*  ♦*
CSF cytokines & JE 
viral PCR ♦ ♦* ♦*
JE serology ♦ ♦
Discharge JE serology
(Day 5-7 of illness 
or discharge date if 
earlier)
♦ ♦
Blood Cytokines ♦ ♦ ♦
Serum for 
measurement of JEV 
neutralizing Antibody
♦ ♦ Pre- & post 
dose
* As clinically indicated
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Appendix Q
A preliminary randomized double blind placebo-controlled trial 
of intravenous immunoglobulin for Japanese encephalitis in 
Nepal
Neurological assessment form
Date ______ Study No:_____
First Initials of child______________________ Age___________ Sex: M F / F F
Cranial nerves
Vision Right _____ Left _______
Fundi Right: Normal F / Abnormal F / Not done F Left: Normal F / Abnormal F / Not done F
Diplopia N F / Y F (describe) ________
Vth nerve Normal F / Abnormal F (specify) _______________
VIIth nerve Normal F / Abnormal F (specify) _______________
Hearing Normal F / Abnormal F (specify) _______________
Tongue 
movement Normal F / Abnormal F (specify) _______________
Pout refl ex: Absent F / Present F
Peripheral nervous system
Neck tone: Normal F / Increased F / Neck rigid F
Limb Tone [Normal (N) /Fixed Flexion (F) / Extension (E) / Gen Increased (I)/ Decreased (D) / Cogwheel (C)
(write letter next to limb space)
Right Arm:_________ Left Arm: ___________
Right Leg ________ Left Leg ____________
Equine feet (toes pointing downwards): Right: No F / Yes F Left: No F / Yes F
Clonus: Right Ankle : No F / Yes F Left Ankle : No F / Yes F
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Tendon Refl exes, Draw:
Code:
- absent
+ reduced
++ normal
+++ increased
   
Plantar 
refl exes:
Right: Flexor (down) F / Extensor (Up) F / No movement F / Equivocal (Unsure) F
Left: Flexor (down) F / Extensor (Up) F / No movement F / Equivocal (Unsure) F
Hemiparesis F / Paraparesis F / Quadraparesis F / Monoparesis F / None F / Unknown F
Tone Overall: Normal F / Generally Flaccid F / Generally Spastic F / Mixed F / Neither F
Response to Pain: Extensor F / Flexor F / Neither F
Abdominal Refl exes:  Present F / absent F
Sensation: Not tested F / Normal F / Abnormal F (specify, or draw over page)___________
Back at school yet school Y F / N F (why not):______________________________________
Any other Comments / Problems : _________________________________________________
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Appendix R
Table showing validation of Liverpool outcome score (109)
Malaysia 
Percent (95% CI)
India 
Percent (95% CI)
Sensitivity 100% (89.1- 100) 100% (91.2- 100)
Specifi city 98.4% (96.5- 99.4) 93.8% (90.7- 96)
Positive predictive value 84.2% (68.7- 94) 65.6% (52.3- 77.3)
Negative predictive value 100% (98.6- 100) 100% (98.5- 100)
Intra observer agreement (kappa value) 1.0 0.9 (0.82- 0.99)
Inter observer agreement (kappa value) 0.94 (0.86- 1.0) 0.79 (0.67- 0.91)
(Lewthwaite P. et al, 2010)
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Appendix S
Figure showing Multi-sectoral Nutrition Planning Framwork of Nepal
(http://scalingupnutrition.org/wp-content/uploads/2013/03/Nepal_MSNP_2013-2017.pdf)
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Appendix T 
Table showing different concentration of sodium in commonly used intrave-
nous fl uids
Commonly used intravenous fl uids Sodium (mmol/L) content
5% dextrose + 0.9 % normal saline 154
5% dextrose + 0.45 % normal saline 77
5% dextrose + 0.25 % normal saline 34
5% dextrose + 0.18 % normal saline 31
Normal saline (0.9% Nacl) 154
Ringer's lactate 130
 (Martin GS, 2016)
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Appendix U
Table shows list of anti-JE drugs
Category Antiviral drugs Target/Mechanism
Non-specifi c broad spectrum Arctigenin Antioxident
Fenofi brate Antioxident
Curcumin Antioxident
Pentoxifylline Assembly or release
Nitazoxanide Early-mid replication cycle
Nucleic acid based siRNA C,M,E,NS1, NS3, NS4B, NS5
PNA UTR
Morpholino Oligomer UTR
Virus replication cycle based Heparan Sulfate Receptor binding
E-binding peptide Receptor binding
NSQ Attachment
Indirubin Attachment
Bovine lactoferrin Receptor binding
Griffi thsin Receptor binding
Recombinant E Receptor binding
MCPIP1 RNA replication
Kaempferol RNA replication
SCH 16 Translation
